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  IX 
General introduction 
 
Palmitoylated proteins constitute an important class of signaling components controlling various 
cellular processes, such as cell proliferation and apoptosis, both frequently deregulated in 
carcinogenesis. The reversible character of the palmitate lipid anchoring is of utmost importance 
for maintaining steady-state protein localization and subsequent signaling. Therefore, targeting 
protein depalmitoylation by inhibiting the depalmitoylating enzymes might be a valid 
therapeutic strategy for modulating aberrant cell signaling.  
Given the importance of Ras mutations in carcinogenesis (33% of all cancers), Ras has been 
considered as an attractive anti-cancer target. In particular, one strategy developed to affect 
aberrant Ras signaling, consists in targeting the Ras depalmitoylating enzyme acyl protein 
thioesterase 1 (APT1). Such APT1 inhibitors could provide a useful tool for studying the biological 
role of APT1 in vivo. Moreover, employed in activity-based proteome profiling experiments such 
inhibitors may allow the identification of their cellular target(s), and possibly of additional 
proteins relevant to the Ras depalmitoylation process. In this context, the first chapter presents 
the development of potent and selective β-lactone APT1 inhibitors termed palmostatin B and 
palmostatin M and their use in a chemical proteomic approach.  
The second chapter consists in getting a better understanding of the apoptosis resistance 
characteristic of Chronic Lymphocytic Leukaemia (CLL). Recently, the lipase inhibitor orlistat and 
later the APT1 inhibitor palmostatin B were shown to restore Fas-mediated apoptotic signaling 
selectively in CLL cells. With the reported importance of Fas palmitoylation for Fas–mediated 
death signaling, absence or dysfunction of Fas palmitoylation may account for the accumulation 
of malignant B-cells characteristic of this disease. To rationalize the observed apoptotic effect, a 
chemical proteomic approach was developed with human cells from leukaemia and healthy 
patients in collaboration with Prof. Wendtner’s group at the academic hospital in Cologne to 
address the cellular target(s) of palmostatin B and in particular to identity target protein(s) 
relevant to Fas depalmitoylation, and therefore possibly involved in CLL pathogenesis.  
In order to evaluate the effect of palmostatin B on palmitoylation levels of proteins at global 
cellular scale, SILAC experiments were subsequently performed in connection to a inert 
alkynylated palmitate analogue (alkyne-16-C carboxylic acid) in double metabolic labelling 
experiments. In this context, chapter 3 covers preliminary experiments performed to this goal.  
  X 
Following the identification of the enzymes catalyzing Ras depalmitoylation, several new Ras 
depalmitoylation inhibitor candidates were developed, which in contrast to the previous -
lactone inhibitors palmostatin B and M, would be regarded as stable transition state mimics of 
the deacylation process. In this context, chapter 4 covers the design, synthesis and in vitro 
evaluation of these new inhibitor candidates (-keto oxazoles, -keto amides, trifluoromethyl 
ketones and pentafluoroethyl ketones).   
Given that most of the compound class investigated for APT1 inhibition were already reported as 
Fatty Acid Amide Hydrolase (FAAH) inhibitors, and given the numerous therapeutic applications 
associated to FAAH inhibition, a global investigation for FAAH inhibition was performed in 
collaboration with Matthias Lehr from the University of Münster. Chapter 5 is about the 
discovery of potent sub-micromolar FAAH inhibitors.  
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Chapter 1: Targeting Ras depalmitoylation   1 
1 Introduction  
1.1 Background cancer  
 
Cancer is a group of over 100 diseases affecting various tissues, characterized by an uncontrolled 
cell proliferation, generating cell aggregates called tumors. Cancer-related deaths are largely due 
to the ability of cancer cells to spread, either by invasion to adjacent tissues, or by implantation 
into distant sites by metastasis. Metastatic tumours trafficking through the bloodstream or 
lymphatic circulation systems are frequently encountered in the late stages of cancers referred 
to as generalized cancers therefore associated with significantly reduced prognosis for survival. 
Today, cancer is an enormous global health problem accounting for one in every eight deaths 
worldwide - more than HIV/AIDS, tuberculosis and malaria combined.  In 2008, the American 
Cancer Society estimated to 12.4 million the number of diagnosed cancers and to 7.6 million the 
number of deaths from cancer around the world. This alarming increased number of diagnosed 
cancers and cancer-related deaths is being driven largely by the adoption of unhealthy lifestyle 
(ex. tobacco, physical inactivity, obesity, poor nutrition) and population aging. In this context, 
many efforts have been directed toward the development of more reliable cancer diagnosing 
and the development of alternative anti-cancer therapies with possibly reduced side effects and 
increased survival rate.  
 
Figure 1.1 Comparison between normal and abnormal cellular behaviours. A) Normal cell division 
followed by apoptosis of injured cells. B) Cancer cell division leading to uncontrolled cellular growth.  
 
Normal cellular behavior is tightly regulated by complex signaling pathways ensuring balance 
between cell proliferation and apoptosis (programmed cell death). Mutations of normal cellular 
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genes, called proto-oncogenes into oncogenes encoding for proteins involved into such signaling 
pathways inevitably results in altered cell growth characteristic for cancers. One key effector of 
the signaling pathways controling cell growth is the protein encoded by the Ras gene. 
  
1.2 Ras proteins and cancer  
 
In the 1980s, the Ras oncogene involved in the Harvey virus causing sarcoma tumor in rats was 
identified1,2 and therefore named H-Ras for Harvey- rat sarcoma.  Later, the two additional 
oncogenic Ras isoforms identified in Kirsten sarcoma viruses1 and in human Neuroblastoma3 
were respectively named as  K-Ras and N-Ras. The Ras subfamily comprising the H-Ras, N-Ras, K-
Ras (K-Ras4A and K-Ras4B) proteins, forms a family of 21 kDa GTP-regulated molecular switches 
cycling between an inactive GDP-bound and an active GTP-bound state, characterized by 
individual conformations (Figure 1.2). Ras activation requires replacement of bound GDP by GTP, 
an intrinsic process accelerated by nucleotide exchange factors (GEFs), whereas Ras inactivation 
occurs through the hydrolysis of bound GTP to GDP (GTPase reaction), an intrinsic process 
accelerated by GTPase activating proteins (GAPs) (Figure 1.2).  
 
 
Figure 1.2 Regulation of Ras activity by the regulatory proteins GAPs and GEFs. GAPs inactivate Ras by 
stimulating the hydrolysis of bound GTP to GDP (GTPase reaction) and GEFs activate Ras by stimulating the 
replacement of bound GDP by GTP.  
 
Once activated, Ras proteins signal through various cell-signaling pathways involved in cell 
proliferation (MAPK or PI3K/Akt). This aspect of Ras regulation is frequently disregulated in Ras-
related cancers due to Ras mutations located at the interface of the Ras:GTP-GAP complex, 
typically at the residue Gly 12, Gly 13 and Gln 61. Indeed, mutations at glycine residues Gly 12 
and/or Gly 13 were shown to prevent the approach of the regulatory protein GAP through its 
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“GAP arginine finger” (Arg789)4(Figure 1.3, A).4,5 In contrast, mutations on the glutamine residue 
Gln 61 was shown to affect the catalytic reaction by disrupting important hydrogen-stabilizing 
interactions (Figure 1.3B).4,5  
A B 
  
Figure 1.3 Ras mutations preventing Ras inactivation by GAPs. A) Crystal structure of the complex formed 
between Ras:GTP (in yellow) and GAP (in red) showing the importance of the Ras residue 12,13 and 61 to 
allow its interaction with the GAP arginine finger (Arg789). B) Hydrogen-stabilizing interactions involved in 
the GAP-mediated GTP hydrolysis. Figure reproduced from the literature.
4,5
  
 
 
 As a result, such mutations do result in a prolongated Ras activation, thereby leading to cancers. 
Indeed, Ras gene mutations occur in 30% of all cancers,6 with K-Ras mutations most frequently 
encountered (85%), followed by N-Ras (15%) and H-Ras (<1%). Ras–mutations have a significant 
implication in some cancers, exemplified by K-Ras mutations found in 90% of all pancreatic 
cancers.6     
 
1.3 Ras proteins  
1.3.1 Ras biosynthesis based on the CAAX motif 
 
In mammals, three Ras genes are expressed encoding for four proteins, H-Ras, N-Ras, K-Ras4A 
and K-Ras4B, ubiquitously expressed at the exception of K-Ras4A. For such a reason, K-Ras will in 
the following discussion refer exclusively to the most abundant form K-Ras4B. These four Ras 
isoforms consist in 189 amino acids with high sequence conservation over their 165 N-terminal 
residues (>90% identity) contrasting with significant divergences (10-15% identity) over their C-
terminal 24 residues therefore referred as their C-terminal hypervariable region (HVR). The HVR 
can be divided into two domains: the linker domain and the membrane-targeting domain.7 The 
Chapter 1: Targeting Ras depalmitoylation   4 
membrane-targeting domain was shown to contain two cooperating signal recognition 
sequences sufficient for Ras trafficking and anchoring to the plasma membrane (PM), a process 
that is necessary for its biological activity (Figure 1.4A). 
 
A B 
  
 
Figure 1.4 Schematic representations of H-Ras, N-Ras, K-Ras4A and K-Ras4B isoforms. A) Divergence of 
Ras isoforms in their HVR, containing the two signal recognition sequences necessary for their stable 
membrane anchoring. B) Structure of palmitoyl and isoprenyl (geranylgeranyl and farnesyl) moieties. 
Figure reproduced from the literature.
7
  
 
 
The first signal recognition sequence is the C-terminal CAAX motif (C stand for cysteine, A for 
aliphatic amino acid and X for any amino acid).8,9 Irreversible S-isoprenylation of the CAAX motif 
by attachment of a isoprenyl group (either C15-farnesyl or C20-geranylgeranyl) on its cysteine 
residue provide Ras proteins with a weak membrane affinity, with geranylgeranylated proteins 
generally more tightly bound to membranes than farnesylated proteins presumably due to their 
longer anchors. H-Ras was found to be exclusively farnesylated in contrast to K-Ras and N-Ras, 
which can be either farnesylated or geranylgeranylated. Isoprenylation10 of cytosolic Ras 
precursors is the first step in a series of post-translational modifications allowing Ras anchoring 
in the endoplasmic reticulum (ER), where the three terminal amino-acids residues (AAX) are 
removed by the endoprotease RCE1 (Ras converting enzyme1).11-13 The carboxyl group of the 
terminal cysteine is subsequently esterified (methyl ester) on the ER by ICMT (isoprenylcysteine 
carboxymethyltransferase).14,15 Correct processing of the CAAX motif was found to be essential 
for the efficient transport of Ras to the PM given that mutations of the CAAX motif9 or deletion 
of RCE1 or ICMT11,12,16-18 were shown to result in Ras mislocalization in the cytosol, associated 
with a complete loss of biological activity. After post-translational modifications of the CAAX 
motif, stable membrane anchoring of Ras to the PM is ensured by a second recognition signal 
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sequence also located in the membrane-targeting domain consisting either in one or two S-
palmitoylation sites, or in a polybasic domain of six consecutive lysine residues (Lys175 to 
Lys180). After methyl esterification, solely prenylated H-Ras and N-Ras proteins are reversibly19 
S-palmitoylated at the Golgi by attachment of palmitate group(s) respectively at Cys 181,184 for 
H-Ras and at Cys 181 for N-Ras. Although their absolute identification is still lacking, Golgi-
localized palmitoyltransferase(s) (PATs) are suspected to be involved in the palmitoyl transfer 
from Palmitoyl-CoA (Pal-CoA). After S-Palmitoylation, fully processed H- and N-Ras proteins 
enter the secretory pathway20 trafficking from the Golgi to the PM, resulting in stable PM 
anchoring ensured by their isoprenyl and palmitate moieties. In contrast, isoprenylated K-Ras 
proteins do not require palmitoylation for their stable PM anchoring given their positively 
charged polybasic lysine-rich sequence which allows electrostatic stabilizing interactions with 
negatively charged phospholipids constituting the plasma membrane. K-Ras directy and quickly 
traffic from the ER to the PM through a poorly characterized transport differing from the 
secretory pathway20,21 (Figure 1.5).  
 
 
 
Figure 1.5 Schematic overview of Ras post-translational modifications. After biosynthesis, cytosolic Ras 
proteins undergo isoprenylation (prenyl group in black) followed by cleavage of AAX tripeptide by RCE1 
and carboxymethylation by ICMT at the ER. Palmitoylation of H- and N-Ras at the Golgi (palmitate tail in 
green) allow their transport to the PM through the secretory pathway. K-Ras bypasses the Golgi and 
reaches the PM directly by a yet uncharacterized pathway. Figure adapted from the literature.
22
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1.3.2 Spatiotemporal Ras distribution  
 
Dynamic Ras isoform localization  
 
Once fully processed, PM-bound H- and N-Ras isoforms were shown to traffic within the cell due 
to the reversible nature of their palmitate moiety. Indeed, recent studies23 on semi-synthetic Ras 
proteins, have pointed out a dynamic de/repalmitoylation cycle regulating H-Ras and N-Ras 
trafficking to ensure their correct spatiotemporal distribution between PM, endosomes, 
endoplasmic reticulum and Golgi. In this model, depalmitoylation detaches H- and N-Ras 
isoforms from the PM and rapidly repartitions solely isoprenylated proteins randomly to any 
cellular membrane by cytosolic diffusion until their new and reversible stable membrane 
trapping by repalmitoylation occurs at the Golgi (Δt = 14 sec). Only after a longer time (Δt = 173 
sec), palmitoylated Ras proteins exit the Golgi and access the PM via the secretory pathway. 20 
The importance of the de/repalmitoylation cycle for correct Ras localization was demonstrated 
either by preventing Ras palmitoylation using 2-bromopalmitate (2-BP),24,25 or by preventing Ras 
depalmitoylation using Ras proteins modified by non-cleavable thioether palmitate-like 
groups.26,27 Both experiments resulted in an incorrect non-specific Ras localization to all 
membrane compartments, when targeting Ras palmitoylation or depalmitoylation respectively 
(Figure 1.6).  
 
 
Figure 1.6 Schematic illustration of the dynamic and unidirectional de/repalmitoylation cycle. A dynamic 
cycle regulates H- and N-Ras isoform distribution between the Golgi and the PM through palmitoylation 
on the Golgi and depalmitoylated at the PM. Figure adapted from the literature.
28
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In contrast, K-Ras partitions rapidly and transiently to various non-specific cellular membranes 
(endoplasmic reticumum, Golgi, Mitochondria) by a dynamic process of PM 
absorption/desorption. Two different repulsion mechanisms for K-Ras desorption from the PM 
have been proposed consisting either in a Ca2+/calmodulin-mediated K-Ras solubilisation29,30 or 
in a PKC–mediated K-Ras phosphorylation at a serine group adjacent to its polybasic stretch.31 
Both proposed mechanisms involved the neutralisation of electrostatic stabilizing interactions 
between the positively charged polybasic lysine-rich sequence of K-Ras and the negatively 
charged phospholipids constituting the PM (Figure 1.7). 
 
Figure 1.7 Proposed dynamic K-Ras absorption/desorption mechanisms. A rapid and transient K-Ras 
partitioning to different endomembranes (ER, Golgi, Mitochondria) was proposed to occur either by 
Ca
2+
/calmodulin-mediated K-Ras solubilisation or by PKC–mediated K-Ras phosphorylation. Electrostatic 
repulsions are shown by red arrows. PKC = Protein kinase C. Figure adapted from the literature.
28
  
 
Steady-state Ras cellular localization  
 
As a result of the de/repalmitoylation cycle, H-Ras and N-Ras are mainly localized at the PM and 
at the Golgi,28 with H-Ras principally localized at the PM given its dually palmitoylation pattern. 
In contrast, N-Ras is predominantly found at the Golgi. Given the predominant K-Ras localization 
at the PM visible in Figure 1.8, the dynamic absorption/desorption mechanism presented above 
in Figure 1.7 may only be occasional or minor. However, the absence of K-Ras at the Golgi is 
consistent with the model described previously in Figure 1.5, in which K-Ras bypasses the Golgi 
to reach directly the PM. These experiments clearly show the importance of the second 
membrane anchor (either palmitate moiety or polybasic stretch) for Ras isoform localization 
given that solely prenylated Ras isoforms (H-, N-and H-Ras) localize unspecifically to all cellular 
membranes, without any distinction (Figure 1.8) 
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Figure 1.8 Subcellular Ras localization. Observation of the cellular localisation of H-Ras, N-Ras and K-Ras 
in MDCK cells cotransfected with the Golgi marker GaIT-CFP and YFP fusion of the Ras proteins. YFP = 
yellow fluorescent protein. Figure reproduced from the literature.
27
  
 
1.3.3 Ras signaling from distinct locations and pathways 
 
Over the past, cell signaling in general, including Ras signaling, was thought to be restricted to 
the plasma membrane. Recent work employing live cell imaging with genetically encoded 
fluorescent probes to visualize GTP-bound Ras, have pointed out that Ras signaling indeed is not 
limited to the PM, with signals generated from the Golgi as well as from various additional 
signaling platforms (endosomes, mitochondria and endoplasmic reticulum).28,32-38 Recently, Ras 
signaling from the PM was shown to be coupled to Ras signaling events occurring at the Golgi 
through the Ras de/repalmitoylation cycle.  
 
Signaling on the PM through the MAPK pathway 
 
Upon external epidermal growth factor (EGF) stimulus, EGF receptors (EGRF) undergo 
conformational changes leading to their dimerization and finally to the transphosphorylation of 
their cytoplasmic tyrosine residues. Receptor phosphorylation in turn generate binding sites 
necessary for the formation of the SHC/GRB2 complex which further order the PM recruitment 
of the Ras guanine nucleotide exchange factor (RasGEFs) called SOS39 (son of sevenless). As 
described previously, subsequent SOS-mediated Ras activation occurs by stimulating the 
replacement of bound-GDP by GTP. Activated Ras:GTP finally recruit the serine-threonine kinase 
Raf to the PM whose activation by phosphorylation further activate a cascade of downstream 
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serine-threonine kinases such as MEK followed by ERK. Through the successive activation of the 
three in-line kinases Raf/MEK/ERK referred to as MAP kinases (MAPK, mitogen activated protein 
kinase),40 emitted signals access the nucleus and order the phosphorylation of transcription 
factors which further activate banks of genes required for cell proliferation (Figure 1.9). 
 
 
Figure 1.9 Schematic illustration of the MAPK signaling pathway. Upon EGF activation, PM-localized Ras 
isoforms signal through the activation of the three in-line kinases Raf, MEK and ERK. GRB2 = growth-factor 
receptor-bound protein-2 and SHC = Src homology/collagen proteins. Figure adapted from the literature.
41
  
 
Signaling on the Golgi apparatus 
 
Following the rapid and transient Ras signaling occurring at the PM upon growth factor stimulus 
(t1/2 = 2.9+/- 0.6 min), a delayed and sustained Ras signaling activity was observed at the Golgi by 
Chiu et al.32 (Δt1/2 = 13.6+/- 4.0 min). Ras activity at the Golgi is dependent on Ras retrograde 
trafficking (from the PM to the Golgi) given that inhibiting Ras depalmitoylation was associated 
to PM-restricted Ras signaling.25 To explain such signaling coupling events, EGFR activation was 
proposed42 not only to activate MAPK signaling at the PM, but also to activate phospholipase 
CPLCinvolved in the degradation of phosphatidylinositols (PI) into diacylglycerol (DAG) and 
inositol trisphosphate (InsP3). In turn, InsP3 liberates calcium (Ca
2+) necessary to activate in 
combination with DAG, the Ras GEF GRP1 (Ras guanine nucleotide-releasing protein 1). Upon 
activation, GRP1 translocates to the Golgi to activate Golgi-localized Ras proteins finally signaling 
through the MAPK Pathway. The calcium release is also responsible for the recruitment of the 
Ras GAP CAPRI (Calcium-promoted Ras inactivator) to the PM in order to inactivate Ras signaling 
occurring from the PM (Figure 1.10).  
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Figure 1.10 Schematic illustration of coupled PM and Golgi Ras signaling events. Model proposed for the 
delayed and sustained Ras-signaling occurring at the Golgi upon growth factor stimulus. Figure adapted 
from the literature.
38
  
 
1.3.4 Ras microlocalization at the plasma membrane 
 
Ras isoforms are localized into distinct microdomains38 or “signaling platforms” within the PM 
consisting either in lipid raft (liquid-ordered) and non-lipid raft (liquid-disordered) domains. Lipid 
raft membranes, rich in cholesterols and sphingolipids, contain essentially proteins harboring 
palmitate chains allowing their insertion into such liquid-ordered structures, whereas 
isoprenylated proteins were found essentially in disordered non-raft fractions.43 K-Ras with an 
isoprenyl lipid anchor was found predominantly localized in non-raft fractions (85% approx.) 
independently of its activation state. However, the PM microlocalization of N-Ras and H-Ras 
anchored by palmitoyl and isoprenyl moieties is much harder to predict. PM-localized N-Ras 
were shown44 to be preferably localized in non-raft fractions, independently of their lipid 
anchors and of their activation state.  In contrast, a dynamic equilibrium has been proposed for 
H-Ras,7 cycling between lipid raft and non-lipid raft fractions regulated by GTP loading. H-Ras 
distributes equally between raft and non-raft domains when GDP-loaded and is essentially 
localized in non-lipid raft membranes when GTP-loaded (Figure 1.11A).   
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    A      
 
   B   C 
 
Figure 1.11 Ras isoforms microlocalization within the PM. A) H-Ras and K-Ras microlocalization within the 
plasma membrane depending of their activation state. B) Schematic representation of K-Ras acidic 
microdomains generated through an electrostatic-induced phospholipids accumulation. C) Schematic 
representation of the dynamic equilibrium of H-Ras cycling between lipid raft membranes and Galectin1-
stabilized non-lipid raft membranes regulated by GTP loading. Figure modified from the literature.
38
  
 
Additionally, GTP-bound Ras isoforms are thought to be localized into distinct microdomains 
within liquid-disordered fractions.7 K-Ras is believed to generate an acidic microdomain by 
attracting phospholipids composing the PM through electrostatic interactions with its polybasic 
stretch (Figure 1.11B). H-Ras is thought instead to generate a Galectin 1 enriched microdomain 
upon activation thereby stabilizing Ras active form (Figure 1.11C).  Such segregation within the 
plasma membrane is likely to complexify Ras signaling occurring at the PM by the generation of 
various and distinct signals.  
 
1.4 Ras as a molecular target for antitumor drugs 
 
Ras has been regarded as an attractive anti-cancer target given its central role in cell signaling 
pathways controlling cell proliferation  (MAPK or Ras/PI3K/Akt), often disregulated in cancer due 
to activating mutations of constituting effectors.  For example, Ras mutations are responsible for 
33% of all cancers. Therefore, many approaches regarded as “signal transduction therapies” 
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were developed.45 Among such approaches presented in Figure 1.12, targeting Ras membrane 
anchoring and localization for example represent an attractive approach to affect aberrant 
oncogenic Ras signaling.   
 
 
 
Figure 1.12 Targeting Ras as an attractive anti-cancer approach. Overview of the four principal 
approaches developed to target oncogenic Ras signaling, consisting in targeting either Ras gene 
expression, Ras functional regulation, Ras signaling or Ras localisation & anchoring. 
 
1.4.1 Targeting mutated-RAS gene expression 
 
Knocking down or silencing specifically mutant Ras genes may also represent a safe and effective 
anti-cancer therapy.46,47 Several methods interfering on mRNA48 to knockdown (down regulate) a 
gene have been developed such as the antisense oligonucleotides (ODNs) and the small 
interfering RNAs technology (siRNA). The first ODNs drug to enter clinical trials was the 20-base 
antisense oligonucleotide ISIS 2503 targeting H-Ras gene; however its application as anti-cancer 
agent remained limited due to toxicity. In contrast, the gene silencing method siRNA 
demonstrated many advantages over the use of antisense oligonucleotides such as a higher 
efficiency, stability and reduced toxicity49,50 and is therefore considered as a promising strategy 
for the treatment of cancers involving Ras mutations. Recently, siRNA knockdown of oncogenic 
Ras-gene (K-,H-,N-RAS) revealed of therapeutic interest, exemplified by a reduced human 
ovarian cancer growth51 when targeting H-Ras, a reduced pancreatic52 and lung53 cancer growth 
when targeting K-Ras or an induced apoptosis in human melanoma cells54 when targeting N-Ras. 
Although improvements in delivery methods have provided cell permeability to negatively 
charge macromolecules, the development of gene cancer therapy remained challenging and 
therefore limited.  
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1.4.2 Targeting Ras functional regulation  
 
An alternative approach to selectively block oncogenic Ras signaling may be to target Ras 
functional regulation. Ras proteins regarded as molecular switches offer the possibility to be 
artificially turned “off” either by stimulating Ras GTPase activity or by inhibiting their activation 
by GEFs. The first approach consisting in developing GTPase inducers remain challenging given 
the difficulty to create in a possibly reduced active site (due to possible mutations on Gly12 
and/or Gly13) suitable hydrogen-stabilizing interactions to allow the GTPase reaction. Therefore, 
a more feasible approach has consisted in the development of interfacial inhibitors to prevent 
the formation of the Ras:GDP–RasGEFs complex necessary for an efficient Ras activation. 
Recently, the crystal structure of Ras in complex with the RasGEFs SOS was solved by Boriack-
Sjodin et al.,55 highlighting regions in the interface essential for the complex assembly called 'hot 
spot', which therefore constitute excellent target for the development of such molecule (Figure 
1.13A). To date, no interfacial inhibitor targeting any Ras:GDP-RasGEFs complex has been 
reported, however the proof of concept was provided with Brefeldin A (BFA) shown to inhibit Arf 
activation by binding at the Arf:GDP - ArfGEFs complex interface (Figure 1.13B).56,57 
 
A B 
 
 
 
Figure 1.13. Targeting Ras functional regulation for the treatment of Ras-related cancers. A) 
Representation of Ras in complex with SOS showing interfacial regions essential for the complex assembly 
('hot spot'), and the binging site for GTP (circled region). B) Structure of the interfacial inhibitor Brefeldin A 
(BFA), binding at the interface of the Arf:GDP–ArfGEFs complex. Figure modified from the literature.
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1.4.3 Targeting Ras signaling pathways  
 
Given the central role of Ras signaling in the control of cell growth, differentiation and apoptosis, 
effort have been focused in targeting aberrant Ras signaling by two distinct approaches 
consisting either in the inhibition of specific kinase receptors/effectors involved in such 
pathways or in disrupting interactions of activated Ras with its downstream effectors.  
 
Inhibitors of kinase receptors/effectors  
 
Various inhibitors of kinases involved in Ras signaling pathways have entered clinical trials, 
exemplified by inhibitors targeting both upstream regulators of Ras, such as growth-factor 
receptor, and downstream effectors, such as the components of the MAPK pathway. The 
number of kinase receptor/effector drug candidate developed attests on the excitement 
surrounding the inhibition of the signaling cascades controlled by Ras such as the MAPK and 
Ras/PI3K/Akt pathways, frequently altered in cancers (Figure 1.14). 
 
 
Figure 1.14 Targeting oncogenic Ras signaling by inhibition of kinase receptors/effectors. Development 
of kinase inhibitors to block respectively the MAPK and Ras/PI3K/Akt pathways frequently altered in 
cancers. PI3K= phosphatidylinositol 3-kinase. Figure adapted from the literature. 
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Epidermal growth factor receptor (EGFR) overexpression or mutational activations are 
commonly seen in various cancers, thus resulting in a persistent Ras activation. In this context, a 
number of EGFR kinase inhibitors were developed,59 such as Gefitinib (Iressa®, ZD1839, 
AstraZeneca Inc), FDA-approved in 2005 for the treatment of non-small cell lung cancer (NSCLC) 
leading to its worldwide commercialization.  In addition, several antibody drugs were developed 
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exemplified by the fully humanized monoclonal antibody Panitumumab (Vectibix®, ABX-EGF, 
Abgenix Inc) FDA-approved in 2006 for the monotherapy treatment of chemotherapy-refractory 
metastatic colorectal cancer. By binding to the EGFR extracellular domain, such anti-body inhibit 
EGFR activation by EGF thereby promoting receptor internalization and down regulation. Despite 
their considerable success, the use of anti-bodies remains limited given their high production 
cost compared to small-molecule inhibitors, which complicate their clinical evaluation.  
 
Many drugs targeting Ras downstream effectors were developed including various MEK 
inhibitors such as PD 9805960 and U0126, which have been extensively used to study the MAPK 
pathway. In this context, PD184352 renamed CI-1040 was discovered as the first MEK inhibitor 
with an in-vivo activity in cancer mouse model61 and as the first MEK inhibitor to enter clinical 
trials (clinical trials terminated in phase II for solubility and degradation issue).62,63 Subsequently, 
additional MEK inhibitors were developed such as PD32590164, optimized from CI-1040 with 
several polar hydroxylamine side chains which enter clinical trials for the treatment of advanced 
breast cancer, colon cancer and melanoma, but failed in phase II due to toxicity. Additionally, the 
Raf kinase has been regarded as an attractive therapeutic target given the strong implication of 
B-Raf mutations in carcinogenesis. In this context, the Raf kinase inhibitor BAY 43-9006 was 
shown to prevent tumor growth by inhibiting not only the MAPK pathway, but also angiogenesis 
(blood vessel growth) by targeting the receptor tyrosine kinases VEGFR (Vascular Endothelial 
Growth Factor Receptor) and PDGFR (Platelet Derived Growth Factor Receptor). As a result, the 
tosyl salt derived from BAY 43-9006 called Sorafenib Tosylate (Nexavar®, Bayer Pharmaceuticals 
Inc.) was FDA-approved for the treatment of advanced kidney cancers in 2005 and for liver 
cancer treatments in 2007 (Figure 1.15) 
  
 
PD 98059 U0126 CI-1040 
  
PD325901 NEXAVAR®(Sorafenib Tosylate) 
 
 
Figure 1.15 Example of MEK and ERK inhibitors developed to affect oncogenic Ras signaling. Kinase 
inhibitors used to block the MAPK and Ras/PI3K/Akt pathways which are frequently altered in cancers.   
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Given the role of the Ras/PI3K/Akt signaling pathway in cell growth and in particularly its 
frequent activation in human cancers such as in multiple myeloma,65 targeting kinase effectors 
PI3K or Akt may as well offer a valuable anti-cancer approach, including for cancers involving Ras 
mutations. 
 
Interfering with RAS:GTP – effector protein interactions  
 
Given the direct interaction of activated Ras with the downstream effectors Raf and PI3K, and 
the essential role of MAPK and PI3K/Akt signaling pathways for cell proliferation, disruption of 
such protein–protein interactions has been regarded as an alternative anti-cancer approach 
(Figure 1.16).  
 
Figure 1.16 Disrupting the interaction of activated Ras with its direct effector as an anti-cancer strategy. 
Targeting the interaction of Ras:GTP with Raf or PI3K as a relevant approach to affect MAPK and 
Ras/PI3K/Akt signaling pathways, frequently altered in cancers.  
 
Classically, designing interfacial inhibitors was referred as challenging given a typically large 
(1000 – 5000 Å2) and flat interface without well-defined binding pockets as found in enzyme 
active sites.  However, X-Ray crystallography has allowed the detection of small region of 
residues in the complex interface crucial for the complex assembly referred to as 'hot spot’, 
suggesting the possibility to inhibit specifically protein/protein interactions with relatively small 
molecules. Given a close homology between Ras and Rap1A, with a strictly conserved effector 
region (residue 32-40) at their interface with RafRBD,66,67 the Rap1A-RafRBD complex68 was used 
as a mimic of the Ras-RafRBD complex to design Ras:GTP-Raf interfacial inhibitors (Figure 1.17A). 
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Figure 1.17 Guideline for the development of Ras:GTP-Raf interfacial inhibitors. A) Representation of the 
Rap1A-RafRBD complex used as a mimic of the Ras-RafRBD complex. B) Structure of Sulindac sulfide, an 
interfacial inhibitor of the Ras-RafRBD complex. RBD=Ras binding domain. Figure modified from the 
literature.
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In this context, several small peptides69,70 derived from the Ras binding domain of Raf were 
designed and were shown in-vitro to inhibit the association of Ras:GTP with Raf (IC50 = 7µM) 
thereby inhibiting Ras-induced signaling. To overcome solubility issues encountered with 
peptide-drugs, efforts to develop small molecules instead have lead to Sulindac sulfide (Figure 
1.17B),71 a weak interfacial inhibitor of the Ras:GTP-Raf complex. More recently, the small 
molecule MCP172 was shown to inhibit Ras signaling through the inhibition of Ras/Raf 
interactions in human cancers and to reverse Ras-transformed phenotypes in HT1080 and Ras-
transformed NIH 3T3 cells. MCP1 was also found highly active in human cancers harboring K-Ras 
mutations thereby providing a real proof of concept. In addition, disrupting the Ras:GTP-PI3K 
complex by creating mutation points into PI3K gene was shown to reduce significantly Ras-
induced lung tumor formation.73 
 
 
1.4.4 Targeting Ras localization and membrane anchoring    
 
Given the importance of Ras correct localization and membrane anchoring for its biological 
function, targeting either Ras post-translational modifications (isoprenylation, post-
isoprenylation, palmitoylation) or Ras de/repalmitoylation cycle at the level of depalmitoylation, 
may represent an attractive approach to disrupt aberrant oncogenic Ras signaling (Figure 1.18).  
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Figure 1.18 Targeting Ras localization and membrane anchoring to affect oncogenic Ras signaling. 
Developed strategies consisting either in targeting Ras isoprenylation, Ras post-isoprenylation, Ras 
palmitoylation or Ras depalmitoylation. RCE1= Ras Converting Enzyme 1, ICMT= isoprenylcysteine carboxyl 
methyltransferase, APT1=acyl-protein thioesterase 1, PATs= protein acyl transferases. 
 
Isoprenylation inhibition 
 
Given the importance of the isoprenyl group (farnesyl or geranylgeranyl group) for Ras biological 
activity through its membrane anchoring, targeting isoprenylation either by inhibiting the 
synthesis of the isoprenylation substrates or by inhibiting the enzymes involved in such 
lipidation process (farnesyltransferase/ geranylgeranyltransferase) represent an attractive anti-
cancer approach. One strategy has consisted in the inhibition of the mevalonate pathway 
essential for the synthesis of the prenylation substrates farnesyl diphosphate (FPP) and 
geranylgeranyl diphosphate (GGPP). In this context, statins were first developed as HMG-CoA 
reductase inhibitors. Given their excessive toxicity, aminobisphosphonates were subsequently 
developed to inhibit the two enzymes isopentenyl diphosphate isomerase (IPPI) and farnesyl 
diphosphate synthase (FPP synthase), however, anti-cancer applications revealed very limited.   
 
Subsequently, FTase inhibitors (FTIs) and GGTase inhibitors (GGTIs) were developed either as 
substrate mimetics, as CAAX peptidominetics or as combined substrate/CAAX mimetics. The 
significant FTIs–induced inhibition of H-Ras farnesylation without apparent toxicity, have lead to 
the development of various FTIs inhibitors. However, FTIs treatments were found to be 
ineffective on N-Ras and K-Ras given their ability to cross-prenylate (alternative prenylation) 
leading to their persistent membrane anchoring and therefore signaling. Given the strong 
implication of K-Ras and N-Ras in carcinogenesis (>99% of all Ras-mutated tumors), alternative 
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approaches were investigated such as the use of GGTI’s either as single agent or in association 
with FTIs for toxicity issues. Finally, dual prenylation inhibitors (DPIs) consisting in simultaneous 
GGTase inhibitors (GGTIs) and FTase inhibitors (FTIs) were developed such as AZD3409 shown to 
inhibit tumor growth in-vivo without any toxicity. Although farnesylation is an obligatory first 
step in Ras post-translational modification, to date, success of therapies targeting Ras 
isoprenylation are very modest (Figure 1.19).   
 
 
Figure 1.19 Targeting Ras isoprenylation. Two main strategies developed consisting either in targeting the 
Mevalonate pathway involved in the synthesis of the isoprenyl substrate (GPP and GGPP) or in targeting 
the enzymes FTase or GGTase catalysing Ras isoprenylation. HMG-CoA=3-hydroxy-3-methylglutaryl 
coenzyme A, DMAPP= Dimethylallyl diphosphate, IPP= Isopentenyl diphosphate, IPPI= Isopentenyl 
diphosphate isomerase, GPP= Geranyl diphosphate, FPP= Farnesyl diphosphate, GGPP= Geranygeranyl 
diphosphate, FTase = Farnesyltransferase, GGTase= Geranylgeranyl transferase. Figure modified from the 
literature.
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Post-isoprenylation inhibition (ICMT, RCE1) 
 
Given an induced cytosolic Ras mislocalization with a complete loss of activity upon RCE1 or 
ICMT delection, targeting post-isoprenylation has emerged as an attractive strategy to affect 
oncogenic-Ras signaling, especially given that such approach by affecting both 
geranylgeranylated and farnesylated Ras proteins would overcome Ras cross-prenylation 
problem encountered with FTIs. However, RCE1 inhibition revealed to have even weaker effects 
than FTI’s monotherapies and ICMT inhibition was found to affect multiple pathways besides 
Ras. Although several ICMT inhibitors entered clinical trials, their evaluation was generally 
confronted to their excessive toxicity due to their low selectivity.  
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Palmitoylation inhibition   
 
Given the importance of the palmitate lipid anchor for the correct Ras cellular localization and 
signaling, targeting Ras palmitoylation may define a new class of anti-cancer agents. In this 
context, a first approach has consisted in a global inhibition of protein palmitoylation by 
inhibiting palmitic acid biosynthesis. Such strategy was shown to induce Ras mislocalization and 
loss of activity with a severe toxicity due to various off targets.75 The alternative approach 
consisting in targeting the enzyme(s) catalysing Ras palmitoylation referred to as protein 
acyltransferases (PATs), has been rarely investigated given the high controversy and questioning 
around such enzymes. To date only two Ras protein acyltransferase inhibitors have been 
reported (Figure 1.20).   
 
  
CERULENIN  
Figure 1.20 Targeting Ras palmitoylation. Structure of the two reported PAT inhibitors developed in order 
to inhibit protein acyltransferases involved into Ras palmitoylation. Cerulenin as a well established PAT 
inhibitor.  
 
Cerulenin was the first established palmitoylation inhibitor of Ras proteins and since recently of 
several additional proteins.76 The Cerulenin-induced antiproliferative effect was shown to be 
exclusively due to its ability to inhibit Ras palmitoylation (IC50= 4.5 µM) and not to its ability to 
inhibit fatty acid synthase (fas) given that some Cerulenin analogues presenting an 
antiproliferative effect were inactive against fas.77 The second PAT inhibitor presented in Figure 
1.20 inhibits the MAKP signaling pathway thereby inducing a significant anti-proliferative effect 
in various human cancer cell lines (with IC50 values typically in the low μM range).
78 
 
Depalmitoylation inhibition  
 
Targeting the Ras acylation cycle at the level of depalmitoylation, may offer a viable alternative 
to PAT inhibitors, as signaling down regulation rather than full inhibition would allow cell 
viability. To date, only three depalmitoylating enzymes have been described consisting in protein 
palmitoylthioesterase-1 (PPT1), acyl protein thioestease 1 (APT1) and acyl protein thioesterase 2 
(APT2). In this context, a large effort has been devoted to address their relevance to Ras 
depalmitoylation. 
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 Protein palmitoylthioesterase-1 (PPT1) 
This enzyme was isolated79 from bovine brain extract and cloned80 based on its ability to 
depalmitoylate H-Ras in-vitro. Later, it was found irrelevant to the Ras cycle due to its 
involvement in the lysosomal81 protein degradation by depalmitoylation,26 exemplified by PPT1 
mutations causing fatal lysosomal storage diseases such as infantile neuronal ceroid 
lipofuscinosis (INCL).82,83 
 
 Acyl protein thioesterase 1 (APT1) or lysophospholipase 1 (LYPA1) 
This enzyme is a 25-kDa cytosolic84 acylhydrolase lysophospholipase 1 (LYPA1), isolated from rat 
liver 85 and pig stomach.86 First described as a lysophospholipase,85,87 LYPA1 was subsequently 
renamed as acyl protein thioesterase-1 (APT1) given its stronger depalmitoylation activity over 
lysophospholipase activity demonstrated by Duncan and Gilman.84 In 2000, the crystal structure 
of human acyl protein thioesterase 1 (hAPT1) was solved88 showing a catalytic triad consisting in 
Ser114, His203 and Asp169, with Ser114 as the nucleophilic residue (Figure 1.21A). Moreover, 
hAPT1 appears to be dimeric with its active site occluded by the dimer interface suggesting the 
necessity of enzyme dissociation to interact with its substrates. Human APT1 is characterized by 
a negative potential surrounding its active site, which is a common feature among esterases and 
lipases to facilitate the expulsion of the negatively charged hydrolysis product like palmitic acid 
in the present case (Figure 1.21B).  
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Figure 1.21 Crystal structure and electrostatic potential of human APT1. A) Representation of the 
secondary structure elements of APT1 with the catalytic triad (Ser114, His203 and Asp169). B) View of the 
electrostatic potential surface of the APT1 dimer and monomer showing the negatively charged catalytic 
site occluded in the dimeric form. Positively charged regions are shown in blue and negative regions in 
red. Figure modified from the literature.
88
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APT1 depalmitoylates in-vitro a wide variety of substrates such as H-Ras proteins,84,89 various 
heterotrimeric G protein subunits,84,90 eNOs,89 RGS4,84 SNAP-23,91 Ghrelin92 and platelets.76 
This wide substrate tolerance commonly encountered with acylating and deacylating enzymes, is 
consistent with the absence of primary consensus sequences surrounding the thioacyl group for 
its recognition by APT1. APT1 seems to depalmitoylate in-vitro structurally different proteins 
from soluble proteins like eNOs to transmembrane proteins like SNAP-23. However, APT1 does 
not depalmitoylate without any discrimination, exemplified by the protein Caveolin89 not 
affected by  APT1 in the conditions used for eNOs deacylation.93 Although APT1 was shown to 
depalmitoyate H-Ras in-vitro, experimental proof of its involvement in Ras depalmitoylation in-
vivo have been lacking until very recently.  
 Acyl protein thioesterase 2 or lysophospholipase 2 (LYPA2) 
This enzyme was purified from pig stomach86 and subsequently cloned.94 Human acyl protein 
thioesterase 2 revealed 66% sequence identity with hAPT1, with in particular a conserved 
catalytic triad. In analogy to APT1, its close homologue APT2 has a highly conserved amino acid 
sequence between various species (mouse, rat, human).95 The crystal structure of APT2 is very 
similar to the structure of APT1 as shown by the superposition of their respective crystal 
structures (Figure 1.22A). In addition, APT2 like APT1 is dimeric with its catalytic site occluded by 
the dimer interface (Figure 1.22B)  
 
 
Figure 1.22 Superposition of human APT1 and human APT2 crystal structures. A) Crystal structure 
overlay of APT1 and APT2 monomers. Green = hAPT2, blue = hAPT1 B) Crystal structure overlay of APT1 
and APT2 dimers, showing their catalytic site occluded by the dimer interface. Green/red = hAPT2, blue = 
hAPT1. Work by Marco Bürger. 
 
 
In contrast, significant differences are visible between APT1 and APT2 in their electrostatic 
potentials at the proximity of their active sites, with APT2 significantly more hydrophobic in 
comparison to APT1 (work by Marco Bürger, Figure 1.23).  
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Figure 1.23 Comparison of human APT1 and human APT2 electrostatic surface potentials. A) View of the 
electrostatic potential surface of the hAPT1 monomer. B) View of the electrostatic potential surface of the 
hAPT2 monomer. Positively charged regions are shown in blue and negative regions in red. Work by 
Marco Bürger. 
 
 
Recently, an increased depalmitoylation rate of GAP-43 (growth-associated protein 43) was 
observed in cells overexpressing APT2, suggesting that APT2 may be involved in GAP-43 
depalmitoylation whereas no effect was observed in cells overexpressing APT1.96 Using the same 
approach, the authors suggested the involvement of APT2 in H-Ras depalmitoylatation.96 Earlier 
experiments already suggested the involvement of second enzyme in Ras depalmitoylation given 
that H-Ras depalmitoylation proceeded normally in yeast strains where the APT1 gene was 
disrupted.90 However, experimental proof of the involvement of APT2 in Ras depalmitoylation in 
vivo, are still lacking. 
 
1.5 APT1 as a Ras depalmitoylating enzyme in vivo  
 
1.5.1 Palmostatin B as a potent APT1 inhibitor 
 
Given the widely conserved character of APT1,84 the ‘Protein Structure Similarity Clustering’ 
(PSSC) approach97,98 was used to develop APT1 inhibitors as tools to investigate the biological 
role of APT1 and in particular its relevance to Ras depalmitoylation. The PSSC approach has 
permitted the identification of gastric lipase as structurally similar to APT1 in their binding sites, 
especially in terms of subfold and in the orientation of their catalytic residues (Figure 1.24A). The 
known gastric lipase inhibitor tetrahydrolipstatin (generic name Orlistat)99 was therefore used 
for the design of APT1 inhibitor candidates harboring an electrophilic -lactone core for the 
nucleophilic attack of APT1 in analogy to gastic lipase inhibition (Figure 1.24B). 
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Figure 1.24 Design of palmostatin B based on a PSSC approach. A) Overlay of the ligand-sensing cores of 
gastric lipase (orange) and APT1 (green) with a similar orientation of their catalytic residues. B) Design of 
-lactone APT1 inhibitors based on the gastric lipase inhibitor tetrahydrolipstatin (orlistat) containing a -
lactone core. Figure reproduced from the literature.
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In-vitro screening for APT1 inhibition using a colorimetric assay have led to the development of 
potent -lactone APT1 inhibitors termed palmostatins comprising palmostatins A, B, C and D, 
among which the (S,S)-trans configured inhibitor palmostatin B was the most potent (Figure 
1.25).25 The advantage of the PSSC approach is clearly shown here given that classical 
approaches would not have allowed a correlation between gastric lipase and APT1 given their 
low sequence identity.  
 
Figure 1.25 Evaluation of palmostatin A,B,C and D as APT1 inhibitors. IC50 values were obtained by 
employing a colorimetric assay using para-nitrophenyl octanoate (PNPO) as substrate (APT1 = 75nM, 
PNPO= 600µM, 30 min. inhibitor pre-incubation). 
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1.5.2  Investigation of the biological role of APT1 in-vivo  
Recently, the first in-vivo evidence of APT1 as a G depalmitoylating enzyme was provided by 
studies conducted in neurons.100 To address the biological role of APT1 in Ras depalmitoylation, 
in-cellulo experiments were performed with the cell permeable palmostatin B.25 Palmostatin B 
induces a random redistribution of palmitoylated Ras isoforms to all cellular membranes 
comparable to that of solely farnesylated Ras proteins. Moreover, by inhibiting Ras 
depalmitoylation, Ras retrograde trafficking from the PM to the Golgi was affected thereby 
resulting in a quasi PM restricted Ras signaling. Palmostatin B uncouples Ras signaling events 
occurring normally between the PM and the Golgi. Additionally, upon palmostatin B treatment, 
a partial phenotypic reversion was induced in H-RasG12V-transformed MDCK-F3 cells with 
restoration of E-cadherin expression at the cell-cell interfaces, whereas K-RasG12V-transformed 
MDCK-F3 cells were unaffected. Recent proteomic analyses have suggested that the cytosolic 
APT1 is itself palmitoylated therefore providing a means for it to access its membrane-localized 
substrates.101 This model was further completed by a prolyl isomerase FKBP12 which may 
promote H-Ras depalmitoylation through the formation of a complex with PM-localized 
palmitoylated Ras isoforms thereby rendering the thioester bond more accessible for the 
membrane associated thioesterase APT1. 102 However, this model well may be modified in the 
future when addressing the relevance of APT2 to Ras depalmitoylation in vivo (Figure 1.26). 
 
 
 
 
 
Figure 1.26 Ras depalmitoylation possibly facilitated by APT1 palmitoylation and FKBP12. Recently 
proposed model of the de/repalmitoylation cycle with FKBP12 binding to PM-localized Ras isoforms to 
facilitate their depalmitoylation by plasma membrane anchored APT1proteins. Figure modified from the 
literature. 
102
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2 Results and discussion  
2.1 Fluorescent enzymatic assay for APT1 inhibition 
2.1.1 Fluorescent coumarin reporter dyes 
 
Extensive efforts in targeting the Ras depalmitoylating enzyme APT1 have led to the 
development of a colorimetric assay measuring the release of para-nitrophenolate from para-
nitrophenyl octanoate (PNPO), used as mimic of palmitic acid thioesters.25 However, with the 
development of highly potent -lactone APT1 inhibitors, a more sensitive fluorometric assay was 
developed allowing an accurate inhibitor characterization with reduced enzyme and substrate 
amounts. 7-Hydroxy-4-methyl coumarin 1 (4-methylumbelliferone; MU) for example constitutes 
an important fluorogenic substrate used to monitor phosphatases,103,104 proteases105,106 and 
glycosidases.107-109 Its fluorinated analogue 6,8-difluoro-7-hydroxy-4-methylcoumarin  2 (6,8-
difluoro-4-methylumbelliferone; DiFMU) display improved properties, exemplified by a lower 
pKa value at 4.7 vs. 7.8, resulting in maximum fluorescence of the cleavage product over a much 
broader pH range, a higher quantum yield (0.89 vs. 0.63) and an increased photostability (5% 
bleaching vs. 22% bleaching after 33 min. of illumination at the wavelength of maximal 
absorption).110 Encouraged by the use of 6,8-difluoro-4-methyl umbelliferyl octanoate 3 
(DiFMUO) to monitor lipase activity (Candida antarctica Lipase B and its mutants),111 DiFMUO 
was chosen as substrate for a new fluorescent enzymatic assay for APT1 inhibition (Figure 1.27). 
 
 
 
Figure 1.27 Coumarins used as fluorogenic substrates or as reporter system. 4-methylumbelliferone 
(MU), 6,8-difluoro-4-methylumbelliferone (DiFMU) and 6,8-difluoro-4-methylumbelliferyl octanoate 
(DiFMUO).  
 
2.1.2 Synthesis of the fluorescent coumarin substrate DiFMUO 
 
The synthesis of DiFMUO commenced with the conversion of fluorinated nitrobenzene 4 into 
3,5-difluoro-2,4-dimethoxynitrobenzene 5 using sodium methoxide (2.4 eqv.) in methanol.112 
The ortho and para directing nitro group in compound 5 accounting for the efficient fluorine 
displacement was subsequently removed in a two step sequence involving nitro group reduction 
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by hydrogenation on Pd/C leading to 1-amino-3,5-difluoro-2,4-dimethoxy benzene 6 followed by 
hydrodediazoniation with HNO2/H3PO2 leading to 1,3-dimethoxy-2,4-difluorobenzene 7 in 84% 
yield.112 Finally, compound 7 was demethylated using BBr3 in DCM for 28 hours leading to 2,4-
difluororesorcinol 8 in 92% yield.112  Fluorinated phenol derivative 8 was subsequently involved 
in a Pechmann condensation113 consisting in a acid catalysed condensation of a phenol 
derivative with a -ketoester to access the coumarin skeleton. Although several alternative 
coumarin syntheses have been reported114 (Perkin, Knoevenagel, Reformatsky and Wittig), the 
Pechmann condensation, regarded as one of the simplest and most straightforward methods, 
was first investigated. Reactions between 2,4-difluororesorcinol 8 and freshly distilled 
ethylacetoacetate have led to a relatively poor yield (10%) when performed in sulfuric acid (22 
eqv.),115 but proceeded smoothly in methanesulfonic acid (25 eqv. CH3SO3H)
110,116 leading to 
coumarin 2 in 84% yield. The lipophilic tail mimicking palmitic acid was subsequently attached to 
the coumarin by esterification117 leading to DiFMUO 3 in 64% yield over 6 steps (Scheme 1.1). 
 
 
 
Scheme 1.1 Synthesis of fluorescent DiFMUO substrate 3. Reagents and conditions: a) NaOMe (2.4 eqv.), 
MeOH, rt, 18h, quantitative. b) 10% Pd(C), H2 (10 Bar), EtOAc/EtOH 1/1, rt, 18h, quantitative. c) NaNO2 
(1.05 eqv.), H3PO2 (20 eqv.), HCl/H2O 1/2, 4°C, 21h, then rt 2h, 84% yield. d) BBr3 (3.0 eqv.), DCM, rt, 28h, 
92% yield. e) CH3COCH2COOEt (1.0 eqv.), MeSO3H (25 eqv.), rt, 28h, 84% yield. f) CH3COCH2COOEt (1.0 
eqv.), H2SO4 (22 eqv.), rt, 20h, 10% yield.  g) n-C7H15COCl (1.1 eqv.), NEt3 (1.5 eqv.), DCM, rt, 8h, 95% yield. 
 
2.2 Additional experiments with the APT1 inhibitor palmostatin B 
2.2.1 Synthesis of palmostatin B and fluorescently labeled analogue  
 
Encouraged by the effect of the APT1 inhibitor palmostatin B on oncogenic Ras signaling and to 
perform additional experiments, two grams of palmostatin B (14) were first prepared following a 
strategy previously established involving an anti-selective aldol reaction.118 The synthesis started 
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with the acylation of compound 9 (synthesized in 76 % from norephedrine by mesitylation, 
followed by N-alkylation119) with dodecanoyl chloride leading to O-dodecylated ephedrine 
auxiliary 10.120 -Hydroxyester 12 was obtained by reaction of ephedrine auxiliary 10 with 
aldehyde 11 in the presence of freshly prepared dicyclohexylborontriflate (c-Hex2BOTf).
121 
Hydrogenolysis of -hydroxyester 12 to hydroxyacid 13 followed by cyclization using 
phenylsulfonyl chloride in pyridine concluded the synthesis of palmostatin B (14) (Scheme 
1.2).122,123  
 
Scheme 1.2 Scale-up synthesis of palmostatin B 14. Reagents and conditions: a) pyridine (1.3 eqv.), 
dodecanoyl chloride (1.0 eqv.), CH2Cl2, rt, 15h, 87% yield. b) Aux 10 (1.2 eqv.), NEt3 (2.5 eqv.), c-Hex2BOTf 
(2.2 eqv.), CH2Cl2, -78°C, 2h then aldehyde 11 (1.0 eqv.), -78°C (1h) then 0°C (1h) and rt  (1h), 63% yield. c) 
Pd(OH)2/C, H2, MeOH, 40°C (30h), 72.5%  yield .d) PhSO2Cl (3.0 eqv.), pyridine, 0°C, over night, 75% yield (2 
grams obtained).  
 
Subsequently, in order to study intracellular processes, and in particular the interaction between 
palmostatin B (14) and APT1 in cells using fluorescence lifetime imaging microscopy (FLIM), a 
TAMRA-labeled palmostatin B analogue (25) was synthesized by a Cu(I)-catalyzed [3+2] dipolar 
cycloaddition124 between acetylene tagged palmostatin B (23) and the azide functionalized 
rhodamine 24. Compound 23 was prepared from aldehyde 11 in a conceptually similar strategy 
as for the synthesis of palmostatin B (14) involving an anti-selective aldol reaction118 with an O-
dodecylated acetylene tagged ephedrine auxiliary 20. The obtained -hydroxyester 21 was 
subsequently hydrogenolysed to -hydroxyacid 22, which was subsequently cyclized to -
lactone 23 using phenylsulfonyl chloride in pyridine.122,123 The synthesis of acetylenic  ephedrine 
auxiliary 20 started from 11-bromo-1-undecene 15 which was converted into 11-dodecanoic 
acid 16 by a Grignard reaction.125 11,12-Dibromododecanoic acid 17, obtained by bromination of 
compound 16,126 was subsequently used to access to the terminal alkyne 18 by double 
elimination. Using a large excess of base such as potassium hydroxide (10 eqv. in refluxing 
ethylene glycol or water or water/ethanol 1:2 or toluene) or potassium tert-butoxide (4.0 eqv. in 
dry THF at 70°C), the reaction did not lead to the desired terminal alkyne 18 but rather to 
various internal alkyne side products. However, the use of sodium amide in liquid ammonia 
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furnished 11-dodecynoic acid 18 in 96% yield, without any purification necessary.126 Treatment 
of carboxylic acid 18 with thionyl chloride in refluxing benzene furnished 11- dodecynoyl 
chloride 19 in 97% yield,127 subsequently used for the acylation of alcohol 9 leading to acetylenic 
ephedrine auxiliary 20.118 Rhodamine derivative 24 was synthesized in 83% yield by treatment of 
commercially available 5/6 TAMRA SE with 3-azidopropyl-1-amine128 (prepared in 73% yield from 
3-chloropropyl-1-amine hydrochloride and NaN3
129) in the presence of triethylamine (Scheme 
1.3).   
 
 
 
Scheme 1.3 Synthesis of tetramethylrhodamine palmostatin B analogue 25. Reagents and conditions: a) 
Mg (2.85 eqv.), Et2O, reflux, 5h then CO2, -40°C (2h), 56% yield. b) Br2 (1.2 eqv.), Et2O, -5°C (2h), 
quantitative. c) NaNH2 (5.5 eqv.), liq. NH3, THF, -45°C (4h) then -35°C (1h), 96% yield. d) SOCl2 (1.5 eqv.), 
benzene, reflux, 3h, 97% yield. e) Pyridine (1.3 eqv.), alcohol 9 (1.0 eqv.), rt (15h), 67% yield. f) Aux 20 (1.2 
eqv.), NEt3 (2.5 eqv.), c-Hex2BOTf (2.2 eqv.), DCM, -78°C, 2h then aldehyde 11 (1.0 eqv.), -78°C (1h) then 
0°C (1h), and rt (1h), 76% yield. g) LiOH.H2O (9.0 eqv.), dioxane/H2O 4/1, 40°C (90h), 87% yield. h) PhSO2Cl 
(3.0 eqv.), pyridine, 0°C, over night, 89% yield. i) Alkynylated -lactone 23 (1.2 eqv.), rhodamine azide 24 
(1.0 eqv.), sodium ascorbate (1.5 eqv.), CuSO4 (0.9 eqv.), EtOH/H2O degased, rt (16h), dark, 83% yield.  
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2.2.2 APT1 as a cellular target of palmostatin B 
 
The attachment of the bulky TAMRA fluorescent group to palmostatin B (14) may affect the 
resulting inhibitory activity due to steric hindrance. However, the chosen attachment point of 
the dye turned out to be appropriated with a weaker but still potent inhibitory effect for 
compound 25 compared to palmostatin B (IC50 (25) = 300nM, IC50 (14) = 5.37+/- 0.38 nM, 
fluorometric assay employing 5nM of enzyme). The cell permeable TAMRA-palmostatin B 
analogue 25 was employed by the Bastiaens group (Nachiket Vartak) to demonstrate the direct 
interaction between palmostatin B and APT1 in cells. Fluorescence lifetime imaging microscopy 
(FLIM) in MDCK cells expressing APT1 tagged with green fluorescent protein (APT1-GFP), 
permitted to observe a significant reduction of GFP fluorescence lifetime due to Foerster 
Resonance Energy Transfer (FRET) from APT1 tagged with green fluorescent protein (APT1-GFP) 
to the TAMRA acceptor 25.25 This distance-dependent transfer of energy proves the molecular 
proximity of the two dyes and therefore revealed APT1 as a cellular target of palmostatin B 
(Figure 1.28).  
 
 
 
 
 
Figure 1.28 APT1 as a cellular target of palmostatin B. Fluorescence lifetime imaging (FLIM) in MDCK cells 
expressing GFP-APT1 (donor) after incubation with palmostatin B analogue 25 (acceptor). A) Significant 
reduction of APT1-GFP lifetime. B) Reduction of APT1-GFP lifetime compared to a GFP-GFP control upon 
incubation with compound 25. Data from Nachiket Vartak. 
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2.2.3 Investigation on palmostatin B selectivity 
 
Further experiments were performed to investigate the selectivity of palmostatin B (14) for APT1 
by studying its inhibitory effect on additional phospholipases potentially relevant to Ras 
signaling. No inhibition of phospholipase C(PLC) could be observed in a cellular assay at 50 
µM palmostatin B concentration.25 However, the effect of palmostatin B on cytosolic 
phospholipase A2 (cPLA2), phospholipase D (PLD) and phospholipase A1 (PLA1) had to be 
addressed in relevant biochemical assays. 
 
Cytosolic phospholipase A2 (cPLA2)  
 
The evaluation of cytosolic phospholipase A2 (cPLA2) inhibition was performed using an HPLC 
assay with UV spectrometric detection as reported in the literature.130 In the assay, the final 
reaction mixture contained 0.2 mM phospholipid substrate 1-stearoyl-2-arachidonoyl-sn-
glycero-3-phosphocholine (SAPC) and 0.1 mM 1,2-dioleoyl-sn-glycerol as substrate. After 
incubation of the substrate with palmostatin B for 5 min at 37°C, cPLA2 (isolated from human 
platelets by anion exchange chromatography) was added and the mixture was incubated at 37°C 
for 60 min. The enzymatic reaction was terminated and 4-un-decyloxybenzoic acid was added to 
the sample as internal standard (IStd). Samples were measured by reverse-phase HPLC with UV 
detection at 200 nm to determine the quantity of arachidonic acid (AA, retention time at 11.7 
min) released from SAPC by cPLA2. The comparison of the peak area obtained for arachidonic 
acid (AA) in the control (no inhibitor), with the peak area of arachidonic acid (AA) in the 
palmostatin B treated sample permit to evaluate the inhibitory effect of palmostatin B on cPLA2. 
No inhibition was observed at 1 µM and 10 µM palmostatin B (14) concentrations. A known 
cPLA2 inhibitor was used to validate the assay and all activity measurements were performed in 
triplicate (Figure 1.29). 
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Sample name AA  Area IStd Area Average (AA/IStd) 
(AA/IStd) 
Std (AA/IStd) cPLA2 residual 
activity Negative 
control 
687673 476703 1,430579 0,076071 100+/- 5% 
PALMB 10  µM 699027 490699 1,434876 0,038552 100+/- 2% 
PLA2 inhibitor   392885 479828 0,818803 - 56.6 % 
Figure 1.29 Investigation of cytosolic phospholipase A2. HPLC analysis showing the amount of 
arachidonic acid (AA) released from 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (SAPC) by 
cPLA2. A) In absence of inhibitor (negative control). B) In presence of palmostatin B (10 µM). C) In 
presence of a known cPLA2 inhibitor at 33 nM (positive control). D) HPLC analysis of the substrate SAPC 
used in the assay ensuring the absence of disturbing peak in the area of the AA peak (t = 11.7 min). E) 
Evaluation of cPLA2 remaining activity by comparison of the ratio AA/IStd between positive controls (no 
inhibitor), and in presence of 10 µM palmostatin B (14). Std = Standard deviation.  
 
Phospholipase A1 (PLA1)  
 
PLA1 inhibition was monitored directly using the EnzChek® Phospholipase A1 substrate (PED-A1) 
which is a dye-labeled glycerophosphoethanolamine with BODIPY® FL dye-labeled acyl chain at 
the sn-1 position and dinitrophenyl quencher-modified head group. The BODIPY® FL pentanoic 
acid entity is released by cleavage of the substrate by PLA1 in the sn-1 position leading to an 
increased fluorescence. The assay developed with MDCK-F3 cell lysates as PLA1-containing 
sample, was validated by using a bacterial recombinant PLA1 enzyme. After incubation of the 
inhibitor/DMSO with MDCK-F3 cell lysate for 2 min. at 37oC, PLA1 substrate (PED-A1) was added 
and the increase of fluorescence measured over time. The remaining PLA1 activity after 
palmostatin B treatment (1 µM, 10 µM and 50 µM) was determined by linear regression 
analyses (r2 ≥ 0.98) of the fluorescence emission increase over time. The background reaction 
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rate with no enzyme present was subtracted and reaction rates were normalized to the reaction 
rate with no inhibitor present (100%). Figure 1.30 shows the curves obtained for PLA1 inhibition 
showing 75+/-4% PLA1 remaining activity at 50 µM palmostatin B, 88+/-3% PLA1 remaining 
activity at 10 µM palmostatin B, and no inhibition at 1 µM palmostatin B (Z’ = 0.90).  
 
Figure 1.30 Investigation of phospholipase A1. Typical activity curves obtained for PLA1 activity 
respectively at 1 µM, 10 µM and 50 µM palmostatin B concentration.  
 
 
Phospholipase D (PLD)  
 
PLD inhibition was monitored indirectly using the Amplex Red reagent (10-acetyl-3,7-
dihydrophenoxazine), a sensitive fluorogenic probe for H2O2. First, PLD cleaves the 
phosphatidylcholine (lecithin) substrate yielding choline and phosphatidic acid. Second, choline 
is oxidized by choline oxidase to betaine and H2O2. Finally, H2O2 in the presence of horseradish 
peroxidise reacts with Amplex Red reagent in a 1:1 stoechiometry to generate the fluorescent 
product, resorufin. The assay was developed with MDCK-F3 cell lysates as PLD-containing sample 
and was validated by using a bacterial recombinant PLD enzyme. H2O2 was used as second 
positive control of the reporter system. After incubation of the inhibitor/DMSO with MDCK-F3 
cell lysate for 2 min. at 37oC, Amplex Red reagent was added as a solution in buffer containing 
HRP, choline oxidase and lecithin and the formation of fluorescent resorufin was recorded over 
time. The remaining PLD activity after palmostatin B treatment (50 µM) was determined by 
linear regression analyses (r2 ≥ 0.98) of the fluorescence emission increase over time. The 
background reaction rate with no enzyme present was subtracted and reaction rates were 
normalized to the reaction rate with no inhibitor present (100%). No inhibition of PLD was 
observed at 50 µM palmostatin B (Figure 1.31).  
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Figure 1.31 Investigation of phospholipase D. No inhibition of PLD by palmostatin B at 50 μM. Typical 
curves for PLD activity at 50 μM palmostatin B. Data based on three independent experiments (Z’= 0.95).  
 
 
2.3 2nd generation of -lactone APT1 inhibitors based on natural substrates  
 
2.3.1 Design based on natural substrate considerations  
 
Subsequently to the discovery of palmostatin B, a 2nd generation of trans -lactone inhibitors 
was designed based on structural similarity with the native APT1 substrates lysophospholipid 
and H-Ras C-terminus presenting common recognition motifs such as an electronegative group 
at a distance of five to six bonds from a (thio)ester functionality and an electropositive tail at ten 
to twelve bonds distance (Figure 1.32A). These considerations led to a proposed assembly 
consisting in a (thio)ester, phosphate and dimethylamino group subsequently replaced by a -
lactone, sulfone and dimethylamino group preferred for convenient synthesis. The sulfone and 
amino group containing fragment was fused using a variable spacer to a trans -lactone core and 
a lipophilic tail mimicking palmitic acid, which served well for palmostatin B (14), was introduced 
on the opposite side of the -lactone core to create affinity for the enzyme lipid-binding pocket. 
The inhibitor design was further evaluated in silico (Steffen Renner), showing strong hydrogen 
bond stabilizing interactions in the APT1 active site at polar residues glutamine Q114 and leucine 
L25, with the inhibitor covalently bound to the nucleophilic residue serine S114. Moreover, polar 
head groups (sulfone and dimethylamino groups) were shown to create additional electrostatic 
stabilizing interactions with the threonine T28 and histidine H203 residue of two different APT1 
monomers. Such interactions were therefore thought to enhance the inhibitory activity by 
stabilizing APT1 under a dimerized inactive form with an active site no longer accessible (Figure 
1.32B). Based on these criteria, a small focussed library of three series of inhibitors denoted A-C 
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was synthesized by C. Hedberg and F. Dekker with variation in spacer length for optimal 
hydrogen bond stabilizing interactions in the enzyme active site. 
A B 
 
 
 
Figure 1.32 Design of 2
nd
 generation -lactone inhibitors. A) Design based on natural substrate 
considerations. B) Docking studies showing the postulated importance of polar head groups (-SO2 and –
NMe2) to stabilize APT1 under an inactive dimerized form via hydrogen bond stabilizing interactions at 
residue T28 and H203.   
 
2.3.2 IC50 re-evaluation of the-lactone library 
 
 
The complete -lactone library, previously screened for APT1 inhibition by C. Hedberg and F. 
Dekker using the colorimetric assay after 30 min pre-incubation, revealed a significantly higher 
inhibitory effect of (S,S) -lactone inhibitors over (R,R) -lactone inhibitors. IC50 values of the 
more potent (S,S) -lactone inhibitors were subsequently re-evaluated employing the developed 
fluorometric assay after 2 min. incubation time, revealing a slow enzyme reactivation. The 
maximal APT1 inhibition was visualized typically after 5 min. measurement time, after which the 
enzyme starts to be reactivated. The slope after 5 min. measurement was used for the 
calculation leading to significantly improved IC50 values generally 100 folds lower as the values 
determined earlier (Figure 1.33). Results obtained using the two assays were consistent as 
shown by the comparison of Figure 1.33A with Figure 1.33B, with an invariable superiority of 
lactones with a spacer length of 4-5 carbons and a sulfone moiety (as pointed out by docking 
studies). Some IC50 values are below half of the enzyme concentration, thereby suggesting the 
stabilization of the enzyme in a dimerized form, as predicted by docking studies. Subsequently, 
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the more potent APT1 inhibitor compound 28 (IC50 = 2.13+/-0.31 nM) was chosen for additional 
in-cellulo experiments and named palmostatin M.   
A B 
  
C  
 
 
 
Figure 1.33 IC50 re-evaluation of the -lactone library. A) Graphical representation of IC50 values obtained 
for the trans -lactone (S,S) of series A, B and C (26-45) using the colorometric assay compared with 
palmostatin B (APT1 = 75 nM, PNPO= 600 µM, 30 min inhibitor pre-incubation). B) Graphical 
representation of IC50 values obtained for trans -lactone (S,S) of series A, B and C using the fluorometric 
assay compared with palmostatin B (APT1= 5 nM, DiFMUO= 15 µM, Ex/Emi.= 358/455 nm, gain= 100, 2 
min inhibitor pre-incubation time). C) Table displaying IC50 values for APT1 inhibition obtained for the 
complete trans -lactone library employing the fluorometric assay described above. Z’ factors were in all 
cases higher than 0.75. Data based on three independent experiments.  
 
2.3.3 Enzyme reactivation over time 
 
In order to monitor the enzyme reactivation, after complete APT1 inhibition ensured by a large 
excess of inhibitor, the consumption of the fluorogenic substrate DiFMUO by reactivated APT1 
was recorded over time.  The enzyme reactivation occurs through the hydrolysis of the 
covalently bound inhibitor-APT1 complex, associated with the conversion of the inhibitor to the 
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-hydroxy acid (Figure 1.34A). As a result, a significant fluorescence increase was observed over 
time in the developed biochemical assay (Figure 1.34B). 
A B 
 
 
Figure 1.34 APT1 reactivation over time. A) Inhibition of APT1 by -lactone inhibitors followed by the 
enzyme reactivation through the hydrolysis of the inhibitor-APT1 complex. B) APT1 reactivation curve 
observed after complete enzyme inhibition with an excess of palmostatin B (14).  
 
Investigation on (S,S) -lactone inhibitors from series A, B and C (26 - 35) revealed half life (t1/2) 
values  for APT1 reactivation in the range of 2 to 3 minutes. Palmostatin B (14) is also affected 
with a t1/2 value in a similar range (Table 1.1).  
 
Table 1.1 Evaluation of APT1 reactivation. Reactivation characteristics determined for (S,S) -lactone 
inhibitors (26-35) and their comparison with palmostatin B (14), with reactivation rates given in sec
-1
 and 
half-life t1/2 in minutes. 
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2.3.4 Resynthesis of the most potent inhibitors (27, Palm M 28) 
 
To further characterize the -lactone inhibitors in cell-based assays, the two most potent APT1 
inhibitors 27 and palmostatin M (28) were chosen and re-synthesized. The synthesis commenced 
with the conversion of commercially available N,N-dimethylamino-1-propyl chloride 
hydrochloride 46 into N,N-(dimethylamino)propyl thioacetate 47 in 82% yield using thioacetic 
acid and triethylamine. Subsequent S-alkylation using iodo esters 48-49 (prepared from the 
corresponding bromo ester through a Finkelstein reaction)131 and Cs2CO3 furnished amino ethyl 
esters 50-51. Reduction of esters 50-51 to alcohols 52-53 followed by Swern oxidation yielded 
aldehydes 54-55 (Scheme 1.4).  
 
 
Scheme 1.4 Synthesis of aldehyde spacers 54 (n= 3) and 55 (n=4). Reagents and conditions: a) AcSH (1.2 
eqv.), NEt3 (3.0 eqv.), CHCl3, reflux, 18h, 82%. b) Cs2CO3 (1.1 eqv.), EtOH, reflux, 2.5h, iodoester 48 or 49 
(1.1 eqv.), 40°C (18h), 92% (50, n=3), 97% (51, n=4). c) LiAlH4 (1.25 eqv.), THF, 0°C (1h) then rt (2h), 91% 
(52, n=3), 93% (53, n=4). d) DMSO (2.4 eqv.), oxalyl chlorid (1.1 eqv.), NEt3 (3.65 eqv.), CH2Cl2, 73% (54, 
n=3), 85% (55, n=4). 
 
Aldehydes 54-55 were involved into an anti-selective aldol reaction118 with O-dodecylated 
ephedrine auxiliary 10 in presence of dicyclohexylborontriflate and triethylamine leading to the 
aldol reaction products 56-57, subsequently oxidized to sulfones 58-59 using oxone®.132 Auxiliary 
removal from 58-59 by hydrogenolysis furnished -hydroxyacids 60-61, subsequently cyclized 
using phenylsulfonyl chloride in pyridine122,123 leading to compound 27 and 28 (Scheme 1.5).  
 
 
Scheme 1.5 Synthesis of trans lactone inhibitors palmostatin M (28) and 27. Reagents and conditions: a) 
Aux 10 (1.2 eqv.), NEt3 (2.5 eqv.), c-Hex2BOTf (2.2 eqv.), CH2Cl2, -78°C, 2h then aldehyde 54-55 (1.0 eqv.), -
78°C (1h),  0°C (2h) and rt (1h), 40% (56, n=3), 33% (57, n=4). b) Oxone® (3.0 eqv.), MeOH/H2O, rt (8h), 
91% (58, n=3), Quant. (59, n=4). c) Pd(OH)2/C, H2, MeOH, 40°C (6h), 65% (60, n=3), 77% (61, n=4). d) 
PhSO2Cl (3.0 eqv.), pyridine, 0°C, overnight, 98% (27, n=3), 92% (28, n=4). 
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2.3.5 Investigation of cis -lactone inhibitors 
 
To confirm the superiority of trans -lactones already pointed out with the palmostatins, cis -
lactone inhibitors derived from the two more potent trans -lactones palmostatin M (28) and 27 
were synthesized. Therefore, O-dodecylated ephedrine auxiliary 63 was synthesized by analogy 
to its enantiomer 10 by acylation of (1R,2S)-norephedrine derived alcohol 62 with dodecanoyl 
chloride. Both O-dodecylated ephedrine auxiliary enantiomers 10 and 63 were subsequently 
involved into a cis-selective aldol reaction with the two previously synthesized aldehydes 54-55 
in the presence of dibutylborontriflate (n-Bu2BOTf) and diisopropylethylamine (DIPEA) leading to 
cis-aldol reaction products 64-67.  -Hydroxyesters 64-67 were subsequently oxidized to 
sulfones 68-71 employing oxone®132 and the chiral auxiliary was removed by hydrogenolysis 
leading tohydroxyacids 72-75. Cyclization of 72-75 using phenylsulfonyl chloride in pyridine 
concluded the synthesis of cis -lactone inhibitors 76-79 (Scheme 1.6). 
 
 
 
Scheme 1.6 Synthesis of cis -lactone inhibitors 76-79. Reagents and conditions: a) pyridine (1.3 eqv.), 
dodecanoyl chloride (1.0 eqv.), CH2Cl2, rt (15h), 87% yield for 10, 80% yield for 63. b) Aux  10 or 63 (1.0 
eqv.), DIPEA (2.5 eqv.), n-Bu2BOTf (2.2 eqv.), CH2Cl2, -78°C (2h) then aldehyde 54 or 55 (1.2 eqv.), -78°C 
(1h), 0°C (1h), rt (1h), 36-55% yield. c) Oxone® (3.0 eqv.), MeOH/H2O, rt (8h), 92-81% yield. d) Pd(OH)2/C, 
H2, MeOH, rt (90h), 29-79% yield. e) PhSO2Cl (3.0 eqv.), pyridine, 0°C, overnight, 13-55% yield. 
 
For a comparison with their trans-homologues palmostatin M (28) and 27, cis -lactones 76-79 
were screened for APT1 inhibition under strictly identical conditions using the fluorometric 
assay. In conclusion, and consistent with IC50 values evaluated for the palmostatins, (R,S)-cis -
lactones 78-79 were slightly less potent compared to their (S,S)-trans diastereoisomers  27 -28, 
but far more potent than (R,R)-trans lactones 37-38 and (S,R)-cis -lactone inhibitors 76-77. 
This observation is in full agreement with the stereochemistry of the -lactone core chosen for 
the design of the 2nd generation of inhibitors using preliminary results for palmostatin A-D as 
guiding arguments.  Moreover, the configuration of the tail holding the polar residues allowing 
hydrogen bond stabilizations in the enzyme active site, was shown to be important for the 
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inhibitory activity. In contrast, the orientation of the lipid tail seems to be much more flexible as 
shown by a similar potency of compounds 27-28 and compounds 78-79 (Figure 1.35). 
 
 
Figure 1.35 Evaluation of the cis -lactones for APT1 inhibition. IC50 values for APT1 inhibition obtained 
for the cis -lactone inhibitors 76-79 compared to their trans-homoloquesusing the fluorometric assay 
(APT1= 5nM, DiFMUO= 15µM, Ex/Emi.= 358/455nm, gain= 100, 2 min inhibitor pre-incubation time), Z’ 
factors were in all cases higher than 0.75. 
 
 
2.3.6 Cellular evaluation of palmostatin M and B 
 
Phenotypic reversion in transformed MDCK-F3 cells 
 
(S,S) trans -lactones from sub-libraries A,B and C (26-35) were subjected to a back-
transformation assay (data from Claas Gerding-Reimers) in which H-RasG12V-transformed 
MDCK-F3 cells were subjected to chronic overnight incubation with a high, but non-cytotoxic 
inhibitor concentration (30 µM) to ensure that—despite inhibitor consumption through 
hydrolysis—the inhibitor concentration remained high enough to fully suppress APT1 activity. H-
RasG12V-transformed MDCK-F3 cells are characterized by a long and spindle-like phenotype 
with reduced cell-cell contact, thereby allowing their clear distinction from untransformed 
MDCK cells. Down-regulation of oncogenic Ras signaling would result in a partial phenotypic 
reversion,25 characterized by change in cell morphology (from spindle-shaped to more round-
shaped) and by the restoration of cell adhesion and cadherin expression at the cell-cell contact 
sites. Compounds from cationic sub-library B (30-32), which proved to be potent APT1 inhibitors 
in the biochemical assay, had none or minor activity in cells, possibly due their poor cell 
permeability. Nevertheless, compounds from sub-library A (26-29) and C (33-35) induce a partial 
phenotypic reversion in transformed MDCK-F3 cells among which palmostatin M (28) turned out 
to be the most potent compound. Palmostatin M was clearly superior to palmostatin B (14) 
judging by E-cadherin expression at the cell surface. Moreover, the phenoptypic reversion 
induced by Palmostatin M was comparable to the effect observed when using the MEK inhibitor 
U0126,133 a known inhibitor of the Raf/MEK/ERK signaling pathway downstream of Ras (Figure 
1.36).  
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Figure 1.36 Palmostatin M-induced phenotypic reversion of MDCK-F3 cells. A) E-cadherin immuno 
staining of HRasG12V-transformed MDCK-F3 cells showing the restoration of E-cadherin expression at the 
cell-cell interfaces (arrow-heads) after treatment with 10 M palmostatin M (28), compared to a DMSO 
control (B). C) HRasG12V-transformed MDCK-F3 cells treated with palmostatin B (14) at 50 M showing a 
similar, but weaker effect on the phenotype. D) HRasG12V-transformed MDCK-F3 cells treated with the 
known MEK-inhibitor U0126 (30 M) used as positive control. Scale bars represent 20 m. Data from 
Claas Gerding-Reimers.  
 
Influence on the MAPK signaling pathway 
 
To demonstrate that oncogenic H-Ras maintains the transformed phenotype through the 
Raf/MEK/ERK signaling pathway, the influence of palmostatin M (28) was further investigated in-
cellulo by Western blotting experiments to visualize ERK phosphorylation. Upon epidermal 
growth factor (EGF) activation, Ras is activated as Ras:GTP mediated by SHC-GRB2-SOS, thereby 
activating  the MAPK signaling pathway through phosphorylation of Raf, MEK followed by ERK. 
Therefore, Ras delocalization induced by palmostatin M (28), due to APT1-inhibition, is expected 
to affect EGF-induced Ras activity, thus leading to a visible attenuation of downstream ERK1/2 
phosphorylation. To validate this hypothesis, several Western blotting experiments were 
performed in HeLa and MDCK-F3 cells to monitor ERK1/2 activation after treatment with various 
palmostatin M (28) concentrations. A known inhibitor of the MAPK signaling pathway, U0126 
(MEK inhibitor) was used as positive control.   
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ERK blots for HeLa cells  
 
After EGF activation, the influence of palmostatin M (28) on ERK1/2 phosphorylation was 
investigated at several inhibitor concentrations and compared to a sample treated with DMSO. 
Signals for phospho ERK1/2 (Figure 1.37A) and total ERK1/2 (Figure 1.37B) were subsequently 
quantified and the ratio phospho ERK1/2/total ERK1/2 normalized to 100% using the sample 
treated with DMSO (Figure 1.37C). A non-EGF activated sample was used as negative control, 
showing as expected no induced ERK1/2 phosphorylation. A concentration-dependent effect of 
palmostatin M (28) on ERK1/2 phosphorylation was observed with an approximate 50% reduction 
of ERK1/2 phosphorylation observed at 5 µM palmostatin M concentration. The MEK inhibitor 
U0126 used as additional positive control surprisingly did not reduce ERK1/2 phosphorylation at 
30 µM concentration. Confronted with reproducibility problems and to confirm the results, 
similar experiments were subsequently performed using MDCK-F3 cells with mutated H-Ras 
(Figure 1.37).  
 
 C  
 
Figure 1.37 Palmostatin B affects MAPK signaling in HeLa cells. Western blotting experiments for ERK1/2 
phosphorylation in HeLa cells (HRP detection system) at various palmostatin M (28) concentrations (15 
µM, 10 µM, 5 µM). A) Phospho-ERK1/2 Western blotting using Supersignal® West Pico Chemiluminescent 
substrate after 2h exposure. Phospho-ERK1/2 antibody (1/10 000) in TBST 2% chocolate slimfast (overnight 
at 4°C), IgG mouse (1/20 000) in TBST (1h, rt). B) Total-ERK Western blotting using Supersignal® West Pico 
Chemiluminescent substrate after overnight exposure. Total-ERK antibody (1/1 000) in TBST 2% BSA (over 
night at 4°C), IgG rabbit (1/10 000) in TBST (1h, rt). C) Graphical representation of the effect of palmostatin 
M (28) and U0126 at various concentrations, on ERK1/2 phosphorylation. Data based on two independent 
experiments.  
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ERK blots for MDCK-F3 cells 
 
A similar protocol was followed to investigate the influence of palmostatin M (28) on MDCK-F3 
cells with mutated H-Ras. Consistent with earlier results, a concentration-dependent effect was 
observed with 50% reduction of ERK1/2 phosphorylation at 10 µM palmostatin M (28), a value in 
a similar range as observed for HeLa cells. However, due to the constitutively active character of 
Ras in this cell line, a higher reproducibility of the results was observed compared to earlier 
experiments performed in HeLa cells. ERK1/2 phosphorylation was normalized to 100% 
corresponding to the sample treated with DMSO which, given the characteristic of the cell line, 
was similar to the inactivated sample (no EGF-treated sample). Unlike in HeLa cells, the MEK 
inhibitor U0126 used as positive control reduces the Raf/MEK/ERK signaling by 30% at 30 µM 
concentration (Figure 1.38).  
 
 C  
 
Figure 1.38 Palmostatin B affects MAPK signaling in MDCK-F3 cells. Western blotting experiments for 
ERK1/2 phosphorylation in MDCK-F3 cells (HRP detection system) at various palmostatin M (28) 
concentrations (1 µM, 5 µM, 10 µM) and U0126 (30 µM, MEK inhibitor) as positive control. A) Phospho-
ERK1/2 Western blotting using Supersignal® West Femto Chemiluminescent substrate after 15 minutes 
exposure. Phospho-ERK1/2 antibody (1/10 000) in TBST 2% chocolate slimfast (overnight at 4°C), IgG mouse 
(1/20 000) in TBST (1h, rt). B) Total-ERK Western blotting using Supersignal® West Pico Chemiluminescent 
substrate after 10 min exposure. Total-ERK antibody (1/1 000) in TBST 2% BSA (overnight at 4°C), IgG 
rabbit (1/10 000) in TBST (1h, rt). C) Graphical representation of the effect of palmostatin M (28) and 
U0126 at various concentrations, on ERK1/2 phosphorylation. Data are based on three independent 
experiments. 
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Disruption of Ras trafficking between the Golgi and the plasma membrane 
 
Palmostatin M (28) would be expected to interrupt the dynamic trafficking of H- and N-Ras 
between the Golgi and the plasma membrane (PM), whereas unpalmitoylated K-Ras should not 
be affected. To validate this hypothesis, MDCK cells expressing the fluorescent protein fusion 
constructs mCitrine-N-Ras, mCitrine-H-Ras or mCitrine-K-Ras, together with an 
unpalmitoylatable mutant mCherry-H-RasC181S,C184S and a Golgi marker, were treated with 
palmostatin M  (1 M) for 3 hours (work by Nachiket Vartak). The influence of palmostatin M on 
N-, H- and K-Ras redistribution was evaluated by comparison with the solely prenylated 
unpalmitoylable H-RasC181S,C184S, known to distribute non-specifically to all membranes.134 
Palmostatin M (28) leads to a complete N-Ras mislocalization after 1 hour treatment, whereas H-
Ras enrichment at the PM was not affected on this timescale. Instead, a complete depletion of 
H-Ras from the Golgi was observed (Figure 1.39). 
 
 
 
Figure 1.39 Disruption of Ras trafficking between Golgi and PM by palmostatin M. A)left: Co-localization 
of mCitrine-N-Ras and mCherry-H-RasC181S,C184S showing palmostatin M-induced mislocalization of 
mCitrine-N-Ras after 60 min. Right: similar experiments with mCitrine-K-Ras showing no effect on 
mCitrine-K-Ras localisation after 150 min. B) Similar experiments with mCitrine-H-Ras showing a minimal 
effect on H-Ras localisation at the plasma membrane after 150 min, but a complete depletion of mCitrine 
H-Ras on the Golgi (arrows), GalT-mCerulean is a Golgi marker. C) Graph showing a faster mCitrine-N-Ras 
aspecific redistribution upon treatment with palmostatin M (28) (black) compared to treatment with 32 
(red). Data from Nachiket Vartak.  
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In addition, K-Ras localization was not affected, thereby demonstrating a specific effect of 
palmostatin M (28) on the acylation cycle. Consistent with earlier cellular evaluations, 
compound 32 from cationic sub-library B, which proved as potent as palmostatin M (28) in-vitro, 
was less effective than palmostatin M. Compound 32 induces a complete unspecific distribution 
of N-Ras after 3 hours, whereas only 1 hour is required for palmostatin M at similar 1µM 
concentration. 
 
 
2.4 Identification of additional Ras depalmitoylating enzymes 
 
2.4.1 Principle of activity-based proteome profiling (ABPP)  
 
To confirm APT1 as a cellular target and to potentially identify additional target proteins relevant 
to the Ras cycle, in-cellulo activity-based proteome profiling (ABPP) experiments were 
performed using cell permeable ABPP pull down probes derived from palmostatin B and 
palmostatin M. In ABPP experiments, reactive chemical probes derived from active small 
molecules are employed to covalently bind to a nucleophilic residue of inhibited enzymes via an 
electrophilic group, thereby allowing the identification of target proteins. -lactone ABPP probes 
have already served as useful tools for ABPP experiments conducted on bacterial,135,136 plant,137 
as well as mammalian proteomes.138 Figure 1.38 describes the chemical proteomic strategy 
employed for in-cellulo labeling experiments. Cells were first incubated with cell permeable 
alkyne probes allowing their covalent binding to their target proteins through their reactive -
lactone groups. After cell lysis, target proteins were tagged through Cu(I)-catalyzed Huisgen 
[3+2]-cycloaddition with a trifunctional fluorescent reporter group such as a biotin-rhodamine-
azide construct allowing their enrichment using biotin/streptavidin affinity. After separation by 
SDS-gel electrophoresis, target proteins were detected by fluorescence read-out and were 
digested with trypsin to allow their identification by mass spectrometry (Figure 1.40). 
 
Figure 1.40 Principle of in-cellulo ABPP labeling experiments. After incubation with a cell permeable -
lactone probe, cells are lysed and target proteins subsequently fluorescently tagged by click ligation. In-gel 
fluorescence scanning, allow the visualization of the target proteins, subsequently identified by mass-
spectrometry.  Ligand = tris((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)amine.  
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2.4.2 Design of cell permeable ABPP probes  
 
Given the improved efficiency of alkyne-ABPP probes over azide-ABPP probes pointed out by 
Sieber and co-workers, several cell permeable ABPP-alkyne probes derived from palmostatin B 
and M were designed and synthesized. Subsequently, in cellulo labeling experiments were 
performed to clarify whether APT1 is the only Ras depalmitoylating enzyme or whether 
palmostatin B and M target additional proteins relevant to the Ras cycle, in particular the closely 
related isoenzyme APT2. The palmostatin B analogue 23 with an alkyne functionality embedded 
in its lipid chain, previously used for the synthesis of fluorescently labeled palmostatin B (25) was 
an obvious ABPP probe candidate. The compound 23 was subsequently validated as suitable pull 
down probe given its APT1 inhibitory activity similar to that of palmostatin B (Scheme 1.7A). An 
attractive approach for the synthesis of a palmostatin M derived probe could be the attachment 
of the alkyne functionality directly on palmostatin M through quarterisation of the amino 
functionality. However given that compounds from cationic sub-library B (30-32), which were 
potent APT1 inhibitors in-vitro, had only weak activity in cellular assays, such probes may 
therefore be inappropriate for in-vivo labeling experiments, possibly due cell permeability issues. 
Instead, two regioisomeric palmostatin M-derived ABPP probes (83 and 94) were designed and 
synthesized with an alkyne group introduced at opposing sites of the molecule to maximize the 
accessibility of the alkyne group for the Cu(I)-catalysed [3+2]-cycloaddition, when covalently 
bound into enzyme active sites. The two ABPP probes 83 and 94 turned out to be as potent as 
palmostatin M (28) for APT1 inhibition using the fluorometric assay, therefore constituting 
suitable pull down probes to target APT1 in cellulo (Scheme 1.7). 
 
Scheme 1.7 Design of suitable ABPP alkyne probes. A) Design of palmostatin B-derived probe 23 showing 
a quasi-similar APT1 inhibitory activity as palmostatin B (14). B) Design of palmostatin M-derived probes 
83 and 94, showing a quasi-similar APT1 inhibitory activity as palmostatin M (28). IC50 values obtained 
using the APT1 fluorometric assay (APT1= 5 nM, DiFMUO= 15 µM, Ex/Emi.= 358/455 nm, gain= 100, 2 min 
inhibitor pre-incubation time). Data based on three independent measurements with Z’> 0.85. 
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2.4.3 Synthesis of palmostatin M-derived probes  
 
A conceptually similar strategy as for the synthesis of the trans -lactone library was used for the 
synthesis of palmostatin M-derived probe 83. The synthesis of compound 83 commenced with a 
dicyclohexyl-borontriflate-mediated anti aldol-reactionbetween aldehyde 55 and O-dodecylated 
ephedrine derivative 20.120 Subsequent S-oxidationof compound 80 with an excess of Oxone® in 
aqueous methanol yielded sulfone 81.132 Auxiliary removal from -hydroxy ester 81 by hydrolysis 
provided -hydroxy acid 82 without epimerization. Subsequent -lactonization with 
phenylsulfonyl chloride in pyridine concluded the synthesis of the ABPP probe 83 (Scheme 1.8). 
21,22 
 
Scheme 1.8 Synthesis of palmostatin M-derived probe 83. Reagents and conditions: a) Aux 20 (1.2 eqv.), 
NEt3 (2.5 eqv.), c-Hex2BOTf (2.2 eqv.), CH2Cl2, -78°C, 2h then aldehyde 55 (1.0 eqv.), -78°C (1h), 0°C (1h), 
then rt (1h), 66% yield. b) Oxone® (3.0 eqv.), MeOH/H2O 2/1, rt (8h), quantitative. c) LiOH.H2O (4.3 eqv.), 
Dioxane/H2O 4/1, 40°C (48 h), 85% yield. d) PhSO2Cl (3.0 eqv.), pyridine, 0°C, overnight, 31% yield.  
 
The synthesis of the regioisomeric probe 94 started with the preparation of alkynylated 
aldehyde 90. Conversion of commercially available pent-4-yn-1-ol 84 into the corresponding 
tosylated alcohol139 85 followed by nucleophilic substitution using 3-(methylamino)propan-1-
ol140 furnished compound 86. Chlorination of alcohol 86 followed by treatment with thioacetic 
acid/NEt3 furnished thioacetate derivative 87 which was then S-alkylated using ethyl 5-
iodopentanoate 49 and t-BuOK leading to ethyl ester 88 in 90% yield.141 Reduction of ethyl ester 
88 to alcohol 89 followed by Swern oxidation yielded aldehyde 90. Subsequent anti-selective 
aldol reaction between  aldehyde 90  and  O-dodecylated ephedrine auxiliary 10 furnished -
hydroxyester 91,118 which was finally S-oxidizedto compound 92 using oxone®.132 Saponification 
of -hydroxyester 92 to -hydroxyacid 93 followed by cyclization122,123 using PhSO2Cl/pyridine 
completed the synthesis of palmostatin M-derived probe 94 (Scheme 1.9).  
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Scheme 1.9 Synthesis of palmostatin M-derived probe 94. Reagents and conditions: a) NEt3 (1.1 eqv.), TsCl 
(1.1 eqv.), CH2Cl2, rt, 20h, 71% yield. b) 85 (1.1 eqv.), MeNH(CH2)3OH (1.0 eqv.), K2CO3 (1.1 eqv.), CH3CN, 
80°C (20h), 81% yield. c) SOCl2 (1.2 eqv.), CH2Cl2, rt (4h). d) AcSH (1.2 eqv.), NEt3 (3.0 eqv.), CHCl3, 60°C 
(18h), 80% yield over two steps. e) t-BuOK (1.05 eqv.), EtOH, rt (30 min.) then ester 49 (1.0 eqv.), rt (20h), 
90% yield. f) LiAlH4 (1.05 eqv.), Et2O, 0°C (1h) then rt (2h), 73% yield. g) Oxalyl chloride (1.1 eqv.), DMSO 
(2.3 eqv.), NEt3 (3.65 eqv.), CH2Cl2, -78°C then rt, 45 min., 91% yield. h) Aux 10 (1.2 eqv.), NEt3 (2.5 eqv.), c-
Hex2BOTf (2.2 eqv.), CH2Cl2, -78°C (2h) then aldehyde 90 (1.0 eqv.), -78°C (1h), 0°C (1h), then rt (1h), 68% 
yield. i) Oxone® (3.0 eqv.), MeOH/H2O 2/1, rt (8h), 90% yield. j) LiOH.H2O (5.5 eqv.), Dioxane/H2O 4/1, 
40°C (24h), 30% yield. k) PhSO2Cl (3.0 eqv.), pyridine, 0°C, over night, 30% yield. 
 
2.4.4 Synthesis of trifunctional fluorophore reporter dye (TrifN3) 
 
Rhodamine-biotin-azide dye TrifN3 (103) was synthesized following a modified protocol from the 
literature128 using a standard 9-fluorenylmethoxycarbonyl (Fmoc) solid phase synthesis on Sieber 
amide resin (95), chosen for its relatively mild cleavage conditions (1% TFA). After removal of the 
Fmoc protecting group using 20% piperidine/N-methylpyrrolidinone, unprotected resin 96 (0.7 
mmol/g) was coupled with Fmoc-L-Lys(4-azidobenzoyl)-OH 97, synthesized in solution from 
Fmoc-LysOH  and  4-azidobenzoyl chloride.142,143 Optimized coupling conditions employed HATU 
(2.0 eqv.), HOBT (2.0 eqv.) and DIPEA (4.0 eqv.) in DMF for 1 hour at rt to decrease the resin 
loading (0.5 mmol/g), initially probably too high for the synthesis of such a bulky molecule. 
Unreacted free amino groups were subsequently protected as N-acetamide using pyridine/acetic 
anhydride in DCM and Fmoc protecting groups were finally removed from azide-functionalized 
resin 98 using 4% DBU in DMF leading to unprotected resin 99. Subsequently, the strategy 
shown in Scheme 1.10 consisting in a coupling reaction with orthogonally protected Fmoc-
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Lys(Alloc)-OH was investigated as it would offer the possibility to introduce a biotin modified 
lysine and only in the last step the fluorescent dye.  
 
 
Scheme 1.10 First strategy for the trifunctional dye synthesis (103). Reagents and conditions: a) 20% 
piperidine/NMP (3 times, 5 ml, 5 min). b) Fmoc-L-Lys(4-azidobenzoyl)-OH 97 (2.0 eqv.), HATU (2.0 eqv.), 
HOBT (2.0 eqv.), DIPEA (4.0 eqv.), DMF, 1h, rt. c) Pyridine/acetic anhydride/DCM 1:1:4, 30 min, rt. d) 4% 
DBU/DMF (6 times, 5 ml, 10min). e) Fmoc-Lys(Alloc)-OH (4.0 eqv.), HATU (4.0 eqv.), HOBT (4.0 eqv.), 
DIPEA (8.0 eqv.), DMF, 3h, rt. f) various unsuccessful attempts to remove the Alloc protecting group.  
 
 
Unfortunately, after attachment of protected Fmoc-Lys(Alloc)-OH onto resin 99, Alloc removal 
from resin 100 was problematic when using tetrakis(triphenylphosphine) palladium due to the 
formation of the Staudinger reduction side product S1. Reduction of catalyst loading and 
optimization of the solvent system permitted a significant reduction in side product S1, but the 
reaction efficiency was also dramatically affected with largely incomplete reactions even after 
several days. Alternative palladium sources such as 30 mol% Pd2(dba)3 subsequently investigated 
were also unsuccessful with incomplete reactions and the formation of the side product S2, 
possibly by reduction of the azido group (Figure 1.41). 
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Figure 1.41 Optimization for the Alloc protecting group removal. Structure of the two side products 
generated during the alloc deprotection, Staudinger side product S1 and primary amide S2.   
 
Given the crucial role of the azido group in the TrifN3 construct (103), the strategy presented in 
Scheme 1.11 was investigated in order to overcome such degradation problems. The coupling 
reaction of intermediate 99 with commercially available Fmoc-Lys(biotinyl-ε-aminocaproyl)-OH, 
permitted after subsequent Fmoc removal (4% DBU in DMF) to attach a rhodamine to the free 
amine upon reaction with 5-(and-6)-carboxytetramethylrhodamine succinimidyl ester (5/6 
TAMRA-SE, 1.35 eqv.) in the presence of triethylamine (6.0 eqv.). Subsequent cleavage from the 
resin using 1% TFA in DCM, followed by purification on reverse phase C18 column, furnished the 
trifunctional dye TrifN3 (103) as a dark red solid in 60% overall yield (Scheme 1.11 ).  
 
Scheme 1.11 New strategy for the trifunctional dye synthesis (103). Reagents and conditions: a) Fmoc-
Lys(biotinyl-ε-aminocaproyl)-OH  (2.0 eqv.), HATU (2.0 eqv.), HOBT (2.0 eqv.), DIPEA (4.0 eqv.), DMF, 22h, 
rt. b) 4% DBU/DMF (6 times, 5 ml, 10min). c) 5/6-TAMRA SE (1.5 eqv.), NEt3 (6.0 eqv.), NMP, rt, dark, 60h. 
d) Cleavage from the resin using 1% TFA/DCM (5*3ml, 10 min). 
 
2.4.5 Confirmation of the -lactone binding mode  
 
The two cell permeable palmostatin M-derived probes 83 and 94 were first subjected to 
analogous activity-based profiling experiments to allow the comparison of their labeling profiles 
after 20 minutes incubation with identical numbers of HeLa cells, at various probe 
concentrations (50/ 10/ 1 µM). In-gel fluorescence detection revealed significantly different 
labeling profiles for the two regioisomeric probes (Figure 1.42A). Labeling experiments 
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conducted with probe 83, embedding the alkyne group in its lipid chain, were characterized by 
three major intense fluorescent bands compared to the negative control, whereas weaker bands 
were detected when using regioisomeric probe 94. To compare their labeling efficiency for 
APT1, the gel was scanned by fluorescence, transferred to a PVDF membrane and used for 
Western blotting analysis for APT1 visualization using a know amount of recombinant hAPT1 as 
reference and internal standard (Figure 1.42B). Probe 83 was several-fold more efficient to label 
APT1 compared to probe 94, although the two probes were displaying similar APT1 inhibitory 
activity in the biochemical assay (IC50 = 4.48 +/- 0.39nM vs. 6.06 +/- 0.87nM respectively for 
probe 83 and 94). The observed discrimination between the two regioisomeric probes indicated 
a preferred orientation of the-lactone into the APT1 active site with its polar head groups (SO2 
and NMe2) penetrating the active site (Figure 1.42C). This suggested binding mode for the -
lactone inhibitors is in accordance with their substrate-based design. Given the accessibility of its 
alkyne group for the fluorescent labeling by [3+2]-cyloaddition when covalently bound to the 
APT1 active site, palmostatin M-derived probe 83 was chosen for further investigation, 
especially for its comparison with palmostatin B-derived probe 23. 
 
C 
 
Figure 1.42 Confirmation of the lactone binding mode. Cellular proteome labeling profile for 
palmostatin M-derived probes 83 and 94 after 20 minutes incubation at various probe concentrations (50 
/10 / 1 µM). A) Fluorescent gel highlighting three major bands corresponding to PPT1 (MW=34.193 kDa), 
APT1 (MW= 24.67 kDa) and APT2 (MW = 24.73 kDa) Conditions: TrifN3 (103) = 20 µM, TCEP:HCl = 0.5 mM, 
ligand = 50 µM, CuSO4 = 0.5 mM, HeLa cells = 2*10
6
. B) Corresponding Western blotting for APT1 
visualization using polyclonal rabbit APT1 antibody showing a stronger affinity of probe 83 compared to 
probe 94 for APT1. Recombinant hAPT1 (25 ng) used as reference. C) Binding mode accounting for the 
observed APT1-labeling efficiency based on the accessibility of the alkyne group for the click ligation. 
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2.4.6 Stronger APT1 inhibition by palmostatin M over palmostatin B  
 
To rationalize the stronger phenotypic reversion induced by palmostatin M over palmostatin B, 
In cellulo ABPP experiments were subsequently performed using the two probes 83 and 23 
respectively derived from palmostatin M and B and their labeling efficiency for APT1 were 
compared under similar conditions. To this end,  probe 83 and probe 23 were compared by 
means of activity based profiling experiments performed with identical cell number, after 20 
minutes probe pre-incubation with concentrations varying from 10 µM to 60 nM. Although their 
fluorescent labeling profiles were quite similar (Figure 1.43A), palmostatin M-derived probe 83 
was several fold more efficient than palmostatin B-derived probe 23 to label APT1. For probe 83, 
detection of labeled APT1 by Western blotting was possible down to 60 nM concentration 
whereas probe 23 required at least 100 nM concentration to observe detectable levels of APT1 
(Figure 1.43B). In conclusion, these results have provided the first cellular proof of a cause-effect 
relationship between a stronger APT1 inhibitory efficiency and a stronger phenotypic reversion 
of palmostatin M (28) as compared to palmostatin B (14).  
 
 
 
 
Figure 1.43 Stronger APT1 inhibition by palmostatin M over palmostatin B. Labeling profile comparison 
between palmostatin B-derived probe 23 and palmostatin M-derived probe 83 after 20 minutes 
incubation with probe concentrations from 10 µM to 60 nM. A) Fluorescent gel highlighting the bands 
corresponding to APT1 (MW= 24.67 kDa) and APT2 (MW = 24.73 kDa). Conditions: TrifN3 (103) = 10 µM, 
TCEP:HCl = 0.5 mM, Ligand = 50 µM, CuSO4 = 0.5 mM, HeLa cells = 7*10
5
. B) Corresponding Western 
blotting for APT1 visualization (polyclonal Rabbit APT1 antibody) showing a stronger APT1 affinity of probe 
83 compared to probe 23.   
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2.4.7 Identification of APT2 as Ras depalmitoylating enzyme 
 
Although Western blotting analysis confirmed APT1 as one of the cellular targets of palmostatin 
B and M, the identification of all fluorescently labeled proteins covalently bound to -lactone 
probes 23 and 83, and especially those relevant to Ras depalmitoylation remained to be 
addressed. Therefore, palmostatin B-derived probe 23 and palmostatin M-derived probe 83 
were subjected to three independent labeling experiments performed at 50 µM. After 
fluorescent scanning and/or silver staining, bands corresponding to fluorescently labeled 
proteins were isolated from the gel and digested with trypsin. Peptide fragments were 
subsequently separated, analyzed by nano-HPLC-MS/MS and finally compared to the SwissProt 
database for protein identification. Only proteins, for which at least two protein specific 
peptides were identified, were chosen for further validation and only those identified in at least 
two out of three independent pull down experiments but not in control pull downs (DMSO 
treated sample) were considered as hits. Table 1.2 display the list of proteins identified by 
proteomic analysis respectively using probe 83 or probe 23 with the probability threshold P 
<0.01. 
Proteins Probe 83 Probe 23 MW (kDa) Protein function 
ADRM1_HUMAN 
No yes 
42412 
Proteasomal ubiquitin receptor ADRM1 OS=Homo 
sapiens GN=ADRM1 PE=1 SV=2 
ATRX_HUMAN 
yes yes 
284801 
Transcriptional regulator ATRX OS=Homo sapiens 
GN=ATRX PE=1 SV=4 
BPNT1_HUMAN 
yes yes 
33713 
3'(2'),5'-bisphosphate nucleotidase 1 OS=Homo sapiens 
GN=BPNT1 PE=2 SV=1 
CDC2_HUMAN 
yes no 
34131 
Cell division control protein 2 homolog OS=Homo 
sapiens GN=CDC2 PE=1 SV=1 
CEBPZ_HUMAN 
yes yes 
121540 
CCAAT/enhancer-binding protein zeta OS=Homo 
sapiens GN=CEBPZ PE=1 SV=2 
CHRD1_HUMAN 
yes yes 
38264 
Cysteine and histidine-rich domain-containing protein 
1 OS=Homo sapiens GN=CHORDC1 PE=1 SV=2 
CLP1L_HUMAN 
yes yes 
62531 
Cleft lip and palate transmembrane protein 1-like 
protein OS=Homo sapiens GN=CLPTM1L PE=2 SV=1 
CLPT1_HUMAN 
yes no 
76277 
Cleft lip and palate transmembrane protein 1 
OS=Homo sapiens GN=CLPTM1 PE=1 SV=1 
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CYBP_HUMAN 
yes yes 
26308 
Calcyclin-binding protein OS=Homo sapiens 
GN=CACYBP PE=1 SV=2 
DUT_HUMAN 
yes yes 
26975 
Deoxyuridine 5'-triphosphate nucleotidohydrolase, 
mitochondrial OS=Homo sapiens GN=DUT PE=1 SV=3 
EGFR_HUMAN 
yes yes 
137612 
Epidermal growth factor receptor OS=Homo sapiens 
GN=EGFR PE=1 SV=2 
ERF1_HUMAN 
no yes 
49228 
Eukaryotic peptide chain release factor subunit 1 
OS=Homo sapiens GN=ETF1 PE=1 SV=3 
ERP29_HUMAN yes yes 29032 
Endoplasmic reticulum protein ERp29 OS=Homo 
sapiens GN=ERP29 PE=1 SV=4 
FADS1_HUMAN 
yes no 
52216 
Fatty acid desaturase 1 OS=Homo sapiens GN=FADS1 
PE=1 SV=1 
GBF1_HUMAN 
yes yes 
208367 
Golgi-specific brefeldin A-resistance guanine nucleotide 
exchange factor 1 OS=Homo sapiens GN=GBF1 PE=1 
SV=2 
GDIR1_HUMAN 
yes yes 
23250 
Rho GDP-dissociation inhibitor 1 OS=Homo sapiens 
GN=ARHGDIA PE=1 SV=3 
HELC1_HUMAN 
yes yes 
252898 
Activating signal cointegrator 1 complex subunit 3 
OS=Homo sapiens GN=ASCC3 PE=1 SV=3 
HINT2_HUMAN 
yes yes 
17208 
Histidine triad nucleotide-binding protein 2 OS=Homo 
sapiens GN=HINT2 PE=1 SV=1 
LYPA1_HUMAN 
yes yes 
24996 
Acyl-protein thioesterase 1 OS=Homo sapiens 
GN=LYPLA1 PE=1 SV=1 
LYPA2_HUMAN 
yes yes 
25063 
Acyl-protein thioesterase 2 OS=Homo sapiens 
GN=LYPLA2 PE=2 SV=1 
MOSC1_HUMAN 
yes yes 
37989 
MOSC domain-containing protein 1, mitochondrial 
OS=Homo sapiens GN=MOSC1 PE=2 SV=1 
MRCKB_HUMAN 
yes yes 
196189 
Serine/threonine-protein kinase MRCK beta OS=Homo 
sapiens GN=CDC42BPB PE=1 SV=2 
MRP1_HUMAN 
yes yes 
172877 
Multidrug resistance-associated protein 1 OS=Homo 
sapiens GN=ABCC1 PE=1 SV=2 
NOC2L_HUMAN 
yes yes 
85707 
Nucleolar complex protein 2 homolog OS=Homo 
sapiens GN=NOC2L PE=1 SV=3 
OLA1_HUMAN 
yes No 
44943 
Obg-like ATPase 1 OS=Homo sapiens GN=OLA1 PE=1 
SV=2 
OTUB1_HUMAN 
yes yes 
31492 
Ubiquitin thioesterase OTUB1 OS=Homo sapiens 
GN=OTUB1 PE=1 SV=2 
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PININ_HUMAN 
yes yes 
81679 Pinin OS=Homo sapiens GN=PNN PE=1 SV=4 
PPT1_HUMAN 
Yes* Yes* 
34627 
Palmitoyl-protein thioesterase 1 OS=Homo sapiens 
GN=PPT1 PE=1 SV=1 
RAC1_HUMAN 
yes yes 
21835 
Ras-related C3 botulinum toxin substrate 1 OS=Homo 
sapiens GN=RAC1 PE=1 SV=1 
RHOG_HUMAN 
yes yes 
21751 
Rho-related GTP-binding protein RhoG OS=Homo 
sapiens GN=RHOG PE=1 SV=1 
RISC_HUMAN 
No yes 
51083 
Retinoid-inducible serine carboxypeptidase OS=Homo 
sapiens GN=SCPEP1 PE=1 SV=1 
RRMJ3_HUMAN 
yes yes 
96972 
Putative rRNA methyltransferase 3 OS=Homo sapiens 
GN=FTSJ3 PE=1 SV=1 
RTN3_HUMAN 
yes No 
113169 Reticulon-3 OS=Homo sapiens GN=RTN3 PE=1 SV=2 
SCAM3_HUMAN 
yes yes 
38661 
Secretory carrier-associated membrane protein 3 
OS=Homo sapiens GN=SCAMP3 PE=1 SV=3 
SPEE_HUMAN 
yes No 
34373 
Spermidine synthase OS=Homo sapiens GN=SRM PE=1 
SV=1 
SPRE_HUMAN 
yes yes 
28316 
Sepiapterin reductase OS=Homo sapiens GN=SPR PE=1 
SV=1 
SYNE2_HUMAN 
yes yes 
801817 Nesprin-2 OS=Homo sapiens GN=SYNE2 PE=1 SV=3 
TM9S4_HUMAN 
yes yes 
75211 
Transmembrane 9 superfamily member 4 OS=Homo 
sapiens GN=TM9SF4 PE=1 SV=2 
TPM4_HUMAN 
yes yes 
28619 
Tropomyosin alpha-4 chain OS=Homo sapiens 
GN=TPM4 PE=1 SV=3 
TYSY_HUMAN 
yes yes 
35978 
Thymidylate synthase OS=Homo sapiens GN=TYMS 
PE=1 SV=3 
 
Table 1.2 Proteins identified by proteomic analysis. Labeling experiments performed in HeLa cells using 
50 µM palmostatin B-derived probe 23 or palmostatin M-derived probe 83. Table showing Protein ID, 
molecular weight (MW) and function of identified proteins. *Protein identified not convincingly.   
 
 
Consistent with Western blotting results, APT1 (or LYPL1) was found among the target proteins 
using both probes. Proteomic analysis also identified among the target proteins, the close 
homologue of APT1 called APT2 (or LYPA2) and with a weaker probability palmitoyl protein 
thioesterase 1 (PPT1). The clear distinction of APT2 from APT1 was possible by nano-LCMS/MS 
based on significantly different peptide signals exemplified by the [M+2H]2+ ion of  
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TYPGVMHSSCPQEMAAVK for LYPA2 and  the [M+2H]2+ ion of  TYEGMMHSSCQQEMMDVK for 
LYPA1 (Figure 1.44).  
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Figure 1.44 Distinction of APT1 from APT2 by nano-LCMS/MS. A) Example showing the total ion 
chromatogram from which the [M+2H]
2+
 signals of the peptides TYPGVMHSSCPQEMAAVK for LYPA2 or 
TYEGMMHSSCQQEMMDVK for LYPA1 were obtained. B) MS/MS-spectrum of the [M+2H]
2+
 ion of 
 
TYPGVMHSSCPQEMAAVK (LYPA2). C) MS/MS-spectrum of the [M+2H]
2+
 ion of TYEGMMHSSCQQEMMDVK 
(LYPA1). 
 
Given its lysosomal localization, PPT1 is unlikely to be involved in-vivo in the Ras 
depalmitoylation process, but rather in lipidated protein degradation in lysosomal 
compartments. In contrast, APT2 or lysophospholipase II (LYPL2) sharing 65% sequence identify 
with APT1 and already reported to have an activity against several lipid substrates94 may 
potentially be involved in the Ras de/reacylation cycle. Encouraged by these promising results, 
the APT2 inhibitory activity for palmostatin B-derived probe 23 and palmostatin M-derived 
probe 83 was further investigated in-vitro by means of a biochemical assay.    
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2.5 Confirmation of the results 
2.5.1 -lactones as in vitro APT2 inhibitors  
 
In order to monitor APT2 inhibition, the fluorometric assay previously developed for APT1 
inhibition was adapted (work by Tobias Zimmermann) by adjusting the enzyme quantity to 50 
nM keeping the concentration of substrate DiFMUO constant (15 µM). Recombinant human 
APT2 protein was expressed by Marco Bürger in analogy to APT1. Consistent with the proteomic 
results, palmostatin M and their corresponding pull down probes 23 and 83 were found as 
potent APT2 inhibitors. To explore differences in substrate specificity between APT1 and APT2, 
the complete trans -lactone library 26-45 was subsequently screened for APT2 inhibition 
leading to the IC50 values presented in Table 1.3.  
 
 
Table 1.3 -lactone as potent APT2 inhibitors. IC50 values for APT2 inhibition obtained for the trans -
lactone inhibitors 26-45 and for ABPP probes derived from palmostatin B (23) and palmostatin M (83 and 
94) using the fluorometric assay (APT2= 50nM, DiFMUO= 15µM, Ex/Emi.= 358/455nm, gain= 100, 2 min 
inhibitor pre-incubation time), Z’ factors were in all cases higher than 0.75. Data based on three 
independent experiments.  
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In analogy to APT1, (S,S)-trans -lactones were several fold more potent APT2 inhibitors 
compared to (R,R)-trans -lactones. In general, a strong correlation between APT1 and APT2 
potency was noticed. However, palmostatin M (28) and the two pull down probes 23 and 83 
were significantly more potent APT2 than APT1 inhibitors judging from IC50 values obtained using 
5 nM APT1 and 50 nM APT2 respectively (Figure 1.45). 
A 
 
B 
 
 
 
Figure 1.45 Strong correlation between APT1 and APT2 activity for the -lactones. Graphical 
representation of IC50 values obtained for (S,S)-trans -lactone (series A, B and C), for palmostatin B, for 
palmostatin B-derived probe 23 and for palmostatin M-derived probe (83, 94). A) For APT2 inhibition using 
the APT2 fluorometric assay (APT2 = 50 nM, DiFMUO= 15 µM, 2 min inhibitor pre-incubation). B) For APT1 
inhibition using the APT1 fluorometric assay (APT1 = 5 nM, DiFMUO= 15 µM, 2 min inhibitor pre-
incubation). Data based on three independent experiments with Z’>0.85.   
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
n=2 n=3 n=4 n=5 n=3 n=4 n=5 n=2 n=4 n=5 PalmB 23 83 94
A
P
T
2
-
IC
5
0
 V
a
lu
e
s
 [
n
M
] 
C A B 
(S,S) -Trans -lactones 
0
1
2
3
4
5
6
7
8
n=2 n=3 n=4 n=5 n=3 n=4 n=5 n=2 n=4 n=5 PalmB 23 83 94
A
P
T
1
-
IC
5
0
V
a
lu
e
s
 [
n
M
] 
C A B 
(S,S) -Trans -lactones 
Chapter 1: Targeting Ras depalmitoylation   59 
2.5.2 APT2 as in vitro Ras depalmitoylating enzyme  
 
To address the relevance of APT2 for the Ras cycle, the ability of APT2 to depalmitoylate Ras 
proteins was evaluated in vitro by mean of an AcryloDated Intestinal Fatty Acid Binding protein 
(ADIFAB) assay using biologically active semi-synthetic N-Ras proteins as substrate (work by 
Kristina Goermer). ADIFAB is an established fluorescent assay for the detection and the 
measurement of released or unbound palmitic acids and is therefore suitable to monitor in vitro 
Ras depalmitoylation.144 The principle of this assay is described in Figure 1.46 A-B. In the absence 
of unbound palmitic acid, the ADIFAB probe gives a fluorescent signal at 432 nm, whereas the 
emission shifts to 505 nm in the presence of unbound palmitic acid.  
By the evaluation of the fluorescence intensity ratio F505nm/F432nm , the concentration of unbound 
palmitic acid as well as the depalmitoylation rate can be calculated for various N-Ras 
concentrations by keeping the other parameters constant (APT1/APT2= 50 nM, ADIFAB= 200 
nM). Finally, the curve presented in Figure 1.46C can be obtained, allowing the determination of 
the maximum velocity (Vmax) and the Michaelis constant (Km), respectively for APT1 or APT2-
mediated depalmitoylation. As a result, APT1 and APT2 were shown to depalmitoylate semi-
synthetic N-Ras proteins in-vitro with a similar affinity for the N-Ras substrate, given their 
comparable KM values (KM = 1.16+/-0.02 µmol/L for APT1 and KM = 1.43+/-0.28 µmol/L for APT2). 
However, APT2 was shown to depalmitoylate Ras faster than APT1, given a Vmax value for APT2 
two fold higher to that of APT1 under identical conditions (Vmax= 0.29 +/- 0.00 nM/s for APT1 and 
Vmax=0.48 +/- 0.02 nM/s for APT2) as shown in  Figure 1.46.  
 
 
 
Figure 1.46 Depalmitoylation of semi-synthetic N-Ras by APT1 and APT2. A) Principle of the ADIFAB 
assay. B) Shift in the fluorescence signal (from 432 nm to 505 nm) when unbound palmitic acids are 
generated. C) In-vitro depalmitoylation of semi-synthetic N-Ras proteins at different concentration 
respectively by APT1 (black curve) and APT2 (red curve) using 50 nM APT1/APT2, 200 nM ADIFAB. Release 
of palmitic acids is monitored by measuring the fluorescence specta (400-650 nm) over time. Data from 
Kristina Goermer.  
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3 Conclusion 
 
In conclusion, potent acyl protein thioesterases inhibitors were developed based on substrate 
similarity design principles. Pull down experiments showed that they effectively target APT1 and 
APT2 in cells. These inhibitors attenuate Ras signaling by interfering with the dynamic Ras 
de/repalmitoylation cycle and induce phenotypic reversal in H-Ras transformed cells. The data 
provide the first experimental proof that both APT1 and APT2 are thioesterases relevant to Ras 
depalmitoylation and signaling. Notably, -lactone inhibitors do not inhibit additional esterases 
relevant to Ras signaling which proves their high selectivity. Taken as a whole, these findings 
suggest that no further hydrolases in general are involved in Ras-depalmitoyation in cells. 
Recently, the APT1/APT2 homologue LPLYP1 (APT3) expressed and purified by Marco Bürger was 
shown to exhibit a different electrostatic surface in the proximity of its active site. It is largely 
positive, in contrast to APT1 and APT2 found highly negative in the same area. This negative 
potential is thought to facilitate the elimination of negatively charged palmitic acids once the 
enzymatic cleavage accomplished thereby suggesting that APT3 may not have a thioesterase 
activity like APT1 and APT2. This hypothesis was subsequently confirmed by Kristina Goermer 
using the ADIFAB assay, showing the inability of APT3 to depalmitoylate biologically active semi-
synthetic N-Ras proteins in vitro. With the discovery of APT1 and APT2 as relevant proteins for 
Ras depalmitoylation, targeting both proteins may constitute a viable anti-cancer approach to 
interfere with aberrant H- and N-Ras signaling.   
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1 Background Chronic Lymphocytic Leukaemia (CLL)  
 
Leukaemia is a group a several diseases affecting white blood cells and accounting for 0.8% of all 
cancer deaths. Chronic lymphocytic leukaemia (CLL) is the most common diagnosed form of 
leukaemia, representing nearly 30% of all leukaemia related deaths.1,2 CLL is characterized by an 
aberrant accumulation of long lived malignant B cells or B-CLL cells3 due to dysfunction in normal 
apoptotic signaling pathways resulting instead in the activation of non-apoptotic pathways.4 This 
uncurable disease affects mainly aged people,1 and is characterized by low chances of self–
remission.5 Moreover, attempts to treat CLL patients employing DNA-damaging chemotherapy6 
had only minor effects thereby resulting in a low survival prognosis, typically 5 years.1 Over 15 
years numerous research groups have been focusing on understanding the mechanisms of this 
age-related disease and in particular the apoptosis resistance characteristic for CLL, in order to 
develop new therapeutic approaches.  
 
2 Fas-mediated signaling pathways in healthy cells 
 
2.1 Fas receptors as key regulators of cell death signaling 
 
Ubiquitously expressed, Fas receptors (also known as CD95 or APO-1) are one of the most 
studied plasma membrane cell death receptors involved in apoptotic cell signaling pathways. 
Like other well-studied members of the TNFR (tumor necrosis factor receptor) superfamily 
(TNFR1, TRAIL DR4 and TRAIL DR5), Fas receptors are characterized by the presence of a death 
domain binding motif (DD = 80 amino acids). Moreover, Fas receptors are constitutively 
palmitoylated in their transmembrane domains (TM) with a palmitoylation site located at the 
cysteine residue Cys 199 in human Fas.7,8 Post-translational lipid modifications together with 
their death domains (DD) are essential for the initiation of Fas-mediated apoptotic signaling.9 A 
simplified representation of Fas receptor proteins is provided in Figure 2.1, showing their 
segmentation into three distinct domains respectively extracellular, transmembrane and 
cytoplasmic domains.  
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Figure 2.1 Simplified Fas receptor structure. Death domain and palmitoylation site of Fas receptors 
reported to be essential for Fas-induced apoptotic cell signaling. TM = transmembrane domain, DD = 
death domain. Figure adapted from the literature.
10
 
 
2.2 Fas palmitoylation initiates Fas trimerization in lipid rafts 
 
S-palmitoylation is a post-translational lipid modification commonly found among signaling 
proteins. Fas palmitoylation is essential for Fas translocation to lipid rafts (liquid ordered plasma 
membrane microdomains)7 as well as for Fas-induced apoptotic signaling.7 Indeed, lipid-raft 
localized and palmitoylated Fas receptors form non covalent pre-assembled trimers by self 
association, with their Fas death domains hindered.11,12 Upon binding to their homotrimeric Fas 
ligands (FasL or CD95L), pre-assembled Fas receptors undergo conformational changes allowing 
homotypic interactions with their death domains, thus resulting in Fas trimerization (Figure 
2.2).12-15  
 
Figure 2.2 Fas palmitoylation initiates Fas trimerization in lipid rafts. Fas palmitoylation induces Fas pre-
assembly in lipid rafts, followed by Fas receptor trimerization upon activation by homotrimeric Fas ligands. 
TM = trans membrane domain, DD = death domain. Figure modified from the literature.
16
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2.3 Fas palmitoylation facilitates Fas internalization 
 
S-palmitoylation is not only essential for Fas trimerization in lipid rafts, but also for Fas 
association with the actin cytoskeleton, which plays an important role in Fas internalization,17 an 
obligatory step for Fas-mediated cell death signaling.7,18 Artificial disruption of Fas palmitoylation 
by mutations, as wells as by competition with palmitic acid analogues, inhibit Fas internalization 
thereby inhibiting Fas-induced apoptosis.7 Fas receptor internalization occurs through 
endocytosis18 to facilitate the assembly of ternary DISC signaling complexes (Death–Inducing 
Signaling Complex) in endosomal compartments.19 Recently, two distinct Fas-mediated 
apoptosis signaling pathways were described referred to as type I or type II, depending on Fas 
internalization efficiency (Figure 2.3).20-22  
 
Figure 2.3 Fas palmitoylation facilitates Fas internalization. Fas internalization occurs by endocytocis 
through Fas - actin association. Figure addapted from literature.
7
  
 
2.4  Distinct Fas signaling depending on Fas internalization 
 
2.4.1 Fas-mediated apoptotic cell signaling pathway type I   
 
In Fas-mediated apoptotic signaling pathway type I, Fas internalization allows the efficient 
recruitment of the cytoplasmic adaptor molecule FADD (Fast Associated Death Domain) through 
a homotypic interaction between FAS and FADD’s respective death domains (DD).13,14,23 
Subsequently, FAS-bound FADD forms a DISC complex23 through an homotypic interaction 
between FADD and procaspase-8’s respective death effector domains (DED).24-26 Such ternary 
complexes are mainly assembled in endosomal compartments after internalization.18 The 
sufficient amount of DISC generated finally allows the direct activation of caspase-8 by 
autoproteolysis due to the close proximity of the two procaspases-8 involved in the DISC 
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complex.27,28 Activated caspase-8 subsequently activates the caspase effector 3 thereby 
triggering Fas-mediated (or extrinsic) apoptotic signals in the cell (Figure 2.4). 
 
Figure 2.4 Fas-mediated apoptotic cell signaling pathway type I (extrinsic death signaling pathway). The 
efficent Fas internalization permits an efficent caspase-8 activation resulting in caspase-3 activation and 
finally to apoptosis. DD= death domain, DED= death effector domain. Figure adapted from the literature. 
9
  
 
2.4.2 Fas-mediated apoptotic cell signaling pathway type II  
 
In Fas-mediated apoptotic signaling pathway type II, Fas internalization is significantly less 
effective leading to considerably reduced DISC formation and, in consequence, to less activated 
caspase-8 rendering the direct activation of effector caspase-3 through the extrinsic death 
signaling pathway impossible. Instead, activated caspase-8 triggers the apoptotic signal by 
activation of the intrinsic death signaling from the mitochondria functioning as an apoptosis 
activation loop.29,30 After caspase 8–induced proteolytic activation of BID proteins, active t-BID 
proteins translocate to the mitochondria and induce Bak protein oligomerization. As a result, 
released cytochrome C (CytC) finally triggers cell death signals via caspase-9 followed by 
caspase-3 activation (Figure 2.5). 
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Figure 2.5 Fas-mediated apoptotic cell signaling pathway type II. The inefficent Fas internalization 
prevent the direct activation of caspase-3 by caspase-8. Instead, caspase-8 activates caspase-3 through 
the intrinsic death signaling pathway at the mitochondria, regarded as an apoptosis amplification loop. 
DD= death domain, DED= death effector domain. Figure adapted from the literature.
31
  
 
2.4.3 Fas-mediated non-apoptotic cell signaling pathways  
 
Originaly, Fas receptors were exclusively related to apoptotic signaling pathways (type I or II).  
However recently, various non-apoptotic Fas-mediated signaling pathways were identified such 
as the nuclear factor κB (NF-κB) signaling pathway and three major MAPK signaling pathways 
(Erk1/2, JNK1/2, P38) controling cell proliferation, motility and invasion.
18,32-38 In contrast to Fas-
mediated apoptotic signaling  pathways which require Fas internalization, non-apoptotic 
signaling pathways occur without Fas receptor internalization18 through the formation of DISC 
complexes at the cell surface.16,39 In case of absence/dysfunction of Fas palmitoylation, Fas 
receptors may be redirected and self-assembled into non-lipid rafts where such non-apoptotic 
signaling may occur as replacement of internalization-dependant apoptotic signaling. This 
hypothesis is consistent with the exclusive dependancy on FasL and Fas extracellular domains for 
Fas trimerization (Figure 2.6).40  
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Figure 2.6 Fas-mediated non-apoptotic cell signaling pathways. Signaling occuring in absence of Fas 
internalization through the formation of DISC complexes at the cell surface. DD= death domain, DED= 
death effector domain. Figure modified from the literature. 
16,33,39
 
 
3 Fas as molecular target for CLL treatment  
 
Given that Fas receptors need to internalize to trigger apoptotic signals, and that Fas 
internalization is facilitated by Fas palmitoylation, absence/dysfunction of Fas palmitoylation 
may account for the accumulation of mature B-cells characteristic for CLL disease. Recently, 
gene expression profiling experiments performed by Wendtner and co-workers41 have 
demonstrated that 21 genes with a phospholipase activity were overexpressed in CLL B-cells in 
comparison with healthy B-cells. Among these genes, seven genes were associated to the 
activity of phospholipase A2, five genes to phospholipase C, two genes to phospholipase D,  and 
one gene to phospholipase A1, lipoprotein lipase (LPL) and APT1 respectively. Notably, LPL was 
shown as the gene presenting the more significant overexpression. The cause-effect relationship 
between the lipase overexpression in CLL cells and the aberrant B-cell accumulation observed in 
CLL disease was further demonstated by Wendtner et al.41 employing the lipase inhibitor orlistat. 
Upon orlistat treatment, an induced apoptosis was observed selectively in CLL cells, whereas no 
apoptosis was observed in healthy B-cells (hPMBCs, human peripheral blood mononuclear cells) 
under similar conditions. Given the strong structural similarity between the APT1/APT2 inhibitor 
palmostatin B (14) and orlistat, identical experiments were performed by Wendtner and co-
workers using palmostatin B. This have shown that not only orlistat but also palmostatin B was 
inducing apoptosis selectively in CLL cells, with a several fold stronger effect of palmostatin B 
compared to orlistat. Given the involvement of APT1 in Ras depalmitoylation,42 its possible 
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involvement in Fas depalmitoylation would be consistent with the importance of Fas 
palmitoylation for Fas-mediated cell death signaling (Figure 2.7).  
 
Figure 2.7 Possible explanation for palmostatin B / orlistat-induced apoptosis in B-CLL cells. Palmostatin 
B/orlistat may inhibit enzymes involved in Fas depalmitoylation therefore allowing Fas internalization, 
which is required to trigger Fas-mediated death signaling type I or type II.  
 
4 Investigation on palmostatin B’s targets in B-CLL cells 
 
4.1 APT1 as a cellular target of palmostatin B 
 
In order to identify the enzyme(s) targeted by palmostatin B in CLL cells, and to identify enzymes 
possibly involved in Fas depalmitoylation,  palmostatin B-derived pulldown probe 23 was used to 
perform ABPP experiments in B-CLL cells and healthy hPMBC cells in collaboration with the 
Wendtner group. In this context, primary CLL and hPMBC cells collected from leukaemic and 
healthy patients, respectively, were incubated for 20 minutes in PBS buffer containing either the 
cell permeable palmostatin-B derived probe 23 at 50 µM concentration or DMSO. After 
subsequent washing followed by cell lysis, samples were frozen and were further processed in 
Dortmund. After evaluation of the sample protein concentration, all samples were adjusted to ~ 
1-1.2 mg/ml protein concentration by dilution with PBS to ensure an optimal Cu(I)- [3+2] 
cycloaddition. Indeed, experience in pulldown experiments revealed a significantly impaired click 
ligation when using concentrated lysates. By analogy to previous labeling experiments, target 
proteins were tagged by reaction with the rhodamine-azide-biotin construct TrifN3 (103). After 
subsequent enrichment using streptavidin beads, an equal amount of sample was loaded on a 
12% SDS-PAGE gel, allowing the comparison of the fluorescent labeling profile obtained 
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respectively using primary CLL and hPMBC cells (Figure 2.8A). As expected, in gel fluorescence 
detection revealed significant differences in the labeling profile obtained with probe 23 in CLL 
and PMBC cells, exemplified by two major intense fluorescent bands in CLL samples compared to 
significantly weaker bands in hPMBC samples. Interestingly, one of these major bands was 
located in the area where APT1/APT2 would be expected to be localized. Therefore, to confirm 
the presence of APT1 among the target proteins and to potentially detect a higher amount of 
labeled APT1 in CLL samples over PMBCs samples, the gel previously scanned for fluorescence 
was subsequently transferred to a PVDF membrane and used for Western blotting analysis for 
APT1 visualization. As a result, APT1 was confirmed as one of the target proteins in both samples 
with a slightly higher amount of labeled APT1 in CLL samples compared to hPMBC samples 
(Figure 2.8B).   
 
 
 
 
Figure 2.8 Comparison of the labeling profile using palmostatin B-derived probe 23 in CLL and hPMBC 
cells. B-CLL cells and hPMBCs cells were incubated for 20 minutes with palmostatin-B derived probe 23 (50 
µM) and compared to their respective DMSO treated control. A) In gel fluorescence scanning highlighting 
several major bands including APT1 (MW= 24.67 kDa). Conditions for healthy PMBC samples: TrifN3 (103) = 
10 µM, TCEP:HCl = 0.5 mM, ligand = 50 µM, CuSO4 = 0.5 mM, lysate 1.5 mg/ml, 500 µM bead suspension, 
1/10 of the sample loaded on the gel.  Condition for B-CLL samples: TrifN3 (103) = 10 µM, TCEP:HCl = 0.5 
mM, ligand = 50 µM, CuSO4 = 0.5 mM, lysate 1.2 mg/ml, 500 µM bead suspension, 1/10 of the sample 
loaded on the gel. B) Corresponding Western blotting analysis for APT1 visualization using polyclonal 
rabbit APT1 antibody. Condition: proteins blocked in TBST 2% chocolate slimfast for 1h at rt, then primary 
APT1 antibody (anti-hAPT1 from rabbit, custom-raised from BioGenes Gmbh as a 0.26 mg/ml suspension) 
applied in 1/50 dilution in TBST 2% chocolate slimfast (overnight at 4°C), then secondary antibody 
(ImmunoPure® antibody, goat anti-rabbit IgG (H+L), horseradish peroxidase, # 31460, Thermo Scientific) in 
a 1/10 000 dilution in PBST for 1h at rt. Final detection using Supersignal ® West Pico Chemiluminescent 
substrat after 30 seconds exposure.   
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4.2 Toward palmostatin B cellular targets - proteomic analysis 
 
Although Western blotting analysis could clearly identify APT1 as one cellular target of 
palmostatin B, proteomic analyses were subsequently performed to identify all proteins 
covalently bound to the -lactone probe 23 and especially those potentially relevant to Fas 
depalmitoylation. In this context, three independent labeling experiments were performed using 
cells from three different healthy and leukaemic patients. After silver staining, fluorescent bands 
corresponding to labeled proteins were isolated and digested with trypsin. Peptide fragments 
were subsequently separated, analyzed by nano-HPLC-MS/MS and finally compared with the 
SwissProt database for protein identification. Only proteins, for which at least two protein 
specific peptides were identified, were chosen for further validation and only those identified at 
least in two out of three independent pulldown experiments but not in control pulldowns 
(DMSO treated sample) were considered as hits. Table 2.1 displays the list of lipases/hydrolases 
identified by proteomic analysis either in hPMBC and/or CLL samples with the probability 
threshold p < 0,01.  
 
Proteins CLL cells hPMBC cells MW (kDa) Protein function 
ABHDA_HUMAN yes yes 33.933 
Ab-hydrolase domain-containing protein 
10, mitochondrial OS=Homo sapiens 
GN=ABHD10 PE=1 SV=1 
ABHDB_HUMAN no yes 34.690 
Ab-hydrolase domain-containing protein 11 
OS=Homo sapiens GN=ABHD11 PE=2 SV=1 
ABHEB_HUMAN yes No** 22.346 
Ab-hydrolase domain-containing protein 
14B OS=Homo sapiens GN=ABHD14B PE=1 
SV=1 
AT2A2_HUMAN no yes 114.757 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 OS=Homo sapiens 
GN=ATP2A2 PE=1 SV=1 (ATP hydrolase) 
AT2A3_HUMAN no yes 113.977 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 3 OS=Homo sapiens 
GN=ATP2A3 PE=1 SV=2 (ATP hydrolase) 
ACOT1_HUMAN no yes 46.277 
Acyl-coenzyme A thioesterase 1 OS=Homo 
sapiens GN=ACOT1 PE=2 SV=1 
BAT5_HUMAN no yes 63.243 
Abhydrolase, Protein BAT5 OS=Homo 
sapiens GN=BAT5 PE=1 SV=3 
CATB_HUMAN no yes 37.822 
Cathepsin B OS=Homo sapiens GN=CTSB 
PE=1 SV=3 (peptidase) 
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CPVL_HUMAN no yes 54.164 
Probable serine carboxypeptidase CPVL 
OS=Homo sapiens GN=CPVL PE=1 SV=2 
ESTD_HUMAN yes yes 31.463 
S-formylglutathione hydrolase OS=Homo 
sapiens GN=ESD PE=1 SV=2 
F18A1_HUMAN no yes 33.990 
Abhydrolase domain-containing protein 
FAM108A1 OS=Homo sapiens 
GN=FAM108A1 PE=2 SV=1 
FAS_HUMAN no yes 273.427 
Fatty acid synthase OS=Homo sapiens 
GN=FASN PE=1 SV=2 
LYPA1_HUMAN yes yes 24.670 
Acyl-protein thioesterase 1 OS=Homo 
sapiens GN=LYPLA1 PE=1 SV=1 
LYPA2_HUMAN Yes* yes 24.637 
Acyl-protein thioesterase 2 OS=Homo 
sapiens GN=LYPLA2 PE=2 SV=1 
MGLL_HUMAN no yes 33.261 
Monoglyceride lipase OS=Homo sapiens 
GN=MGLL PE=2 SV=2 
PAFA2_HUMAN no yes 44.036 
Platelet-activating factor acetylhydrolase 2, 
cytoplasmic OS=Homo sapiens GN=PAFAH2 
PE=1 SV=1 
PLBL1_HUMAN no yes 63.255 
Putative phospholipase B-like 1 OS=Homo 
sapiens PE=1 SV=1 
PLPL6_HUMAN no yes 149.995 
Neuropathy target esterase OS=Homo 
sapiens GN=PNPLA6 PE=1 SV=2 
PPGB_HUMAN no yes 54.466 
Lysosomal protective protein OS=Homo 
sapiens GN=CTSA PE=1 SV=2 (peptidase) 
PPT1_HUMAN no yes 34.193 
Palmitoyl-protein thioesterase 1 OS=Homo 
sapiens GN=PPT1 PE=1 SV=1 
SAMH1_HUMAN no yes 72.201 
SAM domain and HD domain-containing 
protein 1 OS=Homo sapiens GN=SAMHD1 
PE=1 SV=2 (hydrolase) 
EST1_HUMAN no yes 62.521 
Liver carboxylesterase 1 OS=Homo sapiens 
GN=CES1 PE=1 SV=2 
 
Table 2.1 List of lipases/hydrolases identified by mass spectrometry in hPMBC and CLL samples. Labeling 
experiments performed using 50 µM palmostatin B-derived probe 23. Table showing Protein ID, molecular 
weight (MW) of proteins together with their respective function.*Protein identified twice in the positive 
control and once in the negative control with the high probability threshold p <0,01, and identified only in 
the positive control (twice) with the lower probability p <0,001. ** Protein identified once in the positive 
control and not in the negative control with the high probability threshold p <0,01. Data based on three 
distinct cell samples respectively healthy PMBC cells and CLL-B cells.   
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As expected, a larger variety of proteins were identified in healthy hPMBC samples given that 
hPMBC samples not only contain healthy B-cells but also various additional blood cells. Proteins 
identified exclusively in CLL samples or simultaneously in hPMBC and CLL samples may 
potentially be involved in CLL pathogenesis such as ABHDA, ABHEB, ESTD, LYPA1 and LYPA2.  
Interestingly, phospholipases shown to be overexpressed in CLL cells at the gene expression 
level, were not identified among the cellular target of palmostatin B at the exception from APT1. 
In addition, proteomic analysis showing APT1 as a cellular target of palmostatin B in primary 
hPMBC and CLL cells, were found to be consistent with Western blotting experiments. Although 
proteomic analysis could only identify the hydrolase ABHEB in CLL cells and not in hPMBC cells, 
its unique implication in CLL disease is very unlikely. Instead, a CLL overexpression of one (or 
several) protein(s) targeted by palmostatin B is more likely. This hypothesis would indeed be 
consistent with the reported lipase overexpression in CLL cells over healthy B-cells.41 The 
relevance of the proteomic data was confirmed by the strong correlation observed when 
assigning the five proteins with a fluorescent labeling profile obtained previously under similar 
conditions (Figure 2.9).   
 
 
Figure 2.9 Assignment of the proteins identified by proteomic analysis to the fluorescence labeling 
profile. Fluorescent labeling profile using palmostatin B-derived probe 23 after 20 minutes incubation with 
healthy hPMBC cells or B-CLL cells at 50 µM concentrations compared to their respective negative control 
treated with DMSO. The major fluorescent bands were correlated to hydrolase/lipases identified by mass 
spectrometry either exclusively in the CLL sample or simultaneously in CLL and hPMBC samples. Data 
based on three independent experiments.  
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APT1 (or LYPA1) and APT2 (or LYPA2) proteins found in both healthy and CLL cells as a strong 
fluorescent band at approximately 25 kDa, constitute possible Fas depalmitoylating enzyme  
given that both were already shown as Ras depalmitoylating enzymes, and that APT1 was shown 
to be overexpressed in CLL cells by gene expression profiling experiments.41 Moreover, 
palmostatin B inhibit APT1 and APT2 in vitro with a higher efficiency over orlistat (IC50 (APT1, 
Orlistat) = 549 +/-171 nM , IC50 (APT2, Orlistat) = 408 +/- 211 nM, IC50 (APT1, PalmB) = 5.37+/-
0.38 nM , IC50 (APT2, PalmB) = 19.58 +/- 0.87 nM; values obtained with the DiFMUO fluorescent 
assay for APT1 and APT2) which would be consistent with the stronger induced apoptosis 
observed upon palmostatin B treatment compared to orlistat.  
 
Additional Fas depalmitoylation enzyme candidates are the hydrolases ABHDA and ABHEB 
found in both healthy and B-CLL samples as a strong fluorescent band at approximately 35 kDa. 
Although these two proteins have a Ser-Asp-His catalytic triad necessary for their hydrolase 
activity, no depalmitoylating activity is reported. However, given the mitochondrial localization 
of the protein ABHDA, relevance to Fas depalmitoylation is unlikely. In contrast, the protein 
ABHEB which mainly localized in the cytoplasm, and which has a reported hydrolase activity 
toward the ester p-nitrophenyl butyrate in vitro,43 would require additional investigation to 
address its eventual relevance to Fas depalmitoylation. Given its S-formylglutathione hydrolase 
activity,44 the cytosolic serine esterase ESTD presenting a Ser-Asp-His catalytic triad, would also 
require further investigation.  
5 Conclusion  
 
In conclusion, we have succeeded in identifying a number of proteins, whose overexpression in 
CLL cells may potentially be involved in CLL pathogenesis. Wendtner and co-workers are 
currently performing additional experiments in order to address their possible involvement in 
Fas depalmitoylation. In particular, a large effort is spent on APT2 to demonstrate its 
overexpression in CLL cells over healthy B-cells. Although no depalmitoylating activity was 
reported for ABHDA, ABHEB and ESTD, further investigation would also be required given the 
strong intensity of their corresponding bands in the fluorescent labeling profile. In addition, 
given that orlistat was identified as an effective inhibitor of LPL45 and PLA246 (both 
overexpressed in CLL cells) and that both enzymes were not identified among the cellular target 
of palmostatin B, it would be interesting to perform similar labeling experiments using an ABPP-
probe derived from orlistat, in order to know if both compounds are having different target(s) 
both possibly involved in CLL pathogenesis or rather similar target(s) but with different affinity. 
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1 Metabolic labeling of palmitoylated proteins  
 
1.1 Principle of the metabolic labeling  
 
Given that palmitoylated proteins control various cellular processes, the effect of palmostatin B 
(14) on palmitoylated proteins was investigated to potentially discover new applications of 
thioesterase inhibition within the global palmitome. In this context, a metabolic labeling strategy 
based on the reversibility of S-palmitoylation, already reported for the visualization of the 
human palmitome was applied.1 Palmitoylated proteins contained in HeLa cells were 
metabolically labeled by incorporation of the inert palmitate analogue ω16-alkynyl fatty acid 106 
(100 µM). For the metabolic labeling, the cell medium was complemented with 5% of bovine 
serum albumin (BSA) in replacement to fetal bovine serum (FBS), in order to facilitate the 
solubilization of the fatty acid. Subsequently, cells were lysed and alkynylated proteins were 
tagged through a Cu(I)-catalyzed Huisgen [3+2]-cycloaddition using the rhodamine reporter dye 
TriN3 103. After separation by SDS-gel electrophoresis, in gel fluorescence scanning allows for 
the detection of labeled palmitoylated proteins by comparison with a sample treated with 
DMSO (Figure 3.1).    
 
 
 
Figure 3.1 Principle of palmitome labeling experiments. After incubation with ω16-alkynyl fatty acid (106) 
/DMSO for 12 hours, HeLa cells are lysed and alkynytated proteins are subsequently tagged through Cu
(I)
-
catalyzed Huisgen [3+2]-cycloaddition. After separation by SDS-gel electrophoresis, fluorescence scanning 
allows the visualization of fluorescently labeled palmitoylated proteins as well as unspecific binding 
(DMSO sample). Mass spectrometry subsequently allows the identification of the labeled palmitoylated 
proteins.  
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1.2 Synthesis of ω16-alkynyl fatty acid 106  
 
ω16-Alkynyl fatty acid 106 (15-hexadecyn-1-oic acid) was synthesized according to the 
literature1 from commercially available 7-hexadecyn-1-ol 104 in two steps consisting in a zipper 
reaction or base-catalyzed isomerization of an internal alkyne to a terminal alkyne employing 
sodium hydride and 1,3-diaminopropane (DAP). Terminal alkyne 105 was subsequently oxidized 
to carboxylic acid 106 using the Jones reagent (Scheme 3.1).  
 
Scheme 3.1 Synthesis of ω16-alkynyl fatty acid 106. Reagents and conditions: a) NaH (8.0 eqv.), 70°C in 
DAP, then alkyne (1.0 eqv.), 55°C, overnight, 90% yield. b) Jones oxidation (CrO3/H2SO4/H2O) in acetone, 
94% yield.  
 
1.3 Optimization of the labeling conditions   
 
For the optimization of the metabolic labeling experiments, it was chosen to use a relatively 
large amount of HeLa cells (1.5*106 cells) to ensure the visualization of palmitoylated proteins 
which are generally present in low abundance. S-palmitoylated proteins were originally 
postulated to be enriched in lipid rafts due to their palmitate moieties, and therefore their 
solubilization from these detergent resistant membranes would require specific treatments such 
as the use of methyl-β-cyclodextrin. However, a recent global analysis of palmitoylated proteins 
in membrane domains,2 revealed a considerable amount of S-acylated proteins contained in 
non-raft membranes including palmitoylated Ras proteins. Therefore, several mild lysis 
conditions were investigated to solubilize a maximal amount of palmitoylated proteins from 
membranes. After metabolic incorporation of ω16-alkynyl fatty acid 106 (100 µM, 5 hours, 
37°C), HeLa cells were lysed either by sonication in PBS buffer or using detergent-containing lysis 
buffers (1% NP40). After click ligation followed by sample enrichment using streptavidin 
magnetic beads, target proteins were separated by SDS-gel electrophoresis allowing to observe 
the influence of the lysis conditions on the fluorescent labeling profile by comparison with a 
control treated with DMSO. 
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In gel fluorescence scanning revealed a similar labeling profile when using PBS or a phosphate 
buffer containing 1% NP40 (referred to as buffer B), with several strong fluorescent bands 
compared to the negative DMSO control. In particular, one band was located at 21 kDa which 
may correspond to palmitoylated Ras isoforms (~21 KDa for H-Ras, N-Ras and K-Ras4A). In 
contrast, employing the detergent-containing lysis buffer referred to as buffer A, no fluorescent 
bands was observed due to the cleavage of the rhodamine reporter group by mercaptoethanol 
contained in the buffer. However, the labeling profile is likely to be similar to the two previous 
conditions. In addition, given that gels were typically run over night in a DTT-containing loading 
buffer, decrease in fluorescent labeling is also possible. As exclusion of reducing reagent from 
the loading buffer usually results in smearing bands,3 the use of a TCEP-containing loading buffer 
could be an alternative to denaturate proteins. Finally, gel staining techniques allowing the use 
of N3-(azidopropyl)-biotinamide were preferred for protein visualization and were used in all 
newly performed labeling experiments (Figure 3.2). 
 
A B  
  
1. DMSO control  
Mechanical lysis (PBS) 
Click ligation in PBS 
 
2. ω16-alkynyl acid 106 (100µM)   
Mechanical lysis (PBS) 
Click ligation in PBS 
 
3. ω16-alkynyl acid 106 (100µM)  
Detergent lysis (buffer A) 
Click ligation in lysis buffer A  
 
4. ω16-alkynyl acid 106 (100µM)  
Detergent lysis  (buffer B) 
Click ligation in lysis buffer B  
Figure 3.2 Comparison of the fluorescent labeling profile obtained using different lysis conditions. A) 
Principle of the metabolic labeling and explanation for the loss of rhodamine reporter group using thiols 
(-mercaptoethanol (-ME) or DTT). B) Fluorescent gel highlighting few bands not present in the DMSO –
treated control using various lysis conditions. Condition: HeLa cells= 1.5*10 
6
, ω16-alkynyl fatty acid (106) 
/DMSO= 100
 
µM (in a 5% BSA-containing media, 5 hours), lysis, click ligation (TrifN3 (103) = 15 µM, 
TCEP:HCl = 0.5 mM, ligand = 50 µM, CuSO4 = 0.5 mM). Buffer A: 50mM PIPES, 50mM NaCl, 5mM 
MgCl2.6H2O,1% NP40, pH 7.4, mercaptoethanol (0.1%), protease inhibitor cocktail Mini. Buffer B: 150mM 
NaCl, 100mM phosphate buffer pH 7.5, 1% NP40, protease inhibitor cocktail Mini. 
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1.4 Proteomic analyses  
 
Before SILAC quantification, two similar experiments performed either in PBS buffer or in 1% 
NP40 containing PBS buffer, were submitted to proteomic analyses in order to compare their 
labeling efficiency. Importantly, neither the use of BSA nor the use of the detergent-containing 
lysis buffer was a problem; however protein identification was extremely difficult given a high 
number of proteins present in both samples treated with ω16-alkynyl fatty acid and with DMSO 
respectively. Given a relatively simple fluorescent labeling profile similar to Figure 3.2B, 
unspecific binding due to the protein carrier BSA is likely to occur, generating protein aggregates 
which may unspecifically attached to streptavidin beads. One alternative to avoid such a 
problem, would consist in releasing first S-palmitoylated proteins from streptavidin beads by 
employing hydroxylamine (0.32M at pH= 6.8, for 1 hour at 37°C)44 to cleave thioester bonds and 
in a second step to thermo-detach unspecifically bound proteins from the beads consisting in 
non-fluorescently labeled proteins. Therefore, experiences developed to evaluate the effect of 
palmostatin B on palmitoylated proteins will be performed using the hydroxylamine-based 
strategy to limit protein identification problems, and cells will be mechanically lysed in PBS 
buffer for practical reason. 
 
2 Quantification of palmostatin B’s effect on the human palmitome 
 
2.1 Principle of the double metabolic labeling  
 
To quantify the effect of palmostatin B (14) on relative levels of palmitoylated proteins, the 
SILAC (stable isotope labeling with amino acids in cell culture) method was applied to HeLa cells, 
given that such method would permit to avoid risk of quantification errors due to for example 
unequal sampling. Two different cell populations were grown in SILAC media complemented 
either with heavy (isotopic, 13C) or light (normal, 12C) arginine and lysine. The use of both amino 
acid permits to ensure the isotopic labeling of all peptides given that protein digestion with 
trypsin cleaves proteins after lysine and arginine residues. After five cell duplication cycles, the 
amino acid incorporation should be completed. This allows the metabolic labeling of the distinct 
cell populations by incubation of the cells with ω16-alkynyl fatty acid (106) for 12 hours at 100 
µM, in their respective SILAC media in which FBS was replaced by 5% BSA. Subsequently, 
isotopically labeled cells were treated for 3 hours with palmostatin B at a non-cytotoxic 
concentration of 30 µM, whereas the other cell population was treated with DMSO (cell 
incubation in their respective SILAC media). Cells from the obtained populations were finally 
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washed with PBS buffer, treated with trypsin and lysed by sonication in 1 ml PBS, respectively. 
Once their correct and complete amino acid incorporation was determined by mass 
spectrometry, the two resulting cell populations were mixed in a 1:1 ratio based on their 
respective cell concentration, typically more accurate compared to protein concentration. 
Finally, a 1 ml volume of cell lysate containing 5*105 cells taken from each cell populations (106 
cells/ml in total) was tagged through a Cu(I)-catalyzed Huisgen [3+2]-cycloaddition with N3-
(azidopropyl)-biotinamide. After click ligation followed by sample enrichment using streptavidin 
beads, palmitoylated proteins were released using hydroxylamine and beads were subsequently 
boiled 5 min in SDS-loading buffer to detach proteins binding unspecifically to the beads. Finally, 
the hydroxylamine cleavage solution containing released S-palmitoylated proteins was 
concentrated to be fully loaded on a 12 % SDS gel to be compared with proteins released by 
boiling the beads, applied on the gel as a distinct band. A sample of the initial cell lysate mixture 
(taken before initiating the click ligation) was additionally loaded on the gel in order to quantify 
the effect of palmostatin B (14) on the palmitoylation level of proteins. In parallel, the two 
isotopically distinct cell populations were treated only with DMSO, mixed in a 1:1 ratio and 
proceed like previously leading to the three corresponding samples referred to as NH2OH, Lysate 
and Δ used as negative control. After separation by SDS-gel electrophoresis, the gel containing 
all six samples was silver stained revealing a significantly weaker amount of proteins in samples 
obtained after hydroxylamine treatment compared to samples obtained by boiling the beads, 
thereby confirming unspecific binding. After band isolation followed by protein digestion, mass 
spectrometry analysis was performed to compare the relative peak intensity of isotopic peptide 
pairs in all six different samples, with peptide pairs distinguishable by a +6 Da mass difference. 
Given that proteins collected using hydroxylamine are palmitoylated, they may be affected upon 
palmostatin B treatment. For example, H- and N-Ras proteins, whose depalmitoylation is 
inhibited by the APT1/APT2 inhibitor palmostatin B, should present significant differences in the 
relative intensity between their peptide pairs, consistent with a higher Ras palmitoylation level 
in cells treated with palmostatin B compared to control cells treated with DMSO. In contrast, the 
relative intensity between peptide pairs from proteins unspecifically binding to streptavidin 
beads should remain identical to the ratio evaluated for the cell lysate mixture employed. In 
addition, the negative control experiment employing DMSO in both cell populations would be 
expected to lead to identical peptide pair ratios after and before double metabolic labeling 
pulldown experiments (Figure 3.3B).   
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Figure 3.3 Double metabolic labeling experiments to quantify palm B’s effect on palmitoylated proteins. 
A) Principle of the experiment. After metabolic labeling of two cell populations with ω 16—alkynyl fatty 
acid 106 (100 µM), palmostatin B (C=30 µM) and DMSO are added respectively to the two cell populations 
(isotopically labeled and normal). After cell lysis, cell lysates are mixed in a ratio 1:1 (10
6 
total
 
cells/ml) and 
alkynylated proteins are tagged by click ligation (conditions: Biotin-N3 = 30µM, TCEP:HCl = 0.5 mM, ligand 
= 50 µM, CuSO4 = 0.5 mM). After enrichment with streptavidin magnetic beads, thioester linkages are 
cleaved off employing hydroxylamine (0.32M, pH=6.8, 1h, 37°C, sample referred to as NH2OH). Proteins 
remaining on the beads are finally released by boiling the sample in SDS loading buffer (5 min, 96°C, 
sample referred to as Δ). After protein separation by SDS-gel electrophoresis, silver staining allow the 
visualization of proteins contained in the different samples referred to as LYSATE, NH2OH and Δ 
respectively. Bands isolation followed by protein digestion finally allow the evaluation of the relative peak 
intensity of isotopic peptide pairs in all samples. B) Relative peak intensity of isotopic peptide pairs. In 
theory, a 1:1 ratio should be visible for proteins contained in the initial lysate. Proteins obtained using 
hydroxylamine should be affected by palmostatin B in contrast to proteins thermo-detached from the 
beads which should not be affected. In the DMSO control experiment, the relative peak intensity of 
isotopic peptide pairs should not be affected, with ratios identical before and after pulldown experiments. 
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2.2 Result and discussion 
 
In order to limit identification problem, proteins of interested were first released by 
hydroxylamine treatment. In addition, protein digestion was performed on smaller gel pieces in 
order to help for protein identification (typical area of 10 mm2 instead of 1 cm2). Therefore, only 
a restricted part of the gel comprising proteins below 35 kDa was digested, given that the 
APT1/2 inhibitor palmostatin B should influence at least the palmitoylation level of N-and H-Ras 
isoforms (~ 21 KDa). For optimal quantitative proteomic analyses, several points are of utmost 
importance. First, absolute peak intensities need to be sufficient to distinguish between signal 
peaks from background peaks. Second, relative peak intensities of isotopic peptide pairs have to 
be fixed as closed as possible to a ratio of heavy/light labeled peptides (H/L) of 1:1 in order to 
limit quantification errors. Relative ratios of peptide pairs in initial cell lysate mixtures treated 
with palmostatin B/DMSO or only with DMSO were found to vary from H/L = 0.97 to H/L = 1.7 
and from H/L = 0.69 to H/L = 1.70 respectively. In this context, accurate proteomic 
quantifications should be possible. Therefore, in order to evaluate the effect of palmostatin B on 
protein palmitoylation level, relative ratios of isotopic peptide pairs after pulldown were 
compared to initial ratios ( in cell lysate). In the condition of the experiment, the inhibition of 
protein depalmitoylation by palmostatin B should be visible by a H/L ratio above 1, whereas the 
inhibition of protein palmitoylation should lead to a H/L ratio below 1. Relative ratios of isotopic 
peptide pairs in the sample containing palmitoylated proteins, referred to as the NH2OH sample 
were evaluated leading to H/L ratios varying from 0.1 to values largely above 10 (~33). Note: H/L 
ratio values which are not contained in the range [0.1-10] have typically a large statistical 
variability and are therefore too uncertain to be considered. Surprisingly, relative ratios of 
isotopic peptide pairs contained in the sample referred to as Δ, containing in theory only (or 
largely) unspecifically bound proteins were also significantly different from initial ratios, with H/L 
ratios between 0.25 and ~12. In order to rationalize these observations, the control experiment 
performed employing the two cell populations in combination with DMSO was analysed. 
Relative peak intensities of isotopic peptide pairs contained in sample after pulldown 
experiments were also largely modified from initial ratios with H/L ratios varying from values 
below 0.1 to values largely above 10 (~93), and from 0.18 to ~11 in samples referred to as NH2OH 
and Δ respectively. Given that both experiments performed with palmostatin B and DMSO 
respectively, were influenced with a similar magnitude, such effects are therefore very likely not 
due to palmostatin B. Moreover, unspecific binding to streptavidin beads may not explain this 
effect given that proteins would be expected to be enrolled in protein aggregates without any 
distinction between isotopically labeled or normal proteins. Although further investigations 
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would be required, several explanations could be proposed. First, the metabolic labeling with 
ω16-fatty acid 106 may differ between normal and isotopically labeled proteins. Alternatively, 
the availability of the alkyne functionality for the click ligation may be affected by changes in 
protein structures potentially induced by the double labeling (isotopic follow by metabolic 
labelings).   
3 Conclusion and outlook 
 
In conclusion, conditions for the metabolic labeling and the visualization of palmitoylayed 
proteins contained in HeLa cells were successfully optimized, allowing notably the detection of 
an intense fluorescent band at approximately 21 kDa which may correspond to palmitoylated 
Ras isoforms. Subsequently, SILAC experiments employing an inert alkynylated palmitate 
analogue in double metabolic labelling experiments were developed in order to evaluate the 
influence of palmostatin B on the complete palmitome. Although, these experiments did not so 
far permit any quantification, these experiments permitted to stress some points which would 
need further investigation. In particular, relative ratios of isotopic peptide pairs were largely 
modified after pulldown experiments in the DMSO control for an unclear reason. Tentative to 
reproduce this control experiment failed due to bacterial contaminations. However, it would be 
worth to clarify this point before performing any new quantification experiments. After further 
investigations and optimizations, this strategy may allow the systematic evaluation of the effect 
of palmostatin B on the human palmitome, and may lead to the discovery of new interesting 
applications for thelactones in general and of thioesterase-mediated processes in particular.  
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1 Design of stable APT1/2 inhibitor candidates 
 
Subsequently to the discovery of APT1 and APT2 as Ras depalmitoylating enzymes and given that 
targeting these enzymes may constitute a viable approach to interfere with aberrant Ras 
signaling, various new APT1/2 inhibitor candidates were designed, which in contrast to the 
previous -lactone inhibitors, would be regarded as stable transition state mimics of the 
deacylation process. Therefore, thelactone core was replaced by new electrophilic motifs 
such as -keto oxazole, -keto amide and trifluoromethyl ketone, chosen for their steric 
hindrance comparable to thelactone core, which may limit additional strain due to steric 
repulsions with the enzyme. In this context, and in analogy to previous work, functional groups 
allowing stabilizing binding interactions in the enzyme active site (SO2 and NMe2) which served 
well for the inhibitory activity of lactone inhibitors were introduced in the inhibitor side chain  
(R in blue), and their optimal position in the enzyme active site was investigated. When possible, 
a lipophilic tail (in red) mimicking palmitic acid was also introduced on the opposite site of the 
molecule to create affinity for the enzyme lipid-binding pocket (Scheme 4.1). 
 
Scheme 4.1 Design of stable APT1/APT2 inhibitor candidates based on structural similarities with native 
APT1 substrates. A) Depalmitoylation mechanism by the serine hydrolases APT1/APT2, regenerated by 
hydrolysis. B) Designed -lactone APT1/APT2 inhibitors as transition state mimic of the deacylation 
process leading to the slow enzyme regeneration or reactivation. C) Newly designed APT1/APT2 inhibitors 
(-Keto-amide, Keto-CF3/CF2CF3 and -Keto oxazole) as stable transition state mimics of the 
deacylation process.   
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2 -Keto amide inhibitor candidates  
 
2.1 Synthesis of theketo amide library  
 
Synthesis of the amine spacer 
Regarding the amine spacer synthesis, a one step approach consisting in a Mitsunobu1 reaction 
was first investigated for alcohol 109, obtained in 75% through reduction of ester 108. 
Conversion of alcohol 109 into N-Boc protected amine 110 followed by in-situ deprotection 
using TFA, only permits to obtain amine spacer 111 in 14% yield. Attempts to first isolate the less 
polar di-tert butyl carbamate protected amine 110 to perform in a second step the BOC 
deprotection, was also disappointing with compound 110 obtained in a moderate 42% yield 
(Scheme 4.2).  
 
 
Scheme 4.2 Synthesis of amino spacer 111 via a Mitsunobu reaction. Reagents and conditions: a) Cs2CO3 
(1.1 eqv.), EtOH, reflux, 2.5h, iodoester 107 (1.1 eqv.), 40°C, 18h, 75%. b) LiAlH4 (1.25 eqv.), THF, 0°C, 1h 
then rt, 2h, 87% yield. c) PPh3 (4.0 eqv.), DBAD (3.0 eqv.), Di-t-butyliminodicarboxylate (4.0 eqv.), 0°C (30 
min), dry CH2Cl2, 42% yield. d) TFA, 0°C, 1h30, 14% yield (over two steps c and d). 
 
As an alternative, a two step procedure was preferred involving the in-situ formation of a 
brominated intermediate, which reacts with sodium azide through a nucleophilic substitution 
leading to the corresponding azido derivatives.2,3 Reduction of purified azido derivatives 118-121 
by hydrogenation4 completed the synthesis of amine spacers  (n= 2, 3, 5, 6) obtained in a good 
overall yield as no additional purification step on the amine was required (Scheme 4.3). 
 
 
Scheme 4.3 Synthesis of amino spacers through the formation of azido-intermediates. Reagents and 
conditions: a) Cs2CO3 (1.1 eqv.), EtOH, reflux, 2.5h, iodoester (1.1 eqv.), 40°C, 18h, 75-97% yield. b) LiAlH4 
(1.3 eqv.), dry THF, 0°C (1h), rt (2h), 87-93% yield. c) PPh3 (2.0 eqv.), dry DMF, NBS (2.0 eqv.), 55°C (2h), 
NaN3 (7.0 eqv.), 85°C (13h), 54-68% yield. d) 10% Pd(C), dry MeOH, H2, rt (21h), 86-99% yield. 
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Amide coupling reactions with  hydroxy acids 
The importance of protecting groups for coupling reactions with -hydroxy acids was first 
investigated. Therefore, -hydroxy acid 126 was synthesized by the reaction of commercially 
available -brominated carboxylic acid 125 with sodium hydroxide.5 TBDMS-protected -
hydroxy acid 127 was subsequently obtained from 126 in 76% yield using imidazole/TBDMSCl.5,6 
Protected as well as unprotected -hydroxy acids were subsequently investigated for optimal 
coupling conditions with the amine 123 (n=3). Reactions performed using HOBT (1.2 eqv.) and 
EDC:HCl (3.3 eqv.) as coupling agent with an excess of unprotected -hydroxy acid 126 (1.25 
eqv.) were optimal leading to 129 in 76% yield, whereas the use of NMM/ isobutylchloroformate 
was optimal for reactions with protected -hydroxy acid 127 leading to 128 in 56% yield. 
Although TBDMS deprotection of compound 128 with TBAF was performed in 68% yield,5,6 the 
approach starting directly from unprotected -hydroxy acids was more straightforward with a 
higher overall yield.  Subsequently, a Swern oxidation was performed on compound 129 to 
obtain keto-amide 130. However the reaction generated many decomposition products (Scheme 
4.4).  
 
Scheme 4.4 Synthesis ofketo amide 130 from protected and unprotected -hydroxy acids. Reagents 
and conditions: a) NaOH (8.0 eqv.), H2O, 80°C, 24h, 94% yield. b) imidazole (2.0 eqv.), DMF, 0°C, TBDMSCl 
(4.0 eqv.), 24h, rt, 76% yield. c) Amine 123 (1.0 eqv.), unprotected -hydroxy acid (1.25 eqv.), HOBT (1.2 
eqv.), EDC.HCl (3.3 eqv.), rt, overnight, 76% yield. d) N-Methylmorpholine (0.8 eqv.), 
Isobutylchloroformate (0.8 eqv.), Amine 123 (1.2 eqv.), THF, -10°C (1h), rt overnight, 57%. e) TBAF (6.0 
eqv.), THF, rt, overnight, 68% yield. f) DMSO (2.4 eqv.), oxalyl chlorid (1.1 eqv.), NEt3 (3.65 eqv.), CH2Cl2, 
failed. 
 
Amide coupling reactions with  keto acids 
Aware of the relative instability of -keto acids and the possibility of side reactions, coupling 
reactions directly with -keto acids have been regarded as challenging. However, given the 
disappointing results obtained with unprotected or protected -hydroxy acids, coupling 
reactions directly with - keto acids were reconsidered. The synthesis of -keto acid 134 started 
with the -methylenation of the commercially available aldehyde 131 using aqueous formalin 
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and dimethylamine hydrochloride, leading to compound 132 in 76% yield.7 -Methylenated 
aldehyde 132 was subsequently oxidized to carboxylic acid 133 in 86% yield using sodium 
chlorite (NaClO2), sodium phosphate (NaH2PO4) and 2-methyl-2-butene as HCl scavenger.
8 After 
unsuccessful attempts to perform ozonolysis of compound 133,8 the oxidative cleavage of the 
alkene was finally performed via a Lemieux-Johnson oxidation,9-11 involving catalytic amounts of 
osmium tetroxide and sodium periodate in aqueous dioxane, leading finally to -keto acid 134 in 
87% yield (Scheme 4.5).  
 
 
Scheme 4.5 Synthesis of -keto amides (135-137) from -keto acid 134. Reagents and conditions: a) 
NMe2H.HCl (1.2 eqv.), 37% aqueous formalin (1.2 eqv.), 70°C, 24h, 76% yield. b) NaClO2 (2.3 eqv.), 
NaH2PO4 (2.0 eqv.), 2-methyl-2-butene (3.0 eqv.), t-BuOH/H2O (3:1), rt, 4h, 86% yield. c) 6 mol% OsO4, 
NaIO4 (3.0 eqv.), Dioxane/H2O (3:1), rt, overnight, 87% yield. d) Various coupling conditions investigated 
between-keto acid 134 and various amine spacers.  
 
Several coupling conditions were subsequently tested using an excess of -keto acid 134 to 
investigate the possibility to perform coupling reactions directly with -keto acids. Although low 
yields were obtained for this one-step approach, the use of isobutylchloroformate/N-methyl 
morpholine or EDC:HCl as coupling reagents led to a small set of -keto amides, used to evaluate 
their in-vitro APT1 and APT2 inhibitory activity, before considering an alternative synthetic route 
(Table 4.1). 
 
ENTRY Amine  Condition  Yield 
1 
111: n=6 (1 eqv.) HATU (1.5 eqv.), DIPEA (2 eqv.), CH2Cl2, rt , overnight DC 
2 
111: n=6 (1 eqv.) HBTU (1.5 eqv.), DIPEA (2 eqv.), CH2Cl2, rt , overnight DC 
3 
111: n=6 (1 eqv.) NMM(1eqv.), Isobutylchloroformate (1 eqv.), THF, rt, 16h 33% 
4 
124: n=5 (1 eqv.) EDC.HCl (3 eqv.), CH2Cl2, rt , overnight 40% 
5 
122: n=2 (1 eqv.) EDC.HCl (3 eqv.), CH2Cl2, rt , overnight 22% 
 
Table 4.1 Optimisation coupling reactions with -keto-acids. Table showing the coupling reactions 
investigated using an excess of-keto acid 134 (1.2 eqv.). DC= decomposition products.  
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Derivatization to the sulfone using Oxone® 
To investigate the effect of a sulfone on the inhibitory activity, -keto amide 136 was converted 
to its oxidized form 138 using an excess of potassium hydrogen monoperoxysulfate (Oxone®)12 
in aqueous methanol at room temperature. The reaction proceeded through the formation of a 
sulfoxide intermediate, which subsequently converted to the sulfone as single product after 24 
hours.-Keto amide 138 was isolated in 52% yield after reverse phase C18 column 
chromatography (Scheme 4.6). 
 
 
Scheme 4.6 Oxidation of -keto amide 136 into sulfone 138 using Oxone®. Reagents and conditions:  a) 
Oxone® (3.0 eqv.), MeOH:H2O (3:2), 24h, rt, 52% yield. 
 
2.2 In vitro evaluation for APT1/2 inhibition 
 
The small -keto amide library (135-138) was subsequently screened for APT1 inhibition using 
the colorimetric assay based on PNPO after 30 min pre-incubation. The APT1 activity remaining 
at 50 µM was evaluated for each compound based on three independent experiments. No 
promising APT1 inhibitory activity was detected, with a maximal of 25 % APT1 inhibition 
observed using 50 µM of compound 137. Potency for APT1 inhibition is therefore largely below 
that of the -lactone inhibitors under similar conditions. In order to investigate their inhibitory 
effect on APT2, -keto amides were screened using the fluorescent assay based on DiFMUO. 
APT2 activities remaining at 50 µM were evaluated for each compound based on three 
independent experiments. With an activity remaining between 30-50 %, -keto amides were 
significantly weaker APT2 inhibitors (IC50 values slightly below 50 µM) compared to -lactone 
inhibitors, characterized by low nanomolar IC50 values under similar conditions (Table 4.2). 
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Table 4.2 Evaluation of the -keto amide library for APT1/APT2 inhibition. Residual APT1 and APT2 
activity in percentage obtained for -keto amides (135-138) at 50 µM concentration using respectively the 
colorimetric assay (PNPO = 600 µM, APT1 = 75 nM, 30 min inhibitor pre-incubation) and the fluorometric 
assay (DiFMUO = 15 µM, APT2 = 50 nM, 2 min inhibitors pre-incubation). Z’ factors were in all cases higher 
than 0.80. Data based on three independent experiments. 
 
3 -Keto CF2CF3/CF3 inhibitor candidates  
 
3.1 Synthesis of the -keto CF2CF3/CF3 library 
 
The synthesis of - keto CF2CF3/CF3 inhibitor candidates started with ethyl esters hydrolysis into 
their corresponding carboxylic acids 139-143, followed by their conversion in a single step to 
trifluoromethyl ketones 144-148 and pentafluoroethyl ketones 149-153 using respectively ethyl 
trifluoroacetate and ethyl pentafluoroacetate.13 Treatment of carboxylic acids 139-143 with LDA 
generated an enediolate dianion, which was subsequently trifluoro/pentafluoro acetylated. 
After decarboxylation by acidic treatment, trifluoromethyl ketones 145-148 and 
pentafluoroethyl ketones 150-153 were obtained. Reactions proceeded in moderate yield (46-
53% over two steps), but failed when using carboxylic acid 139 (n=2), probably due the 
enediolate instability leading into lithium acrylate and lithium 3-(dimethylamino)propane-1-
thiolate. In order to investigate the effect of sulfone polar head groups on the inhibitory activity, 
compound 148 was further oxidized to compound 154 in 35 % yield, using an excess of oxone® in 
aqueous methanol (Scheme 4.7).12 
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Scheme 4.7 Synthesis of -keto-CF3 and -keto-CF2CF3 libraries. Reagents and conditions: a) NaOH (1.0 
eqv.), H2O:EtOH, rt, 2h. b) Diisopropylamine (3.5 eqv.), n-Buli (3.4 eqv.), -78°C, carboxylic acid 139-143 (1.0 
eqv.), THF, rt (4h), XCOOEt (3.0 eqv., X= CF3 or CF2CF3), -78°C (15 min), 6N HCl, 45-53 % yield (over two 
steps). c) Oxone® (3.0 eqv.), MeOH/H2O (3/2), overnight, rt, 24h, 35% yield. Reactions with carboxylic acid 
139 (n=2) failed in leading to compound 144 and 149.  
 
3.2 In vitro evaluation for APT1/2 inhibition 
 
By analogy to -keto amides, trifluoromethyl ketones and pentafluoroethyl ketones were first 
screened for APT1 inhibition using the colorimetric assay to evaluate the APT1 activity remaining 
at 50 µM compound concentration.  All compound tested were shown to be at best weak APT1 
inhibitors (Table 4.3).   
 
 
Table 4.3 Evaluation of -keto CF2CF3/CF3 libraries for APT1 inhibition. Residual APT1 activity in 
percentage obtained for -keto CF2CF3/CF3 compounds at 50 µM concentration using the colorimetric 
assay (PNPO = 600 µM, APT1 = 75 nM, 30 min inhibitor pre-incubation). Z’factors were in all cases higher 
than 0.80. Data based on three independent experiments. 
 
The APT2 activity remaining at 50 µM compound concentration was evaluated using the APT2 
fluorescent assay. No APT2 inhibitory activity was detected among this family of compound at 50 
µM concentration (Table 4.4). 
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Table 4.4 Evaluation of -keto CF2CF3/CF3 libraries for APT2 inhibition. Residual APT2 activity in 
percentage obtained for -keto CF2CF3/CF3 compounds at 50 µM concentration using the fluorometric 
assay (DiFMUO = 15 µM, APT2 = 50 nM, 2 min inhibitors pre-incubation). Z’ factors were in all cases higher 
than 0.80. Data based on three independent experiments. 
 
4 -Keto oxazole inhibitor candidates  
 
4.1 Synthesis of the -keto oxazole library 
 
Synthesis of C5-functionalized Oxazoles  
Tosylmethyl isocyanide (TosMIC) is a widely used and versatile building block for many organic 
reactions such as for the van Leusen oxazole synthesis consisting in a base-catalysed 
cycloaddition of TosMIC with aldehydes leading to C5-substituted oxazoles.14 Such reactions 
occur through the formation of a 4-tosyl-oxazoline intermediate, which after -elimination of a 
tosyl leaving group (TsH) furnishes the oxazole core (Scheme 4.8).  
 
 
Scheme 4.8 Synthesis of C5-substituted oxazoles using Van Leusen oxazole synthesis. Reaction 
employing the TosMIC reagent to generate the 4-tosyl-oxazoline intermediate 155 undergoing 
subsequently a tosyl group elimination leading to oxazole 156.  
 
For obvious handling reasons, the TosMIC reagent is regarded as an attractive alternative to the 
odorous methyl isocyanide. Therefore, given the numerous TosMIC-mediated reactions reported 
in the literature to access 5-aryl substituted oxazoles, the Van Leusen strategy was first 
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investigated with aldehyde 54. After various reactions with organic and inorganic bases, oxazole 
156 was finally obtained in 16% yield by the successive addition of K2CO3 (1 eqv.) followed by 
KOH (14 eqv.) in refluxing methanol15 or in 30% yield using NaOMe (6 eqv.) in methanol (110°C). 
Subsequently, tosyl-oxazoline intermediate 155 was isolated in 45% yield using potassium 
carbonate (3.0 eqv.) in refluxing acetonitrile (85°C). Attempt to generate oxazole 156 from 
intermediate 155 using various solvent\base combinaisons (DBU, KOH, t-BuOK16,17) failed, 
leading to decomposition products.   
Alternatively, the Schöllkopf oxazole synthesis was investigated consisting in a base-mediated 
reaction of methyl isocyanide (CH3N≡C) with an ethyl ester
18 leading to a transient -keto-
isocyanide, which after rearrangement into its enolic form, cyclize to generate the oxazole ring. 
In contrast to the Van Leusen synthesis mainly applied to aryl aldehydes, numerous C5-alkyl 
substituted oxazoles were already reported in literature with generally good yields.19-21 In this 
context, methyl isocyanide 157 was prepared22 from N-methylformamide in 76% yield and was 
successfully used for the synthesis of C5-substituted oxazoles with various spacer length (n=2-6), 
obtained  in 84-94 % yields (Scheme 4.9).  
 
 
Scheme 4.9 Synthesis of C5-substituted oxazoles using Schöllkopf synthesis. Reagents and conditions: a) 
MeNC (1.34 eqv.), n-Buli (1.5 eqv.), dry THF, -78°C (2h), then ethyl ester (1.0 eqv.), -78°C (3h) then rt (3h).   
 
Oxazole C2-functionalization  
Although C2-metalated oxazoles have been well documented as existing in equilibrium between 
ring-opened and ring-closed forms depending on the nature of the metal, 2-magnesiated 
oxazoles are known to exist predominantly as a ring-closed system allowing their C2-
functionalization. After an optimized 2 hours deprotonation time using isopropylmagnesium 
chloride,23,24 reaction of C2-metalated oxazoles with Weinreb amides 162-163 (prepared from 
N,O-dimethylhydroxylamine hydrochloride and the corresponding acid chlorides23,25) permitted 
the synthesis of sub-library A (164-173) in moderate yields (24-37%) consistent with the 
literature. Moreover, such low yields were not due to isolation problems given that isolated 
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yields were identical to yields evaluated directly from the crude mixture using DMF as internal 
standard (Scheme 4.10).  
 
 
Scheme 4.10 Oxazole C2-fonctionalization using Weinreb amides. Reaction occurring through the 
formation of 2-magnesiated oxazole intermediates, reacting with Weinreb amides 162-163 to furnish 2,5-
disubstituted oxazoles 164-173. Reagents and conditions: a) i-PrMgCl (1.4 eqv.), dry THF, -15°C (2H15), 
Weinreb amide 162 or 163 (1.0 eqv.), -20°C (30 min) then rt (25 h), Yield = 24-37%.  
 
Derivatization to the sulfone  
To investigate the effect of sulfone groups on the inhibitory activity, oxazoles 164-173 were 
oxidized using Oxone®12 leading to -keto-oxazoles 174-183 denoted sub-library B. Purification 
by reverse phase C18 chromatography (RPC18) permitted to significantly increase the yield of the 
reaction, exemplified by compound 180 (n=3, nC7H15) obtained either in 69% or 30% using RPC18 
or silica gel, respectively. Finally, after RPC18 purification compounds 174-183 were obtained in 
good yields between 70-84% (Scheme 4.11). 
 
 
Scheme 4.11 Derivatization to the sufone using Oxone. Synthesis of sub-library B (174-183) by oxidation 
of sub-library A (164-173). Reagents and conditions:  a) Oxone® (3.0 eqv.), MeOH:H2O (3:2), 60 h, rt, 69-
84% yield after RPC18 column. 
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Quaternization of the amino group using methyl iodide 
Sub-library A and sub-library B were quaternized at the dimethylamino functionality by 
treatment with an excess of methyl iodide in acetonitrile,26 yielding cationic sub-library C (184-
189) and D (190-199) respectively. At the exception of oxazole 199 obtained as traces, yields 
were generally good given that products isolation by precipitation was rendered difficult by the 
relatively low reaction scale, typically from 0.052 to 0.105 mmol. (Scheme 4.12) 
 
 
Scheme 4.12 Derivatization by quaternization. Synthesis of cationic sub-library C (184-189) and sub-
library D (190-199) by amino group quarternization. Reagents and conditions: a) MeI (1.16 eqv.), CH3CN, 
rt, 5 h, precipitation in Et2O. Yield = 44-87% excepted for compound 199 (n= 6, X= SO2, n-C7H15) obtained 
as traces.  
 
4.2 In vitro evaluation for APT1/2 inhibition 
 
The -keto oxazole library was screened to evaluate the residual APT1 activity at 50 µM 
compound concentration. Judging from the obtained values, no promising APT1 inhibitory 
activity was detected.  With an activity remaining of 59 %, -keto oxazole 191 was found as a 
weak APT1 inhibitor (IC50 value slightly above 50 µM) compared to -lactone inhibitors, 
characterized by low nanomolar IC50 values under similar conditions (Table 4.5).   
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Table 4.5 Evaluation of the -keto oxazole library for APT1 inhibition. Residual APT1 activity in 
percentage obtained for -keto oxazoles (164-199) at 50 µM concentration using the colorimetric assay 
(PNPO = 600 µM, APT1 = 75 nM, 30 min inhibitor pre-incubation). Z’ factors were in all cases higher than 
0.80. Data based on three independent experiments. 
 
Oxazole sub-libraries A, B, C and D were subsequently investigated for APT2 inhibition using the 
fluorescent assay based on DiFMUO. The APT2 activity remaining at 50 µM was evaluated for 
each compound based on three independent experiments. However, although -keto oxazoles 
inhibit at best 70-75% of APT2 activity at 50 µM concentration, their potency still remain largely 
inferior to that of the -lactone inhibitors (Table 4.6).   
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Table 4.6 Evaluation of the -keto oxazole library for APT2 inhibition. Residual APT2 activity in 
percentage obtained for -keto oxazoles (164-199) at 50 µM concentration using the fluorometric assay 
(DiFMUO = 15 µM, APT2 = 50 nM, 2 min inhibitors pre-incubation). Z’ factors were in all cases higher than 
0.80. Data based on three independent experiments. 
 
5 Conclusion  
 
Although the effort spent to develop -keto-oxazoles,-keto-CF3, - keto-CF2CF3 andketo-
amide APT1/APT2 inhibitors, no or substantially weaker inhibitory activities were obtained in 
comparison to the activity of the -lactone inhibitors under similar conditions. Therefore, a small 
representative set of compounds containing -keto-oxazoles,-keto-CF3, - keto-CF2CF3 and-
keto-amides were investigated on additional serine hydrolases such as cytosolic phospholipase 
A2 (cPLA2) and fatty acid amide hydrolase (FAAH) in collaboration with Matthias Lehr. As a 
result, none of the compounds tested were shown to inhibit cPLA2. However, -keto oxazoles 
revealed as potent FAAH inhibitors and are the object of the last chapter.  
 
 
 
Chapter 4: APT1/2 inhibitor candidates as depalmitoylation transition state mimics                   100  
6 References  
 
(1) Sun, W.; Pelletier, J. C. Tetrahedron Lett. 2007, 48, 7745. 
(2) Al-Masoudi, N.; Al-Soud, Y.; Schuppler, T. J. Carbohydr. Chem. 2005, 24, 237. 
(3) Hanessian, S.; Ducharme, D.; Masse, R.; Capmau, M. L. Carbohydr. Res. 1978, 63, 265. 
(4) Koshi, Y.; Nakata, E.; Miyagawa, M.; Tsukiji, S.; Ogawa, T.; Hamachi, I. J. Am. Chem. Soc. 
2008, 130, 245. 
(5) Masuda, Y.; Yoshida, M.; Mori, K. Biosci., Biotechnol., Biochem. 2002, 66, 1531. 
(6) Diez, E.; Dixon, D. J.; Ley, S. V.; Polara, A.; Rodriguez, F. Helv. Chim. Acta 2003, 86, 3717. 
(7) Nakatsuji, Y.; Nakamura, T.; Yonetani, M.; Yuya, H.; Okahara, M. J. Am. Chem. Soc. 1988, 
110, 531. 
(8) Hon, Y.-S.; Liu, Y.-W.; Hsieh, C.-H. Tetrahedron 2004, 60, 4837. 
(9) Pappo, R.; Allen, D. S., Jr.; Lemieux, R. U.; Johnson, W. S. J. Org. Chem. 1956, 21, 478. 
(10) Iwata, C.; Takemoto, Y.; Doi, M.; Imanishi, T. J. Org. Chem. 1988, 53, 1623. 
(11) Mori, Y.; Kohchi, Y.; Suzuki, M.; Carmeli, S.; Moore, R. E.; Patterson, G. M. L. J. Org. 
Chem. 1991, 56, 631. 
(12) Veleiro, A. S.; Pecci, A.; Monteserin, M. C.; Baggio, R.; Garland, M. T.; Lantos, C. P.; 
Burton, G. J. Med. Chem. 2005, 48, 5675. 
(13) Reeves, J. T.; Song, J. J.; Tan, Z.; Lee, H.; Yee, N. K.; Senanayake, C. H. J. Org. Chem. 2008, 
73, 9476. 
(14) van, L. D.; van, L. A. M. Org. React. 2001, 57, 417. 
(15) Lee, J. C.; Cha, J. K. J. Am. Chem. Soc. 2001, 123, 3243. 
(16) Krishna, P. R.; Reddy, V. V. R.; Sharma, G. V. M. Synlett 2003, 1619. 
(17) Wei, Z.-L.; Xiao, Y.; George, C.; Kellar, K. J.; Kozikowski, A. P. Org. Biomol. Chem. 2003, 1, 
3878. 
(18) Schoellkopf, U.; Schroeder, R. Angew. Chem., Int. Ed. Engl. 1971, 10, 333. 
(19) Wenkert, D.; Chen, T.-F.; Ramachandran, K.; Valasinas, L.; Weng, L.-l.; McPhail, A. T. Org. 
Lett. 2001, 3, 2301. 
(20) Vedejs, E.; Naidu, B. N.; Klapars, A.; Warner, D. L.; Li, V.-s.; Na, Y.; Kohn, H. J. Am. Chem. 
Soc. 2003, 125, 15796. 
(21) Ohba, M.; Izuta, R.; Shimizu, E. Tetrahedron Lett. 2000, 41, 10251. 
(22) Schuster, R. E.; Scott, J. E., Jr.; Casanova, J., Jr. Org. Synth. 1966, 46, No pp. given. 
(23) Nahm, S.; Weinreb, S. M. Tetrahedron Lett. 1981, 22, 3815. 
(24) Pippel, D. J.; Mapes, C. M.; Mani, N. S. J. Org. Chem. 2007, 72, 5828. 
(25) Trost, B. M.; Lee, C. J. Am. Chem. Soc. 2001, 123, 12191. 
(26) Tamayo, A.; Lodeiro, C.; Escriche, L.; Casabo, J.; Covelo, B.; Gonzalez, P. Inorg. Chem. 
2005, 44, 8105 
 
 
 
  
  
 
 
 
 
CHAPTER 5 
DISCOVERY OF POTENT                                                                  
FATTY ACID AMIDE HYDROLASE (FAAH) INHIBITORS 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Chapter 5: Discovery of potent Fatty Acid Amide Hydrolase (FAAH) inhibitors                              101  
 
1 FAAH as a degradating enzyme of the endocannabinoid system  
 
A well-established function of the endogenous cannabinoid system (ECS) is its role in various 
physiological processes, including brain neuromodulation (learning, memory1, motor 
coordination) but also in the regulation of anxiety2, cell proliferation3,4, inflammation5 and 
appetite. In contrast to classical neuronal signals, travelling from pre- to post-synaptic neurons, 
retrograde endocannabinoid signals travel within the brain from post- to pre-synaptic neurons. 
Recently, a model for retrograde ECS signaling has been proposed.6-8 In this model, when an 
action potential reaches the extremity of the pre-synaptic neuron, neurotransmitters such as 
glutamate are released by the pre-synaptic neuron. Released neurotransmitters bind to post-
synaptic glutamate receptors (AMPA or NMPA), which allows calcium ion channels to open, 
leading to a calcium accumulation in post-synaptic neurons. In turn, calcium activates N-acetyl 
transferase (NAT) and phospholipase C (PLC) involved in arachidonoylethanolamide (AEA, 
anandamide) and 2-arachidonoylglycerol (2-AG) biosynthesis from membrane phospholipids 
phosphatidylethanolamine (PE) and phosphatidyl choline (PC) respectively. After biosynthesis, 
endocannabinoids AEA and 2-AG diffuse out of the post-synaptic neuron to bind and activate 
CB1 receptors (CB1R) located on the pre-synaptic neuron. Activated CB1 receptors couple to G-
proteins to regulate calcium and potassium influx and inhibit the release of neurotransmitters.9 
Once the signal is transmitted, endocannabinoids are redirected in the neuron by an unknown 
mechanism to be enzymatically degraded by two well-characterized serine hydrolases, fatty acid 
amide hydrolase (FAAH)2,10-12 and monoacylglycerol lipase (MAGL). FAAH is located in post-
synaptic neurons and cleaves anandamide (AEA) into arachidonic acid (AA) and ethanolamine, 
whereas MAGL is essentially found in pre-synaptic neurons to hydrolyse 2-AG leading to 
arachidonic acid (AA) and glycerol (Figure 5.1).   
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A B 
 
 
Figure 5.1 Overview of the endocannabinoid system. A) General model for the retrograde 
endocannabinoid signaling occurring in the brain from post-synaptic to pre-synaptic neurons. 1- Release of 
neurotransmitter glutamate upon action potential arrival, 2- Glutamate-mediated activation of post-
synaptic receptors (AMPA, NMDA) allowing Ca
2+
 accumulation in the pre-synaptic neuron, 3- Calcium-
mediated activation of NAT and PLC leading to the biosynthesis of AEA and 2-AG from phospholipids, 4- 
CB1R activation by endocannabinoids AEA and 2-AG, 5- Activation of calcium/potassium ion channels and 
interruption of neurotransmitter releasing, 6- Retrograde signal transmitted and enzymatic degradation of 
endocannabinoids AEA and 2-AG respectively by FAAH and MAGL. B) Structure of the two 
endocannabinoids anandamide (AEA), 2-arachidonoylglycerol (2-AG) and of the hydrolysis product 
arachidonic acid (AA). PC = phosphatidylcholine, PLC= phospholipase C, DAG= Diacylglycerol, DAGL = DAG 
lipase, NAT= N-acetyl transferase, PE= phosphatidyl ethanolamine, NAPE= N-acetyl PE, FAAH= fatty acid 
amide hydrolase, MAGL = monoacylglycerol lipase, CB1R= cannabinoid receptor CB1.  Figure adapted from 
the literature.
6 
 
2 FAAH as an attractive therapeutic target  
 
The biological role of FAAH in the degradation of the endocannabinoid AEA was confirmed by an 
increased AEA brain level in mice with FAAH genetically inactivated  (so called FAAH (-/-) mice).10 
Moreover, FAAH knockdown in mice is associated with various therapeutic effects such as 
analgesic,10 anti-inflammatory10 and anxiolytic effects.10 A positive effect on depression13,14 as 
well as an improvement in sleep15 or in memory acquisition and extinction16 was also later 
discovered in knockout FAAH (-/-) mice. Given such promising effects observed in animal 
models, an extensive effort was spent to modulate the ECS by developing FAAH inhibitors17-19 for 
the treatment of various important diseases (neurodegenerative disorders, eating disorders, 
metabolic disorders, and emotional disorders).20-23  
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2.1 First generation FAAH inhibitors 
 
Originally identified in rat24 and porcine brain25 as an anandamide (AEA) amidase, the enzyme 
was subsequently renamed in 1996 as fatty acid amide hydrolase (FAAH) when Cravatt et al.26 
reported a plurality of fatty acid amides hydrolysed by the enzyme purified and cloned from rat 
liver. Given a constant preference of FAAH for anandamide (AEA) over its additionally discovered 
substrates (lauroylethanolamide (C12), myristoylethanolamide (C14), palmitoylethanolamide 
(C16, PEA) and oleoylethanolamide (OAE)), early developed FAAH inhibitors were derived from 
anandamide (AEA). Not surprisingly, the first generation of FAAH inhibitors were poor drug 
candidates due to their ability to bind to CB1 receptors.17 For example, the AEA-derived FAAH 
inhibitor MAFP has an IC50 value of 20 nM for FAAH and an IC50 value of 304 nM for CB1 
receptors. Although this lack of selectivity, MAPF has been successfully used for FAAH co-
crystallization27 revealing an unusual catalytic site consisting in Ser241 –Ser217- Lys142 differing 
from the more commonly seen Asp-His-Ser hydrolase catalytic triad. Subsequently, a new 
approach have consisted in developing inhibitors derived from the FAAH substrates 
oleoylethanolamide (OAE) and palmitoylethanolamide (PEA) instead, given their inability to 
activate CB1 receptors. For example, the OEA-derived FAAH inhibitor EOFP was useful for the 
identification of Ser241 as the nucleophilic residue of FAAH catalytic machinery (Figure 5.2).28  
 
 
Figure 5.2 First generation FAAH inhibitors. A) Structure of the two FAAH substrate extensively used for 
the design of FAAH inhibitors: oleoylethanolamide (OAE) and palmitoylethanolamide (PAE). B) Example of 
1
st
 generation FAAH inhibitors methoxy arachidonoyl fluorophosphonate (MAFP) and ethoxyoleyl 
fluorophosphonate (EOFP) derived from anandamide (AEA) and oleoylethanolamide (OAE) respectively. 
 
2.2 Selective second generation FAAH inhibitors 
 
Subsequently, FAAH inhibitors lacking completely substrate-like structure were discovered. In 
2003, Piomelli and coworkers reported2 the arylcarbamate URB-597 to inhibit FAAH by 
irreversible carbamoylation of the nucleophilic serine residue (Ser241) leading to anxiolytic and 
analgesic activities. In 2004, α-keto oxazole FAAH inhibitors were published by Cravatt et al.29 
among which OL-135 turned out to be highly potent and selective29 and to promote analgesia in 
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vivo.11 As a result, OL-135 has become the starting point for two Structure-Activity Relationships 
studies (SARs) exploring successively the C2-acyl side chain30 and the C5-position of the oxazole 
ring.31 The crystal structure of h/rFAAH32 in complex with OL-135 has allowed to determine an 
enzyme inhibition mode involving the reversible formation of an hemiketal with the nucleophilic 
Ser241 residue. To date, various structurally different FAAH inhibitors were discovered, 
exemplified by theketo heterocycle PHOP33 and the arylcarbamate ML98734 (Figure 5.3)  
 
Figure 5.3 Selective second generation FAAH inhibitors. A) -keto heterocycle PHOP (Ki = 0.2 nM (Rat) 
and Ki= 0.094 nM (human)) and OL-135 (IC50 = 4.6 nM (brain membrane) and IC50 = 0.5 nM (intact 
neurons)). B) Carbamate URB597 (Ki= 4.7 nM) and ML987 (IC50 = 5.3 +/- 1.6 nM).  
 
3 In vitro evaluation of keto-oxazoles for FAAH inhibition 
 
3.1 Principle of the HPLC-based FAAH inhibition assay  
 
Given the fact that keto oxazoles were reported as FAAH inhibitors,29-31 the complete keto 
oxazole library (164-199) was investigated for FAAH inhibition in collaboration with Matthias 
Lehr using microsomes from rat brain as enzyme source and a fluorogenic ethanolamide as 
substrate (Figure 5.4).35 Inhibitory potencies were determined by comparing the amount of 
carboxylic acid (4-pyren-1-ylbutanoic acid) released from the substrate in the presence and in 
the absence of compound after 60 min incubation time. The quantity of fluorescent carboxylic 
acid was measured by reversed-phase HPLC with fluorescence detection (excitation: 340 nm, 
emission: 380 nm) and was quantified using 6-pyren-1-ylhexanoic acid as internal standard 
(IStd). To estimate the inhibitory potency of the tested keto oxazoles, the known FAAH 
inhibitors URB-597, ML987 and PHOP presented in Figure 5.3, were used as references.  
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Figure 5.4 Principle of the HPLC-based assay for FAAH inhibition. A) Fluorometric assay used to evaluate 
the -keto oxazole library (164-199) using 100 µM fluorogenic substrate, FAAH enzyme as crude 
microsome preparation from rat brain after 60 minutes incubation either with DMSO or with the tested 
compound at 37°C. Evaluation of the acid released from the substrate by C18 HPLC measurement using 6-
pyren-1-ylhexanoic acid as internal standard. B) C18 HPLC spectra of the reaction mixture after incubation 
with DMSO or with an FAAH inhibitor.  
 
 
3.2 Keto oxazoles as potent FAAH inhibitors 
 
The complete keto oxazole library (164-199) was screened for FAAH inhibition. FAAH activity 
remaining at 10 µM compound concentration was evaluated based on two independent 
experiments leading to relatively low standard deviations, therefore ensuring the reliability of 
the values. Some of the investigated compounds were potent FAAH inhibitors. The graphical 
representation of the residual enzyme activity obtained for the two series of keto-oxazole 
inhibitors (respectively R=n-C11H23 or R=n-C7H15) at 10 µM concentration, revealed the crucial 
role of a short spacer (n=2 to 3 carbons) for the inhibitory activity. A beneficial effect was also 
observed for compounds substituted at C2 position with long acyl chains (R = n-C11H23), as 
replacement by the shorter chain (R= n-C7H15) resulted generally in a decreased activity. This 
observation was consistent with the reduced activity observed by Boger et al.36 for 1,1,1-
trifluorononan-2-one (R= n-C7H15, Ki= 1.2 µM) compared to the four-carbon longer homologue 
(R=n-C11H23, Ki= 0.14µM) or by Jonsson et al.
37 for octanoylethanolamide (R= n-C7H15) compared 
to lauroylethanolamide (R=n-C11H23). Moreover, an increased number of polar heteroatoms in 
the oxazole C5-side chain resulted in a significant increase in inhibitory potency, with sulfones 
generally more potent than their non-oxidized homologues. At last, the substitution of the 
terminal dimethylamino group (located in the oxazole C5-side chain) by a terminal quaternary 
amino group turned out to affect the inhibitory efficiency negatively (Figure 5.5A).   
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Figure 5.5 Evaluation of the -keto oxazole library for FAAH inhibition. A) Residual enzyme activity in 
percentage obtained for -keto-oxazole inhibitors 164-199 at 10 µM concentration (HPLC assay).B) 
Graphical representation of the residual enzyme activity for the two series of-keto oxazole inhibitors 
(respectively R=n-C11H23 or R=n-C7H15) at 10 µM concentration, IC50 values of the more potent oxazoles are 
also provided. Values obtained based on two independent measurements.  
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IC50 values for the more potent compounds were determined, revealing few compounds with 
low or submicromolar IC50 values (Figure 5.5B). The FAAH inhibitory activity of the more potent 
inhibitor 175 (n=3, SO2, R=n-C11H15, NMe2) was subsequently compared with structurally 
different known FAAH inhibitors screened under similar conditions (PHOP, URB597 and ML987). 
Keto oxazole 175 with an IC50 of 290 nM, is slightly more potent than ML987 (IC50= 340 nM) 
but also significantly less potent than URB597 (IC50= 61 nM) and PHOP (IC50= 2.9 nM). However, 
given that such compounds were initially designed as APT1 inhibitors, their FAAH inhibitory 
activities remain acceptable.  
 
4 Rationalization of the results by docking studies 
 
Using FAAH crystal structure in complex with OL-135,32 docking studies were subsequently 
performed by Ingrid Vetter (MPI Dortmund) on the more potent compound 175 in order to 
rationalize the crucial role of a relatively short spacer (n= 2 or 3 carbons) for the activity and the 
beneficial effect observed with long C2-acyl side chains, or by introducing polar heteroatoms 
(SO2, NMe2) into the C5-oxazole side chain. The electrophilic carbonyl group of the oxazole 175 
was fixed at the serine 241. The importance of a rather short spacer for the FAAH inhibitory 
activity was suggested given that the close homologue with a one carbon longer spacer 176 
(n=4, SO2, NMe2, n-C11H23) was suffering from steric repulsions with the enzymatic pocket. 
Moreover, the reported36,37enzyme preference for inhibitors substituted with long aliphatic side 
chains may be explained by an increased binding affinity in the rather deep and hydrophobic 
acyl binding pocket.27 In order to rationalize the increased activity observed when introducing H-
bond acceptor groups into the C5-oxazole side chain such as SO2 and NMe2, H-donor residues 
provided by the enzyme, and located in a close proximity to the inhibitor were investigated. No 
particular candidates for hydrogen bonding interactions with SO2 and NMe2 groups were 
identified. However, given the positively charged character of the enzyme in the cavity 
containing the sulfone group (in blue), electrostatic stabilizing interactions with SO2 may 
contribute to the inhibitory activity. Following the same idea, stabilizing electrostatic 
interactions between negatively charged enzyme regions (in red) and positively charged groups, 
should contribute to the inhibitor affinity with the enzyme. However, steric repulsions with the 
NMe3
+ group are likely to occur, thereby explaining the decrease in inhibitory potency observed 
with cationic inhibitors compared to inhibitors with NMe2 groups (Figure 5.6). 
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Figure 5.6 Covalent docking studies. Docking of the more potent -keto oxazole inhibitor 175 in FAAH 
active site with the oxazole carbonyl group connected to the nucleophilic serine residue (Ser 241). The 
electrostatic potential surface of the enzyme in the proximity of the C5-side chain of the inhibitor, possibly 
accounts for stabilizing interactions respectively with SO2 and NMe2 groups. Positively charged regions are 
shown in blue and negative regions in red. Figure performed using the Pymol software (Ingrid Vetter). 
 
5 Conclusion 
Originally designed as APT1 inhibitors, some of the keto oxazoles turned out to be potent 
FAAH inhibitors with lowmicromolar or submicromolar IC50 values although lacking an 
heteroaromatic group in C5-position of the oxazole ring, reported to be important for FAAH 
inhibition.31 Importantly, to date only few C5-substituted oxazoles with small non-aromatic 
substituents were reported.31 Our keto oxazole library have permitted to point out the 
importance of short C5-side chains (n=2 or 3 carbons maximum), as well as the importance of 
electrostatic stabilizing interactions for the inhibitory activity. Moreover, the reported36,37 
significance of long C2-acyl chains could also be confirmed, although an improved inhibitory 
effect could very likely be obtained by introducing a C2-acyl side chain terminated by a phenyl 
group (typically located at 6 carbons from the carbonyl group30) like in OL-135. Additionally, the 
keto oxazole library did not inhibit additional serine hydrolases investigated such as APT1, 
APT2 and cPLA2.  
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General conclusions 
Following the discovery of the -lactones palmostatin B and M as the first APT1 inhibitors able to 
prevent Ras depalmitoylation in cells and to induce phenotypic reversal in H-Ras transformed 
cells, various cellular experiments using these cell permeable inhibitors allowed the 
identification of the thioesterases involved in Ras depalmitoylation. First, FLIM experiments 
performed using a fluorescently labeled palmostatin B analogue confirmed APT1 as a cellular 
target of palmostatin B. Second, activity-based proteome profiling (ABPP) experiments using 
alkynylated probes derived from the two inhibitors revealed APT1 and APT2 as unique cellular 
targets of palmostatin M and B. These results were subsequently confirmed by an enzymatic 
assay, showing that -lactones are potent APT2 inhibitors, with an inhibitory potency 
comparable to APT1 inhibition. Finally, APT1 and APT2 were both shown to depalmitoylate semi-
synthetic N-Ras proteins in-vitro. Taken together these findings provide the first experimental 
proof that no further hydrolases employing a similar mechanism of catalysis and possibly no 
further hydrolases in general are involved in Ras depalmitoylation. For these reasons, inhibition 
of the Ras depalmitoylating enzymes APT1 and APT2, may constitute a viable approach to 
interfere with aberrant oncogenic H- and N-Ras signaling. 
A chemical proteomic approach developed using a palmostatin B-derived probe and human cells 
from leukaemic and healthy patients, allowed the identification of proteins possibly involved in 
the restoration of Fas-mediated apoptotic signaling observed upon palmostatin B treatment in 
Chronic Lymphocytic Leukaemia (CLL). Among the target proteins, several lipases were identified 
whose overexpression may prevent Fas palmitoylation and thereby attenuate Fas-mediated 
apoptotic signaling in CLL. Among them, APT1 and APT2 are representing good Fas 
depalmitoylating enzyme candidates given their Ras depalmitoylating activity and the 
overexpression of APT1 in CLL cells. Although more experiments are needed to address their 
possible involvement in Fas depalmitoylation, these first experiments are encouraging and may 
lead to a better understanding of the apoptosis resistance characteristic for CLL.  
SILAC experiments employing an inert alkynylated palmitate analogue in double metabolic 
labelling were performed in order to evaluate the effect of palmostatin B on the complete 
palmitome. Although, these experiments did not so far permit any quantification, this strategy 
may allow the systematic evaluation of the effect of palmostatin B on all palmitoylated proteins. 
This would permit to discover new interesting applications for -lactones in general and 
thioesterase-mediated processes in particular.   
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A major effort was devoted to the design, synthesis and evaluation of new APT1/APT2 inhibitor 
candidates which would in contrast to the previous β-lactone inhibitors, be regarded as stable 
transition state mimics of the deacylation process. Although no interesting APT1/APT2 inhibitory 
activity was discovered, some of the designed -keto oxazoles turned out to be sub-micromolar 
fatty acid amide hydrolase (FAAH) inhibitors. In particular, this work revealed the importance of 
a short C5-side chain, of a long aliphatic chain, and of electrostatic stabilizing interactions for the 
FAAH inhibitory activity of -keto oxazoles substituted at the C5 position with non-aromatic 
substituents.  
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Abbreviations 
 
AA Arachidonic acid 
ABPP Activity based proteome profiling  
AcOH Acetic acid 
AcSH Thioacetic acid 
ADIFAB AcryloDated  Intestinal Fatty Acid Binding protein 
AEA Anandamide 
2-AG 2-Arachidonoylglycerol 
APT1 Acyl protein thioesterase 1 
APT2 Acyl protein thioesterase 1 
 
 
 
 
Bn  Benzyl  
Boc Tert-butyl carboxycarbonyl  
BSA Bovine  serum albumin  
Calc.  Calculated  
CAPRI Calcium-promoted Ras inactivator 
CB1R Cannabinoid receptor CB1 
c-Hex Cyclohexyl 
CLL Chronic Lymphocytic Leukemia  
Da Dalton  
DAP 1,3-diaminopropane 
DAG Diacylglycerol 
DBAD di-tert-butyl azodicarboxylate 
DBU 1,8-Diazabicyclo[5.4.0]undecene-7 
DCM Dichloromethane 
DD Death domain  
DED Death effector domain  
DiFMUO 6,8-difluoro-4-methylumbelliferyl octanoate 
DIPEA N,N-diisopropylethylamine 
DISC Death -inducing signaling complex  
DMF N,N-dimethylformamide 
DMSO Dimethyl sulfoxide 
DPI Dual prenylation inhibitor 
ECS Endocannabinoid system 
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EGF Epidermal growth factor  
EGFR Epidermal growth factor receptor 
Eqv.  Equivalent 
ER Endoplasmic reticulum  
ESI Electron spray ionization 
FAAH Fatty acid amide hydrolase 
FAB  Fast atom bombardment 
FADD Fast associated death domain  
FAS Fatty acid synthase  
Fas Fas cell death receptor 
FBS Fetal bovine serum 
FLIM Fluorescence  lifetime imaging microscopy  
Fmoc 9-Fluorenylmethyloxycarbonyl 
FPP Farnesyl diphosphate 
FRET Foerster  Resonance Energy Transfer 
FTase Farnesyl transferase 
FTI Farnesyl transferase inhibitor 
GAP GTPase  activating 
GC-MS Gas chromatography -mass spectrometry  
GDP Guanosine 5’-diphosphate 
GFP Green fluorescent protein  
GGPP Geranylgeranyl diphosphate 
GGTase Geranylgeranyl transferase 
GGTI Geranylgeranyl transferase inhibitor 
Golgi Golgi apparatus 
GPP Geranyl diphosphate 
GRP1 Ras guanine nucleotide-releasing protein 1 
GTP Guanosine5’-triphosphate 
GEF  Guanine nucleotide exchange factor 
HATU 2-(1H-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium 
hexafluorophosphate Methanaminium 
HBTU O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate 
HOBT Hydroxybenzotriazole 
HPLC High performance liquid chromatography 
HRP Horseradish peroxidase 
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HVR Hyper variable region  
IC50 Concentration corresponding to 50% inhibition   
ICMT Isoprenylcysteine carboxyl methyltransferase 
InsP3 Inositol triphosphate 
IPP Isopentenyl  diphosphate 
IPPI Isopentenyl  diphosphate isomerase 
Km Michaelis constant 
LC-MS Liquid chromatography mass spetrometry  
LDA Lithium diisopropylamide 
MAGL Monoacylglycerol lipase 
MALDI Matrix  assisted  laser desorption  ionization  
MAPK Mitogen activated protein kinase 
NAT N-acetyl transferase  
NBS N-bromosuccinimide 
NMM N-methyl morpholine  
NMP N-methyl pyrrolidine  
NMR Nuclear magnetic resonance  
MTBE Methyl tert-butyl ether 
ODNs Oligonucleotides 
OEA oleoylethanolamide 
Oxone® Potassium  hydrogen monoperoxysulfate 
PAT Protein acyl transferase 
PC Phosphatidylcholine 
PDGFR Platelet  derived growth factor receptor  
PE Phosphatidyl ethanolamine 
PM Plasma membrane  
PMBCs Peripheral mononuclear  blood cells  
PNPO Paranitro phenyl octanoate  
PPT1 Palmitoylthioesterase 1 
PSSC Protein Structure Similarity Clustering  
RBD Ras binding domain  
RCE1 Ras Converting enzyme 1 
Rf Retention factor  
RPC18 Reverse phase C18 chromatography  
rt Room temperature 
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SDS Sodium dodecylsulfate 
SE Succinimidyl ester 
SILAC Stable isotope labeling by/with amino acids in cell culture 
siRNA Small interfering RNA 
SOS Son of sevenless 
T1/2 Half life 
TAMRA Tetramethylrhrodamine  
TBDMS tert-butyldimethylsilyl 
TBAF Tetrabutylammonium fluoride 
TFA Trifluoro acetic acid 
Tf Triflate  
TLC Thin layer chromatography  
THF Tetrahydrofuran  
TNFR Tumor necrosis factor receptor  
TM Transmembrane domain  
TosMIC Tosyl methyl isocyanide 
Ts Tosyl group 
VEGFR Vascular  endothelial  growth factor receptor  
Vmax Maximun velocity  
 
 
[]D 
20 Optical rotation at 20°C 
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EXPERIMENTAL PART  
1 Materials and methods 
1.1 Laboratory devices and materials 
 
Laboratory Name Name given by the company Company 
Autoklav  Varioklav®400 Thermo scientific, USA 
Sterile bench Microflow 
Hera Safe type HS12 Kendro laboratory, D 
NUAIRE, class II Integra Biosciences, D 
CO2- incubator  
NUAIRE IR Autoflow and NUAIRE DHD 
Autoflow  
Integra Biosciences, D 
 
 
Ice machine AF80 Scotsman, USA 
Fluorescence scanner  Typhoon TRIO + 
TM
 variable Mode Imager  GE Healthcare 
LI-COR scanner  Odyssey Infrared Imaging System LI-COR Biosciences, D 
pH- meter  Mettler Toledo FiveEasy Mettler Toledo 
Semi-dry transfer device  Trans-Blot ® SD BioRad, USA 
Power supply device Power PAC 1000 BioRad, USA 
Ultrasonic bath  EMMI® 30HC AMAG, D 
Vacuum concentrator  Concentrator 5301 Eppendorf, D 
UV spectrometer  Biophotometer Eppendorf, D 
Vortex devices Vortex Genie 2 Carl Roth, D  
Centrifuge  Centrifuge 5415R Eppendorf, D 
Balance  BP301S Sartorius, D  
PVDF-transfer membrane  Immobilon®-FL Millipore, USA 
Film for WB development CL-Xposure 
TM
 film (#34091) Thermo scientific, USA   
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Cell culture flask  
BD Falcon 
TM
 175 cm
2
 (#353045) BD Biosciences, USA  
BD Falcon 
TM
 75 cm
2
 (#353135) BD Biosciences, USA  
Falcon tubes  
50 ml  falcon tube (# 5044455) Sarstedt, D  
15 ml falcon tube (#5044452) Sarstedt, D   
Eppendorf tubes  Safe lock tube 2 ml  Eppendorf, D 
Cell culture dish  
BD Falcon 
TM
 Easy grip tissue culture dish                           
( #353004) 
 
BD Biosciences, USA  
Microscope Leitz , Labovert type 090-122.012 ERNST LEITZ WETZLAR, D 
Shaker  VIBRAX VXR Basic IKA 
Thermo shaker Thermomixer comfort Eppendorf, D 
Plate reader Infinite M200  TECAN 
Sonicator for cell lysis Sonoplus HD2070 BANDELIN 
96 well plate for absorbance  
353072-microtest
 TM 96, 
sterile, flat 
bottom 
Becton Dickinson labware, USA 
96 well plate for fluorescence 
Costar®Assay plate, sterile, flat bottom, 
black (#3616) 
Corning Incorporated, USA  
Commercial SDS- gel 12% 
12% precise
 TM
 protein gels (10 wells, 
#25202) 
Thermoscientific, USA 
Commercial SDS- gel 4-20 % 
4-20 % precise 
TM
 protein gels (10 wells, 
#25204) 
Thermoscientific, USA 
Device to run large gel  PROTEAN II xi 20 cm Cell  BioRad, hercules, USA 
Device to run precast gel  Cell –Surelock
 TM
 Novex Mini-cell  Invitrogen  
Cell counting chamber Neubauer Cell counting chamber Carl Roth, D 
Cell scrapers BD Falcon 
TM 
Cell scrapers  ( #353085) BD Biosciences, USA  
Scalpel  B-Braun, Surgical Disposable Scalpel Aesculap, D  
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1.2 Chemical and reagents 
 
Product Name Company 
DMEM high glucose (4.5g/l) mit L-glutamin PAA, Pasching, A 
Penicillin (10. 000U/ml) –Streptomycin (10 mg/ml) in 0.9% NaCl  Sigma Aldrich, D 
Sodium pyruvate solution (100 mM) Sigma Aldrich, D 
Trypsin-EDTA (1*) – cell culture laboratory  PAA, Pasching, A; and 
GIBCO-Invitrogen, D 
Recombinante trypsin-proteomic analysis (#03 708 969 001) Roche 
Acetic acid (CAS = 64-19-7) J.T. Baker, Holland  
Developing solution for Western blot  (#100296) TETENAL-Eukobrom , D  
 
Fixing solution for Western blot (#102762) TETENAL-Eukobrom , D  
 
NaF ( CAS= 7681-49-4, MW = 41.99) Sigma Aldrich, D 
Ethanol absolute (CAS = 64-17-5) Sigma Aldrich, D 
Na3VO4 (CAS= 13721-39-6, MW= 183.91) Sigma Aldrich, , D 
Na2S2O3 anhydrous (CAS = 7772-98-7, MW = 158.11)  Alfa Aesar  
AgNO3 (CAS = 7761-88-8, MW = 169.87) Sigma Aldrich, D 
Na2CO3 (CAS = 497-19-8, MW = 105.99)  
Riedel-deHäen ®, Sigma 
Aldrich, D 
Formaldehyde 37%, for molecular biology, CAS= 7732-18-5 Fischer Sicentific  (BP531-
500) 
EDTA. disodium (CAS = 6381-92-6, MW= 372.34) Gerbu Biotechnik, D 
Concentrated 37% HCl (CAS = 7647-01-0) J.T. Baker, Holland 
TFA  for peptid synthesis (CAS= 76-05-1) Carl Roth,  D 
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Acetonitrile HPLC grade (CAS= 75-05-8) Fisher Scientific 
Methanol  (CAS = 67-64-1) J.T. Baker, Holland   
t-butanol  (CAS = 75-65-0) Sigma Aldrich, D 
Bradford Reagent - Bio-Rad-protein assay (#500-0006) Bio-Rad laboratories, D 
Acetone reagent ACS (CAS = 67-56-1) Sigma Aldrich, D  
Acrylamid 4K- solution 30%  AppliChem , D  
Complete Mini EDTA-free protease inhibitor  Roche Diagnostics, D 
Dimethylsulfoxyde research grade (DMSO) Serva, D  
1,4-Dithio-D,L-threitol  hight purity (DTT) (CAS = 3483-12-3, MW = 154.25)   Gerbu Biotechnik, D  
Sodium HEPES salts (CAS = 75277-39-3, MW = 260.3, #25249) Serva, D 
Recombinant human epidermal Growth Factor (EGF) , #PHGO315 Invitrogen, USA  
Ethylenglycol-bis(2-Aminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA),                              
(CAS = 67-42-5, MW =  380.35) 
Sigma Aldrich, D 
Glycerol 99% (CAS = 56-81-5) Riedel-deHäen ®, Sigma 
Aldrich, D  
Glycin 99%  (CAS= 56-40-6, MW = 75.07) Carl Roth, D 
TRIS
.
HCl  (CAS= 1185-53-1, MW = 121.14) Carl Roth, D 
Sodium HEPES  (CAS = 75277-39-3, MW= 260.29) Serva, D  
Bromophenol blue-Na salt Serva, D 
NaCl (CAS = 7647-14-5, MW = 58.44)  Sigma Aldrich, D  
Iodoacetamide (CAS = 144-48-9, MW= 184.96) Sigma Aldrich, USA 
Fetal bovine serum (FBS) (#10270) GIBCO-Invitrogen,  D 
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KCl (CAS = 7447-40-7, MW = 74.55) J.T. Baker , Holland  
Na2HPO4 ; 2H2O (CAS= 10028-24-7, MW = 177.99) Merck, D 
KH2PO4 (CAS= 7778-77-0, MW = 136.09) J.T. Baker  Holland  
N,N,N’, N’-tetramethylethylendiamine, electrophoresis reagent                                    
(TEMED, CAS = 110 – 18-9, MW= 116.21 ) 
Sigma Aldrich, D 
NP-40 Alternative (CAS = 9016-45-9, #492016) CalBiochem , D   
Tween 20 (CAS= 9005-64-5) Serva, D 
Triton X-100 (CAS= 9002-93-1) Serva, D 
Chocolate powder Slim fast 
Streptavidin magnetic beads  (4 mg/ml), #S1420S New england Biolabs  
Super Signal ®  West Pico Chemiluminescence substrate   Thermo Scientific, USA 
Super Signal ®  West femto Chemiluminescence substrate   Thermo Scientific, USA 
U0126  (CAS= 109511-58-2, MW= 380.50, #662005) CalBiochem, USA  
BSA –fatty acid free (CAS = 9048-46-8) Sigma Aldrich, D 
CuSO4 ; 5 H2O (CAS= 7758-99-8, MW =249.68 ) Sigma Aldrich, D 
TCEP
.
HCl (CAS = 51805-45-9, MW= 286.65, #20490) Thermo Scientific, USA  
Urea 99%, ACS Reagent, (CAS= 57-13-6, MW=60.06) Sigma Aldrich,  D 
Amonium persultate analytical grade  (CAS= 7727-54-0, MW = 228.2, #13375) Serva, D  
Dodecylsulfate sodium (SDS-b, CAS= 151-21-3, MW = 288.38) Gerbu Biotechnik, D 
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PageRuler 
TM
 prestained protein ladder plus (#SM1811) 
Fermentas 
Tryptan blue solution (CAS = 72-57-1, #93595) 
Fluka, D   
Guanidine hydrochloride (CAS= 50-01-1, MW= 95.53, #369079) 
CalBiochem, USA  
TBTA 97%, Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl] amine                                            
(CAS= 510758-28-8 , MW= 530.63) 
Sigma Aldrich, D 
SILAC kit (MS10030) 
Invitrogen 
Light lysine (# 32462) 
Invitrogen 
Heavy lysine (# 32457) 
Invitrogen 
Light arginine (#32460) 
Invitrogen 
Heavy arginine (#MS10009) 
Invitrogen 
 
1.3 Buffers and solutions 
 
Buffer Composition 
5 * SDS-PAGE – loading buffer 
0.225 M TRIS
.
HCl pH=6.8 
50% glycerol 
5% SDS-b 
0.05% Bromophenol Blue 
0.25M DTT 
10* SDS- PAGE - running buffer  (big gel) 
2.5 M Glycine 
0.25 M TRIS
.
HCl 
35 mM SDS-b 
1* Running buffer (small commercial gel) 
1M TRIS
.
HCl 
0.9 M HEPES.Na 
35 mM SDS-b 
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10* PBS  ( 10* phosphate buffered saline) 
1.37 M NaCl 
27 mM KCl 
0.1 M Na2HPO4 
20 mM KH2PO4 
pH= 7.4 
10* TBS 
0.2 M TRIS
.
HCl 
1.5 M NaCl 
pH = 7.4 
PBST PBS + 0.1% Tween 20 
TBST TBS + 0.1% Tween 20 
Transfer or blotting buffer 
25 mM TRIS
.
HCl 
0.2 M Glycine 
MeOH / H2O = 1/4 
 
Ripa buffer 
 
50 mM TRIS
.
HCl pH= 7.4 
1% NP40 
150 mM NaCl 
1mM EDTA 
1mM Na3VO4 
Membrane stripping buffer  6M guanidine Hydrochloride 
 
1.4 Antibodies 
1.4.1 Primary antibodies 
 
Antigen  Type  Organism  Company  (concentration) 
APT1 Polyclonal  Rabbit  BioGenes Gmbh - 0.26 mg/ml  
Phospho-ERK1/2 Monoclonal  Mouse Sigma Aldrich (#M8159) 
Total ERK1/2 Monoclonal  Rabbit  Cell signalling (#M4695) 
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1.4.2 Secondary antibodies 
 
Antigen  Description Company  
HRP rabbit ImmunoPure® antibody, goat anti-rabbit IgG (H+L) Thermo Scientific (# 31460) 
HRP mouse  ImmunoPure® antibody, goat anti-mouse IgG (H+L) Pierce (# 31430) 
 
1.5 Growth medias for cell culture  
 
Media Composition  
MDCK-F3 cells (normal media) 
500 ml DMEM  
 25 ml FBS 
 5ml non essential amino acid 
 5 ml sodium pyruvate 
 3 ml penicilium/streptomycin 
HeLa cells (normal media) 
500 ml DMEM 
50 ml FBS 
5ml non essential amino acid 
5 ml sodium pyruvate 
3 ml penicilium/streptomycin 
 HeLa cells (palmitome experiments) 
 
500 ml DMEM 
5% BSA (fatty acid free) 
5ml non essential amino acid 
5ml sodium pyruvate 
3 ml penicilium/streptomycin 
Starving media (ERK phosphorylation) 
 
500 ml DMEM 
5ml non-essential amino acids 
5ml sodium pyruvate 
3ml penicillium /streptomycin 
Experimental part   125 
 HeLa SILAC media  heavy or light                                 
(for 100 ml media)  
80.6ml DMEM-Flex Medium (kit)  
2.25ml glucose (kit)  
2ml L-glutamine (kit)  
10 ml FBS 
1ml penicillium /streptomycin 
1 ml non essential amino acid 
1 ml sodium pyruvate 
10 mg lysine (light or heavy) 
10 mg arginine (light or heavy) 
150 µl phenol red (kit)  
HeLa SILAC starving media  (heavy or light) 
80.6ml DMEM-Flex Medium (kit)  
2.25ml glucose (kit)  
2ml L-glutamine (kit)  
1ml penicillium /streptomycin 
1 ml non essential amino acid 
1 ml sodium pyruvate 
10 mg lysine (light or heavy) 
10 mg arginine (light or heavy) 
150 µl phenol red (kit)  
 
1.6 Cell culture methods 
1.6.1 Counting cells 
 
The cell number can be evaluated using a Neubauer cell counting chamber. To limit the risk of 
error, the cell suspension is first diluted with tryptan blue, by a factor 4, chosen for simplicity 
reason. The use of tryptan blue permits to distinguish living cells from dead cells, with dead cells 
stained in blue. After proper cell re-suspension in tryptan blue to ensure the absence of cell 
aggregates, the diluted cell suspension is placed in the counting chamber and living cells located 
into the counting grid consisting in 4 large outer squares (holding 16 small squares in each) were 
counted. The number of cell contained in 1 ml of the initial cell suspension can subsequently be 
obtained by multiplying this number by factor 104.   
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1.6.2 Splitting cells 
 
When cells are confluent (no space anymore for a new cell duplication cycle), cells need to be 
splitted. Splitting cells consist in detaching cells from their previous cell culture flask and in 
seeding some of them into a new cell culture flask. Splitting cells should be performed regularly, 
typically twice a week with HeLa cells and slightly more often with MDCK-F3 cells. After 
discarding the old growing media, cells are washed twice with PBS and are incubated for 2-5 min 
at 37°C, 5% CO2 with some trypsin/EDTA solution (typically 1 ml for a 75 cm
2 cell culture flask, 
and 2 ml for a 175 cm2 cell culture flask) to, allow their complete detachment (visualization 
under microscope). Cells are subsequently diluted with new cell growing media (typically 1/9 
dilution) and incubated at 37°C before repeating the operation.  
1.6.3 Freezing cells  
 
After cells trypsination, a volume of cell suspension corresponding to 106 cells is centrifuged (5 
min, 1.2*103 rpm) and the cell pellet is washed twice by centrifugation followed by re-
suspension in PBS. After the last centrifugation step, PBS is discarded and 0.25 ml of DMEM 
media containing 10% DMSO and 10% FBS, is added to the cells, which are subsequently frozen 
at -80°C, before being placed in liquid nitrogen for long term storage.  
1.6.4 Thawing cells  
 
Thawing cells consist in defrosting cells in order to place them under culture. A cell aliquot is 
carefully defrosted by keeping it for few minutes into a 37°C water bath and the content is 
quickly transferred into a 75 cm2 cell culture flask, containing 10 ml of pre-warmed cell growing 
media. After incubation of the cells at 37°C for one day, the media is subsequently replaced by 
fresh media in order to remove the DMSO originally contained into the aliquot.  
 
1.7 Proteins methods 
1.7.1 Preparation of cell lysate 
 
Cell lysis consists in the cell disruption leading to a free protein suspension. Two different 
methods are commonly used to lyse cells either by mechanical cell disruption using a sonicator 
(3*10 sec, 30% power, on ice) or by using a lysis buffer containing 1-2% detergent such as NP-40, 
Tween 20, Triton-X100. Typically, 30 minutes incubation in a detergent-containing buffer are 
sufficient to ensure complete cell destruction. For pull down experiments, and in particular for 
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proteomic analysis, the sonication method is preferred in order to avoid detergent 
contamination problem which may complicate proteins identification by mass spectrometry.  
 
1.7.2 Determination of protein concentration  
 
Protein concentrations are commonly evaluated by means of a Bradford assay. The Bradford 
solution is first titrated by measuring the absorbance of several known protein containing 
samples used in quantity ensuring an absorbance value below 1. Typically the measurement of 
the absorbance at 595nm of BSA used in a range varying from 0 to 5 µg (in the Bradford solution) 
permit to determine the linear relation between protein quantity and absorbance, which can be 
used to evaluate the protein concentration of unknown sample. To get reliable values, 
measurements need to be performed in an absorbance range below 1, typically the addition of 
1-2 µl of the unknown sample into 1 ml of Bradford solution is sufficient.  
 
1.7.3 Proteins separation on SDS-PAGE  
SDS- gel PAGE preparation  
Two glass plates (inner and outer) are first assembled. The interspace between the two glass 
plates is ¾ filled with the chosen resolving gel preparation and the remaining interspace 
subsequently filled with ethanol to get a flat base line. After complete polymerization (typically 
30 minutes for a small gel, and 1 hour for a large gel), the ethanol layer is removed and the 
remaining interspace is completely filled with a gel stacking preparation and a comb is rapidly 
added. After complete polymerisation of the second layer of the gel, the gel can be assembled 
into the running chamber (typically after an additional 30 minutes for a small gel or 1 hour for a 
large gel).  
 Composition for 10 ml of 12% resolving gel preparation:   
- 3.3 ml H2O 
- 4.0 ml 30% acrylamide mix 
- 2.5 ml 1.5M TRIS.HCl, pH= 8.8 
- 0.1 ml 10% SDS 
- 0.1 ml 10% ammonium persulfate 
- 0.01 ml TEMED  
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 Composition for 10 ml of 11% resolving gel preparation:   
- 3.45 ml H2O 
- 3.45 ml 30% acrylamide mix 
- 2.5 ml 1.5M TRIS.HCl, pH= 8.8 
- 0.1 ml 10% SDS  
- 0.1 ml  10% ammonium persulfate 
- 0.01 ml TEMED 
 
 Composition for 1 ml stacking gel preparation:  
- 0.68 ml H2O 
- 0.17 ml 30% acrylamide mix 
- 0.13 ml 1M TRIS.HCl, pH= 6.8 
- 0.01 ml 10% SDS 
- 0.01 ml 10% ammonium persulfate 
- 1 µl TEMED  
 
 
 Volume require for one small gel (1 mm thickness, size: 8 cm * 8 cm, 10 pockets): 
-  5 ml resolving gel preparation  
-  1 ml stacking gel preparation 
 
 
 Volume require for one large gel (1 mm thickness, size: 20 cm*20 cm, 15 pockets): 
-  25 ml resolving gel preparation  
-  5 ml stacking gel preparation 
 
Sodium Dodecyl Sulfate Poly Acrylamide Gel Electrophoresis or SDS–PAGE electrophoresis is 
commonly used to separate proteins according to their size. Since different proteins with similar 
molecular weight may migrate differently on the gel, due to their differences in secondary, 
ternary or quaternary structure, the anionic detergent SDS is added to the running buffer and in 
the gel to reduce proteins to their primary (linearized) structure and coat them with uniform 
negative charges. Additional reducing reagents such as TEMED also enter in the composition of 
the gel in order to reduce disulfide bonds present in the proteins. After dilution into 5*SDS 
loading buffer, proteins containing sample are boiled at 96°C for 5 min to denaturate proteins. 
Once the gel is properly assembled and the apparatus filled with SDS-running buffer, the comb is 
removed and the samples are loaded onto the different pockets of the gel. Typically, 25 µl can 
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be loaded on a small gel (10 pockets, 1 mm thickness) whereas up to 200 µl can be loaded onto a 
large gel (15 pockets, 1 mm thickness) without any risk of contamination within the different 
pocket of the gel. A prestained protein ladded is also usually applied in one gel pocket in order 
to estimate the molecular weight of proteins given their localization in the gel. Typically 3 µl of 
ladder is sufficient for a small gel, whereas large gels require 10 µl of ladder. Once the different 
sample properly loaded onto the gel, a suitable amperage is applied to make proteins moved 
into the gel. For a small gel, 30 mA is typically applied for 45 min (60 mA for 2 gels), whereas 
large gels are usually run overnight by convenience using 12 mA for 12 hours for one gel (24 mA 
for 2 gels). Large gels require the use of a cooling system to avoid any overheating of the system 
that might affect the quality of the gel. Once the run is completed, the two glass plates are 
removed carefully, and the gel is either transferred into a PVDF membrane for Western blotting 
analysis or trypsin-digested for proteomic analysis after proteins detection (in-gel fluorescence 
scanning or silver staining).  
 
1.8 Western blotting methods 
 
1.8.1 Semi- dry protein transfer 
 
In semi-dry blotting, the electrodes are placed directly in contact with the gel/membrane 
sandwich to allow an efficient proteins transfer. Usually PVDF-membranes are preferred given 
their possibility to be stripped to remove bound antibody thereby allowing multiple uses. PVDF 
membranes are first activated by immersion for 5 min in methanol, and are subsequently pre-
incubated together with the gel and 4 pieces of blotting paper into blotting buffer for 5-10 min. 
Note: the size of the membrane and blotting papers should be adjusted to the size of the gel for 
an optimal protein transfer. The sandwich gel/membrane can subsequently be assembled in the 
transfer device, by disposing first two blotting papers, recovered by the membrane, followed by 
the gel. Two additional blotting papers are then added to recover the gel and a particular 
attention is then given to ensure the absence of air bubble which may affect the quality of the 
protein transfer. Usually the voltage or time needed for the transfer is evaluated depending on 
the surface of the membrane. Typically 5 mA are applied for 30 min to transfer proteins 
contained in 1 cm2 of gel. For more information, refer to the manual of the transfer device. 
Typically, the transfer of a small gel (8cm*4cm) require approximately 45 minutes at 25 Volts. A 
correct evaluation of the time require for the transfer is crucial given that an over estimation 
would lead to a partial or to a complete protein transfer into the blotting papers. A short control 
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of the transfer of the prestained ladder, by detaching carefully one corner of the gel from the 
membrane, is therefore a good way to follow the protein transfer.  
 
1.8.2 Specific protein visualization  
 
After protein transfer, specific proteins can be visualized by Western blotting analysis. The 
membrane is first blocked by incubation for 1 hour at rt in a suitable blocking buffer and the 
primary antibody is subsequently applied to the membrane in an appropriate dilution, typically 
overnight at 4°C. The membrane is washed with PBST or TBST (3 times, 10 min) to remove 
unbound antibodies before applying a secondary antibody for HRP detection in an appropriate 
dilution, typically for 1 hour at rt. After new PBST or TBST washing steps (3 times, 10 min), the 
membrane can be developed using the Supersignal ® West Pico Chemiluminescent substrat or 
Supersignal ® West Femto Chemiluminescent substrat from Thermo Scientific. Table 1 contained 
the specific antibody dilution optimized for APT1, phosphor-ERK1/2 and total-ERK1/2 visualization.  
 
APT1 (HeLa pull down)  Solution Composition 
Blocking buffer PBST + 2% chocolate slim fast 
Primary antibody 
(BioGenes) 
1/50 dilution in blocking buffer 
Secondary antibody                       
(# 31460) 
1/10 000 dilution in PBST 
Detection Kit Pico  (few minutes) 
APT1 (CLL pull down) 
 
Blocking buffer PBST + 2% chocolate slim fast 
Primary antibody 
(BioGenes) 
1/50 dilution in blocking buffer 
Secondary antibody                           
(# 31460) 
1/10 000 dilution in PBST 
Detection Kit Pico  (few minutes) 
 Phospho-ERK1/2                
(MDCKF3 cells) 
Blocking buffer TBST + 2% chocolate slim fast 
Primary antibody 
(#M8159) 
1/1000 dilution in blocking buffer 
Secondary antibody                          
(# 31430) 
1/20 000 dilution in TBST 
Detection kit Femto (few minutes) 
Total-ERK1/2                  
(MDCKF3 cells) 
Blocking buffer TBST + 2% chocolate slim fast 
Primary antibody 
(#M4695) 
1/1000 dilution in TBST + 2% BSA 
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Secondary antibody                           
(# 31460) 
1/10 000 dilution in TBST 
Detection kit Pico (few minutes) 
 Phospho-ERK1/2                                           
( HeLa cells) 
Blocking buffer TBST + 2% chocolate slim fast 
Primary antibody 
(#M8159) 
1/10 000 dilution in blocking buffer 
Secondary antibody                           
(# 31430) 
1/20 000 dilution in TBST 
Detection kit Pico (2 hours) 
Total-ERK1/2                                      
(HeLa cells) 
Blocking buffer TBST + 2% chocolate slim fast 
Primary antibody 
(#M4695) 
1/1000 dilution in TBST + 2% BSA 
Secondary antibody                          
(# 31460) 
1/10 000 dilution in TBST 
Detection kit Pico (overnight) 
Table 1: Summary of the Western blotting conditions used for the detection of APT1, phospho-ERK1/2 and 
total-ERK1/2respectively. 
 
1.8.3 Stripping PVDF- membranes  
 
As already mentioned PVDF-membranes offer the possibility to be used several times which is 
very appreciable when investigating different Western blotting conditions. Immersion of the 
membrane into stripping buffer until complete transparency (few sec to 1 minute) permits to 
wash away bound antibodies. After being washed several time with PBST or TBST (3 times, 10 
min), the membrane recover its original aspect, and needs to be blocked before to be re-used. 
This process can usually be performed 2 to 3 times without affecting the emitted signal. 
 
1.9 Target identification methods 
1.9.1 General protocol for target identification in HeLa cells  
 
Pull down experiments were performed using a protocol modified from the literature.1 After 
removal of the HeLa cells growing media, HeLa cells were washed twice with PBS and trypsinized 
according to a standard protocol (2-3 min incubation at 37°C). After complete detachment, HeLa 
cells were re-suspended in their growing media and the cell suspension was washed 3 times by 
centrifugation (1500 rpm, 5 min, rt)  followed by re-suspension in PBS. The obtained cell pellet 
was finally re-suspended into PBS to achieve a suspension containing 2*106 cells/ml. 
Experiments for enrichment were carried out in 947 µl cell suspension volume, such as when the 
click chemistry reagents were added, the total reaction was 1 ml. 947 µl of the 2*106 cells/ml 
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suspension was incubated 20 minutes at rt with the pull down probe (23 or 83 or 94) by addition 
of 1 µl of a suitable DMSO stock solution. Subsequently, the probe excess was removed by three 
successive centrifugation (4000 rpm, 5 min, 4°C) / ice-cold PBS washing steps. After re-
suspension into 948 µl of PBS, cells were lysed by sonication at 0°C (3 times, 10 sec, 30% power) 
and the click ligation was initiated by addition of the rhodamine-biotin-azide dye 103 (10 to 30 
µM final concentration, as a 10 mM stock DMSO solution), followed by the addition of a 0.5 mM 
aqueous TCEP reducing reagent solution and 50 µM ligand TBTA (as a DMSO/t-BuOH 1/4 
solution). After addition of 0.5 mM aqueous CuSO4 solution, the reaction was gently vortexed 
and incubated at rt for 1 hour. Proteins were subsequently precipitated by addition of an equal 
volume of cold acetone (1 ml) to the reaction, which was kept at -20°C for approximately 30 min. 
After centrifugation (13000 rpm, 10 min, 4°C), the supernatant was discarded and precipitated 
proteins were washed 3 times by successive centrifugation (13 000 rpm, 4°C)/ ice-cold MeOH 
(0.6 ml) washing steps. For an higher efficiency, proteins were re-suspended by sonication (1 
time, 5 sec, 30% power) between all washing steps. For such experiments, samples were 
prepared in duplicate and were finally combined before enrichment with streptavidin magnetic 
beads so as the quantity of proteins contained in each aliquot correspond to 4*10 6 cells. After a 
new centrifugation step (13 000 rpm, 10 min, 4°C), proteins were re-suspended in 1 ml of PBS 
containing 0.2% SDS by sonication (10 sec, 30% power, rt). Note: The sample should not be 
cooled while sonificating into PBS buffer containing 0.2% SDS as proteins should not precipitate. 
Subsequently, the sample was incubated at rt for 1 hour with 250 µl of streptavidin magnetic 
beads suspension (prewashed twice with PBS) under rotatory stirring. After enrichment, beads 
were washed successively with PBS buffer containing 0.2% SDS (3 times, 1 ml), with 6M urea 
aqueous solution (2 times, 1 ml) and with PBS (3 times, 1 ml). Target proteins were subsequently 
released from the beads by boiling the sample in 30 µl of 5* SDS loading buffer (96°C, 5 min). 
After centrifugation (13 000 rpm, 5 min, rt), beads were discarded and the sample fully loaded 
on a 12% SDS-PAGE gel (PROTEAN II xi 20 cm Cell from BioRad, 1 mm spacer, 15 wells comb), 
which was then scanned for fluorescence using a Typhoon TRIO + TM variable Mode Imager from 
GE Healthcare (fluorescence measurement, grey scale, emission filter 580BP 30 Cy3, TAMRA, 
AlexaFluor 546, PMT: 600, laser: green 532, sensibility normal). Data were analysed using the 
software ImageQuant™ TL from GE Healthcare. After fluorescence scanning, the gel was either 
used for proteomic analyses or for Western blotting experiments for specific protein 
visualization. Note: for proteomic analyses, each sample was fully loaded onto 2 different 
pockets of a small commercially available 12% gel, which were subsequently digested together. 
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The use of commercial gel is preferred for proteomic analyses in order to avoid contamination 
problem especially with PEG. 
 
 
1.9.2 General protocol for target identification in PMBC and CLL cells 
 
Protocol for fluorescence detection and Western blotting analysis Primary PMBC and CLL 
cells were collected from healthy and leukemia patients respectively. The blood from patients 
was first treated with the antibody complex RosetteSep® capable to bind to all non B-cells. 
Subsequent centrifugation over the Ficoll densient medium permits to pellet complexes 
together with red blood cells and to isolate purified B-CLL cells. Subsequently, B-CLL cells were 
washed with PBS and re-suspended in IMDM Medium containing 10% FCS and 1% penicilium/ 
streptomycin. A similar procedure was used for the isolation of PMBC cells, at the exception 
from antibody complexes which were omitted. PMBC and CLL cells were subsequently incubated 
for 20 minutes either with probe 23 (50 µM) or with DMSO in IMDM medium containing 10% 
FCS and 1% penicilium/streptomycin. After removal of excess probe, cells were re-suspended 
into 1 ml of PBS, lysed and frozen to be further processed in Dortmund. Usually      ~108 cells 
were contained in each aliquot to ensure a sufficient protein concentration. Samples were 
subsequently adjusted to 1.2-1.5 mg protein/ml by dilution with PBS to ensure an optimal Cu(I)-
catalyzed Huisgen [3+2]-cycloaddition. Labeling experiments were subsequently performed 
following the protocol decribed above with TrifN3 (103) = 10 µM, TCEP= 0.5 mM, TBTA ligand= 
50 µM, CuSO4 =0.5 mM and 750 µl beads.  For these experiments, PMBC and CLL samples were 
prepared in duplicate and were combined two by two before enrichment with streptavidin 
magnetic beads. Finally, proteins were released from the beads in 5*SDS loading buffer, and  
1/10 of each sample was loaded on a 12% SDS-PAGE gel (PROTEAN II xi 20 cm Cell from BioRad, 
1 mm spacer, 15 wells comb). The gel was then used for in gel fluorescence scanning and 
Western blotting analysis for APT1 visualization. All the experiments were performed using cells 
from different patients.  
 
 CLL cells (10013), treated with probe 23 / DMSO  
 PBMC cells (10081), treated with probe 23 / DMSO 
 
Protocol for proteomic analysis:    
A similar protocol was followed for proteomic analysis with the exception that the dye 103 was 
used at 30 µM final concentration and that each reaction was performed in quadruplet to be 
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combined before sample enrichment with 750 µl streptavidin beads. Finally PMBC cells samples 
were fully loaded on a 12% commercially available gel as two bands, which were digested 
together. In contrast, only half of the final CLL sample was loaded as two bands on the gel, which 
was then used for proteomic analyses. All the experiments were performed in triplicate using 
cells from different patients.  
 
 PMBC cells (10353/10354), treated with probe 23 / DMSO  
 PMBC cells (10080/10084), treated with probe 23 /DMSO  
 PMBC cells (10081), treated with probe 23 / DMSO 
 CLL cells (10293), treated with probe 23 /DMSO 
 CLL cells (10245), treated with probe 23 /DMSO 
 CLL cells (10012), treated with probe 23 /DMSO 
 
 
1.9.3 General protocol for palmitome experiments  
 
Protocol for visualization of the palmitome by fluorescence  
Pull down experiments were performed using a protocol modified from the literature.2 
Approximately 106 HeLa cells were seeded in a 10 cm diameter dish for 12 hours. After removal 
of the HeLa growing media, cells were washed twice with PBS and were incubated with 100 µM 
ω16-alkynyl fatty acid 106 in 5% BSA containing starving media for 5 hours at 37°C. 
Subsequently, cells were washed three times with PBS before being collected (typically 1.5*106 
cells are obtained from one 10 cm diameter dish) either by trypsination or using a cell scraper in 
the presence of various lysis buffers. Cells were finally obtained in 1 ml total volume (PBS or lysis 
buffer) corresponding to a suspension containing approximately 1.5*106 cells /ml. Cells were 
lysed by sonication at 0°C (3 times, 10 sec, 30% power) and the experiment was subsequently 
performed using a similar protocol as described above using TrifN3 (103) = 15 µM, TCEP= 0.5 
mM, TBTA ligand= 50 µM, CuSO4 =0.5 mM, 500 µl streptavidin beads. For such experiments, 
samples were prepared in duplicate and were finally combined before enrichment with 
streptavidin magnetic beads such that the quantity of proteins contained in each aliquot 
corresponds to approx. 3*10 6 cells. Proteins were released from the beads in 5*SDS loading 
buffer, and  the sample was fully  loaded on a 12% SDS-PAGE gel (PROTEAN II xi 20 cm Cell from 
BioRad, 1 mm spacer, 15 wells comb). Finally, in gel fluorescence scanning allowed the 
visualization of labeled palmitoylated proteins.  
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Protocol for SILAC proteomic quantification  
HeLa cells were grown in SILAC media complement either with heavy (isotopic, 13C) or light 
(normal, 12C) arginine and lysine amino acids respectively for 5 cell duplication cycles, with the 
media exchanged once. Subsequently, cells treated with isotopic amino acids were seeded in 
two 75 cm2 flasks (A,B), and cells treated with normal amino acids were seeded in two 75 cm2 
flasks (C,D) in their respective SILAC growing media. After 6 hours incubation, the growing media 
was removed, cells were washed three times with PBS, and treated for 12 hours with ω16-
alkynyl fatty acid 106 at 100µM final concentration in their growing media respectively, in which 
FBS was replaced by 5% BSA. Cells were subsequently washed with PBS (3 times) and were 
incubated for 3 hours with DMSO or palmostatin B 14 (30 µM final concentration) in their 
respective media containing 5% BSA. After trypsination, cells were washed three times by 
centrifugation (1500 rpm, 5 min, rt) followed by re-suspension into PBS. The four distinct cell 
pellets were finally re-suspended in 1 ml PBS leading to sample A= 5*105cells/ml (ω16-alkynyl 
fatty acid 106, isotopic labeled cells, DMSO), B= 8*105cells/ml (ω16-alkynyl fatty acid 106, 
isotopic labeled cells, palmostatin B), C= 1.9*106 cells/ml (ω16-alkynyl fatty acid 106, non-
isotopic labeled cells, DMSO), D= 2.1*106 cells/ml (ω16-alkynyl fatty acid 106, non-isotopic 
labeled cells, DMSO). The incorporation of isotopic or normal amino acids (arginine, lysine) was 
determined by mass spectrometry for the four cell populations leading to a complete absence of 
isotopic labeled peptides in sample C and D as expected, whereas sample A and B were found to 
have respectively  97% and 92% of isotopic labeled peptides. Therefore, 1 ml of each 1:1 mixture 
of B/C (296 µl of C + 703 µl of B) and A/D (192µl of D + 808 µl of A) were prepared to be used like 
previously for pull down experiments using using TrifN3 (103) = 30 µM, TCEP= 0.5 mM, TBTA 
ligand= 50 µM, CuSO4 =0.5 mM, 750 µl streptavidin beads. For such experiment, only 1 ml of 
each cell mixture B/C and A/D were used for the complete experiment and the ratio 1:1 was 
evaluated based on cell concentration more accurate compared to protein concentrations. 
Finally, proteins presenting thioester linkages were released from the beads using 
hydroxylamine (0.32M, pH 6.8, for 1 hour at 37°C). After concentration to dryness, samples were 
resuspended in SDS loading buffer and were loaded on a 12% SDS gel as two distinct bands 
corresponding to the sample referred to as “NH2OH B/C” and “NH2OH A/D” respectively. 
Streptavidin magnetic beads were subsequently boiled in SDS loading buffer for 5 min at 96°C to 
collect remaining proteins leading to two samples referred to as “Δ B/C” and “Δ A/D”. A small 
aliquot of each initial lysate mixure (referred to as  ”LYSATE B/C” and sample “LYSATE A/D”) was 
collected before initiating the click ligation, in order to check the initial ratio of isotopic peptide 
pairs which should be close to 1:1. The six different samples  referred to as sample “NH2OH B/C”, 
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sample “NH2OH A/D”, sample “Δ B/C”, sample “Δ A/D”, sample “LYSATE B/C” and sample “A/D 
LYSATE”, were subsequently fully loaded on a commercially available 12% small SDS-PAGE gel 
(PROTEAN II xi 20 cm Cell from BioRad, 1 mm spacer, 15 wells comb). After silver staining, bands 
were cut and proteins were digested with trypsin to be submitted for proteomic analyses.  
 
 
1.10 Proteomic analysis protocols 
 
1.10.1 Silver staining protocol 
 
Gels were usually silver stained using the following protocol prior to the protein digestion. The 
gel was first fixed for 1 hour at rt using EtOH/AcOH/H2O (4/1/5) and was washed with EtOH/H2O 
3/7 (2 times, 10 minutes) followed by H2O (1 time, 10 minutes). The gel was subsequently 
treated with aqueous 0.02% w/v Na2S2O3 solution for 1 minute and was washed with water 
(3*20 sec). A cold 0.1% w/v AgNO3 aqueous solution was added to the gel, subsequently stored 
for 20 minutes at 0°C. The gel was washed with water (6*20 sec) and a developing solution 
consisting in 3% w/v Na2CO3, 0.05% v/v formaldehyde in water was added to the gel until bands 
with a suitable intensity were visible. Note: The developing solution should be replaced by a 
fresh solution when turning yellow. Once satisfying bands were obtained, the solution was 
discarded and the gel was washed for 1 minute with water before termination of the reaction by 
adding 0.05 M aqueous EDTA solution. Bands can subsequently be isolated using a scalpel and 
transferred as small gel pieces into a 1.5 ml Eppendorf tube, and the protein content can be 
subsequently digested using trypsin.  
 
1.10.2 Trypsin-digestion protocol 
 
Gel pieces were first washed with buffer A (50 mM NH4HCO3
 in water) for 10 min at 37°C (450 
rpm) followed by buffer B (50% buffer A, 50% MeCN) for 10 min at 37°C (450 rpm). Two 
additional washing steps were performed like previously successively with buffer A and B. 
Proteins were subsequently reduced at 56°C (450 rpm) for 30 minutes using 10 mM DTT as a 
solution in buffer A. The solution was discarded and replaced by 5 mM iodoacetamide as a 
solution in buffer A. The alkylation reaction was performed at room temperature for 30 min (450 
rpm). Samples were subsequently washed like previously at 37°C (450 rpm) for 10 min 
successively with buffer A, B, A and B. After the last washing step, the washing solution was 
discarded and the gel pieces were dried using a vacuum concentrator for 10 min. Subsequently, 
100 µl of a 100 µg/ml trypsin solution in 1 mM HCl, were dissolved in 900 µl buffer A. Finally, 70 
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µl of the obtained trypsin solution were added to the gel pieces which were subsequently 
incubated at 37°C (450 rpm) for 15 min. After addition of buffer A (100 µl), the gel pieces were 
incubated at 30°C (450 rpm) for 15 hours. After digestion, the liquid was transferred into a new 
1.5 ml Eppendorf tube and peptides were extracted by incubation of the gel pieces with 1% TFA 
in water at 37°C (450 rpm) for 15 min. The extract was combined to the previously collected one 
and the operation repeated one time with 1% TFA aqueous solution followed by a last extraction 
step using 2% TFA in H2O/CH3CN (1/1). Combined extracts were finally concentrated to dryness 
using a vacuum concentrator and submitted to mass spectrometry analysis.  
 
1.10.3 Mass spectrometry analysis                                                                                                                                                                                                                                  
    
For protein identification, tryptic peptides were separated and analyzed by nano-HPLC-MS/MS. 
The separations were carried out on an Ultimate 3000 nano-HPLC (Dionex, Idstein, Germany) 
equipped with one analytical pump connected to a nano flow splitter, a flow manager, an 
autosampler and a variable two wavelength UV detector. MS and MS/MS experiments were 
carried out on an Orbitrap mass spectrometer equipped with a LTQ XL linear ion trap (Thermo 
Electron Corporation, Dreieich, Germany). All solvents were LC-MS grade. Lyophilized tryptic 
peptides were dissolved in 25 µl 0.1 % TFA, and 10 µl were injected and enriched onto a C18 
PepMap 100 column (3 µm, 100 Å, 300 µm ID * 5 mm, Dionex, Idstein, Germany) using 0.1 % TFA 
and a flow rate of 30 µl/min for 5 min. Peptides were separated on a C18 PepMap 100 column (3 
µm, 100 Å, 75 µm ID * 150 mm) using a linear gradient starting with 96.8 % solvent A / 3.2 % 
solvent B and increasing to 62.0 % solvent A / 38.0 % solvent B in 145 min with a flow rate of 300 
nl/min (solvent A: water containing 0.1 % formic acid; solvent B: acetonitrile containing 0.1 % 
formic acid). The nano-HPLC was online coupled to the Orbitrap mass spectrometer using a 
standard coated Pico Tip (ID 20 µm, Tip-ID 10 µM, New Objective, Woburn, MA, USA). Precursor 
scans were carried out in the Orbitrap with a resolution of 60000. MS/MS data of the 5 most 
intense and at least two-fold charged ions were simultaneously recorded in the linear trap. For 
protein identification, data was analyzed using SwissProt database (version 56.7) using the 
MOWSE algorithmn brief, a MS/MS ion search was performed for full enzymatic trypsin 
cleavages allowing one miscleavage. The taxonomy was set to Homo sapiens (human). For 
protein modifications carbamidomethylation was chosen as fixed modification and oxidation of 
methionine as variable. The mass accuracy was set to 5 ppm for peptide masses and 0.5 Da for 
MS/MS data. The significance threshold was set to P <0.01. Only proteins for which at least two 
protein specific peptides were identified are chosen for further validation and only those 
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identified in at least two out of three independent pull down experiments, but not identified in 
the control pull downs (DMSO treated sample) were considered hits.  
 
 
1.11 Erk phosphorylation protocol  
 
Cells were seeded on a 6 cm diameter dish (3-7*105 cells/dish) and were incubated at 37°C for 
approximately 18 hours. After being washed with PBS (3 times), cells were treated with 
palmostatin M (28)/ DMSO as a solution in starving media. After 1 hour incubation at 37°C, cells 
were washed with PBS (3 times) and EGF was subsequently added to the cells as a solution into 
starving media (final concentration 200 ng/µl). After 10 min EGF-activation, cells were washed 
twice with ice-cold PBS buffer and subsequently lysed with 60 µl RIPA buffer on ice. Sodium 
fluoride (NaF, 50mM final concentration), sodium vanadate (Na3VO4, 1mM final concentration), 
10 µl mercaptoethanol and one complete Mini EDTA-free protease inhibitor tablet were freshly 
added to 10 ml of RIPA buffer. Cells were scrapped on ice and transferred into a 1.5 ml 
Eppendorf tube which was maintained on ice at least for 20 min and were subsequently 
sonicated (ultrasonic bath, 3x10 min) to ensure complete cell destruction. Samples were 
centrifuged (13 000 rpm, 4°C, 15 min) and the protein concentration of the supernatant 
(previously transferred into a new 1.5 ml Eppendorf tube) was determined by a Bradford assay. 
An equal amount of proteins (approx. 30 µg proteins) was boiled in 5*SDS loading buffer and 
was loaded as one band on a 11% SDS-PAGE gel. The gel was subsequently run for maximal 
separation, transferred on a PVDF membrane and used for Western blotting analysis for 
phospho-ERK1/2 detection. The membrane was subsequently stripped and re-used for total ERK1/2 
detection, allowing the determination of the ratio phosphor-ERK1/2 / total ERK1/2 for the tested 
compound which was normalized to 100% using a control treated with DMSO after EGF 
activation. As negative control, a NON-EGF activated DMSO sample was used, whereas the 
known MEK inhibitor U0126 was used as additional positive control at 30 µM concentration.  
 
 
1.12 Determination of phospholipase A1, A2, D inhibition  
 
Assay for cytosolic phospholipase A2 (cPLA2) activity  
Materials: 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (SAPC), 1,2-dioleoyl-sn-
glycerol, arachidonic acid (AA), EDTA-Na2, 4-undecyloxybenzoic acid, nor-dihydroguaiaretic acid 
(NDGA) 
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Development of the assay: The evaluation of cytosolic phospholipase A2 (cPLA2) inhibition was 
performed using an HPLC assay with UV spectrometric detection as reported in literature.3  The 
final reaction mixture contained 0.2 mM phospholipid substrate 1-stearoyl-2-arachidonoyl-sn-
glycero-3-phosphocholine (SAPC) and 0.1 mM 1,2-dioleoyl-sn-glycerol as enzyme substrate. 
After incubation of the substrate with palmostatin B (14) at 10 µM final concentration for 5 min 
at 37°C, cPLA2 (isolated from human platelets by anion exchange chromatography) was added to 
the mixture subsequently incubated at 37°C for 60 min. The enzyme reaction was terminated by 
addition of a mixture of acetonitrile, methanol and 3 mM aqueous EDTA-Na2, which contained 4-
undecyloxybenzoic acid as internal standard (IStd) and nor-dihydroguaiaretic acid (NDGA) as 
oxygen scavenger. After addition of dilute NaOH, the sample was cleaned up by solid phase 
extraction using reverse-phase C18 column. Samples were subsequently analysed by reverse-
phase HPLC with UV detection at 200 nm to determine the quantity of arachidonic acid (AA, 
retention time at 11.7 min) released by cPLA2. The comparison of the peak area obtained for 
arachidonic acid (AA) in the control (no inhibitor), with the peak area of arachidonic acid (AA) in 
the palmostatin B-treated sample allow the evaluation of the cPLA2 inhibitory activity of 
palmostatin B at 10 µM. A known cPLA2 inhibitor was used as positive control and all activity 
measurements were performed in triplicate. 
 
 
Assay for phospholipase A1 (PLA1) activity  
Materials: The evaluation of phospholipase A1 (PLA1) inhibition was performed using the assay 
kit EnzChek® Phospholipase A1 purshased from Invitrogen. Phospholipase A1 substrate (PED-
A1), dioleoylphosphatidylchlorine (DOPC), phospholipase A1 (Lecitase® Ultra, bacterial 
recombinant enzyme), dioleoylphosphatidylglycerol (DOPG), dimethylsulfoxyde (DMSO), and 
5*Phospholipase A1 reaction buffer (250 mM Tris-HCl, 0.7M NaCl, 10 mM CaCl2, pH 7.4) were 
provided in the kit. The protease-inhibitor cocktail was purchased from Roche.  
MDCK-F3 cell lysate preparation: MDCK-F3 cells were trypsinized accordingly to a standard 
protocol and were washed three times by successive centrifugation (1500 rpm, 5 min, rt) 
followed by re-suspension into PBS. The cell pellet was subsequently re-suspended into 0.6 ml of 
cold aqueous lysis-buffer (50 mM Tris.HCl, 150 mM NaCl, 5 µM DTT, pH 8.0) containing freshly 
added protease-inhibitor cocktail solution (obtained by dissolving 1 tablet into 1 ml of d-H20) in a 
ratio buffer/ protease-inhibitor 10/1. Cells were disrupted by sonication (5 times, 5 sec, 30% 
power) at 0°C and then stored at -80°C.  
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Development of the assay: MDCK-F3 cell lysates (PLA1-containing sample) were diluted with 1* 
PLA1 Reaction buffer leading to a 1.59 mg/ml protein concentration. The enzyme activity was 
monitored directly using the EnzChek® Phospholipase A1 substrate (PED-A1) which is a dye-
labeled glycerophosphoethanolamines with BODIPY® FL dye-labeled acyl chain at the sn-1 
position and dinitrophenyl quencher-modified head group. The BODIPY® FL pentanoic acid entity 
is released by cleavage of the substrate by PLA1 in the sn-1 position leading to an increased 
fluorescence. The enzyme activity was determined by measuring the release of fluorescence 
using a Tecan Infinite M200 microplate reader in a 96 well format. Reactions were carried out 
into a 100 µl reaction volume. The assay developed on MDCK-F3 cell lysates (PLA1-containing 
sample) was validated by using a bacterial recombinant PLA1 enzyme. In the assay, 1 µL of 
inhibitor DMSO stock solutions with different concentrations (C stock= 5 mM leading to a final 
concentration of 50 µM, C stock= 1 mM leading to a final concentration of 10 µM, C stock= 0.1 
mM leading to a final concentration of 1µM) was mixed with 49 µl of cell lysate (1.59 mg/ml) 
and the mixture was incubated for 2 min. at 37oC. The same quantity of DMSO (1 µl) was also 
added to the controls. A substrate solution was subsequently prepared by adding 30 µl of 10 
mM of DOPC in Ethanol, 30 µl 10 mM of DOPG in Ethanol, 30 µl 1mM of PLA1 substrate in 1* 
reaction buffer to 9 ml of 1* PLA1 reaction buffer. Subsequently, 50 µl of the prepared substrate 
solution was added to each reaction (sample and controls) and after 2 min. lag time the 
formation of fluorescence was recorded (λex = 470 nm, λem = 515 nm, Gain = 100) over 1 hour at 
15 sec. intervals at 37oC. During the incubation and in between measurements the reaction 
mixture was shaken. The residual PLA1 activity at 50 µM palmostatin B was determined by linear 
regression analyses (r2 ≥ 0.98) of the fluorescence emission increase over time. The background 
reaction rate with no enzyme present was subtracted and the reaction rates were normalized to 
the reaction rate with no inhibitor present (100%). Experiments were preformed in triplicate and 
the linear regression analysis was performed with Microsoft Excel.  
 
 
Assay for phospholipase D (PLD) activity 
Materials: The PLD evaluation was performed using the assay kit Amplex® Red Phospholipase D 
purshased from Invitrogen. Amplex Red reagent (10-acetyl-3,7-dihydrophenoxazine), 
dimethysulfoxide (DMSO), horseradish peroxidase (HRP), hydrogen peroxide (H2O2), 5* Reaction 
buffer (250 mM Tris.HCl, 25 mM CaCl2, pH 8.0), Choline oxidase from Alcaligenes sp. and L--
Phosphatidylcholine (lecithin) were provided in the kit. Phospholipase D from Streptomyces 
Chromofuscus was purchased from Sigma.  
Experimental part   141 
MDCK-F3 cell lysate preparation: prepared like above for PLA1 assay.  
Development of the assay: MDCK-F3 cell lysates (PLD-containing sample) were diluted with 1* 
PLD Reaction buffer leading to a 1.79 mg/ml protein concentration. The enzyme activity was 
monitorated indirectly using the Amplex Red reagent, a sensitive fluorogenic probe for H2O2. 
First, PLD cleaves the phosphatidylcholine (lecithin) substrate to yield choline and phosphatidic 
acid. Second, Choline is oxidized by choline oxidase to betaine and H2O2. Finally, H2O2 in 
presence of horseradish peroxidase, reacts with Amplex Red reagent in a 1:1 stoechiometry to 
generate the highly fluorescent product, resorufin. The enzyme activity was evaluated by 
measuring the release of fluorescent resorufin using a Tecan Infinite M200 microplate reader in 
a 96 well format. Reactions were carried out into a 200 µl reaction volume. The assay developed 
on MDCK-F3 cell lysates (PLD-containing sample) was validated by using a bacterial recombinant 
PLD enzyme, and 99 µl of a 10 µM H2O2 solution in 1*reaction buffer was used as second 
positive control. 1 µl of 10 mM inhibitor DMSO stock solution (final concentration = 50 µM in V 
total = 200 µl) was mixed with 99 µl of the MDCK-F3 cell lysate (1.79 mg/ml by Bradford test) 
and the mixture was subsequently incubated for 2 min. at 37°C. The same quantity of DMSO (1 
µl) was also added to the controls. Subsequently, a 100 µM of Amplex Red reagent solution in 
1*PLD reaction buffer was prepared containing 2U/ml HRP, 0.2U/ml choline oxidase and 0.5 mM 
lecithin. Finally, 100 µl of the prepared substrate solution was added to each reaction (sample 
and controls) and after 2 min. lag time the formation of fluorescence was recorded (λex = 540 
nm, λem = 590 nm, Gain = 90) over 1 hour at 15 sec. intervals at 37
oC. During the incubation and 
in between measurements the reaction mixture was shaken. The residual PLD activity at 50 µM 
palmostatin B was determined by linear regression analyses (r2 ≥ 0.98) of the fluorescence 
emission increase over time. The background reaction rate with no enzyme present was 
subtracted and the reaction rates were normalized to the reaction rate with no inhibitor present 
(100%). Experiments were performed in triplicate and the linear regression analysis was 
performed with Microsoft Excel.  
 
1.13 Enzymatic assays for APT1 and APT2  
 
1.13.1 Molecular cloning, expression and purification of APT1/2  
 
Human acyl protein thioesterase 1 (APT1) was expressed and purified as described previously.4  
APT2 was produced under the same conditions as already described for APT1, with the following 
changes: the apt2 gene (cDNA clone IRATp970G0114D, imaGenes, Berlin) was Gateway cloned 
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into a pGEX expression vector, modified to contain a PreScission protease recognition sequence 
between the apt2 and the gst gene. The construct was then expressed as GST-APT2 fusion 
protein in E. coli BL21 (DE3) Codon+ RIL cells at 20 °C for 16 hours. The fusion protein was loaded 
on a GSH column and APT2 was separated from GST by overnight incubation of the column with 
PreScission protease, and finally purified to homogeneity by gel filtration. 
 
 
1.13.2 Biochemical assay protocols  
 
Colorimetric enzymatic assay for APT15 
The enzyme activity was determined by measuring the release of para-nitrophenolate (PNP) 
from para-nitrophenyl octanoate (PNPO) by absorbance employing 75 nM of enzyme and 600 
µM of substrate PNPO. The assay was developed in a 96 well format on a TECAN plate reader. 
The assay was performed in buffer containing 20 mM HEPES, 150 mM NaCl, which was titrated 
to pH 7.52-7.55 using concentrated HCl solution (37%). In the assay, 50 μl inhibitor solutions 
(with varying concentration) in HEPES buffer with 0.01% (v/v) Triton-X100 was mixed with 30 μl 
APT1 solution (240 nM) in HEPES buffer with 0.01% (v/v) Triton-X100. The mixture was 
incubated for 30 min at 37 °C. Subsequently, 20 µl of an emulsion of PNPO (3.0 mM) in HEPES 
buffer containing 0.25% (v/v) Triton-X100 was added to the reaction mixture and after 2 min. lag 
time. The extinction at 401 nm was subsequently measured over 40 min. with 1 min. intervals at 
37 oC. The substrate emulsion was prepared by vigorous stirring of PNPO in buffer containing 
10% (v/v) Triton-X100 and subsequent dilution to give an emulsion with 3.0 mM PNPO and 
0.25% (v/v) Triton-X100. During the incubation and in between measurements, the reaction 
mixture was shaken for 10 sec with 30 sec intervals with 600 rpm.  
 
 
Fluorescent enzymatic assay for APT1: 
The enzyme activity was determined by measuring the release of fluorescent 6,8-difluoro-4-
methylumbelliferone (DiFMU, 2) from 6,8-difluoro-4-methylumbelliferyl octanoate (DiFMUO, 3) 
by fluorescence (λex = 358 nm, λem = 455 nm) employing 5 nM of enzyme and 15 µM of substrate 
DiFMUO. The assay was developed in a 96 well format on a TECAN plate reader. The assay was 
performed in buffer containing 20 mM HEPES, 150 mM NaCl, which was titrated to pH 7.52-7.55 
using concentrated HCl solution (37%). In the assay, 50 μl inhibitor solutions (with varying 
concentration) in HEPES buffer with 0.01% (v/v) Triton-X100 was mixed with 30 μl APT1 solution 
(16.6 nM) in HEPES buffer with 0.01% (v/v) Triton-X100. The mixture was incubated for 2 min at 
37 °C. Subsequently, 20 µl of a solution of DiFMUO (75 µM) in HEPES buffer containing 0.09% 
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(v/v) Triton-X100 was added to the reaction mixture. The substrate solution was prepared by 
dissolving 2.4 mg of DiFMUO in 100 µl DMSO. Then, 900 µl HEPES buffer containing 10% (v/v) 
Triton-X100 was added and the mixture was vigorously stirred. 200 µl of the resulting mixture 
were subsequently dissolved into 19.8 ml of HEPES buffer to afford a solution containing 75 µM 
DiFMUO and 0.09% (v/v) Triton-X100. After 2 min. lag time, the formation of fluorescent DiFMU 
was recorded (λex = 358 nm, λem = 455 nm) over 35 min. at 35 sec. intervals at 37 
oC. During the 
incubation and in between measurements, the reaction mixture was shaken for 10 sec with 30 
sec intervals with 600 rpm.  
 
 
Fluorescent enzymatic assay for APT2:  
The enzyme activity was determined as described previously for APT1, at the exception that 50 
nM of APT2 was used. The preparation of the substrate DiFMUO solution remained unchanged 
from the one previously described for the APT1 fluorometric assay. 50 μl of inhibitor solutions 
(with varying concentrations) in HEPES buffer with 0.01% (v/v) Triton-X100 was first mixed with 
30 μl of APT2 solution (166 nM) in HEPES buffer with 0.01% (v/v) Triton-X100. After 2 min 
incubation at 37°C, 20 μl of a solution of DiFMUO (75 µM) in HEPES buffer containing 0.09% (v/v) 
Triton-X100 was subsequently added to the reaction , and the formation of DiFMU recorded 
over time by analogy to the fluorometric APT1 assay.  
 
 
1.13.3 Enzyme activity remaining- determination  
Linear regression was performed using the Microsoft Excel software. The reaction rate was 
determined by linear regression analyses (r2 ≥ 0.98) of the fluorescence\extinction increase over 
time. The background reaction rate with no enzyme present was substracted and reaction rates 
were normalized to the reaction rate with no inhibitor present (100%) leading to the enzyme 
activity remaining in percent.  
 
 
1.13.4 IC50-determination                                                                
Linear regression was performed using the Microsoft Excel software and nonlinear curve fitting 
was performed using the Excel-fit plug-in software. For IC50 determination, 12 concentrations 
around the IC50 value were measured in triplicate. Inhibition plots were fitted to Equation 1 in 
which y is the reaction rate at concentration of the inhibitor x, A1 is the minimum reaction rate 
(no enzyme present), A2 the maximum reaction rate (no inhibitor present), p is the Hill-slope and 
x0 is the IC50.  
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Equation 1: Equation used for IC50 evaluation.   
 
1.13.5 Enzyme reactivation - t1/2 determination  
 
Conditions to monitor APT1 reactivation were optimised as follows using 5 nM enzyme and 15 
µM DiFMUO. The assay was developed in a 96 well format on a TECAN plate reader. The assay 
was performed in a buffer containing 20 mM HEPES, 150 mM NaCl, which was titrated to a pH 
7.52-7.55 using concentrated HCl solution (37%). In the assay, 5 μl APT1 solution (100 nM) in 
HEPES buffer with 0.01% (v/v) Triton-X100 was incubated for 4 min at 37°C with an excess of 
inhibitor (5 μl of a 200 nM inhibitor solution in HEPES buffer with 0.01% (v/v) Triton-X100, 
leading to a final concentration of 10 nM). After 4 minutes incubation (corresponding to the 
complete enzyme inactivation), 90 µl of a solution of DiFMUO (16.6 µM) in HEPES buffer 
containing 0.09% (v/v) Triton-X100 was added to the reaction mixture. The substrate solution 
was prepared by dissolving 0.53 mg of DiFMUO in 100 µl DMSO. Then, 900 µl HEPES buffer 
containing 10% (v/v) Triton-X100 was added and the mixture was vigorously stirred. 200 µl of 
the resulting mixture were subsequently dissolved into 19.8 ml of HEPES buffer to afford a 
solution containing 16.6 µM DiFMUO and 0.09% (v/v) Triton-X100. After 2 min. lag time, the 
formation of fluorescent DiFMU was recorded (λex = 358 nm, λem = 455 nm) over 1 hour at 15 
sec. intervals at 37oC. During the incubation and in between measurements the reaction mixture 
was shaken (600 rpm) for 5 sec with 30 sec intervals. The reaction rate was determined by linear 
regression analyses (r2 ≥ 0.98) of the fluorescence emission increase over time. The background 
reaction rate with no enzyme present was substracted and reaction rates were normalized to 
the reaction rate with no inhibitor present (100%). Linear regression was performed using 
Microsoft Excel software and nonlinear curve fitting was performed using the Excel-fit plug-in 
software. For t1/2 (half-life) determination, values were measured in triplicate. The fluorescence 
emission increase over time plots were fitted to the first order Equation 2 in which y is the 
reactivation rate, Ao is the initial fluorescence and K the rate constant for reactivation. The half-
life value (t1/2) is then given by the following relation t 1/2 = ln (2)/K.  
 
y = Ao exp (- Kt)  
 
Equation 2: Equation used for t 1/2 determination.  
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2 Chemical Synthesis        
2.1 General methods and procedures   
      
All chemicals were obtained from Aldrich, Acros or Novabiochem, and were used without 
further purification except when noted. Triethylamine was distilled over calcium hydride and 
stored over potassium hydroxide. Solvents were used as received or passed over a drying 
column (DCM, THF, DMF). Flash chromatography was performed using silica gel for 
chromatography 0.035-0.070 mm, 60Å purchased from Acros Organic. 1H spectra were recorded 
on a Varian Mercury- 400 Oxford NMR spectrometer. Chemical shifts are reported in δ values 
relative to tetramethylsilane and coupling constants J are reported in Hz. Melting points were 
recorded on a Büchi Melting point B-540. IR spectra were recorded on a Bruker Tensor 27 and 
specific optical rotation ([]D
20) on a Polartronic HH8 from Schmidt and Haensch. HPLC-MS 
measurements were performed using an Agilent 1100 Series instrument. GC-MS spectra were 
recorded on a Hewlett Packard, HP6890 series GC system, equiped with a Hewlett Packard, 
HP5973 series mass selective detector.  
2.1.1 Spacer synthesis 
 
General procedure for Finkelstein reaction.6 Bromoethylester (56 mmol, 1.0 eqv.) and NaI (67 
mmol, 1.2 eqv.) were dissolved into acetone (35 ml), and the reaction mixture was heated under 
reflux for 15-20 hours (T = 85°C). NaBr salts were subsequently filtered on a sintered funnel 
containing 5-10 cm silica gel and the silica washed with 50% EtOAc/cyclohexane. After 
concentration of the filtrate, iodoethylester was obtained and used in the next step.  
General procedure for S-alkylation. To a two neck round bottom flask equipped with a large 
egg-shape stirring bar, containing a solution of  N,N-(dimethylamino)propyl thioacetate 47 (26.5 
mmol, 1.0 eqv.) in absolute ethanol (40 ml) was added Cs2CO3 (29 mmol, 1.1 eqv.) in one 
portion. A reflux condenser was mounted and the apparatus was flushed with argon and kept 
under positive argon pressure for the further manipulations. The mixture was refluxed for 2 
hours, until TLC analysis indicated the complete disappearance of 47 and the formation of a 
much more polar thiol intermediary product (TLC eluent EtOAc/cylohexane 1/2). The mixture 
was cooled to 0°C and a solution of iodoethylester (29  mmol, 1.1 eqv.) in absolute ethanol (10 
ml) was added dropwise to the mixture which was stirred at rt for 1 hour and then kept at 40°C 
until TLC indicated the disappearance of the thiol intermediary product (approx. 12 hours, TLC 
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system as above). After concentration to dryness, the residue was diluted with EtOAc/H2O 1/2 
(200ml) and was stirred until all solids dissolved. The phases were separated and the aqueous 
layer was extracted with EtOAc (2x50 ml). The combined organic extracts were washed with 
water (50 ml), brine (100 ml) and subsequently dried over anhydrous MgSO4. Filtration and 
evaporation under reduced pressure lead to the coresponding S-alkylated compound which was 
used without any further purification step.  
General procedure for Reduction. To an oven dried 250 ml round bottom flask was added LiAlH4 
(29.5 mmol, 1.25 eqv.), followed by a large egg-shaped stirring bar. The flask was flushed with 
argon, set under positive argon pressure and subsequently cooled to 0°C. Dry THF (50 ml) was 
added under rapid stirring and the resulting suspension was stirred at 0°C for 15 min. A solution 
of ethylester derivative (23.6 mmol, 1.0 eqv.) in dry THF (10 ml) was added dropwise over 10 
min to the reaction mixture at such a rate that the temperature was kept around 0°C. The 
mixture was stirred for 1 hour at 0°C followed by 2 hours at rt and was quenched at 0°C by 
dropwise addition of H2O (1.1 ml) (caution, gas evolution), followed by 1N NaOH (2.2 ml) and 1.1 
ml H2O. The thick suspension gets thinner upon aging and was diluted with further 50 ml THF. 
Two spoons of Celite were added and the mixture was allowed to age for another 30 min at rt. 
The resulting free running suspension was filtered over Celite in a sintered funnel. The filter cake 
was re-suspended in THF/MeOH 10/1 (50 ml) and was refluxed for 10 min in order to dissolve all 
products. After hot filtration over Celite, the combined organic extracts were evaporated under 
reduced pressure. Al-salt traces remaining were removed by suspending the residue in 6 N 
NaOH (20 ml) and CH2Cl2 (100 ml). The organic layer was separated and extracted with CH2Cl2 
(3x30 ml), washed with brine and dried over Na2SO4. After concentration under reduced 
pressure, the corresponding alcohol was obtained, which was used directly in the next step.  
General procedure for Swern oxidation. To a -78°C (dry-ice) cold oxalyl chloride solution (14.4 
mmol, 1.1 eqv.) in dry CH2Cl2 (10 ml) was added dropwise over 10 minutes DMSO (31.4 mmol, 
2.4 eqv.) as a solution in dry CH2Cl2 (10 ml). After 20 minutes at -78°C, the alcohol (13.1 mmol, 
1.0 eqv.) was added dropwise (over 10 minutes) to the reaction as a solution in dry CH2Cl2 (10 
ml). The mixture was subsequently stirred for 20 minutes at -78°C. Et3N (47.7 mmol, 3.65 eqv.) 
was added over 10 minutes to the mixture which was stirred for 10 minutes at -78° followed by 
45 minutes at rt. The reaction was quenched with water (50 ml) and phases were separated. The 
aqueous layer was extracted with CH2Cl2 (3x20 ml) and the combined organic extracts were 
washed with H2O (20 ml), brine (2x50 ml) and dried over Na2SO4. After evaporation under 
reduced pressure, the corresponding aldehyde was obtained and used directly in the next step. 
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2.1.2 -lactone synthesis 
 
Aldol reactions 
General procedure for ephedrine auxiliary synthesis.7,8 In a round bottom flask was added 
(1S,2R) or (1R,2S)-Norephedrine (52.9 mmol, 1.0 eqv.) and NEt3 (63.4 mmol, 1.2 eqv.) in dry DCM 
(200 ml). Mesilylenesulfonyl chloride (52.5 mmol, 1.0 eqv.) was added dropwise at 0°C to the 
reaction which was stirred at 0°C for 2 hours. The reaction was diluted with diethylether (200 
ml), and subsequently washed with water, 1M HCl, Water, saturated NaHCO3 and brine. 
Combined organic layers were finally dried and concentrated under reduced pressure. 
Recrystallized from DCM and hexane finally lead to mesylated intermediate compound which 
was alkylated using benzylbromide (63.4 mmol, 1.2 eqv.) and K2CO3 (78.5 mmol, 1.5 eqv.) in 
refluxing CH3CN (230 ml) for 10 hours. The reaction was subsequently was filtered over silica in a 
sintered funnel to remove K2CO3 salts and the silica was washed with several portion of 
EtOAc/cyclohexane 50:50. The organic phases were concentrated under reduced pressure and 
the ephedrine auxiliary (9 or 62) finally recrystalized from Et2O and Petrolum.  
General procedure for O-dodecylated ephedrine auxiliary synthesis.7 To a solution of (1S,2R) or 
(1R,2S) 2-(N-benzyl-N-mesitylene-sulfonyl)amino-1-phenyl-1-propanol (19.5 mmol, 1.0 eqv.) and 
pyridine (25.4 mmol, 1.3 eqv.) in dry CH2Cl2 (80 ml) was added dropwise dodecanoyl chloride 
(19.5 mmol, 1.0 eqv.) at 0°C. The reaction was stirred at rt until completion (15-30 hours) and 
diluted with diethylether. The mixture was washed successively with water, 1N HCl, water, 
saturated NaHCO3 solution and brine. The organic extracts were dried over anhydrous MgSO4, 
concentrated under reduced pressure and purified by flash chromatography (accordingly to each 
case) leading to the corresponding O-dodecylated ephedrine auxiliary (10 or 63). 
General procedure for anti-selective aldol reaction. Protocol modified from the literature.7-10 An 
oven dried Schlenk-vessel under argon pressure was charged with (1S,2R) or (1R,2S)  O-
dodecylated ephedrine auxiliary 10 or 63 (17.4 mmol, 1.2 eqv.) and dry CH2Cl2 (56 ml). The 
reaction was cooled to -78 oC with acetone/dry ice, and Et3N (43.5 mmol, 2.5 eqv.) was 
subsequently added followed by a dropwise addition (over 20 min) of freshly prepared c-
Hex2BOTf (1 M in hexane, 38.3 mmol, 2.2 eqv.). The resulting mixture was stirred at -78 
oC for 2 
hours and the aldehyde (16.5 mmol, 1.0 eqv.) was subsequently added dropwise (over 10 min) 
as a solution in dry CH2Cl2 (14 ml). The resulting mixture was stirred at -78 
oC for 1 hour followed 
by 1 hour at 0 oC and 1 hour at rt. The reaction was quenched at 0°C by slow addition of 
methanol (80 ml), 50% H2O2 (1.2 eqv. compared to boron triflate) and 1M phosphate buffer pH 
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7.0  (58 ml). CAUTION: hydrogen peroxide generates a strong gas formation. The mixture was 
stirred vigorously at rt overnight, and concentrated under reduced pressure. The residue was 
diluted with CH2Cl2 (200 ml) and H2O (100 ml) and the organic layer was extracted with H2O 
(2x100 ml) followed by brine (100 ml) and finally dried over anhydrous MgSO4. After evaporation 
to dryness, the residue was co-evaporated with several portions of mesitylene (at 40°C, under 1 
mbar) to remove the cyclohexanol formed during the reaction. The residue was then purified by 
flash column chromatography (5 -25 % ETOAc/cyclohexane) leading to the corresponding trans 
β-hydroxyester.  
General procedure for cis-selective aldol reaction. 7 An oven-dried 100 ml round bottom flask, 
was charged with (1S,2R) or (1R,2S)  O-dodecylated ephedrine auxiliary 10 or 63  (1.0 eqv.) and 
dry CH2Cl2 (0.3M) under argon. The reaction was cooled to -78°C with acetone/dry ice, and 
freshly distilled DIPEA (2.5 eqv.) was subsequently added followed by a dropwise addition (over 
20 min) of n-Bu2BOTf (1M in DCM, 2.2 eqv.). The resulting mixture was stirred at -78°C for 2 
hours and the aldehyde (1.2 eqv.) was subsequently added dropwise (over 10 min) as a solution 
in dry CH2Cl2 (0.9M). The reaction was subsequently stirred at -78°C for 1hour followed by 1 hour 
at 0°C and 1 hour at rt. The reaction was quenched at 0°C by slow addition of methanol (80 ml), 
50% H2O2 (1.2 eqv. compared to boron triflate) and 1M phosphate buffer pH 7.0  (58 ml). 
CAUTION: hydrogen peroxide generates a strong gas formation. The mixture was stirred 
vigorously at rt overnight, and concentrated under reduced pressure. The residue was diluted 
with CH2Cl2 (200 ml) and H2O (100 ml) and the organic layer was extracted with H2O (2x100 ml) 
followed by brine (100 ml) and finally dried over anhydrous MgSO4. After evaporation to 
dryness, the residue was co-evaporated with several portions of mesitylene (at 40°C, under 1 
mbar) to remove the cyclohexanol formed during the reaction. The residue was then purified by 
flash column chromatography accordingly to each case leading to the corresponding cis β-
hydroxyester.  
O-dodecylated ephedrine auxiliary removal 
General procedure for hydrogenolysis.  In a round bottom flask was added the -hydroxyester 
(1.8 mmol, 1.0 eqv.) together with Pd(OH)2 on carbon (1.8 g) under argon. Subsequently, dry 
MeOH (30 ml) was added and the reaction mixture was flushed under H2. The resulting mixture 
was stirred at 40°C until completion, monitored by TLC (eluent: 10% MeOH/DCM). The reaction 
was then filtered over Celite in a sintered funnel to remove the palladium and the celite was 
washed with sereval portions of methanol. After concentration under reduced pressure, the 
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obtained residue was subsequently purified by flash chromatography accordingly to each case 
leading to the corresponding -hydroxyacid.  
General procedure for saponification. In a round bottom flask was added the -hydroxyester 
(3.85 mmol, 1 eqv.) and LiOH.H2O (5-9 eqv.) in dioxane/ H2O (4/1) The resulting mixture was 
stirred at 40°C-45°C until completion. After completion, glacial acetic acid (5-9 eqv.) was added 
at 0°C to the reaction mixture which was stirred for 30 min at 0°C and subsequently 
concentrated under reduced pressure. Purification of the residue flash chromatography 
(accordingly to each case) finally lead to the corresponding β-hydroxyacids.  
-Lactonization 
General procedure for β-lactonization.11,12 A 100 ml round bottom flask, was charged with β-
hydroxyacid  (7.07 mmol, 1.0 eqv.) and anhydrous pyridine (100 ml) under argon. The reaction 
was cooled to 0°C benzenesulfonyl chloride (14.15 mmol, 2.0 eqv.) was added dropwise to the 
reaction as a solution in dry pyridine (10 ml).  The reaction mixture was subsequently stirred at 0 
°C for 3 hours and then stored without stirring at 0°C for 24 hours. The mixture was diluted with 
DCM (250 ml) and the organic layer was extracted with saturated Na2CO3 (100 ml), water (100 
ml), brine (100 ml) and was finally dried over anhydrous MgSO4. After evaporation to dryness, 
the residue was purified by flash chromatography accordingly to each case leading to the 
corresponding -lactone.  
 
2.1.3 Keto amide synthesis 
 
Generale procedure for azide formation.13,14 To a ice-cold solution of alcohol (1.12 mmol, 1.0 
eqv.) and PPh3 (2.25 mmol, 2.0 eqv.) in dry DMF (6.5 ml) was added N-bromosuccinimide (2.25 
mmol, 2.0 eqv.). The mixture was heated for 2 hours at 55°C under argon. The avancement of 
the reaction was monitorated by TLC (eluent MeOH/DCM 2/8) showing the formation of a less 
polar compound. After completion, MeOH (0.5 ml) was added at 0°C to the mixture (to 
decompose the excess of NBS) followed by NaN3 (7.84 mmol, 7.1 eqv.). The mixture was heated 
under argon for 5 hours at 80°C under vigorous stirring. The reaction was concentrated under 
reduced pressure and the DMF removed by coevaporation with several portions of n-Butanol. 
The residue was dissolved in CHCl3/water and the layers separated. The aqueous phase was 
basified using 2M NaOH and extracted with CHCl3 (3*50 ml). The combined organic layers were 
dried over anhydrous MgSO4, concentrated under reduced pressure and purified by flash 
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chromatography (eluent: gradient 1-10% MeOH/DCM) leading to the corresponding azide 
substate.  
 
Generale procedure for reduction azide into amine.15 In a round bottom flask was added the 
azido derivative (0.46 mmol, 1.0 eqv.) together with 10 mol% Pd on carbon under argon. 
Subsequently, dry MeOH (20 ml) was added and the reaction mixture was flushed under H2. The 
resulting mixture was stirred at rt until completion (TLC system 10%MeOH/DCM), typically 21 
hours. The reaction was then filtered over Celite in a sintered funnel to remove the palladium 
and the celite was washed with sereval portions of methanol. After concentration under 
reduced pressure, the corresponding amine was obtained and used directly in the next step.  
 
Generale procedure for amide formation.  
Method A.16  In a round bottom flask was added α-keto acid (1.4 mmol, 1.2 eqv.), amine (1.2 
mmol, 1.0 eqv.) and EDC.HCl (3.5 mmol, 3.0 eqv.) in dry DCM (20 ml). The reaction mixture was 
subsequently stirred at rt for 16-24 hours. The mixture was then poured into DCM (50 ml) and 
the organic layer was washed with 1M NaOH followed by brine and finally dried over anhydrous 
MgSO4. After concentrated under reduced pressure, the residue was purified by flash 
chromatography (eluent: 1-5% MeOH/DCM) leading to the corresponding α-ketoamide.  
 
Method B.17 To α- keto acid (0.26 mmol, 1.2 eqv.) in dry THF (1 ml) was added dropwise at -
10°C, N-Methylmorpholine (0.21 mmol, 1.0 eqv.) followed by isobutylchloroformate (0.21 
mmol, 1.0 eqv.). The reaction mixture was stirred for 10 min at -10°C and the amine (0.21 
mmol, 1.0 eqv.) was added to the reaction mixture as a solution in dry THF (1ml). The reaction 
mixture was subsequently stirred for 1 hour at -10°C followed by 16 hours at rt. After 
concentration under reduced pressure, the residue was dissolved in EtOAc and was washed 
with brine. After drying over anhydrous MgSO4, the organic layer was concentrated under 
reduced pressure and purified by flash chromatography (eluent: 1-5% MeOH/DCM) leading to 
the α-ketoamide. 
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2.1.4 Trifluoromethy ketone and pentafluoroethyl ketone synthesis.  
 
Generale procedure for ester saponification. To a solution of ethy ester (0.38 mmol, 1.0 eqv.) in 
EtOH (0.5 ml) was added 2M NaOH (0.38 mmol, 1.0 eqv.) to the reaction mixture which was 
stirred at rt for 2 hours. The reaction was monitorated by TLC using MeOH/DCM 2/8. After 
completion, the reaction mixture was extracted with Et2O and the organic layer discarded.The 
aqueous layer was acidified to approx. pH 3.0 using concentrated HCl and was lyophilised 
leading to the carboxylic acid which was used directly in the next step (contain some NaCl salts).  
 
Generale procedure for -keto-CF3 or -keto-CF2CF3 formation.
18  Carboxylic acid (0.38 mmol, 
1.0 eqv.) was resuspended in dry THF (0.9 ml) at -20°C. In parallele, a LDA solution was prepared 
in-situ by dropwise addition of n-Buli (2.5 M in hexane, 1.29 mmol, 3.4 eqv.) at -78°C to a 
solution of freshly distilled diisopropylamine (1.33 mmol, 3.5 eqv.) in dry THF (0.7 ml). The 
prepared LDA solution was subsequently added dropwise over 10 min to the previous reaction 
which was subsequently stirred at rt for 4 hours. In a separate flask, the enediolate solution was 
added dropwise at -78°C to a solution of CF3CO2Et or CF3CF2CO2Et (1.14 mmol, 3.0 eqv.) in dry 
THF (0.4 ml). After complete addition, the mixture was aged for 15 min at -78°C and was 
quenched with 6N HCl (0.7 ml). The reaction mixture was subsequently diluted with EtOAc, the 
layers were separated and the organic phase was dried over anhydrous MgSO4. After 
concentration under reduced pressure, the residue was purified by flash chromatography 
(gradient 1-8 % MeOH/DCM) leading to the keto-CF3 or keto-CF2CF3 derivative respectively.  
 
2.1.5  Keto- oxazole synthesis 
 
General procedure for C5-substituted oxazole formation.19-21 To a solution of methyl isocyanide 
(5.8 mmol, 1.34 eqv.) in anhydous THF (13.5 ml) was added dropwise at -78°C nBuLi (2.5M in 
hexane, 6.5 mmol, 1.5 eqv.) to the reaction mixture which was then stirred at -78°C for 2 hours. 
A solution of ethyl ester (4.3 mmol, 1.0 eqv.) in dry THF (3 ml) was added dropwise (over 30 min) 
to the reaction mixture which was then stirred for 3 hours at -78°C followed by 3 hours at rt. The 
mixture was quenched with brine (100ml) and extracted with Et2O (3* 100 ml). The combined 
organic extracts were subsequently dried over anhydrous MgSO4, concentrated under reduced 
pressure and purified by flash chromatography (gradient 1-4 % MeOH/DCM using NEt3 pre-
treated column) leading to the corresponding C5-substituted oxazole.  
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General procedure for Weinreb amide synthesis.22,23 To a solution of N,O-dimethylhydroxyl 
amine hydrochloride (3.9 g, 39 mmol, 1.1 eqv.) and pyridine (82 mmol, 2.2 eqv.) in dry CH2Cl2 (55 
ml), was added dropwise  the acid chloride (36.5 mmol, 1.0 eqv.) at 0°C over 15 min. The mixture 
was allowed to warm to rt and was stirred for 5 hours at rt. The mixture was then diluted with 
EtOAc (200 ml), washed with 1N HCl (100 ml*2), saturated aqueous NaHCO3 (50 ml*2) and brine 
(50 ml). The organic layer was dried over anhydrous MgSO4 and concentrated under reduced 
pressure leading to the corresponding Weinreb amide which was used directly in the next step. 
 
General procedure for oxazole C2-functionalization.23,24To a 100 ml round bottom flask 
equipped with a stirring bar, argon inlet, was added C5-substituted oxazole (8.7 mmol, 1 eqv.) as 
a solution in freshly distilled THF (20ml). I-PrMgCl (2 M in THF, 11.3 mmol, 1.4 eqv.) was added 
over 10 min to the mixture previously cooled to -15°C which was then stirred for 2 hours 
between -15°C to -20°C. A solution of Weinreb amide (8.65 mmol, 1.0 eqv.) as a solution in 
distilled THF (15ml) was added dropwise to the reaction mixture at such a rate that the 
temperature was kept between -20°C and -25°C (addition over 25 min). The reaction was stirred 
at -20°C for 10 min and at rt for 25 hours. The mixture was quenched with water (25ml) and 
extracted with EtOAc (4*150 ml) and brine (100 ml). Saturated NH4Cl solution was added to the 
aqueous layer which was extracted with EtOAc. The combined organics layers were dried over 
anhydrous MgSO4, concentrated under reduced pressure and purified by flash chromatography 
(eluent: gradient 1-2% MeOH/DCM) leading to the C2-functionalized oxazoles. 
 
 
2.1.6 Library diversification  
 
General procedure for oxidation into sulfone.25 To a solution of thioether derivative (5.05 
mmol, 1.0 eqv.) in MeOH (130 ml) was added at 0°C oxone® (15.13 mmol, 3 eqv.) as a 
suspension in water (80 ml). The reaction mixture was stirred at rt for 8-24 hours before being 
quenched with saturated Na2S2O3 solution and diluted with EtOAc (100 ml). The two layers were 
separated and the aqueous layer was basified to approx. pH 12.0 using saturated NaHCO3. After 
extraction of the aqueous layer with several portions of EtOAc, the combined organic layers 
were dried over MgSO4, filtered and concentrated under reduced pressure leading to the 
corresponding sulfone which was used directly in the next step.  
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General procedure for amine quaternization.26 To a solution of oxazole (0.074 mmol, 1.0 eqv.) 
in CH3CN (0.8 ml) was added dropwise at 0°C methyl iodide (0.085 mmol, 1.16 eqv.) as a solution 
in CH3CN (0.3 ml). The reaction mixture was stirred at rt for 5 hours and the quaternized 
ammonium salt was finally precipatated with Et2O, filtered and washed with Et2O.  
 
2.2 Synthesis of the fluorescent Substrate DiFMUO (3) 
 
 
3,5-Difluoro-2,4-dimethoxynitrobenzene (5).27 To a solution of 2,3,4,5-tetrafluoronitrobenzene 
4 (5 g, 25.4 mmol, 1.0 eqv.) in 70 ml MeOH under argon at 4°C, was added a freshly prepared 
sodium methoxide solution (27.6% wt in MeOH, 61.0 mmol, 2.4 eqv.) obtained by refluxing for 4 
hours  Sodium (1.41 g)  into MeOH (12 ml). The yellow mixture was stirred at rt for 18 hours and 
was monitored by TLC (EtOAc/cyclohexane 1/6). The reaction was quenched with 1M citric acid 
(2.53 mmol, 0.1 eqv.) and the reaction was concentrated under reduced pressure. The residue 
was taken up in Et2O, washed with 1M citric acid (2x100 ml), brine (100 ml), dried over 
anhydrous MgSO4, concentrated under reduced pressure and purified by flash chromatography 
(EtOAc/cyclohexane 1/40) leading to 3,5-difluoro-2,4-dimethoxynitrobenzene 5 as a pale yellow 
solid in a quantitative yield. Rf = 0.53 (EtOAc /cyclohexane 1/6). mp = 32.2 - 32.6°C. IR: 1532cm
-1 
(N-O stretch), 1361 cm-1 (N-O stretch). 1H NMR (400 MHz, CDCl3): δ 7.50 (dd, J = 2.3, 11.0, 1H, 
Haro), 4.12 (t, J = 2.0, 3H, OCH3), 4.01 (d, J = 1.1, 3H, OCH3). 
19F NMR (377 MHz, CDCl3): δ 142.2 
(d, J = 6.5, 1F), 132.3 – 132.4 (m, 1F). 13C NMR (100 MHz, CDCl3): δ 149.4 (dd, J = 6.3, 249.6, CF), 
246.2 (dd, J = 5.3, 246.2, CF), 142.0 (dd, J = 11.6, 13.7, COMe), 140.9 (dd, J = 3.7, 13.6, COMe), 
136.6 (dd, J = 2.1, 7.3, CNO2), 108.2 (dd, J = 3.3, 26.4, CH), 62.9 (dd, J = 1.0, 4.5, OCH3), 61.8 (t, J = 
4.2, OCH3). HRMS (ESI) calc. for C8H7F2NO4 [M+H]
+ 220.0416, found 220.0417. GCMS found 219 
for [M]+..  
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1-Amino-3,5-difluoro-2,4-dimethoxybenzene (6).27 To an autoclave flask was added a large egg-
shaped stirring bar followed by a solution of 3,5-difluoro-2,4-dimethoxynitrobenzene 5 (5.46 g, 
24.9 mmol, 1.0 eqv.) in EtOAc/EtOH 1/1 (14 ml) and catalytic 10 mol% Pd on carbon (0.55g). The 
hydrogenation was performed at 10 bar, at rt for 18 hours with progress monitored by TLC 
(EtOAc/Cyclohexane 1/9). After completion of the reaction, the catalyst was collected on Celite 
over a glass frit via filtration. The filtrate was concentrated under reduced pressure, leading to 1-
amino-3,5-difluoro-2,4-dimethoxybenzene 6 in a quantitative yield as a pale brown oil. Rf = 0.18 
(EtOAc/cyclohexane 1/9). IR: 3550-3270 cm-1 (amino group). 1H NMR (400 MHz, CDCl3): δ 6.24 
(dd, J = 2.3, 12.0, 1H, Haro), 3.85 (t, J = 2.0, 3H, OCH3), 3.84 (d, J = 1.0, 3H, OCH3), 3.79 (brs, 2H, 
NH2). 
19F NMR (377 MHz, CDCl3): δ 135.7 (dd, J = 4.6, 12.0, 1F), 147.2 (s, 1F). 
13C NMR (100 MHz, 
CDCl3): δ 152.1 (dd, J = 6.6, 239.5,CF), 150.1 (dd, J = 7.9, 243.7, CF), 135.8 (dd, J = 5.5, 11.9, 
COMe), 131.7 (dd, J = 3.5, 12.1, CNH2), 128.5 (dd, J = 13.4, 15.9, COMe), 97.5 (dd, J = 2.8, 23.4, 
CH), 62.3 (t, J = 2.6, OCH3), 60.9 (dd, J = 1.1, 4.7, OCH3). HRMS (ESI) calc. for C8H9F2NO2 [M+H]
+ 
190.0674, found 190.0670. GCMS found 189 for [M]+..  
 
 
1,3-Dimethoxy-2,4-difluorobenzene (7).27  To a 250 ml round bottom flask was added a large 
egg-shaped stirring bar followed by a solution of 1-amino-3,5-difluoro-2,4-dimethoxybenzene 6 
(4.25 g, 22.47 mmol, 1.0 eqv.) in 75 ml of conc. HCl/ H2O (1/2). The mixture was cooled to 0°C 
and treated with a cold 6 M aqueous sodium nitrite NaNO2 solution (4 ml, 23.65 mmol, 1.05 
eqv.). The mixture was stirred for 15 min at 0°C and H3PO2 (50% wt in water, 50 ml, 449.35 
mmol, 20.3 eqv.) was added over 5 min. The resulting mixture was kept at 4°C for 21 hours 
under argon followed by 2 hours at 20°C. The mixture was diluted with water and extracted with 
Et2O (3x150 ml). After concentration under reduced pressure, the residue was dissolved into 
Et2O, washed with water (1x150 ml), brine (1x150ml) and dried over anhydrous MgSO4. After 
filtration and evaporation to dryness, the residue was purified by flash column chromatography 
(cyclohexane/EtOAc 95/5) leading to 1,3-dimethoxy-2,4-difluoro benzene 7 as a colorless oil. 
Yield = 84%. Rf = 0.44 (EtOAc/cyclohexane 5/95). 
1H NMR (400 MHz, CDCl3): δ 6.78 (ddd, J = 4.0, 
9.3, 10.5, 1H, Haro), 6.57 (ddd, J = 4.4, 9.0, 9.0, 1H, Haro), 3.99 (t, J = 1.2, 3H, OCH3), 3.84 (s, 3H, 
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OCH3). 
19F NMR (377 MHz, CDCl3): δ 138.9 -139.0 (m, 1F), 150.3 (d, J = 8.4, 1F). 
13C NMR (100 
MHz, CDCl3): δ 150.0 (dd, J = 3.6, 239.2, CF), 146.0 (dd, J = 5.4, 251.3, CF), 145.1 (dd, J = 2.9, 
9.3,COMe), 137.3 (dd, J = 12.0, 26.6,COMe), 109.9 (dd, J = 4.2, 20.3, CH), 106.2 (dd, J = 2.0, 
8.5,CH), 61.7 (t, J = 3.4, OCH3), 56.7 (s, OCH3). HRMS (EI) calc. for C8H8F2O2 [M
+.] 174.0487, found 
174.0489. GCMS found 174 for [M+.].  
 
 
2,4-Difluororesorcinol (8).27 A solution of 1,3-dimethoxy-2,4-difluorobenzene 7 (3.14 g, 18.05 
mmol, 1.0 eqv.) in anhydrous CH2Cl2 (60 ml) at 20°C under argon was treated with BBr3 (1M in 
CH2Cl2, 54 ml, 54 mmol, 3.0 eqv.) via syringe over 5 min. The reaction was monitored by TLC, 
EtOAc/cyclohexane 1/3, showing a complete conversion after 28 hours. The reaction was 
carefully quenched with water and the mixture subsequently stirred until all precipitate 
dissolved. The suspension was extracted with Et2O and the organic layer was washed with brine 
(1x100 ml), dried over anhydrous MgSO4, concentrated under reduced pressure and purified by 
flash column chromatography (EtOAc/cyclohexane 30/70) to afford  2,4-difluororesorcinol 8 as a 
colorless crystalline solid. Yield = 92%. Rf = 0.14 (EtOAc /cyclohexane 25/75). mp = 101.6-
102.3°C. 1H NMR (400 MHz, DMSO): δ 10.08 -  9.79 (brs, 1H, OH), 9.69 -  9.42 (brs, 1H, OH), 6.76 
(ddd, J = 2.3, 9.2, 10.7, 1H, Haro), 6.34 (ddd, J = 5.0, 9.2, 9.2, 1H, Haro). 19F NMR (377 MHz, 
DMSO): δ 144.8 -144.9 (m, 1F), 155.0 -155.1 (m, 1F). 13C NMR (100 MHz, DMSO): δ 145.5 (dd, J = 
4.1, 230.1, CF), 142.1 (dd, J = 2.2, 10.2, COH), 141.8 (dd, J = 6.0, 236.1, CF), 134.4 (dd, J = 13.5, 
17.0, COH), 109.7 (dd, J = 3.7, 19.2, CH), 105.6 (dd, J = 1.7, 7.8, CH). HRMS (EI) calc. for C6H4F2O2  
[M+.] 146.0174, found 146.0178. GCMS found 146 for [M+.] 
 
 
6,8-Difluoro-7-hydroxy-4-methyl-2H-chromen-2-one (2).28 In a 10 ml round-bottom flask, 
equipped with a stirring bar and a septum, was added concentrated sulfuric acid (2.59 g, 24.8 
mmol, 18.1 eqv.) followed by a dropwise addition of a solution of 2,4-difluororesorcinol 8 (200.9 
mg, 1.37 mmol, 1.0 eqv.) in freshly distillated ethyl acetoacetate (179.5mg, 1.38 mmol, 1.0 eqv.). 
The temperature of the reaction was keept below -10°C during the addition. After 20 min at -
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10°C, the reaction mixture was allowed to warm at rt for 20 hours, and the advancement of the 
reaction was monitorated by TLC using as eluent EtOAc/cyclohexane 2/5. After completion, the 
reaction mixture was diluted with water and extracted with several portions of EtOAc. The 
combined organic layers were dried over anhydrous MgSO4 and concentrated under reduced 
pressure leading to a low mass recovery (25 mg crude). Subsequenty the aqueous layer was 
extracted with various solvent such as DCM, benzene and 1-fluorobenzene to improve the 
compound recovery. Finaly, compound 2 was obtained in 10% yield. Identical characterization as 
when the reaction was performed in methane sulfonic acid.  
 
6,8-Difluoro-7-hydroxy-4-methyl-2H-chromen-2-one (2).29,30 In a 250 ml round-bottom flask, 
equipped with a stirring bar and a septum was placed 2,4-difluororesorcinol 8 (2.04 g, 13.97 
mmol, 1.0 eqv.) and freshly distilled ethyl acetoacetate (1.83 g, 14.06 mmol, 1.0 eqv.). MeSO3H 
(23 ml, 351 mmol, 25.1 eqv.) was added dropwise to the reaction mixture keeping the 
temperature at 0°C. The mixture was stirred 20 min at 0°C and at rt for 28 hours (reaction 
monitored by TLC, eluent EtOAc/cyclohexane 2/5). The mixture was cooled to 0°C and was 
quenched with water (25 ml). The precipitate formed was collected on a filter and washed with 
cold water (3x20ml).The crude product was dissolved with 1M sodium hydroxide (60 ml) and the 
resulting solution was filtered. The coumarin was reprecipitated from the filtrate by slow 
additon of H2SO4 until approx. pH 1.0. After filtration, the solid was washed with 3 portions of 
cold water (20 ml) and subsequently dried under reduced pressure leading to coumarine 2 as a 
white solid. Yield = 84%. Rf = 0.17 (EtOAc/cyclohexane 1/1). mp = 154 -155°C (conform with 
literature). IR: 1682 cm-1 (ester group). 1H NMR (400 MHz, DMSO): δ 11.45 (brs, 1H, OH), 7.47 
(dd, J = 2.0, 11.4, 1H, H-C=CF), 6.30 (s, 1H, -CHCO), 2.36 (d, J = 1.0, 3H, -CH3).
 19F NMR (377 MHz, 
DMSO): δ 136.6 (t, J = 9.9, 1F), 154.3 (d, J = 8.3, 1F). 13C NMR (100 MHz, DMSO): δ 158.6 (s, CO), 
152.9 (t, J = 2.6, -CMe), 148.3 (dd, J = 5.2, 237.7, CF), 139.2 (dd, J = 2.0, 9.4, -C(OCOR)), 139.2 (dd, 
J = 6.6, 242.4, CF), 137.4 (dd, J = 12.8, 17.9, COH), 112.2 (s, CH), 110.7 (d, J = 9.0, CIV), 106.1 (dd, J 
= 3.2, 21.3, CH), 18.1 (s, CH3). HRMS (ESI) calc. for C10H6F2O3 [M+H]
+ 213.0358, found 213.0357. 
GCMS found 212 for [M+.].  
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6,8-Difluoro-4-methyl-2-oxo-2H-chromen-7-yl octanoate (3).31 To a suspension of 6,8-difluoro-
7-hydroxy-4-methyl-2H-chromen-2-one 2 (52.1 mg, 0.245 mmol, 1.0 eqv.) in CH2Cl2 (4 ml) was 
added NEt3 (38.4 mg, 0.375 mmol, 1.5 eqv.). Subsequnetly, octanoyl chloride (44 mg, 0.268 
mmol,1.1 eqv.) was added to the reaction mixture which was stirred for 8 hours at rt (reaction 
monitored by TLC EtOAc/cyclohexane 1/1). The reaction was quenched with water (25 ml) and 
extracted with CH2Cl2 (4x15 ml). The combined organic extracts were dried over anhydrous 
MgSO4, filtered, concentrated under reduced pressure and the residue purified by flash column 
chromatography (EtOAc/cyclohexane 1/5) leading to DiFMUO subtrate (3) as a white solid. Yield 
= 95%. Rf = 0.78 (EtOAc/cyclohexane 1/1). mp = 86.2 - 86.6°C. IR: 1777 cm
-1, 1745 cm-1, 1724cm-1 
(ester groups). 1H NMR (400 MHz, CDCl3): δ 7.18 (dd, J = 2.3, 9.7, 1H, H-C=CF),  6.36 (d, J = 1.2, 
1H, -CHCO coumarine), 2.68 (t, J = 7.4, 2H, -CH2COOR), 2.41 (d, J = 1.3, 3H, -CH3 coumarine), 1.83 
– 1.75 (m, 2H), 1.57 - 1.28 (m, 8H), 0.90 (t, J = 6.9, 3H, -CH3).
 19F NMR (377 MHz, CDCl3): δ 130.1 
(d, J = 9.4, 1F), 142.9 (s, 1F). 13C NMR (100 MHz, CDCl3): δ 169.7 (s, CO lipid tail), 158.4 (s, CO 
coumarine), 151.0 (t, J = 2.6, -CMe), 150.9 (dd, J = 2.9, 246.6, CF), 142.9 (dd, J = 4.8, 255.0, CF), 
139.2 (dd, J = 3.1, 9.8, -C(OCOR)), 130.0 (dd, J = 13.1, 17.8, -C(OCOR)), 118.1 (dd, J = 1.4, 8.5, CIV), 
116.2 (s, CH), 105.5 (dd, J = 4.0, 21.5, CH), 33.4 (s), 31.5 (s), 28.8 (s), 28.7 (s), 24.7 (s), 22.5 (s), 
18.7 (s, CH3 coumarine), 13.9 (s, CH3 terminal). HRMS (ESI) calc. for C18H20F2O4 [M+H]
+ 339.1402, 
found 339.1403. GCMS found 338 for [M+.].  
 
2.3 Synthesis of palmostatin B (14)  
 
 
N-benzyl-N-((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)-2,4,6-trimethylbenzenesulfonamide (9). 
Compound 9 was synthesized following the general procedure for ephedrine auxiliary synthesis 
using 52.9 mmol of (1S,2R)-Norephedrine. The mesylated intermediate was obtained in 96% 
yield as a white solid. Rf =0.61 (EtOAc/cyclohexane 1/1). 
1H NMR (400 MHz, CDCl3): δ
 7.34 - 7.20 
(m, 5H, Haro), 6.93 (s, 2H, Haro), 4.96 (d, J = 8.8, 1H, -CH(OH)), 4.74 (d, J = 2.8, 1H, -NH), 3.54-
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3.40 (m, 1H, -CHNHR), 2.63 (s, 6H, 2*-CH3, Mes), 2.27 (s, 3H, -CH3, Mes), 0.83 (d, J = 6.8, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 142.2, 140.3, 138.9 (2C), 134.2, 131.9 (2C), 128.3 (2C), 127.6, 125.9 
(2C), 75.6, 54.5, 22.9 (2C), 20.9, 14.6. (NMR analysis consistent with the literature8). Alcohol 9 
was obtained in 82% as a white solid. Rf =0.46 (EtOAc/cyclohexane 2/8). mp= 122-123°C. 
1H 
NMR (400 MHz, CDCl3): δ
 7.36 - 7.15 (m, 8H, Haro), 7.09 – 7.04 (m, 2H, Haro), 6.91 (s, 2H, Haro), 
4.97 (brs, 1H,- CH(OH)), 4.77 (d, J = 16, 1H, -CH2Bn), 4.54 (d, J = 16, 1H, -CH2Bn), 3.82 (dq, J = 1.6, 
7.0, 1H, -CHNSO2Mes(Bn)), 2.63 (s, 6H, 2*-CH3, Mes), 2.28 (s, 3H, -CH3, Mes), 1.03 (d, J = 6.8, 3H, -
CH3). 
13C NMR (100 MHz, CDCl3): δ 142.6, 142.1, 140.1 (2C), 138.6, 133.4, 132.1 (2C), 128.5 (2C), 
128.1 (2C), 127.7 (2C), 127.3, 127.2, 125.5 (2C), 76.5, 59.6, 49.0, 22.9 (2C), 20.8, 9.9. (NMR 
analysis consistent with the literature8). 
 
 
(1S,2R)-2-(N-benzyl-N-mesitylenesulfonyl)amino-1-phenyl-1-propyldodecanoate (10). 
Compound 10 was synthesized following the general procedure for O-dodecylated ephedrine 
auxiliary synthesis using 19.5 mmol of dodecanoyl chloride. Reaction time 30 hours at rt. 
Purification by flash chromatography (eluent 10-15% EtOAc/cyclohexane) lead to compound 10 
(m= 10.5 g). Yield = 87% (white solid). Rf =0.61 (EtOAc/cyclohexane 2/8). []D
20 = - 20.5 (c = 0.2, 
CHCl3). mp = 59.9 - 60.2°C (recrystallisation from EtOAc/hexane). IR: 1734 cm
-1 (ester, C=O 
stretch). 1H NMR (400 MHz, CDCl3): δ
  7.36 - 7.15 (m, 8H, Haro), 6.92 - 6.84 (m, 4H, Haro), 5.82 
(d, J = 4.0, 1H, -CHOCOR), 4.73 (d, J = 16. 4, 1H, -CHPh), 4.58 (d, J = 16. 8, 1H, -CHPh),  4.08 - 3.99 
(m, 1H, CHN(Bn)Mes), 2.51 (s, 6H, CH3 (Mes)), 2.27 (s, 3H, CH3 (Mes)), 2.21 - 2.01 (m, 2H), 1.52 - 
1.42 (m, 2H), 1.35 - 1.14 (m, 16H), 1.11 (d, J = 6.8, 3H, -CH3), 0.87 (t, J = 6.8, 3H, -CH3).
 13C NMR 
(100 MHz, CDCl3): δ 172.0, 142.5, 140.2, 138.7, 138.5 133.3, 132.1, 128.4, 128.3, 127.7, 127.3, 
127.0, 125.9, 77.9, 56.6, 48.1, 34.2, 31.9, 29.6, 29.4, 29.3, 29.2, 29.0, 24.6, 22.9, 22.7, 20.9, 14.1, 
12.8. HRMS (ESI) calc. for C37H51NO4S [M+H]
+ 606.3612, [M+Na]+ 628.3431, found [M+H]+ 
606.3607, [M+Na]+ 628.3424. LCMS (ESI) found 605.82 for [M+H]+, found 622.93 for [M+NH4]
+, 
found 628.20 for [M+Na]+, found 1227.98 for [2M+NH4]
+ . 
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3-(3,4-Dimethoxyphenyl)propanal (11). Compound 11 was synthesized following the general 
procedure for Swern oxidation using 17.2 mmol of 3-(3,4-dimethoxyphenyl)propan-1-ol. Yield = 
94% (m= 3.28g, yellow oil). Rf = 0.61 (MeOH/CH2Cl2 1/9) or Rf = 0.21 (EtOAc/cyclohexane 2/8). IR: 
1721 cm-1 (C=O). 1H NMR (400 MHz, CDCl3): δ
  9.82 (t, J = 1.6, 1H, -CHO), 6.82-6.70 (m, 3H, Haro), 
3.87 (s, 3H, -OCH3), 3.85 (s, 3H, -OCH3), 2.91 (t, J = 7.4, 2H), 2.79 - 2.73 (m, 2H, -CH2CHO). 
13C 
NMR (100 MHz, CDCl3): δ 201.5, 148.9, 147.4, 132.8, 120.0, 111.6, 111.3, 55.8, 55.7, 45.4, 27.6. 
HRMS (EI) calc. for C11H14O3 [M
+.] 194.0937, found 194.0933. GCMS found 194 for [M+.].  
 
 
(S)-((1S,2R)-2-(N-benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl)2-((S)-3-(3,4-
dimethoxyphenyl)-1-hydroxypropyl)dodecanoate (12). Compound 12 was synthesized following 
the general procedure for anti-selective aldol reaction using 17.42 mmol of O-dodecylated 
ephedrine auxiliary 10. Purifiaction by flash chromatography (5-25 % EtOAc/cyclohexane) yield 
β-hydroxyester 12 (m = 2.6 g). Yield = 63 % (yellow oil). Rf =0.40 (EtOAc/cyclohexane 30/70). 
[]D
20= - 26.1 (c = 2.0, CHCl3). IR: 1736 cm
-1 (ester, C=O stretch). 1H NMR (400 MHz, CDCl3): 7.24 - 
7.11 (m, 8H, Haro), 6.90 - 6.66 (m, 7H, Haro), 5.85 (d, J = 5.6, 1H, -CHOCOR), 4.69 (d, J = 16.4, 1H, 
-CHPh), 4.46 (d, J = 16.4, 1H, -CHPh), 4.23 - 4.13 (m, 1H, -CHN(Bn)Mes), 3.85 (s, 3H, -OCH3), 3.84 
(s, 3H, -OCH3), 3.71 - 3.63 (m, 1H, -CHOH), 2.81 - 2.54 (m, 2H), 2.48 - 2.32 (m, 1H, -CHCOOR), 2.41 
(s, 6H, CH3 (Mes)), 2.27 (s, 3H, CH3 (Mes)), 1.81 - 1.45 (m, 4H), 1.35 - 0.92 (m, 19H), 0.88 (t, J = 
6.8, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 174.5, 148.9, 147.2, 142.4, 140.3 (2C), 138.1, 137.8, 
134.4, 133.2, 132.0 (2C), 128.3 (2C), 128.2 (2C), 128.1, 127.9 (2C), 127.2, 126.6 (2C), 120.2, 
111.8, 111.3, 78.2, 71.5, 56.4, 55.9, 55.8, 51.2, 48.1, 37.3, 31.9, 31.6, 29.7, 29.5, 29.5, 29.4, 29.3, 
29.2, 27.0, 26.9, 22.8, 22.7, 20.8, 14.3, 14.1. HRMS (ESI) calc. for C48H65NO7S [M+H]
+ 800.4554, 
[M+NH4]
+ 817.4820, [M+Na]+ 822.43740, found [M+H]+ 800.4559, [M+NH4]
+ 817.48247, [M+Na]+ 
822.43728. LCMS (ESI) found 816.79 for [M+NH4]
+.  
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 (S)-2-((S)-3-(3,4-dimethoxyphenyl)-1-hydroxypropyl)dodecanoic acid (13). Compound 13 was 
synthesized following the general procedure for hydrogenolysis using 10.41 mmol of β-
hydroxyester 12 and approximately 12 g of Pd(OH)2. After 30 hours reaction at 40°C, purification 
by flash chromatography using 1% MeOH/DCM to remove the unpolar impurities, then gradient 
2-5% MeOH/DCM to collect -hydroxyacid 13 (m= 2.97 g). Yield = 73% (colorless oil). Rf = 0.30 
(EtOAc/cyclohexane 1/1). []D
20= - 10.4 (c = 0.13, CHCl3). IR: 1705 cm
-1 (acid, C=O stretch). 1H 
NMR (400 MHz, CDCl3): δ 6.79 - 6.67 (m, 3H, Haro), 3.84 (s, 3H, -OCH3), 3.83 (s, 3H, -OCH3), 3.76 - 
3.68 (m, 1H, -CHOH), 2.83 - 2.55 (m, 2H), 2.50 - 2.34 (m, 1H,-CHCOOR), 1.90 - 1.50 (m, 4H), 1.41 - 
1.16 (m, 16H), 0.86 (t, J = 6.8, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 180.2, 148.8, 147.2, 134.2, 
120.2, 111.8, 111.3, 71.4, 55.8, 55.7, 51.1, 37.1, 31.8, 31.5, 29.5 (2C), 29.4, 29.3 (2C), 29.2, 27.2, 
22.6, 14.0. HRMS (ESI) calc. for C23H38O5 [M+H]
+ 395.27920, found [M+H]+  395.27894. LCMS (ESI) 
found 411.87 for [M+NH4]
+.  
 
 (3S,4S)-3-decyl-4-(3,4-dimethoxyphenethyl)oxetan-2-one (Palmostatin B, 14). Compound 14 
was synthesized following the general procedure for β-lactonization using 7.07 mmol of -
hydroxyacid 13. Purification by flash chromatography (gradient 2-5% EtOAc/toluene) lead to -
lactone 14 (m= 2.0 g). Yield=75% (white solid). Rf = 0.5 (EtOAc/cyclohexane 30/70). mp = 45.8-
46°C (after recrystallisation from hexane). []D
20 = - 29.4 (c = 0.15, CHCl3). IR: 1801 cm
-1 (β-
lactone, C=O stretch). 1H NMR (400 MHz, CDCl3): δ 6.83 - 6.79 (m, 1H, Haro), 6.75 - 6.69 (m, 2H, 
Haro), 4.22 (ddd, J = 4.0, 5.3, 8.0, 1H, -CHOCOR), 3.87 (s, 3H, -OCH3), 3.86 (s, 3H, -OCH3), 3.19 
(ddd, J = 4.0, 6.8, 8.5, 1H, -CHCO), 2.80 -2.60 (m, 2H), 2.19 - 1.99 (m, 2H), 1.84 - 1.61 (m, 2H), 
1.46 - 1.20 (m, 16H), 0.88 (t, J = 7.0, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 171.4, 149.0, 147.6, 
132.7, 120.2, 111.6, 111.4, 77.1, 56.2, 55.9, 55.8, 36.4, 31.8, 30.9, 29.5, 29.4, 29.3, 29.3, 29.2, 
27.8, 26.9, 22.7, 14.1. HRMS (ESI) calc. for C23H36O4 [M+H]
+ 377.26864, [M+NH4]
+ 394.29519, 
[M+Na]+ 399.25058, found [M+H]+ 377.26858, [M+NH4]
+ 394.29495, [M+Na]+ 399.25012. LCMS 
(ESI) found 393.90 for [M+NH4]
+ 
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2.4 Synthesis of palmostatin B-derived pull down probe (23) 
 
 
11-Dodecanoic acid (16).32,33  In a two neck-round bottom flask was added freshly crushed Mg (5 
g, 200 mmol, 2.85 eqv.) followed by dry Et2O (27 ml). 11-Bromo-1-undecene 15 (15 ml, 70 mmol, 
1.0 eqv.) as a solution in dry Et2O (45 ml) was slowly added to the reaction mixture which was 
subsequently heated under reflux for 5 hours. The excess of magnesium was removed by 
transferring the solution via syringe into a new flask. The obtained Grignard solution was cooled 
to -40°C and CO2 gas was bubbled through the solution for 2 hours (CO2 source: dry-ice placed 
into a separated flask connected via a tubing system to avoid humidity). The reaction was 
quenched with water and subsequently basified to pH 12.0 using NaOH. The two phases were 
separated and the organic layer discarded. The aqueous layer was acidify using 18% HCl and 
extracted with several portion of EtOAc. The combined organic extracts were dried over 
anhydrous MgSO4 and concentrated under reduced pressure leading to compound 16, which 
was used directly in the next step without further purification. Yield = 56% (yellow oil). Rf = 0.61 
(EtOAc/cyclohexane 1/1). IR: 1708 cm-1 (acid, C=O stretch). 1H NMR (400 MHz, CDCl3): δ 5.81 
(ddt, J = 6.8, 10.4, 17.2, 1H, -CH=CH2), 4.99 (ddt, J = 1.6, 2.4, 17.0, 1H, -C=CH2), 4.92 (ddt, J = 1.2, 
2.0, 10.2, 1H, -C=CH2), 2.34 (t, J = 7.4, 2H, -CH2COOH ), 2.03 (dt, J = 6.8, 8.0, 2H, -CH2-CH=CH2), 
1.71 – 1.59 (m, 2H), 1.42 - 1.23 (m, 12H). 13C NMR (100 MHz, CDCl3): δ 180.2, 139.1, 114.1, 34.0, 
33.8, 29.4, 29.3, 29.2, 29.1, 29.0, 28.9, 24.6. HRMS (ESI) calc. for C12H22O2 [M+H]
+ 199.1692, 
found 199.1692. GCMS found 198 for [M+.].  
 
 
11,12-Dibromododecanoic acid (17).34  To a solution of 11-dodecanoic acid 16 (5.9 g, 29.7 mmol, 
1.0 eqv.) in dry Et2O (50 ml) was added Br2 (1.9 ml, 36 mmol, 1.2 eqv.) at -5°C. The mixture was 
stirred at -5°C for an additional 2 hours and was quenched using saturated Na2S2O3 aqueous 
solution. The organic layer was dried over anhydrous MgSO4 and concentrated under reduced 
pressure leading to compound 17, which was used directly in the next step. Yield = quantitative 
(yellow viscous oil). Rf = 0.61 (EtOAc/cyclohexane 1/1). IR: 1706 cm
-1 (acid, C=O stretch). 1H NMR 
(400 MHz, CDCl3): δ 4.15 (ddt, J = 3.4, 4.3, 9.3, 1H, -CHBrCH2Br), 3.83 (dd, J = 4.4, 10.4, 1H, -
CH2Br), 3.62 (dd, J = 10.0, 9.4, 1H, -CH2Br), 2.35 (t, J = 7.4, 2H, -CH2COOH), 2.16 - 2.06 (m, 1H, -
CH2-CHBrCH2Br), 1.83 - 1.72 (m, 1H, -CH2-CHBrCH2Br), 1.68 – 1.58 (m, 2H), 1.47 - 1.22 (m, 12H). 
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13C NMR (100 MHz, CDCl3): δ 178.7, 53.1, 36.3, 35.9, 33.8, 29.3, 29.2, 29.1, 29.0, 28.7, 26.7, 24.6. 
HRMS (ESI) calc. for C12H22Br2O2 [M-H]
- 354.9914, found 354.9918.  
 
 
11- Dodecynoic acid (18).34,35 In a round bottom flask containing NaNH2 (commercial quality, 
Aldrich, 0.602 g, 15.4 mmol, 5.5 eqv.) was condensed liquid NH3 (10 ml) at - 60°C. A solution of 
11,12-dibromododecanoic acid 17 (1 g, 2.8 mmol, 1.0 eqv.) in dry THF (4 ml) was added 
dropwise to the reaction mixture which was subsequently stirred at -45°C for 4 hours followed 
by 1 hour at -35°C. The reaction was quenched by addition of NH4Cl (1g) and the ammonia was 
evaporated. Water was added dropwise to the mixture which was then acidified with 
concentrated HCl and diluted with ice-cold water. After several extractions with Et2O, combined 
organic layers were washed with brine, dried over anhydrous MgSO4 and concentrated under 
reduced pressure leading to compound 18, which was used directly in the next step. Yield =96% 
(yellow oil). Rf = 0.41 (EtOAc/cyclohexane 1/1). IR: 3306 cm
-1 (C≡C-H stretch), 2118 cm-1 (-C≡C- 
stretch), 1706 cm-1 (acid, C=O stretch). 1H NMR (400 MHz, CDCl3): δ 2.32 (t, J = 7.4, 2H, -
CH2COOH), 2.16 (dt, J = 2.8, 7.2, 2H, -CH2-C≡C), 1.91 (t, J = 2.8, 1H, -C≡CH), 1.66 – 1.56 (m, 2H), 
1.54 - 1.46 (m, 2H), 1.43 - 1.23 (m, 10H). 13C NMR (100 MHz, CDCl3): δ 180.3, 84.6, 68.0, 34.0, 
29.2, 29.1, 28.9, 28.6, 28.4, 24.6, 18.3. HRMS (ESI) calc. for C12H20O2 [M-H]
-   195.1390, found 
195.1392. GCMS found 196 for [M+.].  
 
 
11- Dodecynoyl chloride (19).36 To a solution of 11- dodecynoic acid 18 (3.5 g, 17.8 mmol, 1.0 
eqv.) in dry benzene (21 ml) was added thionyl chloride (2 ml, 26.7 mmol, 1.5 eqv.). After 3 
hours under reflux, the mixture was concentrated under reduced pressure leading to compound 
19 which was used directly in the next step. Yield = 97% (brown oil). IR: 3306 cm-1 (C≡C-H 
stretch), 2117 cm-1 (-C≡C- stretch), 1795 cm-1 (C=O stretch). 1H NMR (400 MHz, CDCl3): δ 2.86 (t, J 
= 7.4, 2H, -CH2COCl), 2.16 (dt, J = 2.8, 7.2, 2H, -CH2-C≡C), 1.91 (t, J = 2.8, 1H, -C≡CH), 1.74 – 1.64 
(m, 2H), 1.55 - 1.45 (m, 2H), 1.42 - 1.22 (m, 10H). 13C NMR (100 MHz, CDCl3): δ 173.7, 84.6, 68.0, 
47.0, 29.0, 28.9, 28.8, 28.6, 28.4, 28.3, 24.7, 18.3.  
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(1S,2R)-2-(N-benzyl-N-mesitylenesulfonyl)amino-1-phenyl-1-propyldodec-11-ynoate (20).  
Compound 20 was synthesized following the general procedure for O-dodecylated ephedrine 
auxiliary synthesis using 16.3 mmol of limiting reagent, reaction time 15 hours. Purification using 
a gradient 1-5% EtOAc/cyclohexane for the flash chromatography leads to compound 20. Yield = 
67% (yellow oil). Rf = 0.66 (EtOAc/cyclohexane 20/80). []D
20= – 30.7 (c = 0.16, CHCl3). IR: 3304 
cm-1 (C≡C-H stretch), 2116 cm-1 (-C≡C- stretch), 1741 cm-1 (ester, C=O stretch). 1H NMR (400 
MHz, CDCl3): δ
 7.34 - 7.15 (m, 8H, Haro), 6.92 - 6.86 (m, 4H, Haro), 5.81 (d, J = 4.0, 1H, -CHOCOR), 
4.73 (d, J = 16.8, 1H, -CHPh), 4.57 (d, J = 16.4, 1H, CHPh), 4.08 - 4.01 (m, 1H, CHN(Bn)Mes), 2.50 
(s, 6H, CH3 (Mes)), 2.27 (s, 3H, CH3 (Mes)), 2.17 (dt, J = 2.8, 7.2, 2H, -CH2-C≡C), 1.93 (t, J = 2.8, 1H, 
-C≡CH), 1.55 - 1.44 (m, 6H), 1.40 - 1.31 (m, 2H), 1.29 - 1.17 (m, 8H), 1.12 (d, J = 6.8, 3H, -CH3). 
13C 
NMR (100 MHz, CDCl3): δ 171.9, 142.4, 140.2, 138.6, 138.6, 133.4, 132.1, 128.4, 128.3, 127.8, 
127.4, 127.1, 125.9, 84.7, 77.9, 68.0, 56.7, 48.1, 34.1, 29.2, 29.1, 29.0, 28.9, 28.7, 28.4, 24.6, 
22.9, 20.9, 18.4, 12.9. HRMS (ESI) calc. for C37H47NO4S, [M+H]
+ 602.3298, [M+Na]+ 624.3118, 
[M+NH4]
+ 619.3564,  found [M+H]+ 602.3296, [M+Na]+ 624.3111, [M+NH4]
+ 619.3563. LCMS (ESI) 
found 618.93 for [M+NH4]
+.  
 
(S)-((1S,2R)-2-(N-benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl)2-((S)-3-(3,4-
dimethoxy phenyl)-1-hydroxypropyl)dodec-11-ynoate (21). Compound 21 was synthesized 
following the general procedure for the anti-selective aldol reaction using 5.20 mmol of limiting 
reagent. Purification using a gradient 5-7% EtOAc/cyclohexane for the flash chromatography 
leads to compound 21.  Yield =76% (yellow oil). Rf = 0.3 (EtOAc/cyclohexane 30/70). []D
20= - 
33.3 (c = 0.27, CHCl3). IR: 3291 cm
-1 (C≡C-H stretch), 2115 cm-1 (-C≡C- stretch), 1736 cm-1 (ester, 
C=O stretch). 1H NMR (400 MHz, CDCl3): δ 7.24 - 7.11 (m, 8H, Haro), 6.88 - 6.67 (m, 7H, Haro), 
5.86 (d, J = 5.6, 1H, -CHOCOR), 4.69 (d, J = 16.4, 1H, -CHPh), 4.46 (d, J = 16.4, 1H, -CHPh), 4.23 - 
4.15 (m, 1H, -CHN(Bn)Mes), 3.85 (s, 3H, -OCH3), 3.84 (s, 3H, -OCH3), 3.71 - 3.62 (m, 1H, -CHOH), 
2.83 - 2.55 (m, 2H), 2.48 - 2.38 (m, 7H, -CHCOOR, CH3 (Mes)), 2.27 (s, 3H, CH3 (Mes)), 2.16 (dt, J = 
2.8, 6.8, 2H, -CH2-C≡C), 1.93 (t, J = 2.8, 1H, -C≡CH), 1.80 - 1.61 (m, 2H), 1.58 – 1.40 (m, 4H), 1.37 – 
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0.94 (m, 13H). 13C NMR (100 MHz, CDCl3): δ 174.5, 148.9, 147.2, 142.5, 140.3, 138.1, 137.8, 
134.3, 133.1, 132.0, 128.3, 128.3, 128.1, 127.9, 127.2, 126.7, 120.2, 111.8, 111.3, 84.7, 78.1,  
71.5, 68.1, 56.4, 55.9, 55.8, 51.3, 48.1, 37.3, 31.6, 29.7, 29.4, 29.1, 28.9, 28.6, 28.4, 27.0, 26.9, 
22.8, 20.9, 18.4, 14.4. HRMS (ESI) calc. for C48H61NO7S [M+H]
+ 796.4241, [M+Na]+ 818.4061, 
[M+NH4]
+ 813.4507, found [M+H]+ 796.4248 [M+Na]+ 818.4057, [M+NH4]
+ 813.4510. LCMS (ESI) 
found 813.04 for [M+NH4]
+.  
 
(S)-2-((S)-3-(3,4-dimethoxyphenyl)-1-hydroxypropyl)dodec-11-ynoic acid (22).  Compound 22 
was synthesized following the general procedure for saponification on 3.85 mmol of β-
hydroxyester 21 by reaction with 9.0 eqv. LiOH.H2O at 40-45°C  for 90 hours. Purification by 
chromatography using 1% MeOH/CH2Cl2 to remove unpolar impurities, then gradient 2-5% 
MeOH/CH2Cl2 to collect compound 22  (separation monitored by TLC using eluent 
EtOAc/cyclohexane 1/1). Yield = 87% (yellow oil). Rf = 0.71 (MeOH/CH2Cl2 10/90). []D
20= - 29.0 (c 
= 0.1, CHCl3). IR: 3291 cm
-1 (C≡C-H stretch), 2115 cm-1 (-C≡C- stretch), 1704 cm-1 (acid, C=O 
stretch). 1H NMR (400 MHz, CDCl3): δ 6.79 - 6.67 (m, 3H, Haro), 3.84 (s, 3H, -OCH3), 3.83 (s, 3H, -
OCH3), 3.76 - 3.68 (m, 1H, -CHOH), 2.83 - 2.55 (m, 2H), 2.50 - 2.34 (m, 1H, -CHCOOH), 2.15 (dt, J = 
2.8, 7.0, 2H, -CH2-C≡C), 1.91 (t, J = 2.8, 1H, -C≡CH), 1.87 - 1.42 (m, 6H), 1.39 - 1.17 (m, 10H). 
13C 
NMR (100 MHz, CDCl3): δ 180.5, 148.9, 147.3, 134.1, 120.2, 111.8, 111.3, 84.6, 71.6, 68.1, 55.9, 
55.8, 37.6, 31.6, 29.5, 29.3, 29.0, 28.7, 28.4, 27.3, 18.3. HRMS (ESI) calc. for C23H34O5 [M+H]
+ 
391.2479, [M+Na]+ 413.2298, [M+NH4]
+ 408.2744, found [M+H]+ 391.2485, [M+Na]+ 413.2300, 
[M+NH4]
+ 408.2749. LCMS (ESI) found 407.98 for [M+NH4]
+.   
 
 
(3S,4S)-3-(dec-9-ynyl)-4-(3,4-dimethoxyphenethyl)oxetan-2-one (23). Compound 23 was 
synthesized following the general procedure for β-lactonization using 3.32 mmol of compound 
22 (reaction monitored by TLC using EtOAc/cyclohexane 3/7). Purification by flash 
chromatography using gradient 2-5% EtOAc/toluene followed by recrystallisation into 
EtOAc/pentane to remove the remaining traces of the cis-β-lactone. Yield=89% (white solid). Rf = 
Experimental part   165 
0.50 (EtOAc/cyclohexane 30/70). mp= 33.2-33.5°C (after recrystallisation from EtOAc/pentane). 
[]D
20 = – 51.9 (c = 0.21, CHCl3). IR: 3244 cm
-1 (C≡C-H stretch), 2115 cm-1 (-C≡C- stretch), 1795 cm-
1 (β-lactone, C=O stretch). 1H NMR (400 MHz, CDCl3): δ 6.83 - 6.79 (m, 1H, Haro), 6.75 - 6.69 (m, 
2H, Haro), 4.21 (ddd, J = 4.1, 5.2, 8.1, 1H, -CHOCOR), 3.87 (s, 3H, -OCH3), 3.86 (s, 3H, -OCH3), 3.18 
(ddd, J = 4.0, 6.9, 8.4, 1H, -CHCO), 2.81 - 2.59 (m, 2H), 2.17 (dt, J = 2.6, 7.0, 2H, -CH2-C≡C), 2.15 - 
1.98 (m, 2H), 1.93 (t, J = 2.6, 1H, -C≡CH), 1.84 - 1.61 (m, 2H), 1.55 - 1.47 (m, 2H), 1.45 - 1.22 (m, 
10H). 13C NMR (100 MHz, CDCl3): δ 171.4, 148.9, 147.5, 132.7, 120.1, 111.5, 111.3, 84.7, 77.1, 
68.1, 56.2, 55.9, 55.8, 36.4, 30.9, 29.2, 29.1, 28.9, 28.6, 28.4, 27.7, 26.9, 18.3. HRMS (ESI) calc. 
for C23H32O4 [M+H]
+ 373.2373, [M+Na]+ 395.2193, found [M+H]+ 373.2376, [M+Na]+ 395.2194. 
LCMS (ESI) found 373.07 for [M+H]+ .  
 
2.5 Synthesis of TAMRA-labeled palmostatin B analogue (25) 
 
 
Rhodamine-azide (24).37 In a 1 ml glass vial was added 5/6-TAMRA-SE (9 mg, 0.0167 mmol, 1.0 
eqv.) into MeOH (0.3 ml). Then 3-azido propylamine 38 (20.1 mg, 0.201 mmol, 12.0 eqv.) 
followed by NEt3 (12µl, 0.085 mmol, 5.0 eqv.) were added to the reaction mixture, which was 
stirred at rt for 20 hours (in the dark). After concentrated under reduced pressure, the residue 
was subsequently diluted with 1% citric acid (10 ml), and the aqueous layer extracted with 
several portion of DCM (5* 10 ml). The combined organic layer was finally extracted with brine 
(10 ml), and concentrated without being dried with any deshydrating reagents to avoid the 
strong absorption problem occuring with MgSO4 or Na2SO4. The crude was finally purified by 
RPC18 column (2g) using a CH3CN/H2O gradient (0- 100% CH3CN) leading to compound 24 in 81% 
yield (m = 6.9 mg) as a dark red solid. Rf = 0.48 (EtOAc/AcOH/MeOH/H2O 5/2/2/1, fluorescent 
single spot). 1H NMR (400 MHz, CDCl3, assignment includes both isomers): δ 8.43 (brs, 0.5H), 
8.19 (d, J = 7.6, 0.5H), 8.07 (d, J = 8.0, 0.5H), 8.01 (d, J = 8.0, 0.5H), 7.85 - 7.69 (m, 0.5H), 7.63 
(brs, 1H), 7.22 (d, J = 8.0, 0.5H), 6.79 (d, J = 8.8, 1H), 6.75 (d, J = 8.8, 1H), 6.56 - 6.49 (m, 4H), 3.57 
(q, J = 6.4, 1H), 3.47 - 3.40 (m, 2H), 3.34 (t, J = 6.8, 1H), 3.07 (s, 6H), 3.06 (s, 6H), 1.93 (m, 1H), 
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1.84 (m, 1H). HRMS (ESI) calc. for C28H28N6O4, [M+H]
+ 513.2245, found [M+H]+ 513.2238. LCMS 
(ESI) found 513.07 for [M+H]+ .  
 
 
TAMRA- palmostatin B derived compound (25)39. In a round bottom flask was added 
rhodamine-azide 24 (0.0169 mmol, 1.0 eqv.) and the corresponding alkynylated -lactone 23 
(7.8 mg, 0.0209 mmol, 1.2 eqv.) into degassed EtOH (0.7 ml). Subsequently 1M degassed CuSO4 
aqueous solution (15 µl, 0.01521 mmol, 0.9 eqv.) was added to the reaction mixture followed by 
2 M degassed aqueous sodium ascorbate solution (13 µl, 0.02535 mmol, 1.5 eqv.). The reaction 
mixture was then stirred at rt in the dark for 16 hours. The avancement of the reaction was 
monitorated by LCMS analysis. After concentration under reduced pressure, the crude was 
purified by RPC18 column (2g) using a CH3CN/H2O gradient (0- 100% CH3CN) leading to compound 
25 in 83% yield (m = 10 mg) as a dark red solid. The purification was monitorated by the MALDI 
analysis of each fraction collected. Rf = 0.48 (EtOAc/AcOH/MeOH/H2O 5/2/2/1, fluorescent single 
spot). IR: 1814.91 cm-1 (-lactone, C=O stretch). 1H NMR (400 MHz, CDCl3, assignment includes 
both isomers): δ 8.44 (brs, 0.5H), 8.14 (d, J = 8.0, 0.5H), 8.01 (brs, 1H), 7.58 (s, 0.5H), 7.48 - 7.31 
(m, 1.5H), 7.24 (d, J= 7.6, 0.5H), 7.10 - 6.95 (m, 0.5H), 6.81 - 6.78 (m, 1H), 6.74 - 6.68 (m, 2H), 
6.65 - 6.59 (m, 2H), 6.51 - 6.46 (m, 2H), 6.44 - 6.38 (m, 2H), 4.43 (t, J = 6.4, 1H), 4.47 (t, J = 6.4, 
1H), 4.21 (ddd, J = 3.3, 7.8, 7.8, 1H), 3.86 (s, 3H, -OCH3), 3.85 (s, 3H, -OCH3), 3.50 (q, J = 5.8, 1H), 
3.39 (q, J = 5.8, 1H), 3.18 (ddd, J = 3.6, 7.6, 11.1, 1H), 3.00 (s, 6H), 2.99 (s, 6H), 2.80 - 2.57 (m, 
4H), 2.27 - 1.97 (m, 4H), 1.83 - 1.53 (m, 4H), 1.45 - 1.19 (m, 10H). HRMS (ESI) calc. for C51H60N6O8, 
[M+H]+ 885.4545, found [M+H]+ 885.4547. LCMS (ESI) found 885.26 for [M+H]+ .  
 
2.6 Synthesis trans -lactone inhibitors 27 and palmostatin M (28) 
 
 
N,N-(Dimethylamino)propyl thioacetate (47). To a 500 ml round bottom flask equipped with a 
large egg-shaped stirring bar, argon inlet, reflux condenser and pressure equalized dropping 
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funnel was added N,N-dimethylamino-1-propyl chloride hydrochloride 46 (20.0 g, 126.6 mmol, 
1.0 eqv.), followed by 200 ml CHCl3. After the apparatus had been flushed with argon, the 
resulting suspension was cooled to 0°C and NEt3 (52.57 ml, 379 mmol, 3.0 eqv.) was added 
dropwise at such a rate that the temperature of the reaction mixture kept at approx. 10°C. The 
dropping funnel was rinsed with CHCl3 (2*5 ml) and refilled with thioacetic acid (10.8 ml, 151.9 
mmol, 1.2 eqv.) which was added dropwise to the reaction mixture at such a rate that the 
temperature was kept below 20°C. The addition was completed in 30 min and the dropping 
funnel was rinsed with CHCl3 (2*5 ml) and replaced by a stopper. The ice-bath was removed and 
the resulting homogeneous mixture was heated to gentle reflux for 20 hours. The reaction 
mixture was allowed to cool to rt and was extracted with ice-cold 1N NaOH (3x90 ml), followed 
by H2O (100 ml). Combined aqueous layers were extracted with CHCl3 (2x100 ml) and combined 
CHCl3 extracts were washed with brine (200 ml), allowed to separate completely (some 
formation of emulsion) over 30 min and subsequently dried twice over anhydrous MgSO4 
(2x30g, stirring with the drying agent for 30 min each time). After filtration over Celite and  
concentration under reduced pressure, the crude was purified by distillation under reduced 
pressure (8 mm Hg) through a short Vigreux column (150 mm), yielding compound 47 as slight 
yellow oil. bp 73-76°C at 8.0 mm Hg. Yield = 82% Note: It is important that the crude product is 
dry (water-free) before attempting distillation. If not dry, heating of the material will result in 
formation of a tar-like residue and low yield of impure material. IR 1689 cm-1 (C=O stretch). 1H 
NMR (400 MHz, CDCl3): δ 2.90 (t, J = 7.2, 2H, -CH2S), 2.31 (t, J = 7.2, 2H, -CH2N), 2.32 (s, 3H, -
COCH3), 2.21 (s, 6H, N(CH3)2), 1.74 (p, J = 7.2, 2H). 
13C NMR (125 MHz, CDCl3): δ 195.7, 58.5, 45.5, 
30.7, 27.8, 27.1. HRMS (ESI) calc. for C7H15NOS [M+H]
+ 162.0947, found 162.0946. GCMS found 
161 for [M+.].  
 
Ethyl-4-iodobutanoate (48). Compound 48 was synthesized following the general procedure for 
Finkelstein reaction on 67 mmol ethyl-4-bromobutanoate. Yield = 96% (yellow oil). Rf = 0.43 
(EtOAc/cyclohexane 5/95). IR: 1729 cm-1 (ester, C=O stretch). 1H NMR (400 MHz, CDCl3): δ 4.12 
(q, J = 7.0, 2H, -CH2CH3), 3.22 (t, J = 6.8, 2H, -CH2COOR), 2.41 (t, J = 7.2, 2H, -CH2I), 2.1 (dd, J = 6.8, 
7.2, 2H), 1.24 (t, J = 7.0, 3H, -CH2CH3).
13C NMR (125 MHz, CDCl3): δ 172.2, 60.4, 34.8, 28.5, 14.2, 
5.4. HRMS (ESI) calc. for C6H11IO2 [M+H]
+ 242.9877, found [M+H]+ 242.9879. GCMS found 197 for 
[M-OEt+.]. 
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Ethyl-5-iodopentanoate (49). Compound 49 was synthesized following the general procedure 
for Finkelstein reaction on 119 mmol ethyl-5-bromopentanoate. Yield = 92% (yellow oil). Rf = 
0.41 (EtOAc/cyclohexane 5/95). IR: 1729 cm-1 (ester, C=O stretch).  1H NMR (400 MHz, CDCl3): δ 
4.11 (q, J = 7.2, 2H, -CH2CH3), 3.17 (t, J = 6.8, 2H, -CH2COOR), 2.31 (t, J = 7.4, 2H, -CH2I), 1.85 (dd, J 
= 6.8, 7.4, 2H), 1.72 (p, J = 7.4, 2H), 1.24 (t, J = 7.2, 3H, -CH2CH3). 
13C NMR (125 MHz, CDCl3): δ 
173.0, 60.3, 33.1, 32.7, 25.7, 14.2, 5.8. HRMS (ESI) calc. for C7H13IO2 [M+Na]
+ 278.9852, found 
[M+Na]+ 278.9856. GCMS found 211 for [M-OEt+.]. 
 
 
Ethyl 4-(3-(dimethylamino)propylthio)butanoate (50). Compound 50 was synthesized following 
the general procedure for S-alkylation using 68.7 mmol of thioacetate 47 (no purification 
needed). Yield = 92% (slight yellow oil). Rf = 0.48 (AcOH/ EtOAc/MeOH/H2O 3/3/3/2). IR: 1732 
cm-1 (ester, C=O stretch). 1H NMR (400 MHz, CDCl3): δ 4.01 (q, J = 7.2, 2H, -COCH2CH3), 2.43 (t, J = 
7.2, 2H, -CH2S), 2.41 (t, J = 7.4, 2H, -CH2S), 2.30 (t, J = 7.2, 2H, -CH2COOEt), 2.22 (t, 2H, J = 7.4, -
CH2NMe2), 2.09 (s, 6H, N(CH3)2), 1.83 – 1.74 (m, 2H), 1.66 – 1.56 (m, 2H), 1.12 (t, J = 7.2, 3H, -
COCH2CH3). 
13C NMR (125 MHz, CDCl3): δ 172.8, 60.1, 58.4, 45.2, 32.8, 31.2, 29.5, 27.5, 24.5, 
14.0. HRMS (ESI) calc. for C11H23NO2S [M+H]
+ 234.1522, found 234.1521. GCMS found 233 for 
[M+.].  
 
Ethyl 5-(3-(dimethylamino)propylthio)pentanoate (51). Compound 51 was synthesized 
following the general procedure for S-alkylation using 40.3 mmol of thioacetate 47 (no 
purification needed).  Yield = 97% (slighlt yellow oil). Rf = 0.50 (AcOH/EtOAc/MeOH/H2O 
3/3/3/2). IR: 1733 cm-1 (ester, C=O stretch). 1H NMR (400 MHz, CDCl3): δ 4.05 (q, J = 7.2, 2H, -
COCH2CH3), 2.47 (t, J = 7.2, 2H, -CH2S), 2.45 (t, J = 7.2, 2H, -CH2S), 2.32 (t, J = 7.4, 2H, -CH2COOEt), 
2.24 (t, J = 7.4, 2H, -CH2NMe2), 2.19 (s, 6H, (N(CH3)2), 1.74 - 1.60 (m, 4H), 1.59 - 1.49 (m, 2H), 1.18 
(t, J = 7.2, 3H, -COCH2CH3). 
13C NMR (125 MHz, CDCl3): δ 173.2, 60.1, 58.4, 45.2, 33.7, 31.6, 29.7, 
28.9, 27.4, 24.0, 14.1. HRMS (ESI) calc. for C12H25NO2S [M+H]
+ 248.1679, found 248.1678. GCMS 
found 247 for [M+.].  
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4-(3-(Dimethylamino)propylthio)butan-1-ol  (52). Compound 52 was synthesized following the 
general procedure for ester reduction using 21 mmol of ethylester 50. Yield = 91% (colorless oil). 
Rf = 0.28 (AcOH/EtOAc/MeOH/ H2O 3/3/3/2). 
1H NMR (400 MHz, CDCl3): δ 3.43 (t, J = 6.2, 2H, -
CH2OH), 2.39 (t, J = 7.2, 2H, -CH2S), 2.38 (t, J  = 7.0, 2H, -CH2S), 2.23 – 2.20 (m, 2H, -CH2NMe2), 
2.07 (s, 6H, N(CH3)2), 1.64 – 1.55 (m, 2H), 1.54 - 1.43 (m, 4H). 
13C NMR (125 MHz, CDCl3): δ  61.3, 
58.2, 45.0 (2C), 31.6, 31.6, 29.5, 27.1, 25.7. HRMS (ESI) calc. for C9H21NOS [M+H]
+ 192.1416, 
found 192.1413. GCMS found 191 for [M+.].  
 
 
5-(3-(Dimethylamino)propylthio)pentan-1-ol (53). Compound 53 was synthesized following the 
general procedure for ester reduction using 40.3 mmol of ethylester 51. Yield = 93% (slight 
yellow oil). Rf = 0.33 (AcOH/EtOAc/ MeOH/H2O 3/3/3/2). 
1H NMR (400 MHz, CDCl3): δ 3.58 (t, J 
= 6.6, 2H, -CH2OH), 2.50 (t, J = 7.4, 2H, -CH2S), 2.49 (t, J = 7.2, 2H, -CH2S), 2.32 (t, J = 7.2, 2H, 
CH2NMe2), 2.19 (s, 6H, N(CH3)2), 1.77 – 1.65 (m, 2H), 1.63-1.50 (m, 4H), 1.46-1.38 (m, 2H). 
13C 
NMR (125 MHz, CDCl3): δ 62.3, 58.6, 45.3 (2C), 32.2, 32.0, 29.9, 29.3, 27.5, 25.0. HRMS (ESI) 
calc. for C10H23NOS [M+H]
+ 206.1573, found  206.1571. LC-MS (ESI) found 205.99 for [M+H]+. 
 
4-(3-(Dimethylamino)propylthio)butanal (54). Compound 54 was synthesized following the 
general procedure for Swern oxidation using 6.27 mmol of alcohol 52. Yield = 73% (slight yellow 
oil). Rf = 0.54 (EtOAc/AcOH/ MeOH/H2O 3/3/3/2). IR: 1722 cm
-1 (C=O). 1H NMR (400 MHz, CDCl3): 
δ 9.76 (t, J = 1.2, 1H, -CHO), 2.55 (dt, J = 1.2, 7.2, 2H, -CH2CHO), 2.52 (t, J = 7.2, 2H, -CH2S), 2.50 
(t, J = 7.4, 2H, -CH2S), 2.32 (dd, J = 7.4, 2H, -CH2NMe2), 2.19 (s, 6H, N(CH3)2), 1.89 (dd, J = 7.2, 7.4, 
2H), 1.71 (p, J = 7.4, 2H). 13C NMR (125 MHz, CDCl3): δ 201.7, 58.8, 45.6, 42.8, 31.6, 29.9, 27.8, 
22.0. HRMS (ESI) calc. for C9H19NOS [M+H]
+ 190.1260, found 190.1258. GCMS found 189 for 
[M+.]. 
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5-(3-(Dimethylamino)propylthio)pentanal (55). Compound 55 was synthesized following the 
general procedure for Swern oxidation using 15.6 mmol of alcohol 53. Yield = 85% (yellow oil). Rf 
= 0.50 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1721 cm
-1 (C=O). 1H NMR (400 MHz, CDCl3): δ 9.76 
(t, J = 1.6, 1H, -CHO), 2.54 (t, J = 7.4, 2H, -CH2S), 2.53 (t, J = 7.2, 2H, -CH2S), 2.45 (dt, J = 1.6, 7.2, 
2H, -CH2CHO), 2.38 (t, J = 7.4, 2H, -CH2NMe2), 2.25 (s, 6H, N(CH3)2), 1.80 - 1.69 (m, 4H), 1.66 - 
1.57 (m, 2H). 13C NMR (125 MHz, CDCl3): δ 202.1, 58.5, 45.3, 43.3, 31.8, 29.9, 28.9, 27.5, 21.2. 
HRMS (ESI) calc. for C10H21NOS [M+H]
+ 204.1416, found 204.1413. GCMS found 203 for [M+.].  
 
 
(2S)-(1S,2R)-2-((N-benzyl-N-mesitylsulfonyl)amino)-1-phenylpropyl-2-((S)-4-(3-
(dimethylamino) propylthio)-1-hydroxybutyl) dodecanoate (56). Compound 56 was synthesized 
following the general procedure for anti-selective aldol reaction using 4.6 mmol of aldehyde 54. 
After purification by column chromatography (1-3% MeOH/CH2Cl2), compound 56 is obtained as 
colorless oil in 40% yield, as a single diastereoisomer. Rf = 0.44 (10% MeOH/CH2Cl2). []D
20 = -28.3 
(c = 1.0, CHCl3). 
1H NMR (500 MHz, CDCl3): δ 7.29 - 7.13 (m, 8H, Haro), 6.85 - 6.82 (m, 4H, Haro), 
5.83 (d, J = 5.7, 1H, -CHOCOR), 4.75 (d, J = 16.5, 1H, -CHPh), 4.52 (d, J = 16.5, 1H, -CHPh), 4.19 - 
4.13 (m, 1H, -CHN(Bn)Mes), 3.70 - 3.65 (m, 1H, -CHOH), 2.55 - 2.50 (m, 4H), 2.44 (s, 6H), 2.42 - 
2.36 (m, 4H), 2.28 (s, 3H), 2.24 (s, 6H), 1.80 - 1.40 (m, 8H), 1.32 - 0.96 (m, 19H), 0.89 (t, J = 6.7, 
3H, -CH3). 
13C NMR (125 MHz, CDCl3): δ 174.7, 142.7, 140.5, 138.5, 138.1, 133.4, 132.2, 128.5, 
128.4, 128.2, 128.1, 127.4, 126.8, 78.3, 71.9, 58.7, 56.6, 51.6, 48.3, 45.5, 34.3, 32.1, 32.0, 29.9, 
29.8, 29.7, 29.6, 29.5, 29.4, 27.6, 27.2, 25.7, 23.0, 22.8, 21.0, 14.5, 14.3. HRMS (ESI) calc. for 
C46H71N2O5S2 [M+H]
+ 795.4799, found 795.4798. LC-MS (ESI) found 795.47 for [M+H]+.  
 
 
(2S)-(1S,2R)-2-((N-benzyl-N-mesitylsulfonyl)amino)-1-phenylpropyl-2-((S)-5-(3-
(dimethylamino) propylthio)-1-hydroxypentyl) dodecanoate (57).  Compound 57 was 
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synthesized following the general procedure for anti-selective aldol reaction using 4.7 mmol of 
aldehyde 55. After purification by column chromatography (1-3% MeOH/CH2Cl2), compound 57 
is obtained as colorless oil in 33% yield, as a single diastereoisomer. Rf = 0.30 (8% MeOH/CH2Cl2). 
[]D
20 =  -27.4 (c = 1.0, CHCl3). 
1H NMR (500 MHz, CDCl3): δ 7.29 - 7.13 (m, 8H, Haro), 6.85 - 6.82 
(m, 4H, Haro), 5.83 (d, J = 5.5, 1H, -CHOCOR), 4.75 (d, J = 16.2, 1H, -CHPh), 4.52 (d, J = 16.5, 1H, -
CHPh), 4.19 - 4.13 (m, 1H, -CHN(Bn)Mes), 3.68 - 3.63 (m, 1H, -CHOH), 2.58 - 2.46 (m, 4H), 2.45 - 
2.39 (m, 10H), 2.30 - 2.27 (m, 7H), 1.80 - 1.74 (m, 2H), 1.60 - 1.33 (m, 8H), 1.32 - 0.96 (m, 21H), 
0.89 (t, J = 7.0, 3H, -CH3). 
13C NMR (125 MHz, CDCl3): δ 174.7, 142.7, 140.5, 138.5, 138.0, 133.4, 
132.2, 128.5, 128.4, 128.2, 128.1, 127.4, 126.8, 78.2, 72.2, 58.7, 56.5, 51.5, 48.3, 45.4, 34.9, 32.2, 
32.0, 31.1, 30.1, 29.8, 29.7, 29.6, 29.5, 29.4, 27.5, 27.3, 25.0, 23.0, 22.8, 21.0, 14.5, 14.3. HRMS 
(ESI) calc. for C47H73O5N2S2 [M+H]
+ 809.4955, found 809.4956. LCMS (ESI) found 809.52 for 
[M+H]+.  
 
 
(S)-((1S,2R)-2-(N-benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl)2-((S)-4-(3-
(dimethyl amino)propylsulfonyl)-1-hydroxybutyl) dodecanoate (58). Compound 58 was 
synthesized following the general procedure for oxidation into sulfone using 2.0 mmol of sulfide 
derivative 56, reaction time 8 hours. Yield = 91% (white semi-solid). Rf = 0.26 (10% MeOH/DCM). 
[]D
20 = - 30.6 (c = 0.31, CHCl3). IR: 1734 cm
-1 (ester, C=O stretch), 1312 cm-1 (SO2 asym. stretch), 
1149cm-1 (SO2 sym. Stretch). 
1H NMR (400 MHz, CDCl3): δ 7.28 - 7.11 (m, 8H, Haro), 6.90 - 6.79 
(m, 4H, Haro), 5.85 (d, J = 5.2, 1H, -CHOCOR), 4.64 (d, J = 16.2, 1H, -CHPh), 4.47 (d, J = 16.3, 1H, -
CHPh), 4.25 - 4.09 (m, 1H, -CHN(Bn)Mes), 3.77 - 3.65 (m, 1H, -CHOH), 3.11 (t, J = 7.4, 2H, -
CHSO2), 3.02 (t, J = 8.0, 2H, -CHSO2), 2.85 (t, J = 7.2, 2H, -CH2N(Me)2), 2.54 (s, 6H, CH3 (Mes)), 
2.43 (s, 7H, N(CH3)2, -CHCOOR), 2.27 (s, 3H, CH3 (Mes)), 2.22 -1.85 (m, 4H), 1.69 - 1.37 (m, 4H), 
1.35 - 0.94 (m, 19H), 0.88 (t, J = 7.0, 3H, CH3). 
13C NMR (125 MHz, CDCl3): δ 174.2, 142.5, 140.2 
(2C), 138.3, 137.9, 133.1, 132.1 (2C), 128.3 (2C), 128.2 (2C), 128.1, 127.9 (2C), 127.2, 126.6 (2C), 
78.2, 71.3, 56.7, 56.5, 52.9, 51.8, 49.2, 48.1, 43.9 (2C), 33.2, 31.9 (2C), 29.5 (2C), 29.5, 29.4, 29.3, 
29.3, 27.1, 22.9, 22.7, 20.9, 18.8, 18.4, 14.2, 14.1. HRMS (ESI) calc. for C46H70N2O7S2 [M+H]
+ 
827.46972, found [M+H]+ 827.46967. LCMS (ESI) found 827.18 for [M+H]+.  
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 (S)-((1S,2R)-2-(N-benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl)2-((S)-5-(3-
(dimethyl amino)propylsulfonyl)-1-hydroxypentyl) dodecanoate (59). Compound 59 was 
synthesized following the general procedure for oxidation into sulfone using 1.79 mmol of 
sulfide derivative 57, reaction time 8 hours. Yield = quantitative (yellow semi-solid). Rf = 0.22 
(10% MeOH/DCM). []D
20 = - 30.0 (c = 0.25, CHCl3). IR: 1735 cm
-1 (ester, C=O stretch), 1314 cm-1 
(SO2 asym. stretch), 1150 cm
-1 (SO2 sym. stretch). 
1H NMR (400 MHz, CDCl3): δ 7.27 - 7.11 (m, 8H, 
Haro), 6.90 - 6.81 (m, 4H, Haro), 5.86 (d, J = 5.6, 1H, -CHOCOR), 4.67 (d, J = 16.4, 1H, -CHPh), 4.46 
(d, J = 16.4, 1H, -CHPh), 4.24 - 4.11 (m, 1H, -CHN(Bn)Mes), 3.69 - 3.61 (m, 1H, -CHOH), 3.04 (t, J = 
7.8, 2H, -CH2SO2), 2.95 (t, J = 8.0, 2H, -CH2SO2), 2.58 (t, J = 6.8, 2H, -CH2N(Me)2), 2.42 (s, 7H, CH3 
(Mes), -CHCOOR), 2.35 (s, 6H, N(CH3)2), 2.27 (s, 3H, CH3 (Mes)), 2.11 - 2.01 (m, 2H), 1.90 - 1.75 
(m, 2H), 1.67 - 1.44 (m, 4H), 1.42 - 0.96 (m, 21H), 0.88 (t, J = 7.0, 3H, -CH3). 
13C NMR (125 MHz, 
CDCl3): δ 174.4, 142.5, 140.3 (2C), 138.3, 137.9, 133.2, 132.1 (2C), 128.3 (2C), 128.2 (2C), 128.1, 
127.9 (2C), 127.2, 126.6 (2C), 78.1, 71.6, 58.8, 56.5, 53.1, 51.6, 49.8, 48.1, 44.1 (2C), 34.2, 31.9 
(2C), 29.7, 29.5, 29.5, 29.5, 29.3, 29.3, 27.1, 24.5, 22.9, 22.7, 21.9, 20.8, 18.6, 14.2, 14.1. HRMS 
(ESI) calc. for C47H72N2O7S2 [M+H]
+ 841.4854,  found [M+H]+ 841.4854. LCMS (ESI) found 841.21 
for [M+H]+.  
 
 
(S)-2-((S)-4-(3-(dimethylamino)propylsulfonyl)-1-hydroxybutyl)dodecanoic acid (60). 
Compound 60 was synthesized following the general procedure for hydrogenolysis on 1.82 
mmol of -hydroxyester 58, reaction time 6 hours.  Purification by column chromatography 
using MeOH/CH2Cl2 4/96 to first remove unpolar impurities followed by Et3N/MeOH/CH2Cl2 
2/10/88 to elute compound 60. Yield = 65% (white semi-solid). Rf = 0.62 (AcOH/EtOAc 
/MeOH/H2O 3/3/3/2).  []D
20 = -8.2 (c = 1.0, MeOH/CH2Cl2 1/4). IR: 1615 cm
-1 (acid, C=O stretch), 
1279 cm-1 (SO2 asym. stretch), 1135 cm
-1 (SO2 sym. stretch). 
1H NMR (400 MHz, CDCl3): δ 3.63 - 
3.53 (m, 1H, -CHOH), 3.18 - 3.01 (m, 4H, -CH2SO2), 2.93 (t, J = 7.4, 2H, -CH2N(Me)2), 2.60 (s, 6H, -
N(CH3)2), 2.25 - 2.17 (m, 1H, -CHCOOH), 2.12 - 2.09 (m, 2H), 2.01 - 1.83 (m, 2H), 1.69 - 1.17 (m, 
20H), 0.81 (t, J = 6.8, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 181.1, 71.6, 55.9, 52.9, 52.2, 49.2, 
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42.9 (2C), 34.2, 31.7, 30.1, 29.6, 29.5, 29.5, 29.4, 29.2, 27.7, 22.5, 18.9, 18.0, 13.9. HRMS (ESI) 
calc. for C21H43O5NS [M+H]
+ 422.2935, found 422.2929. LCMS (ESI) found 422.37 for [M+H]+.  
 
 
(S)-2-((S)-5-(3-(dimethylamino)propylsulfonyl)-1-hydroxypentyl)dodecanoic acid (61). 
Compound 61 was synthesized following the general procedure for hydrogenolysis on 1.81 
mmol of -hydroxyester 59, reaction time 6 hours. Purification by column chromatography using 
MeOH/CH2Cl2 10/90 to first remove unpolar impurities followed by Et3N/MeOH/CH2Cl2 2/10/88 
to elute compound 61. Yield= 77% (white semi-solid). Rf = 0.59 (AcOH/EtOAc/MeOH/H2O 
3/3/3/2).  []D
20= -6.4 (c = 1.0, MeOH/CH2Cl2 1/4). IR: 1648 cm
-1 (acid, C=O stretch), 1270 cm-1 
(SO2 asym. stretch), 1134 cm
-1 (SO2 sym. stretch). 
1H NMR (400 MHz, CDCl3): δ 3.64 - 3.55 (m, 1H, 
-CHOH), 3.12 – 2.95 (m, 4H, -CH2SO2), 2.95-2.83 (m, 2H, -CH2N(Me)2), 2.55 (s, 6H, -N(CH3)2), 2.30 
- 2.22 (m, 1H, -CHCOOH), 2.17 ( p, J = 7.6, 2H), 1.91 - 1.77 (m, 2H), 1.75 - 1.39 (m, 6H), 1.37 - 1.14 
(m, 16H), 0.86 (t, J  = 6.8, 3H). 13C NMR (100 MHz, CDCl3): δ 181.1, 71.8, 55.9, 52.6, 52.0, 49.6, 
43.1 (2C), 35.4, 31.8, 30.2, 29.7, 29.6, 29.6, 29.5, 29.3, 27.8, 24.2, 22.6, 22.2, 18.6, 14.1. HRMS 
(ESI) calc. for C22H45O5NS [M+H]
+ 436.3091, found 436.3086. LCMS (ESI) found 436.42 for [M+H]+.  
 
 
(3S,4S)-4-(3-(3-(dimethylamino)propylsulfonyl)propyl)-3-decyloxetan-2-one (27). Compound 27 
was synthesized following the general procedure for -lactonization on 1.06 mmol of -
hydroxyacid 60.  Purification by column chromatography (1-5% MeOH/DCM) yield compound 27 
as a white solid in 98% yield. Rf = 0.36 (MeOH/CH2Cl2 1/9). mp = 85.2- 85.5°C (after 
recrystallisation from EtOAc/hexane).  []D
20 = -28.2 (c = 0.11, CHCl3). IR: 1798 cm
-1 (β-lactone, 
C=O stretch), 1252 cm-1 (SO2 asym. stretch), 1121 cm
-1 (SO2 sym. stretch). 
1H NMR (400 MHz, 
CDCl3): δ 4.20 (ddd, J = 4.1, 5.4, 7.5, 1H, -CHOCOR), 3.16 (ddd, J = 4.0, 6.7, 8.5, 1H, -CHCO), 3.06 - 
2.94 (m, 4H, -CH2SO2), 2.36 (t, J = 6.6, 2H, -CH2NMe2), 2.17 (s, 6H, -N(CH3)2), 2.02 - 1.61 (m, 8H), 
1.45 - 1.13 (m, 16H), 0.82 (t, J = 7.0, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 170.6, 76.9, 57.2, 
56.3, 51.9, 50.6, 44.9 (2C), 32.9, 31.7, 29.4, 29.3, 29.1, 29.1 (2C), 27.5, 26.7, 22.5, 19.7, 18.1, 
13.9. HRMS (ESI) calc. for C21H41O4NS [M+H]
+ 404.2829, found [M+H]+ 404.2817. LCMS (ESI) 
found 404.22 for [M+H]+. 
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(3S,4S)-4-(4-(3-(dimethylamino)propylsulfonyl)butyl)-3-decyloxetan-2-one (palmostatin M, 
28). Compound 28 was synthesized following the general procedure for -lactonization on 0.091 
mmol of -hydroxyacid 61. Purification by column chromatography (1-5% MeOH/DCM) yield 
compound 28 as a white solid in 92 % yield. Rf = 0.33 (MeOH/CH2Cl2 1/9). mp = 69.1- 69.4°C 
(after recrystallisation from EtOAc/hexane). []D
20 = -18.7 (c = 0.2, CHCl3). IR: 1799 cm
-1 (β-
lactone, C=O stretch), 1266 cm-1 (SO2 asym. stretch), 1120 cm
-1 (SO2 sym. stretch).
1H NMR (400 
MHz, CDCl3): δ
  4.19 (ddd, J = 4.0, 5.6, 7.4, 1H, -CHOCOR), 3.16 (ddd, J = 3.9, 6.7, 8.7, 1H, -CHCO), 
3.02 - 2.98 (m, 4H, -CH2SO2), 2.40 (t, J = 6.6, 2H, -CH2NMe2), 2.21 (s, 6H, -N(CH3)2), 2.02 - 1.49 (m, 
8H), 1.44 - 1.16 (m, 18H), 0.85 (t, J = 7.0, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 171.0, 77.3, 
57.3, 56.2, 52.4, 50.6, 45.0 (2C), 33.8, 31.8, 29.5, 29.4, 29.2, 29.2 (2C), 27.7, 26.8, 24.2, 22.5, 
21.5, 19.7, 14.0. HRMS (ESI) calc. for C22H43O4NS [M+H]
+ 418.2986, found [M+H]+ 418.2981. 
LCMS (ESI) found 418.27 for [M+H]+. 
 
2.7 Synthesis of cis -lactone inhibitors derived from 27 and 28  
 
 
N-benzyl-N-((1R,2S)-1-hydroxy-1-phenylpropan-2-yl)-2,4,6-trimethylbenzenesulfonamide (62). 
Compound 62 was synthesized following the general procedure for ephedrine auxiliary synthesis 
using 52.9 mmol of (1R,2S)-Norephedrine. The mesylated intermediate was obtained in 90% 
yield as a white solid. Rf =0.53 (EtOAc/cyclohexane 1/1). 
1H NMR (400 MHz, CDCl3): δ
 7.34 - 7.20 
(m, 5H, Haro), 6.93 (s, 2H, Haro), 4.96 (d, J = 8.8, 1H, -CH(OH)), 4.74 (d, J = 2.8, 1H, -NH), 3.54-
3.40 (m, 1H, -CHNHR), 2.63 (s, 6H, 2*-CH3, Mes), 2.27 (s, 3H, -CH3, Mes), 0.83 (d, J = 6.8, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 142.2, 140.3, 138.9 (2C), 134.2, 131.9 (2C), 128.3 (2C), 127.6, 125.9 
(2C), 75.6, 54.5, 22.9 (2C), 20.9, 14.6. (NMR analysis consistent with the literature8). Alcohol 62 
was obtained in 79 % as a white solid. Rf =0.45 (EtOAc/cyclohexane 2/8). mp= 121-122°C. 
1H 
NMR (400 MHz, CDCl3): δ
 7.36 - 7.15 (m, 8H, Haro), 7.09 – 7.04 (m, 2H, Haro), 6.91 (s, 2H, Haro), 
4.97 (brs, 1H,- CH(OH)), 4.77 (d, J = 16, 1H, -CH2Bn), 4.54 (d, J = 16, 1H, -CH2Bn), 3.82 (dq, J = 1.6, 
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7.0, 1H, -CHNSO2Mes(Bn)), 2.63 (s, 6H, 2*-CH3, Mes), 2.28 (s, 3H, -CH3, Mes), 1.03 (d, J = 6.8, 3H, -
CH3). 
13C NMR (100 MHz, CDCl3): δ 142.6, 142.1, 140.1 (2C), 138.6, 133.4, 132.1 (2C), 128.5 (2C), 
128.1 (2C), 127.7 (2C), 127.3, 127.2, 125.5 (2C), 76.5, 59.6, 49.0, 22.9 (2C), 20.8, 9.9. (NMR 
analysis consistent with the literature8). 
 
 
(1R,2S)-2-(N-benzyl-N-mesitylenesulfonyl)amino-1-phenyl-1-propyl dodecanoate (63). 
Compound 63 was synthesized following the general procedure for O-dodecylated ephedrine 
auxiliary synthesis using 12.0 mmol of compound 62, reaction time 15 hours. Purification using 
2,5% EtOAc/cyclohexane as eluent for the flash chromatography lead to compound 63 in 80% 
yield (white solid). Rf =0.61 (EtOAc/cyclohexane 2/8). []D
20 = +22.5 (c = 0.2, CHCl3). mp = 59.9 - 
60.2°C (recrystallisation from EtOAc/hexane). IR: 1734 cm-1 (ester, C=O stretch). 1H NMR (400 
MHz, CDCl3): δ
  7.36 - 7.15 (m, 8H, Haro), 6.92 - 6.84 (m, 4H, Haro), 5.82 (d, J = 4.0, 1H, -CHOCOR), 
4.73 (d, J = 16. 4, 1H, -CHPh), 4.58 (d, J = 16. 8, 1H, -CHPh),  4.08 - 3.99 (m, 1H, CHN(Bn)Mes), 2.51 
(s, 6H, CH3 (Mes)), 2.27 (s, 3H, CH3 (Mes)), 2.21 - 2.01 (m, 2H), 1.52 - 1.42 (m, 2H), 1.35 - 1.14 (m, 
16H), 1.11 (d, J = 6.8, 3H, -CH3), 0.87 (t, J = 6.8, 3H, -CH3).
 13C NMR (100 MHz, CDCl3): δ 172.0, 
142.5, 140.2, 138.7, 138.5 133.3, 132.1, 128.4, 128.3, 127.7, 127.3, 127.0, 125.9, 77.9, 56.6, 48.1, 
34.2, 31.9, 29.6, 29.4, 29.3, 29.2, 29.0, 24.6, 22.9, 22.7, 20.9, 14.1, 12.8. HRMS (ESI) calc. for 
C37H51NO4S [M+H]
+ 606.3612, [M+Na]+ 628.3431, found [M+H]+ 606.3607, [M+Na]+ 628.3424. 
LCMS (ESI) found 605.82 for [M+H]+, found 622.93 for [M+NH4]
+, found 628.20 for [M+Na]+, found 
1227.98 for [2M+NH4]
+ . 
 
 
(2S)-(1S,2R)-2-((N-benzyl-N-mesitylsulfonyl)amino)-1-phenylpropyl-2-((R)-4-(3-
(dimethylamino) propylthio)-1-hydroxybutyl) dodecanoate (64). Compound 64 was synthesized 
following the general procedure for cis-selective aldol reaction using 4.95 mmol of O-
dodecylated ephedrine auxiliary 10 followed by purification by flash chromatography using 1-3% 
MeOH/DCM. Yield = 43 % (slight yellow oil). Rf = 0.41 (10% MeOH/DCM).  []D
20 = +23.4 (c = 1.03, 
CHCl3). IR: 1735 cm
-1 (ester, C=O stretch). 1H NMR (400 MHz, CDCl3): δ
  7.30 - 7.11 (m, 8H, Haro), 
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6.91 - 6.82 (m, 4H, Haro), 5.85 (d, J = 5.2, 1H, -CHOCOR), 4.69 (d, J = 16.4, 1H, -CHPh), 4.48 (d, J = 
16.4, 1H, -CHPh), 4.18 - 4.09 (m, 1H, -CHN(Bn)Mes), 3.70 - 3.62 (m, 1H, -CHOH), 2.57 - 2.23 (m, 
22H), 1.84 - 1.02 (m, 27H), 0.88 (t, J = 7.0, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 174.2, 142.5, 
140.3 (2C), 138.2, 137.9, 133.1, 132.1 (2C), 128.4 (2C), 128.3 (2C), 128.0, 127.7 (2C), 127.2, 126.5 
(2C), 78.2, 71.2, 58.4, 56.5, 50.9, 48.2, 45.1 (2C), 33.1, 31.9, 31.8, 29.7, 29.6, 29.6, 29.5, 29.4, 
29.3 27.7, 27.2, 27.1, 26.1, 22.9 (2C), 22.7, 20.9, 14.1, 13.9. HRMS (ESI) calc. for C46H70N2O5S2 
[M+H]+ 795.4799,  found [M+H]+ 795.4797. LCMS (ESI) found 795.46 for [M+H]+.  
 
 
(2S)-(1S,2R)-2-((N-benzyl-N-mesitylsulfonyl)amino)-1-phenylpropyl-2-((R)-5-(3 
(dimethylamino) propylthio)-1-hydroxypentyl) dodecanoate (65). Compound 65 was 
synthesized following the general procedure for cis-selective aldol reaction using 4.95 mmol of 
O-dodecylated ephedrine auxiliary 10 followed by purification by flash chromatography using 1-
3% MeOH/DCM. Yield = 55 % (slight yellow oil). Rf = 0.41 (10% MeOH/DCM).  []D
20 = -22.7 (c = 
1.2, CHCl3). IR: 1734 cm
-1 (ester, C=O stretch). 1H NMR (400 MHz, CDCl3): δ
  7.29 - 7.20 (m, 8H, 
Haro), 6.92 - 6.81 (m, 4H, Haro), 5.84 (d, J = 5.2, 1H, -CHOCOR), 4.69 (d, J = 16.4, 1H, -CHPh), 4.48 
(d, J = 16.4, 1H, -CHPh), 4.23 - 4.08 (m, 1H, -CHN(Bn)Mes), 3.72 - 3.57 (m, 1H, -CHOH), 2.75 - 2.67 
(m, 2H, -CH2N(Me)2), 2.54 (t, J = 6.8, 2H, -CH2S), 2.51 - 2.47 (m, 8H, -CH2S, CH3 (Mes)), 2.44 (s, 6H, 
N(CH3)2), 2.34 -2.26 (m, 1H, -CHCOOR), 2.26 (s, 3H, CH3 (Mes)), 1.88 (p, J = 7.4, 2H), 1.63 - 1.02 
(m, 27H), 0.87 (t, J = 7.0, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 174.2, 142.5, 140.2 (2C), 138.2, 
137.9, 133.0, 132.0 (2C), 128.3 (2C), 128.2 (2C), 128.0, 127.6 (2C), 127.2, 126.5 (2C), 78.1, 71.5, 
58.4, 56.4, 50.9, 48.1, 45.2 (2C), 33.6, 32.0, 31.8, 29.8, 29.5, 29.5, 29.4, 29.3, 29.3, 29.2, 27.7, 
27.3, 27.1, 25.2, 22.9 (2C), 22.6, 20.8, 14.1, 13.9. HRMS (ESI) calc. for C47H72N2O5S2 [M+H]
+ 
809.4955,  found [M+H]+ 809.4953. LCMS (ESI) found 809.50 for [M+H]+.  
 
 
(2R)-(1R,2S)-2-((N-benzyl-N-mesitylsulfonyl)amino)-1-phenylpropyl-2-((S)-4-(3-
(dimethylamino) propylthio)-1-hydroxybutyl) dodecanoate (66). Compound 66 was synthesized 
following the general procedure for cis-selective aldol reaction using 4.78 mmol of O-
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dodecylated ephedrine auxiliary 63 followed by purification by flash chromatography using 1-3% 
MeOH/DCM. Yield = 36 % (slight yellow oil). Rf = 0.41 (10% MeOH/DCM).  []D
20 = +22.4 (c = 1.3, 
CHCl3). IR: 1734 cm
-1 (ester, C=O stretch). 1H NMR (400 MHz, CDCl3): δ
  7.28 - 7.13 (m, 8H, Haro), 
6.92 - 6.81 (m, 4H, Haro), 5.85 (d, J = 5.2, 1H, -CHOCOR), 4.69 (d, J = 16.4, 1H, -CHPh), 4.48 (d, J = 
16.4, 1H, -CHPh), 4.18 - 4.09 (m, 1H, CHN(Bn)Mes), 3.70 - 3.62 (m, 1H, -CHOH), 2.66 - 2.49 (m, 
4H), 2.49 - 2.37 (m, 14H), 2.33 - 2.24 (m, 4H), 1.84 (p, J = 7.4, 2H), 1.77 - 1.03 (m, 25H), 0.88 (t, J = 
6.8, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 174.2, 142.6, 140.3 (2C), 138.2, 137.9, 133.1, 132.1 
(2C), 128.4 (2C), 128.3 (2C), 128.0, 127.7 (2C), 127.2, 126.5 (2C), 78.2, 71.3, 58.1, 56.5, 51.1, 
48.2, 44.7 (2C), 33.1, 31.9, 31.8, 29.6, 29.6, 29.5, 29.4, 29.3, 29.2, 27.7, 27.3, 26.3, 26.0, 22.9 
(2C), 22.7, 20.9, 14.1, 13.8. HRMS (ESI) calc. for C46H70N2O5S2 [M+H]
+ 795.4799,  found [M+H]+ 
795.4797. LCMS (ESI) found 795.44 for [M+H]+.  
 
 
(2R)-(1R,2S)-2-((N-benzyl-N-mesitylsulfonyl)amino)-1-phenylpropyl-2-((S)-5-(3-
(dimethylamino) propylthio)-1-hydroxypentyl) dodecanoate (67). Compound 67 was 
synthesized following the general procedure for cis-selective aldol reaction using 4.78 mmol of 
O-dodecylated ephedrine auxiliary 63 followed by purification by flash chromatography using 1-
3% MeOH/DCM. Yield = 47 % (slight yellow oil). Rf = 0.41 (10% MeOH/DCM).  []D
20 = +20.2 (c = 
1.2, CHCl3). IR: 1732 cm
-1 (ester, C=O stretch). 1H NMR (400 MHz, CDCl3): δ
  7.27 - 7.12 (m, 8H, 
Haro), 6.92 - 6.82 (m, 4H, Haro), 5.85 (d, J = 4.8, 1H, -CHOCOR ), 4.69 (d, J = 16.4, 1H, -CHPh), 
4.48 (d, J = 16.4, 1H, -CHPh), 4.19 - 4.10 (m, 1H, -CHN(Bn)Mes), 3.70 - 3.62 (m, 1H, -CHOH), 3.11- 
3.02 (m, 2H, -CH2N(Me)2), 2.78 (s, 6H, CH3 (Mes)), 2.57 (t, J = 6.8, 2H, -CH2S), 2.49 (t, J = 7.0, 2H, -
CH2S), 2.45 (s, 6H, N(CH3)2), 2.35 - 2.29 (m, 1H, -CHCOOR), 2.27 (s, 3H, CH3 (Mes)), 2.04 - 1.95 (m, 
2H), 1.62 - 1.01 (m, 27H), 0.88 (t, J = 7.0, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 174.3, 142.7, 
140.3 (2C), 138.2, 137.9, 133.1, 132.1 (2C), 128.4 (2C), 128.3 (2C), 128.0, 127.6 (2C), 127.2, 126.4 
(2C), 78.3, 71.6, 57.7, 56.6, 51.1, 48.2, 43.9 (2C), 33.5, 31.9, 31.8, 29.6, 29.6, 29.5, 29.4, 29.3, 
29.1, 28.6, 27.7, 27.3, 25.1, 24.6, 22.9 (2C), 22.6, 20.8, 14.1, 13.8. HRMS (ESI) calc. for 
C47H72N2O5S2 [M+H]
+ 809.4955,  found [M+H]+ 809.4953. LCMS (ESI) found 809.48 for [M+H]+.  
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(S)-((1S,2R)-2-((N-benzyl-N-mesitylsulfonyl)amino)-1-phenylpropyl)-2-((R)-4-(3-
(dimethylamino) propylsulfonyl)-1-hydroxybutyl) dodecanoate (68). Compound 68 was 
synthesized following the general procedure for oxidation into sulfone using 1.69 mmol of 
sulfide derivative 64, reaction time 8 hours (no purification). Yield = 96 % (slight yellow oil). Rf = 
0.41 (10% MeOH/DCM). []D
20 = - 15.8 (c = 1.1, CHCl3). IR: 1734 cm
-1 (ester, C=O stretch), 1314 
cm-1 (SO2 asym. stretch), 1150 cm
-1 (SO2 sym. Stretch). 
1H NMR (400 MHz, CDCl3): δ 7.26 - 7.13 
(m, 8H, Haro), 6.95 - 6.80 (m, 4H, Haro), 5.89 (d, J = 5.2, 1H, -CHOCOR), 4.69 (d, J = 16.4, 1H, -
CHPh), 4.48 (d, J = 16.4, 1H, -CHPh), 4.23 - 4.08 (m, 1H, -CHN(Bn)Mes), 3.71 - 3.62 (m, 1H, -
CHOH), 3.04 - 2.84 (m, 4H, -CH2SO2), 2.50 (t, J = 7.0, 2H, -CH2N(Me)2), 2.45 (s, 6H, CH3 (Mes)), 
2.29 (s, 6H, N(CH3)2), 2.28 -2.24 (m, 4H, CH3 (Mes), -CHCOOR), 2.09 – 0.99 (m, 27H), 0.88 (t, J = 
7.0, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 173.9, 142.6, 140.2 (2C), 138.0, 137.8, 132.9, 132.1 
(2C), 128.4 (2C), 128.3 (2C), 128.1, 127.6 (2C), 127.3, 126.5 (2C), 78.1, 70.9, 57.1, 56.5, 52.5, 
51.1, 49.9, 48.1, 44.7 (2C), 32.3, 31.9 (2C), 29.6 (2C), 29.5, 29.4, 29.3, 27.7, 27.3, 22.9, 22.7, 20.9, 
19.3, 19.1, 14.1, 13.9. HRMS (ESI) calc. for C46H70N2O7S2 [M+H]
+ 827.4697, [M+Na]+ 849.4516, 
found [M+H]+ 827.4696, [M+Na]+ 849.4508. LCMS (ESI) found 827.43 for [M+H]+.  
 
 
(S)-((1S,2R)-2-((N-benzyl-N-mesitylsulfonyl)amino)-1-phenylpropyl)-2-((R)-5-(3-
(dimethylamino) propylsulfonyl)-1-hydroxypentyl) dodecanoate (69). Compound 69 was 
synthesized following the general procedure for oxidation into sulfone using 1.31 mmol of 
sulfide derivative 65, reaction time 8 hours (no purification). Yield = 92 % (slight yellow oil). Rf = 
0.39 (10% MeOH/DCM).  []D
20 = - 16.4 (c = 1.0, CHCl3). IR: 1734 cm
-1 (ester, C=O stretch), 1315 
cm-1 (SO2 asym. stretch), 1151 cm
-1 (SO2 sym. Stretch). 
1H NMR (400 MHz, CDCl3): δ 7.28 - 7.12 
(m, 8H, Haro), 6.93 - 6.81 (m, 4H, Haro), 5.88 (d, J = 5.2, 1H, -CHOCOR), 4.69 (d, J = 16.4, 1H, -
CHPh), 4.48 (d, J = 16.4, 1H, -CHPh), 4.20 - 4.08 (m, 1H, -CHN(Bn)Mes), 3.68 - 3.61 (m, 1H, -
CHOH), 3.10 - 2.90 (m, 4H, -CH2SO2),  2.60 (t, J = 7.0, 2H, -CH2N(Me)2), 2.45 (s, 6H, CH3 (Mes)), 
2.36 (s, 6H, N(CH3)2), 2.30 - 2.24 (m, 4H, CH3 (Mes), -CHCOOR), 2.13 – 1.01 (m, 29H), 0.88 (t, J = 
7.0, 3H, -CH3).
 13C NMR (100 MHz, CDCl3): δ 174.1, 142.6, 140.2 (2C), 138.1, 137.8, 132.9, 132.1 
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(2C), 128.4 (2C), 128.3 (2C), 128.1, 127.6 (2C), 127.2, 126.5 (2C), 78.1, 71.2, 57.1, 56.4, 52.9, 
50.9, 49.9, 48.1, 44.6 (2C), 33.2, 31.8 (2C), 29.6, 29.5, 29.5, 29.4, 29.3, 27.7, 27.2, 25.0, 22.9, 
22.6, 21.7, 20.9, 19.1, 14.1, 13.9. HRMS (ESI) calc. for C47H72N2O7S2 [M+H]
+ 841.4854, [M+Na]+ 
863.4673, found [M+H]+ 841.4853, [M+Na]+ 863.4663. LCMS (ESI) found 841.46 for [M+H]+.  
 
 
(R)-((1R,2S)-2-((N-benzyl-N-mesitylsulfonyl)amino)-1-phenylpropyl)-2-((S)-4-(3-
(dimethylamino) propylsulfonyl)-1-hydroxybutyl) dodecanoate (70). Compound 70 was 
synthesized following the general procedure for oxidation into sulfone using 1.73 mmol of 
sulfide derivative 66, reaction time 8 hours (no purification). Yield = 98 % (slight yellow oil). Rf = 
0.40 (10% MeOH/DCM).  []D
20 = + 15.7 (c = 1.05, CHCl3). IR: 1733 cm
-1 (ester, C=O stretch), 1313 
cm-1 (SO2 asym. stretch), 1150 cm
-1 (SO2 sym. Stretch). 
1H NMR (400 MHz, CDCl3): δ 7.27 - 7.13 
(m, 8H, Haro), 6.96 - 6.81 (m, 4H, Haro), 5.89 (d, J = 4.8, 1H, -CHOCOR), 4.69 (d, J = 16.4, 1H, -
CHPh), 4.48 (d, J = 16.4, 1H, -CHPh), 4.23 - 4.09 (m, 1H, -CHN(Bn)Mes), 3.68 - 3.61 (m, 1H, -
CHOH), 3.08 - 2.85 (m, 4H, -CH2SO2), 2.61 (t, J = 7.0, 2H, -CH2N(Me)2), 2.45 (s, 6H, CH3 (Mes)), 
2.37 (s, 6H, N(CH3)2), 2.31 - 2.24 (m, 4H, CH3 (Mes), -CHCOOR), 2.18 - 1.01 (m, 27H), 0.88 (t, J = 
7.0, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 173.9, 142.6, 140.2 (2C), 138.0, 137.8, 132.9, 132.1 
(2C), 128.4 (2C), 128.3 (2C), 128.1, 127.6 (2C), 127.3, 126.5 (2C), 78.1, 70.9, 57.0, 56.5, 52.5, 
51.1, 49.8, 48.1, 44.6 (2C), 32.3, 31.9 (2C), 29.6 (2C), 29.5, 29.4, 29.3, 27.7, 27.3, 22.9, 22.7, 21.4, 
20.9, 19.1, 14.1, 13.9. HRMS (ESI) calc. for C46H70N2O7S2 [M+H]
+  827.4697,  found [M+H]+ 
827.4695. LCMS (ESI) found 827.43 for [M+H]+.  
 
 
(R)-((1R,2S)-2-((N-benzyl-N-mesitylsulfonyl)amino)-1-phenylpropyl)-2-((S)-5-(3-
(dimethylamino) propylsulfonyl)-1-hydroxypentyl) dodecanoate (71). Compound 71 was 
synthesized following the general procedure for oxidation into sulfone using 2.24 mmol of 
sulfide derivative 67, reaction time 8 hours (no purification). Yield = 81% (slight yellow oil). Rf = 
0.39 (10% MeOH/DCM).  []D
20 = +18.3 (c = 1.3, CHCl3). IR: 1733 cm
-1 (ester, C=O stretch), 1315 
cm-1 (SO2 asym. stretch), 1150 cm
-1 (SO2 sym. Stretch). 
1H NMR (400 MHz, CDCl3): δ 7.27 - 7.11 
Experimental part   180 
(m, 8H, Haro), 6.91 - 6.81 (m, 4H, Haro), 5.88 (d, J = 5.2, 1H, -CHOCOR), 4.69 (d, J = 16.4, 1H, -
CHPh), 4.48 (d, J = 16.4, 1H, -CHPh), 4.22 - 4.11 (m, 1H, -CHN(Bn)Mes), 3.68 - 3.61 (m, 1H, -
CHOH), 3.10 - 2.96 (m, 4H, -CH2SO2),  2.57 (t, J = 6.8, 2H, -CH2N(Me)2), 2.45 (s, 6H, CH3 (Mes)), 
2.34 (s, 6H, N(CH3)2), 2.30 - 2.24 (m, 4H, CH3 (Mes), -CHCOOR), 2.04 (p, J = 7.4, 2H), 1.90 – 1.02 
(m, 27H), 0.88 (t, J = 7.0, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 174.1, 142.6, 140.2 (2C), 138.1, 
137.8, 132.9, 132.1 (2C), 128.4 (2C), 128.3 (2C), 128.1, 127.6 (2C), 127.2, 126.5 (2C), 78.2, 71.2, 
57.2, 56.4, 52.9, 50.9, 50.1, 48.1, 44.8 (2C), 33.2, 31.8 (2C), 29.6, 29.5, 29.5, 29.4, 29.3, 27.7, 
27.1, 25.0, 22.9, 22.6, 21.7, 20.8, 19.2, 14.1, 13.8. HRMS (ESI) calc. for C47H72N2O7S2 [M+H]
+ 
841.4854, found [M+H]+ 841.4853. LCMS (ESI) found 841.46 for [M+H]+.  
 
 
(S)-2-((R)-4-(3-(dimethylamino)propylsulfonyl)-1-hydroxybutyl)dodecanoic acid (72). 
Compound 72 was synthesized following the general procedure for hydrogenolysis using 1.61 
mmol substrate 68, reaction time 90 hours at rt. Purification by flash chromatography using 10% 
MeOH/DCM to first remove unpolar impurities, then MeOH/ DCM /NEt3 10/88/2 to elute 
compound 72 (Column monitored by TLC using EtOAc/AcOH/MeOH/H2O 3/3/3/2 as eluent). 
Yield = 29% (white solid). Rf = 0.72 (EtOAc/AcOH/MeOH/H2O 6/3/3/2).  []D
20 = - 2.9 (c = 1.06, 
CHCl3/MeOH 1/1). IR: 1600 cm
-1 (acid, C=O stretch), 1273 cm-1 (SO2 asym. stretch), 1134 cm
-1 
(SO2 sym. stretch). 
1H NMR (400 MHz, CDCl3): δ
  3.84 - 3.77 (m, 1H, -CHOH), 3.18 - 3.01 (m, 4H, -
CH2SO2), 2.95 - 2.83 (m, 2H, -CH2N(Me)2), 2.58 (s, 6H, -N(CH3)2), 2.45 - 2.37 (m, 1H, -CHCOOH), 
2.24 - 2.12 (m, 2H), 2.09 - 1.90 (m, 2H), 1.76 - 1.17 (m, 20H), 0.87 (t, J = 6.8, 3H, -CH3). 
13C NMR 
(100 MHz, CDCl3): δ 180.0, 71.7, 56.0, 52.9, 52.2, 49.6, 43.2 (2C), 31.9, 31.8, 29.8, 29.6, 29.6, 
29.5, 29.3, 28.1, 27.9, 22.6, 19.4, 18.5, 14.1. HRMS (ESI) calc. for C21H43NO5S [M+H]
+ 422.2935, 
found [M+H]+ 422. 2929. LCMS (ESI) found 422.28 for [M+H]+. 
 
 
(S)-2-((R)-5-(3-(dimethylamino)propylsulfonyl)-1-hydroxypentyl)dodecanoic acid (73). 
Compound 73 was synthesized following the general procedure for hydrogenolysis using 1.20 
mmol substrate 69, reaction time 90 hours at rt. Purification by flash chromatography using 10% 
MeOH/DCM to first remove unpolar impurities, then MeOH/ DCM /NEt3 10/88/2 to elute 
compound 73 (Column monitored by TLC using EtOAc/AcOH/MeOH/H2O 3/3/3/2 as eluent).Yield 
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= 79% (white solid). Rf = 0.46 (EtOAc/AcOH/MeOH/H2O 6/3/3/2).  []D
20 = + 3.6 (c = 1.04, CHCl3). 
IR: 1615 cm-1 (acid, C=O stretch), 1277 cm-1 (SO2 asym. stretch), 1130cm
-1 (SO2 sym. stretch). 
1H 
NMR (400 MHz, CDCl3): δ
  3.76 - 3.69 (m, 1H, -CHOH), 3.10 - 2.96 (m, 4H, -CH2SO2), 2.93 -2.78 (m, 
2H, -CH2N(Me)2), 2.53 (s, 6H, -N(CH3)2), 2.40 - 2.34 (m, 1H, -CHCOOH), 2.20 - 2.07 (m, 2H), 1.98 - 
1.75 (m, 2H), 1.71 - 1.17 (m, 22H), 0.87 (t, J = 7.0, 3H, -CH3).
 13C NMR (100 MHz, CDCl3): δ 180.2, 
71.9, 55.9, 52.3 (2C), 49.6, 43.2 (2C), 32.9, 31.9, 29.8, 29.7, 29.6, 29.6, 29.3, 28.1, 27.7, 24.3, 
22.7, 22.1, 19.0, 14.1. HRMS (ESI) calc. for C22H45NO5S [M+H]
+ 436.3091, found [M+H]+ 436.3085. 
LCMS (ESI) found 436.31 for [M+H]+.  
 
 
(R)-2-((S)-4-(3-(dimethylamino)propylsulfonyl)-1-hydroxybutyl)dodecanoic acid (74). 
Compound 74 was synthesized following the general procedure for hydrogenolysis using 1.69 
mmol substrate 70, reaction time 90 hours at rt. Purification by flash chromatography using 10% 
MeOH/DCM to first remove unpolar impurities, then MeOH/ DCM /NEt3 10/88/2 to elute 
compound 74 (Column monitored by TLC using EtOAc/AcOH/MeOH/H2O 3/3/3/2 as eluent). 
Yield = 65% (white solid). Rf = 0.63 (EtOAc/AcOH/MeOH/H2O 6/3/3/2).  []D
20 = + 1.7 (c = 1.04, 
CHCl3/MeOH 1/1). IR: 1599 cm
-1 (acid, C=O stretch), 1280 cm-1 (SO2 asym. stretch), 1111 cm
-1 
(SO2 sym. stretch). 
1H NMR (400 MHz, CDCl3): δ
  3.83 - 3.78 (m, 1H, -CHOH), 3.18 - 3.01 (m, 4H, -
CH2SO2), 2.95 - 2.83 (m, 2H, -CH2N(Me)2), 2.57 (s, 6H, -N(CH3)2), 2.37 - 2.30 (m, 1H, -CHCOOH), 
2.19 - 2.09 (m, 2H), 2.07 - 1.83 (m, 2H), 1.68 - 1.17 (m, 20H), 0.84 (t, J = 6.8, 3H, -CH3). 
13C NMR 
(100 MHz, CDCl3): δ 180.1, 71.5, 56.0, 52.8, 52.4, 49.5, 43.2 (2C), 32.0, 31.9, 29.8, 29.6, 29.6, 
29.5, 29.3, 28.0, 28.0, 22.6, 19.2, 18.4, 14.0. HRMS (ESI) calc. for C21H43NO5S [M+H]
+ 422.2935, 
found [M+H]+ 422.2929. LCMS (ESI) found 422.29 for [M+H]+. 
 
 
(R)-2-((S)-5-(3-(dimethylamino)propylsulfonyl)-1-hydroxypentyl)dodecanoic acid (75). 
Compound 75 was synthesized following the general procedure for hydrogenolysis using 1.81 
mmol substrate 71, reaction time 90 hours at rt. Purification by flash chromatography using 10% 
MeOH/DCM to remove  unpolar impurities, then MeOH/DCM/NEt3 10/88/2 to elute compound 
75 (Column monitored by TLC using EtOAc/AcOH/MeOH/H2O 3/3/3/2 as eluent). Yield = 74% 
(white solid). Rf = 0.51 (EtOAc/AcOH/MeOH/H2O 6/3/3/2). []D
20 = - 3.8 (c = 1.06, CHCl3). IR: 
Experimental part   182 
1614 cm-1 (acid, C=O stretch), 1277 cm-1 (SO2 asym. stretch), 1129 cm
-1 (SO2 sym. stretch). 
1H 
NMR (400 MHz, CDCl3): δ
  3.76 - 3.69 (m, 1H, -CHOH), 3.10 - 2.96 (m, 4H, -CH2SO2), 2.93 -2.77 (m, 
2H, -CH2N(Me)2), 2.54 (s, 6H, -N(CH3)2), 2.40 - 2.34 (m, 1H, -CHCOOH), 2.20 - 2.07 (m, 2H), 1.98 - 
1.75 (m, 2H), 1.71 - 1.17 (m, 22H), 0.87 (t, J = 6.8, 3H, -CH3).
 13C NMR (100 MHz, CDCl3): δ 180.3, 
71.9, 55.8, 52.3 (2C), 49.6, 43.1 (2C), 32.9, 31.9, 29.8, 29.7, 29.6, 29.6, 29.3, 28.1, 27.8, 24.3, 
22.7, 22.1, 18.9, 14.1. HRMS (ESI) calc. for C22H45NO5S [M+H]
+ 436.3091, found [M+H]+ 436.3085. 
LCMS (ESI) found 436.32 for [M+H]+. 
 
 
(3S,4R)-4-(3-(3-(dimethylamino)propylsulfonyl)propyl)-3-decyloxetan-2-one (76). Compound 
76 was synthesized following the general procedure for -lactonization using 0.37 mmol of -
hydroxyacid 72.  Reaction uncomplete, with a ratio trans/cis -lactone 1:1. Purification by flash 
chromatography using 1-5 % MeOH/DCM, followed by several recrystalization in 
EtOAc/pentane. Yield = 23 % (yield low due to a ratio 1:1 cis/trans -lactone). White solid. Rf = 
0.52 (10% MeOH/DCM). mp = 54.8°C- 55.3°C.  []D
20 not measured  as final product not 
enantiopure (cis/trans -lactone 1:0.2). IR: 1814 cm-1 (β-lactone, C=O stretch), 1279 cm-1 (SO2 
asym. stretch), 1118cm-1 (SO2 sym. Stretch). 
1H NMR (400 MHz, CDCl3): δ
  4.53 (ddd, J = 3.0, 6.4, 
9.7, 1H, -CHOCOR), 3.67 (ddd, J = 6.9, 6.9, 8.9, 1H, -CHCO), 3.19 - 2.98 (m, 4H, -CH2SO2), 2.72 - 
2.57 (m, 2H, -CH2NMe2), 2.39 (s, 6H, -N(CH3)2), 1.21 - 1.43 (m, 8H), 1.45 - 1.20 (m, 16H), 0.87 (t, J 
= 6.8, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 171.4, 74.8, 56.7, 53.1, 52.5, 49.9, 43.9 (2C), 31.9, 
29.5, 29.5, 29.3, 29.3 (2C), 28.9, 27.5, 23.9, 22.7, 18.7, 18.4, 14.1. HRMS (ESI) calc. for C21H41NO4S 
[M+H]+ 404.2829,  found [M+H]+ 404.2822. LCMS (ESI) found 404.09 for [M+H]+. 
 
 
(3S,4R)-4-(4-(3-(dimethylamino)propylsulfonyl)butyl)-3-decyloxetan-2-one (77). Compound 77 
was synthesized following the general procedure for -lactonization using 0.82 mmol of -
hydroxyacid 73. Reaction uncomplete, with cis -lactone as main product. Purification by flash 
chromatography using 1-5 % MeOH/DCM, followed by several recrystalization in EtOAc/hexane. 
Yield = 46 % (slight yellow solid). Rf = 0.58 (10% MeOH/DCM). mp = 36.5°C-36.8°C. []D
20 not 
measured  as final product not enantiopure (cis/trans -lactone 1: 0.1). IR: 1811 cm-1 (β-lactone, 
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C=O stretch), 1272 cm-1 (SO2 asym. stretch), 1126 cm
-1 (SO2 sym. Stretch). 
1H NMR (400 MHz, 
CDCl3): δ
  4.53 (ddd, J = 3.9, 6.4, 9.7, 1H, -CHOCOR), 3.62 (ddd, J = 6.6, 6.6, 8.1, 1H, -CHCO), 3.05 
(t, J = 7.7, 2H, -CH2SO2), 2.98 (t, J = 8.0, 2H, -CH2SO2), 2.43 (t, J = 6.5, 2H, -CH2NMe2), 2.24 (s, 6H, -
N(CH3)2), 2.08 - 1.42 (m, 10H), 1.40 - 1.17 (m, 16H), 0.87 (t, J = 7.0, 3H, -CH3). 
13C NMR (100 MHz, 
CDCl3): δ 171.7, 74.9, 57.4, 52.9, 52.7, 50.7, 45.1 (2C), 31.8, 29.7, 29.5, 29.5, 29.3, 29.3, 29.3, 
27.6, 24.7, 23.9, 22.6, 21.6, 19.7, 14.1. HRMS (ESI) calc. for C22H43NO4S [M+H]
+ 418. 2986, found 
[M+H]+ 418.2980. LCMS (ESI) found 418.11 for [M+H]+. 
 
 
(3R,4S)-4-(3-(3-(dimethylamino)propylsulfonyl)propyl)-3-decyloxetan-2-one (78). Compound 
78 was synthesized following the general procedure for -lactonization using 0.98 mmol of -
hydroxyacid 74. Reaction uncomplete, with cis -lactone as main product. Purification by flash 
chromatography using 1-5 % MeOH/DCM, followed by several recrystalization in EtOAc/hexane. 
Yield = 55 % (slight yellow solid). Rf = 0.55 (10% MeOH/DCM). mp = 61.9°C-62.2°C. []D
20 not 
measured as final product not enantiopure (cis/trans -lactone 1:0.2). IR: 1808 cm-1 (β-lactone, 
C=O stretch), 1270 cm-1 (SO2 asym. stretch), 1127 cm
-1 (SO2 sym. Stretch). 
1H NMR (400 MHz, 
CDCl3): δ
  4.52 (ddd, J = 3.1, 6.4, 9.9, 1H, -CHOCOR), 3.62 (ddd, J = 6.9, 6.9, 9.1, 1H, -CHCO), 3.11 - 
2.91 (m, 4H, -CH2SO2), 2.36 (t, J = 6.8, 2H, -CH2NMe2), 2.17 (s, 6H, -N(CH3)2), 2.07 -1.39 (m, 8H), 
1.38 - 1.15 (m, 16H), 0.83 (t, J = 7.0, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 171.4, 74.6, 57.2, 
52.9, 51.9, 50.6, 44.9 (2C), 31.7, 29.4, 29.3, 29.2, 29.1 (2C), 28.8, 27.3, 23.8, 22.5, 19.6, 18.6, 
13.9. HRMS (ESI) calc. for C21H41NO4S [M+H]
+ 404.2829,  found [M+H]+ 404.2822. LCMS (ESI) 
found 404.07 for [M+H]+. 
 
 
(3R,4S)-4-(4-(3-(dimethylamino)propylsulfonyl)butyl)-3-decyloxetan-2-one (79). Compound 79 
was synthesized following the general procedure for -lactonization using 1.17 mmol of -
hydroxyacid 75. Reaction uncomplete, with a ratio trans/cis -lactone 1:1. Purification by flash 
chromatography using 1-5 % MeOH/DCM followed by several recrystalization in EtOAc/pentane. 
Yield = 13 % (yield low due to a ratio 1:1 cis/trans -lactone).White solid. Rf = 0.52 (10% 
MeOH/DCM). mp = 34.9-35.2°C. []D
20 not measured  as final product not enantiopure (cis/trans 
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-lactone 1:0.2). IR: 1812 cm-1 (β-lactone, C=O stretch), 1272 cm-1 (SO2 asym. stretch), 1127 cm
-1 
(SO2 sym. Stretch). 
1H NMR (400 MHz, CDCl3): δ
  4.53 (ddd, J = 3.9, 6.4, 9.8, 1H, -CHOCOR), 3.62 
(ddd, J = 7.1, 7.1, 8.5, 1H, -CHCO), 3.06 (t, J = 7.7, 2H, -CH2SO2), 2.99 (t, J = 7.7, 2H, -CH2SO2), 2.46 
(t, J = 6.7, 2H, -CH2NMe2), 2.26 (s, 6H, -N(CH3)2), 2.05 - 1.47 (m, 10H), 1.38 - 1.16 (m, 16H), 0.87 
(t, J = 6.7, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 171.7, 74.9, 57.3, 52.8, 52.7, 50.6, 45.0 (2C), 
31.8, 29.7, 29.5, 29.5, 29.3, 29.3, 29.2, 27.6, 24.7, 23.9, 22.6, 21.6, 19.6, 14.0. HRMS (ESI) calc. 
for C22H43NO4S [M+H]
+ 418.2985, found [M+H]+ 418.2981. LCMS (ESI) found 418.12 for [M+H]+. 
 
2.8 Synthesis of palmostatin M-derived pull down probe 83  
 
 
(S)-((1S,2R)-2-(N-benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl)2-((S)-5-(3-
(dimethyl amino)propylthio)-1-hydroxypentyl)dodec-11-ynoate (80). Compound 80 was 
synthesized following the general procedure for the anti-selective aldol reaction using 10.40 
mmol of aldehyde 55,  followed by purification by flash chromatography using 1-3% 
MeOH/CH2Cl2. Yield = 66% (yellow oil). Rf = 0.65 (MeOH/CH2Cl2 10/90). []D
20 = - 38.4 (c = 0.18, 
CHCl3). IR: 3304 cm
-1 (C≡C-H stretch), 2116 cm-1 (-C≡C- stretch), 1736 cm-1 (ester, C=O stretch). 1H 
NMR (400 MHz, CDCl3): δ 7.20 – 7.09 (m, 8H, Haro), 6.87 - 6.81 (m, 4H, Haro), 5.82 (d, J = 5.6, 1H, 
-CHOCOR), 4.69 (d, J = 16.4, 1H, -CHPh), 4.48 (d, J = 16.4, 1H, -CHPh), 4.13 – 4.07 (m, 1H, -
CHN(Bn)Mes), 3.68 - 3.61 (m, 1H, -CHOH), 2.56 - 2.44 (m, 6H, -CH2N(Me)2, -CH2S), 2.44 - 2.38 (m, 
7H, -CHCOOR, CH3 (Mes)), 2.31 (s, 6H, N(CH3)2), 2.27 (s, 3H, CH3 (Mes)), 2.14 (dt, J = 2.8, 7.2, 2H, -
CH2-C≡C), 1.93 (t, J = 2.8, 1H, -C≡CH), 1.78 (p, J = 7.2, 2H), 1.61 - 0.95 (m, 23H). 
13C NMR (100 
MHz, CDCl3): δ 174.4, 142.5, 140.3, 138.3, 137.8, 133.1, 132.0, 128.3, 128.2, 128.0, 127.9, 127.2, 
126.6, 84.6, 77.9, 71.9, 68.1, 58.3, 56.3, 51.3, 48.1, 45.0, 34.7 32.0, 29.7, 29.6, 29.4, 29.4, 29.1, 
28.8, 28.6, 28.4, 27.0, 24.7, 22.8, 20.8, 18.3, 14.4. HRMS (ESI) calc. for C47H68N2O5S2 [M+H]
+ 
805.4642, found 805.4639. LCMS (ESI) found 805.29 for [M+H]+.  
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(S)-((1S,2R)-2-(N-benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl)2-((S)-5-(3-
(dimethyl amino)propylsulfonyl)-1-hydroxypentyl) dodec-11-ynoate (81). Compound 81 was 
synthesized following the general procedure for oxidation into sulfone using 5.04 mmol of 
sulfide derivative 80, reaction time 8 hours. Yield = quantitative (white semi-solid). Rf = 0.55 
(MeOH/CH2Cl2 10/90). []D
20= - 29.7 (c = 0.62, CHCl3). IR: 3284 cm
-1 (C≡C-H stretch), 2115 cm-1 (-
C≡C- stretch), 1734 cm-1 (ester, C=O stretch), 1314 cm-1 (SO2 asym. stretch), 1150cm
-1 (SO2 sym. 
Stretch). 1H NMR (400 MHz, CDCl3): δ 7.26 - 7.11 (m, 8H, Haro), 6.89 - 6.80 (m, 4H, Haro), 5.86 
(d, J = 5.6, 1H, -CHOCOR), 4.74 (d, J = 16.8, 1H, -CHPh), 4.55 (d, J = 16.6, 1H, -CHPh), 4.23 - 4.15 
(m, 1H, -CHN(Bn)Mes), 3.69 - 3.61 (m, 1H, -CHOH), 3.02 (t, J = 7.6, 2H, -CH2SO2), 2.94 (t, J = 8.0, 
2H, -CH2SO2), 2.52 (t, J = 7.0, 2H, -CH2N(Me)2), 2.45 - 2.39 (m, 7H, -CHCOOR, CH3 (Mes)), 2.31 (s, 
6H, N(CH3)2), 2.26 (s, 3H, CH3 (Mes)), 2.16 (dt, J = 2.4, 6.8, 2H, -CH2-C≡C), 2.07 - 1.97 (m, 2H), 1.93 
(t, J = 2.4, 1H, -C≡CH), 1.89 - 0.95 (m, 23H). 13C NMR (100 MHz, CDCl3): δ 174.3, 142.5, 
140.3,138.1, 137.8, 133.1, 132.0, 128.3, 128.3, 128.1, 127.9, 127.3, 126.7, 84.7, 78.1, 71.6, 68.1, 
57.3, 56.4, 52.9, 51.4, 50.2, 48.1, 44.9, 34.3, 29.5, 29.4, 29.1, 28.9, 28.6, 28.4, 27.0, 24.6, 22.9, 
21.9, 20.8, 19.4, 18.3, 14.4. HRMS (ESI) calc. for C47H68N2O7S2 [M+H]
+ 837.4541, found 837.4538. 
LCMS (ESI) found 837.26 for [M+H]+.  
 
 
(S)-2-((S)-5-(3-(dimethylamino)propylsulfonyl)-1-hydroxypentyl) dodec-11-ynoic acid (82). 
Compound 82 was synthesized following the general procedure for saponification using 5.01 
-hydroxyester 81 by reaction with 4.3 eqv. LiOH.H2O at 40°C for 48 hours. Purification 
by flash chromatography using 10% MeOH/CH2Cl2 to remove unpolar impurities, then 
MeOH/CH2Cl2/NEt3 10/88/2 to collect compound 82 (separation monitored by TLC using 
EtOAc/AcOH/MeOH/H2O 3/3/3/2 as eluent). Yield = 85% (white semi-solid). Rf = 0.28 (AcOH/ 
EtOAc/MeOH/H2O 3/14/3/2).  []D
20 not measured as contained some residual NEt3.  IR: 3306 
cm-1 (C≡C-H stretch), 2114 cm-1 (-C≡C- stretch), 1628 cm-1 (acid, C=O stretch), 1270 cm-1 (SO2 
asym. stretch), 1132cm-1 (SO2 sym. stretch).
1H NMR (400 MHz, CDCl3): δ 3.62 - 3.55 (m, 1H, -
CHOH), 3.10 (t, J = 7.4, 2H, -CH2SO2), 3.02 (t, J = 7.6, 2H, -CH2SO2), 2.95 - 2.87 (m, 2H, -
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CH2N(Me)2), 2.57 (s, 6H, -N(CH3)2), 2.29 - 2.22 (m, 1H, -CHCOOH), 2.20 - 2.11 (m, 2H), 2.15 (dt, J = 
2.8, 7.2, 2H, -CH2-C≡C), 1.92 (t, J = 2.8, 1H, -C≡CH), 1.91 - 1.77 (m, 2H), 1.74 - 1.22 (m, 18H). 
13C 
NMR (100 MHz, CDCl3): δ 181.0, 84.7, 71.8, 68.1, 55.9, 52.7, 52.1, 49.6, 43.1, 35.3, 30.1, 29.6, 
29.3, 29.0, 28.7, 28.4, 27.8, 24.3, 22.2, 18.5, 18.3. HRMS (ESI) calc. for C22H41NO5S [M+H]
+ 
432.2778, found 432.2770. LCMS (ESI) found 432.14 for [M+H]+.    
 
 
(3S,4S)-3-(dec-9-ynyl)-4-(4-(3-(dimethylamino)propylsulfonyl) butyl)oxetan-2-one (83). 
Compound 83 was synthesized following the general procedure for β-lactonization using 3.93 
mmol of -hydroxyacid 82. Purification by flash chromatography using gradient 1-5% 
MeOH/CH2Cl2. Yield = 31% (yellow oil). Rf = 0.47 (MeOH/CH2Cl2 10/90). []D
20 = -23.5 (c = 0.22, 
CHCl3). IR: 3276 cm
-1 (C≡C-H stretch), 2115 cm-1 (-C≡C- stretch), 1814 cm-1 (β-lactone, C=O 
stretch), 1279 cm-1 (SO2 asym. stretch), 1118cm
-1 (SO2 sym. Stretch).
1H NMR (400 MHz, CDCl3): δ 
4.15 (ddd, J = 4.8, 4.8, 7.4, 1H, -CHOCOR), 3.12 (ddd, J = 4.0, 6.8, 8.6, 1H,-CHCO), 2.96 (t, J = 7.8, 
2H, -CH2SO2), 2.91 (t, J = 7.8, 2H, -CH2SO2), 2.32 (dt, J = 0.8, 6.8, 2H, -CH2NMe2), 2.14 (d, J = 0.8, 
6H, -N(CH3)2), 2.09 (dt, J = 2.6, 7.1, 2H, -CH2-C≡C), 1.95 - 1.38 (m, 13H), 1.38 - 1.14 (m,10H). 
13C 
NMR (100 MHz, CDCl3): δ 170.9, 84.4, 77.1, 68.0, 57.1, 56.0, 52.2, 50.4, 44.9, 33.6, 28.9, 28.9, 
28.6, 28.3, 28.1, 27.5, 26.6, 23.9, 21.3, 19.6, 18.1. HRMS (ESI) calc. for C22H39NO4S [M+H]
+ 
414.2673, found 414.2667. LCMS (ESI) found 414.01 for [M+H]+.  
 
2.9 Synthesis of palmostatin M-derived pull down probe 94  
 
 
Toluene-4-sulfonic acid pent-4-ynyl ester (85).40 To a solution of 4-pentyn-1-ol 84 (0.5 g, 5.94 
mmol, 1.0 eqv.) and NEt3 (0.91 ml, 6.53 mmol, 1.1 eqv.) in dry CH2Cl2 (5 ml) was added dropwise 
at 0°C (over 20 min) a solution of TsCl (1.27 g, 6.53 mmol, 1.1 eqv.) in CH2Cl2 (15 ml). The mixture 
was subsequently stirred for 20 min at 0°C, and for 20 hours at rt. The mixture was poured into 
ice–cold water and the separated aqueous layer was extracted with CHCl3 (3x50ml). Combined 
organic extracts were washed with water, brine and dried over MgSO4. After concentrated under 
reduced pressure, the residue was purified by flash chromatography (gradient 5-20% 
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EtOAc/cyclohexane) leading to compound 85. Yield=71% (colorless oil). Rf = 0.41 
(EtOAc/cyclohexane 20/80). IR: 3290 cm-1 (C≡C-H stretch), 2119 cm-1 (-C≡C- stretch), 660 cm-1 
(C≡C-H bend).1H NMR (400 MHz, CD3CN): δ
  7.79 (d, J = 8.4, 2H, Haro), 7.34 (d, J = 8.0, 2H, Haro), 
4.14 (t, J = 6.2, 2H, -CH2OTs), 2.44 (s, 3H, -CH3), 2.25 (dt, J = 2.4, 6.8, 2H, -CH2-C≡C), 1.87 (t, J = 
2.4, 1H, -C≡CH), 1.86-1.82 (m, 2H). 13C NMR (100 MHz, CDCl3): δ 144.8, 132.8, 129.8 (2C), 127.9 
(2C), 82.1, 69.4, 68.7, 27.7, 21.6, 14.7. HRMS (ESI) calc. for C12H14O3S [M+H]
+ 239.0736, found 
239.0737. GCMS found 238 for [M+.]. 1H NMR conformed to literature 40.  
 
 
3-(Methyl(pent-4-ynyl)amino)propan-1-ol (86).41 A mixture of 3-(methylamino)propan-1-ol 
(7.75 g, 87 mmol, 1.0 eqv.), toluene-4-sulfonic acid pent-4-ynyl ester 85 (23.1 g, 97 mmol, 1.1 
eqv.) and K2CO3 (13.3 g, 97 mmol, 1.1 eqv.) in CH3CN (420 ml) was heated under reflux for 20 
hours under argon. The mixture was cooled to rt, filtered, concentrated under reduced pressure 
and purified by flash chromatography using CHCl3/MeOH/NH4OH 93/5/2 as eluent to afford 
compound 86. Yield=81% (colorless oil). Rf = 0.60 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 3295 
cm-1 (C≡C-H stretch), 2115 cm-1 (-C≡C- stretch), 627 cm-1 (C≡C-H bend). 1H NMR (400 MHz, 
CDCl3): δ
 5.19 - 5.05 (sbr, 1H, -OH), 3.78 (t, J = 5.0, 2H, -CH2OH), 2.59 (t, J = 5.8, 2H, -CH2N), 2.47 
(t, J = 7.2, 2H, -CH2N), 2.25 (s, 3H, -CH3), 2.22 (dt, J = 2.5, 7.2, 2H, -CH2-C≡C), 1.95 (t, J = 2.6, 1H, -
C≡CH), 1.75 - 1.67 (m, 4H). 13C NMR (100 MHz, CDCl3): δ 83.8, 68.6, 64.7, 58.6, 57.1, 41.9, 27.6, 
26.0, 16.3. HRMS (ESI) calc. for C9H17NO [M+H]
+ 156.1383, found 156.1379. LCMS (ESI) found 
155.98 for [M+H]+.  
 
 
S-3-(Methyl(pent-4-ynyl)amino)propyl ethanethioate (87). To a solution of 3-(methyl(pent-4-
ynyl)amino)propan-1-ol 86 (11 g, 70 mmol, 1.0 eqv.) in dry CH2Cl2 (450 ml) was added SOCl2 (6.2 
ml, 85 mmol, 1.2 eqv.) at 0°C. The mixture was stirred for 4 hours at rt and was concentrated 
under reduced pressure leading to a chlorinated intermediate: Rf = 0.62 (MeOH/CH2Cl2 10/90). 
IR: 3288 cm-1 (C≡C-H stretch), 2111 cm-1 (-C≡C- stretch), 704 cm-1 (C≡C-H bend). 1H NMR (400 
MHz, CDCl3): δ
  2.90 (t, J = 7.2, 2H, -CH2Cl), 2.41 (t, J = 6.8, 2H, -CH2N), 2.39 (t, J = 7.0, 2H, -CH2N),  
2.31 (s, 3H, -CH3N), 2.22 (dt, J = 2.4, 6.8, 2H, -CH2-C≡C), 1.93 (t, J = 2.4, 1H, -C≡CH), 1.77 - 1.68 (m, 
4H). 13C NMR (100 MHz, CDCl3): δ  81.2, 70.7, 55.2, 54.0, 41.6, 40.3, 26.7, 22.3, 15.9. HRMS (ESI) 
calc. for C9H16ClN [M+H]
+ 174.1044, found 174.1041. LCMS (ESI) found 173.98 for [M+H]+. The 
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chlorinated intermediate was taken into CHCl3 (330 ml) and NEt3 (29 ml, 210 mmol, 3.0 eqv.) 
followed by thioacetic acid (6 ml, 84 mmol, 1.2 eqv.) were added dropwise (over 30 min) to the 
reaction mixture which was subsequently heated under reflux for 18 hours. The mixture was 
poured into a separatory funnel and washed several times with cold 1N NaOH, followed by 
water. The combined organic extracts were washed with brine, dried over anhydrous MgSO4, 
concentrated under reduced pressure and purified by flash chromatography (2% MeOH/CH2Cl2) 
leading to compound 87 as a brown oil. Yield = 80% over two steps. Rf = 0.64 (MeOH/DCM 
10/90). IR: 3295 cm-1 (C≡C-H stretch), 2116 cm-1 (-C≡C- stretch), 622 cm-1 (C≡C-H bend), 1688 cm-
1 (C=O). 1H NMR (400 MHz, CDCl3): δ
  2.90 (t, J = 7.2, 2H, -CH2S), 2.40 (t, J = 7.2, 2H, -CH2N), 2.38 
(t, J = 7.2, 2H, -CH2N), 2.32 (s, 3H, -CH3N), 2.22 (dt, J = 2.5, 7.2, 2H, -CH2-C≡C), 2.18 (s, 3H, -
CH3CO), 1.94 (t, J = 2.5, 1H, -C≡CH), 1.72 (p, J = 7.2, 2H), 1.69 -1.63 (m, 2H). 
13C NMR (100 MHz, 
CDCl3): δ 196.0, 84.3, 68.3, 56.3, 56.2, 42.0, 30.6, 27.2, 27.0, 26.2, 16.2. HRMS (ESI) calc. for 
C11H19NOS [M+H]
+ 214.1260, found 214.1258. LCMS (ESI) found 213.94 for [M+H]+.  
 
 
Ethyl-5-(3-(methyl(pent-4-ynyl)amino)propylthio)pentanoate (88).42 To a solution of S-3-
(methyl(pent-4-ynyl)amino)propyl ethanethioate 87 (0.9 g, 4.25 mmol, 1.0 eqv.) in absolute 
EtOH (35 ml) was added t-BuOK (0.5 g, 4.46 mmol, 1.05 eqv.). The reaction mixture was stirred 
for 30 min at rt and a solution of ethyl 5-iodopentanoate 49 (1.1 g, 4.25 mmol, 1.0 eqv.) in EtOH 
(15 ml) was added dropwise to the reaction mixture which was then stirred at rt for 20 hours. 
After concentration under reduced pressure, the residue was diluted with H2O/EtOAc 1/5 
(200ml) and the two layers separated. The aqueous layer was extracted with EtOAc and 
combined organic layers were concentrated under reduced pressure leading to compound 88, 
which was used directly in the next step. Yield = 90% (yellow oil). Rf = 0.64 (MeOH/CH2Cl2 10/90). 
IR: 3293 cm-1 (C≡C-H stretch), 2116 cm-1 (-C≡C- stretch), 629 cm-1 (C≡C-H bend), 1731 cm-1 (ester, 
C=O stretch). 1H NMR (400 MHz, CDCl3): δ
  4.12 (q, J = 7.2, 2H, -OCH2CH3), 2.52 (t, J = 7.2, 2H, -
CH2N), 2.51 (t, J = 7.2, 2H, -CH2N), 2.41 (t, J = 7.0, 2H, -CH2S), 2.40 (t, J = 7.2, 2H, -CH2S), 2.31 (t, J 
= 7.4, 2H, -CH2CO), 2.22 (dt, J = 2.4, 7.2, 2H, -CH2-C≡C), 2.19 (s, 3H, -CH3N), 1.94 (t, J = 2.8, 1H, -
C≡CH), 1.76 - 1.57 (m, 8H), 1.25 (t, J = 7.2, 3H, -OCH2CH3). 
13C NMR (100 MHz, CDCl3): δ 173.4, 
84.3, 68.3, 60.3, 56.6, 56.3, 42.2, 33.8, 31.7, 29.9, 29.0, 27.3, 26.2, 24.2, 16.2, 14.2. HRMS (ESI) 
calc. for C16H29NO2S [M+H]
+ 300.1992, found 300.1992. LCMS (ESI) found 299.98 for [M+H]+.  
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5-(3-(Methyl(pent-4-ynyl)amino)propylthio)pentan-1-ol (89). To an oven dried 250 ml round 
bottom flask was added LiAlH4 (0.67 mmol, 17.7 mmol, 1.05 eqv.), followed by a large egg-
shaped stirring bar. The flask was flushed with argon, set under positive argon pressure and 
subsequently cooled to 0°C. Dry Et2O (30 ml) was added under rapid stirring and the resulting 
suspension was stirred at 0°C for 15 min. A solution of compound 88 (5.04 g, 16.8 mmol, 1.0 
eqv.) in dry Et2O (20 ml) was added dropwise over 10 min to the reaction mixture at such a rate 
that the temperature was kept around 0°C. The mixture was stirred for 1 hour at 0°C followed by 
2 hours at rt and was quenched at 0°C by dropwise addition of H2O (1.1 ml) (caution, gas 
evolution), followed by 1N NaOH (2.2 ml) and 1.1 ml H2O. The thick suspension gets thinner 
upon aging and was diluted with further 50 ml Et2O. Two spoons of Celite were added and the 
mixture was allowed to age for another 30 min at rt. The resulting free running suspension was 
filtered over Celite in a sintered funnel. The filter cake was re-suspended in Et2O/MeOH 10/1 (50 
ml) and was refluxed for 10 min in order to dissolve all products. After hot filtration over Celite, 
the combined organic extracts were evaporated under reduced pressure. Al-salt traces 
remaining were removed by suspending the residue in 6 N NaOH (20 ml) and CH2Cl2 (100 ml). 
The organic layer was isolated, extracted with CH2Cl2 (3x30 ml), washed with brine and dried 
over over Na2SO4. After concentration under reduced pressure, the compound 89 was obtained, 
which was used directly in the next step. Yield = 73 % (yellow oil). Rf = 0.42 (MeOH/CH2Cl2 
10/90). IR: 3295 cm-1 (C≡C-H stretch), 2116 cm-1 (-C≡C- stretch), 629 cm-1 (C≡C-H bend). 1H NMR 
(400 MHz, CDCl3): δ
  3.62 (t, J = 6.4, 2H, -CH2OH), 3.52 - 3.47 (bs, 1H, -OH), 2.52 (t, J = 7.4, 2H, -
CH2N), 2.51 (t, J = 7.4, 2H, -CH2N), 2.40 (t, J = 7.2, 2H, -CH2S), 2.41 (t, J = 7.2, 2H, -CH2S), 2.21 (dt, J 
= 2.4, 6.8, 2H, -CH2-C≡C), 2.19 (s, 3H, -CH3N), 1.94 (t, J = 2.8, 1H, -C≡CH), 1.76 - 1.54 (m, 8H), 1.50 
- 1.41 (m, 2H). 13C NMR (100 MHz, CDCl3): δ 84.3, 68.3, 62.5, 56.5, 56.3, 42.2, 32.2, 32.0, 29.9, 
29.4, 27.3, 26.1, 25.0, 16.2. HRMS (ESI) calc. for C14H27NOS [M+H]
+ 258.1886, found 258.1886. 
LCMS (ESI) found 257.97 for [M+H]+. 
 
 
5-(3-(Methyl(pent-4-ynyl)amino)propylthio)pentanal (90). Compound 90 was synthesized 
following the general procedure for Swern oxidation using 5.4 mmol of alcohol 89. Yield = 91% 
(brown oil). Rf = 0.51 (AcOH/ EtOAc/MeOH/H2O 3/3/3/2). IR: 3289 cm
-1 (C≡C-H stretch), 2115 cm-
Experimental part   190 
1 (-C≡C- stretch), 631 cm-1 (C≡C-H bend), 1721 cm-1 (C=O) .1H NMR (400 MHz, CDCl3): δ
  9.76 (t, J = 
1.6, 1H, -CHO), 2.53 (t, J = 7.2, 2H, -CH2N ), 2.52 (t, J = 7.2, 2H, -CH2N), 2.45 (dt, J = 1.6, 7.2, 2H, -
CH2CHO), 2.45 - 2.38 (m, 4H, -CH2S), 2.22 (dt, J = 2.4, 7.2, 2H, -CH2-C≡C), 2.20 (s, 3H, -CH3N), 1.93 
(t, J = 2.4, 1H, -C≡CH), 1.78 - 1.57 (m, 8H). 13C NMR (100 MHz, CDCl3): δ 202.2, 77.2, 68.6, 56.3, 
56.1, 45.7, 43.4, 41.9, 31.7, 29.8, 28.9, 21.2, 16.2, 8.8. HRMS (ESI) calc. for C14H25NOS  [M+H]
+ 
256.1730, found 256.1732. GCMS found 254 for [M+.].  
 
 
(S)-((1S,2R)-2-(N-benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl)2-((S)-1-hydroxy-5-
(3-(methyl(pent-4-ynyl)amino)propylthio) pentyl) dodecanoate (91). Compound 91 was 
synthesized following the general procedure for the anti-selective aldol reaction using 7.11 
mmol of aldehyde 90  followed by purification by  flash chromatography using 1-3% 
MeOH/CH2Cl2. Yield = 68 % (white–beige semi solid). Rf = 0.54 (MeOH/CH2Cl2 10/90). []D
20 = - 
32.3 (c = 0.19, CHCl3). IR: 1733 cm
-1 (ester, C=O stretch), alkyne not apparent. 1H NMR (400 MHz, 
CDCl3): δ 7.31 - 7.11 (m, 8H, Haro), 6.87 - 6.81 (m, 4H, Haro), 5.98 – 5.89 (brs, 1H, -OH), 5.80 (d, J 
= 5.2, 1H, -CHOCOR), 4.75 (d, J = 16.8, 1H, -CHPh), 4.59 (d, J = 16.5, 1H, -CHPh), 4.13 – 4.07 (m, 
1H, -CHN(Bn)Mes), 3.73 - 3.60 (m, 1H, -CHOH), 2.60 - 2.49 (m, 4H, -CH2NMe), 2.45 - 2.40 (m, 7H, 
-CHCOOR, CH3 (Mes)), 2.28 (s, 3H, CH3 (Mes)), 2.27 (s, 3H, -NCH3), 2.07 - 1.91 (m, 5H, -CH2S, -CH2-
C≡C, -C≡CH), 1.69 - 1.35 (m, 12H, including -CH2S), 1.33 - 0.96 (m, 21H), 0.88 (t, J = 6.8, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 174.6, 142.6, 140.3, 138.4, 137.9, 133.2, 132.1, 128.3, 128.2, 128.0, 
127.9, 127.2, 126.6, 78.1, 77.2, 72.1, 63.7, 62.6, 56.5, 53.4, 51.4, 48.2, 34.7, 31.9, 29.6, 29.5, 
29.5, 29.4, 29.3, 29.3, 27.8, 27.2, 24.7, 24.1, 22.9, 22.7, 21.6, 20.9, 14.2, 14.1 (signal at 84 pm for 
quaternary alkyne not visible). HRMS (ESI) calc. for C51H76N2O5S2 [M+H]
+ 861.5268, found 
861.5268. LCMS (ESI) found 861.28 for [M+H]+.   
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(S)-((1S,2R)-2-(N-benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl)2-((S)-1-hydroxy-5-
(3-(methyl(pent-4-ynyl)amino) propylsulfony) pentyl)dodecanoate (92). Compound 92 was 
synthesized following the general procedure for oxidation into sulfone using 4.36 mmol of 
sulfide derivative 91, reaction time 8 hours (no purification needed). Yield = 90% (white solid). Rf 
= 0.57 (MeOH/CH2Cl2 10/90). []D
20 = - 24.0 (c = 0.82, CHCl3). IR: 3309 cm
-1 (C≡C-H stretch), 2115 
cm-1 (-C≡C- stretch), 1735 cm-1 (ester, C=O stretch), 1315 cm-1 (SO2 asym. stretch), 1151cm
-1 (SO2 
sym. Stretch). 1H NMR (400 MHz, CDCl3): δ 7.27 - 7.11 (m, 8H, Haro), 6.89 - 6.80 (m, 4H, Haro), 
5.85 (d, J = 5.6, 1H, -CHOCOR), 4.72 (d, J = 16.4, 1H, -CHPh), 4.52 (d, J = 16.5, 1H, -CHPh), 4.23 - 
4.14 (m, 1H, -CHN(Bn)Mes), 3.70 - 3.57 (m, 1H, -CHOH), 3.02 (t, J = 7.6, 2H, -CH2SO2), 2.94 (t, J = 
8.0, 2H, -CH2SO2), 2.67 - 2.50 (m, 4H, -CH2NMe), 2.86 - 2.70 (m, 1H, -CHCOOR), 2.42 (s, 6H, CH3 
(Mes)), 2.28 (s, 3H, CH3 (Mes)), 2.27 (s, 3H, -NCH3), 2.23 (dt, J = 2.4, 6.8, 2H, -CH2-C≡C), 1.96 (t, J = 
2.8, 1H, -C≡CH), 1.91 - 1.36 (m, 10H), 1.33 - 0.95 (m, 21H), 0.88 (t, J = 6.8, 3H, -CH3).
 13C NMR 
(100 MHz, CDCl3): δ 174.4, 142.5, 140.3, 138.2, 137.8, 133.0, 132.1, 128.3, 128.3, 128.1, 127.9, 
127.3, 126.6, 78.1, 77.2,  71.6, 69.2, 56.4, 55.7, 55.4, 53.0, 51.4, 50.2, 48.1, 44.5, 34.3, 31.9, 29.7, 
29.6, 29.5, 29.5, 29.3, 29.3, 27.1, 24.6, 22.9, 22.7, 22.5, 22.3, 21.8, 20.9, 16.04, 14.1 (signal  at 84 
pm for quaternary alkyne not visible). HRMS (ESI) calc. for C51H76N2O7S2 [M+H]
+ 893.5167, found 
893.5167. LCMS (ESI) found 893.27 for [M+H]+.  
 
 
(S)-2-((S)-1-hydroxy-5-(3-(methyl(pent-4-ynyl)amino) propyl sulfonyl)pentyl) dodecanoic acid 
(93). Compound 93 was synthesized following the general procedure for saponification using 
0.174 mmol of -hydroxyester 92 by reaction with 5.5 eqv. LiOH.H2O at 40°C for 24 hours. 
Purification by flash chromatography using MeOH/CH2Cl2 10/90 to remove unpolar impurities, 
then MeOH/CH2Cl2/ NEt3 10/88/2 to elute compound 93 (separation monitored by TLC using 
EtOAc/AcOH/MeOH/ H2O 3/3/3/2). Yield = 30% (white semi-solid). Rf = 0.5 (AcOH/EtOAc/MeOH/ 
H2O 3/14/3/2).  []D
20 not measured as contained some residual NEt3. IR: 3311 cm
-1 (C≡C-H 
stretch), 1714cm-1 (acid, C=O stretch), 1272 cm-1 (SO2 asym. stretch), 1131cm
-1 (SO2 sym. 
Stretch). 1H NMR (400 MHz, CDCl3): δ 3.56 - 3.49 (m, 1H, -CHOH), 3.02 (t, J = 8.0, 2H, -CH2SO2), 
2.96 (t, J = 8.0, 2H, -CH2SO2), 2.60 (t, J = 7.0, 2H, -CH2N), 2.56 (t, J = 7.4, 2H, -CH2N), 2.28 (s, 3H, -
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NCH3), 2.25 - 2.18 (m, 3H, -CHCOOH, -CH2-C≡C), 2.07 - 1.98 (m, 2H), 1.96 (t, J = 2.6, 1H, -C≡CH), 
1.89 - 1.42 (m, 8H), 1.37 - 1.17 (m, 18H), 0.85 (t, J = 6.8, 3H, -CH3). 
13C NMR (100 MHz, CDCl3): δ 
181.4, 83.4, 71.7, 68.9, 55.6, 55.3, 52.9, 51.9, 50.2, 41.0, 35.9, 31.8, 30.6, 29.7, 29.6, 29.6, 29.3, 
27.8, 25.1, 24.9, 22.6, 22.1, 19.3, 16.0, 14.0. HRMS (ESI) calc. for C26H49NO5S [M+H]
+ 488.3404, 
found 488.3396. LCMS (ESI) found 488.21 for [M+H]+.  
 
 
(3S,4S)-3-decyl-4-(4-(3-(methyl(pent-4-ynyl)amino)propyl-sulfonyl)butyl) oxetan -2-one (94). 
Compound 94 was synthesized following the general procedure for β-lactonization using 0.49 
mmol -hydroxyacid 93 (reaction monitored by TLC using MeOH/CH2Cl2 10/90). Purification by 
flash chromatography using gradient 1-5% MeOH/CH2Cl2. Yield=30% (yellow oil). Rf = 0.41 
(MeOH/CH2Cl2 10/90).  []D
20 = -22.1 (c = 0.1, CHCl3). IR: 3308 cm
-1 (C≡C-H stretch), 2116 cm-1 (-
C≡C- stretch), 1799 cm-1 (β-lactone, C=O stretch), 1265 cm-1 (SO2 asym. stretch), 1120cm
-1 (SO2 
sym. Stretch). 1H NMR (400 MHz, CDCl3): δ 4.22 (ddd, J = 4.1, 5.6, 7.3, 1H, -CHOCOR), 3.19 (ddd, J 
= 4.0, 6.6, 8.6, 1H, -CHCO), 3.07 (t, J = 8.0, 2H, -CH2SO2), 2.98 (t, J = 7.8, 2H, -CH2SO2), 2.52 – 2.41 
(m, 4H, -CH2N), 2.23 (td, J = 2.6, 7.0, 2H, -CH2-C≡C), 2.22 (s, 3H, -NCH3), 2.06 - 1.97 (m, 2H), 1.95 
(t , J = 2.8, 1H, -C≡CH), 1.94 - 1.55 (m, 8H), 1.47 - 1.18 (m, 18H), 0.88 (t, J = 7.0, 3H, -CH3). 
13C 
NMR (100 MHz, CDCl3): δ 171.1, 84.1, 77.2, 68.6, 56.3, 55.8, 55.7, 52.4, 50.7, 41.6, 33.9, 31.8, 
29.5, 29.4, 29.3, 29.3, 27.7, 26.9, 25.9, 24.3, 22.6, 21.5, 19.7, 16.0, 14.1. HRMS (ESI) calc. for 
C26H47NO4S [M+H]
+ 470.3299, found 470.3291. LCMS (ESI) found 470.05 for [M+H]+.  
 
2.10 Synthesis of the trifunctional fluorophore reporter dye TrifN3 (103) 
 
 
Fmoc-L-Lys (4-azidobenzoyl)-OH (97).43 Into a round-bottom flask was added Fmoc-LysOH (2.27 
g, 6.13 mmol, 1.0 eqv.) in 25% aqueous K2CO3/dioxane 1/1 (50 ml). 4-Azidobenzoyl chloride (6.13 
mmol, 1 eqv., obtained quantitatively following  the literature 44) as a solution in dioxane (5 ml) 
Experimental part   193 
was added dropwise to the reaction mixture which was stirred at rt for 2 days. The reaction was 
monitorated by TLC using MeOH/DCM 1/9. The reaction was quenched with water and 
extracted with tert-butylmethylether. The aqueous layer was acidified to approx. pH 2.0 using 
concentrated HCl and was extracted with several portions of CHCl3. The combined organic 
extracts were dried over anhydrous MgSO4, concentrated under reduced pressure and purified 
by flash chromatography (gradient 1-10% MeOH/DCM) leading to compound 97 as yellow oil. 
Yield =70% over 2 steps from 4-azidobenzoic acid. Rf = 0.3 (10% MeOH/DCM). 
1H NMR (400 MHz, 
CDCl3): δ 7.78 - 7.63 (m, 4H, Haro), 7.58 - 7.42 (m, 2H, Haro), 7.39 - 7.29 (m, 2H, Haro), 7.29 - 
7.15 (m, 2H, Haro), 6.96 - 6.81 (m, 2H, Haro), 6.75 - 6.52 (brs, 1H, NH), 5.95 - 5.74 (brs, 1H, NH), 
4.50 - 4.02 (m, 4H), 3.52 - 3.22 (m, 2H), 2.04 - 1.14 (m, 6H). 13C NMR (100 MHz, CDCl3): δ 167.1, 
156.4, 143.7, 143.5, 143.1, 141.1, 130.7, 128.7, 127.6, 126.9, 124.9, 119.9, 118.7, 66.9, 53.4, 
47.0, 39.5, 32.1, 29.6, 28.5, 22.4. HRMS (ESI) calc. for C28H27N5O5, [M+H]
+= 514.2085, [M+Na]+= 
536.1905; found [M+H]+= 514.2079, [M+Na]+= 536.1897. LCMS (ESI) found 511.99 for [M-H]-, 
found 1024.93 for [2M-H]-, found 1537.12 for [3M-H]-. 
 
Trifunctional dye containing biotin-rhodamine-azide functionality (103, TrifN3).
 37 Compound 
103 was synthesized on Sieber Amide resin 95 (Novabiochem, loading = 0.69 mmol/g) using a 
standard Fmoc solid phase strategy. Fmoc protected resin (500 mg) was deprotected with 20% 
piperidine/NMP (3*10 ml, 5 min) and washed (NMP, 2*10 ml, 5 min; DCM, 2*10 ml, 5 min; DMF, 
3*10 ml, 5 min) to remove excess reagents. Fmoc-L-Lys (4-azidobenzoyl)-OH 97 (354 mg, 0.69 
mmol, 2 eqv.)43,44 was coupled to the resin for 1 hour at rt using HATU (262 mg, 0.69 mmol, 2 
eqv.), HOBT (114 mg, 0.69 mmol, 2 eqv.) and DIPEA (178 mg, 0.239 ml, 1.38 mmol, 4 eqv.) in 
DMF (4 ml). The resin was washed (DMF, 7*10 ml, 5 min; DCM, 3*10 ml, 5 min) and dried under 
reduced pressure for 1 hour. The loading of the resin was determined by absorbance 0.49 
mmol/g. Unreacted free amino groups were protected as N-acetamide by treatment of the resin 
for 30 min at rt with pyridine/acetic anhydride/ DCM 1/1/4 (12 ml). After washing the resin 
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(DCM, 7*10 ml, 5 min), Fmoc protected groups were deprotected using 4% DBU/DMF (6*10 ml, 
10 min) and the excess of reagent washed away (DMF, 5*10 ml, 5 min; DCM, 3*10 ml, 5 min; 
DMF, 2*10 ml, 5 min). Commercially available Fmoc-Lys(biotinyl-ε-aminocaproyl)-OH (350 mg, 
0.495 mmol, 2 eqv.) was coupled as described above in DMF for 7 hours. The resin was washed 
(DMF, 5*10 ml, 5 min; DCM, 3*10 ml, 5 min) and the remaining free amino groups protected as 
previously. After Fmoc deprotection with 4% DBU/DMF (6*10 ml, 10 min), the rhodamine was 
appended to the free amine upon reaction with 5/6 TAMRA-SE (178 mg, 0.33 mmol, 1.35 eqv.) 
using NEt3 (0.280 ml, 1.98 mmol, 6 eqv.) in NMP (10 ml). The resin was washed with NMP (3*10 
ml, 10 min), followed by DCM (3*10 ml, 10 min), MeOH (3*10ml, 10 min), and DCM/MeOH 1/1. 
The compound was cleaved from the resin using 1% TFA/DCM (5*3ml, 10 min). Toluene (20 ml) 
was added to the obtained red solution and the solvent evaporated under reduced pressure. 
The trifunctional dye 103 was obtained in 60% overall yield, after purification on reverse phase 
C18 cartridge as a dark red solid. Rf= 0.43 (AcOH/EtOAc/MeOH/H2O 3/6/3/2), fluorescent as a 
single spot. HRMS (ESI) calc. for C60H75N13O10 S [M+H]
+ 1170.5553, found [M+H]+ 1170.5561. 
LCMS (ESI) found 1170.40 for [M+H]+ .  
 
2.11 Synthesis of C16-ω-alkynyl fatty acid (106) 
 
 
Hexadec-15-yn-1-ol (105).2 Compound 105 was synthesized using a Alkyne Zipper reaction 
decribed in literature. Sodium Hydride (60% in mineral oil, 2.0 g, 50 mmol, 6.0 eqv.) was added 
to a 100 ml round bottom flask, together with a magnetic stirring bar. The flask was back-filled 
with argon and sodium hydride was washed with dry hexane (2x30 ml), taking care to remove as 
much of the hexane as possible. Diaminopropane (50 ml) was added via a cannula, and the 
resulting suspension was stirred at rt until gas evolution ceased (10 min). The temperature was 
slowly raised to 50°C and kept there until most of the NaH went into solution (30 min), 
temperature was then raised to 70°C for 30 min in order to complete dissolution. The resulting 
clear brown solution was allowed to cool to rt and 7-hexadecyn-1-ol 104 (2.0 g, 8.4 mmol, 1.0 
eqv.) dissolved in diaminopropane (10 ml) was added via a syringe. The resulting mixture was 
stirred at 50°C for 16 hours. After cooling to 0°C, water (20 ml), was slowly added over 5 min and 
the reaction mixture was aged for 20 min at 0°C. Subsequently, the reaction mixture was poured 
into 200 ml ice water under stirring, follow by addition of ice (100 g) to lower the temperature to 
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10°C. The reaction mixture was extracted with MTBE (3x100 ml), and the combined organic 
extracts were washed with water (2x100 ml), saturated NH4Cl (100 ml), water (100 ml) and brine 
(200 ml), followed by drying over Na2SO4. After evaporation to dryness, the residue was purified 
by filtration through a pad of silica (3 cm diameter, 5 cm long), eluting with EtOAc-Hexane 1:1, 
yielding compound 105 in 90% yield (yellow oil which solidifies upon standing). Rf = 0.48 
(EtOAc/cyclohexane 1/1). Analysis in accordance with data reported in literature. 1H NMR (400 
MHz, CDCl3): δ 3.65 (t, J = 5.2, 2H, -CH2OH), 2.17 (dt, J = 2.0, 5.6, 2H, -CH2-C≡C), 1.93 (t, J = 2.1, 
1H, -C≡CH), 1.62 - 1.47 (m, 4H), 1.45 – 1.18 (m, 20H). 13C NMR (100 MHz, CDCl3): δ 84.8, 68.0, 
63.1, 32.8, 29.6 (2C), 29.5 (3C), 29.4, 29.4, 29.1, 28.7, 28.5, 25.7, 18.4.  
 
 
Hexadec-15-ynoic acid (106).2 Hexadec-15-yn-1-ol 105 (1.6 g, 6.3 mmol, 1.0 eqv.) was dissolved 
in 30 ml acetone and added to a 100 ml round bottom flask, equipped with a large egg-shaped 
stirring bar. The flask was cooled to 0°C and Jones reagent (18.9 mmol, 3.0 eqv., prepared from 
CrO3 (1.87g, 18.9 mmol) and conc. H2SO4 (1.6 ml) in 3 ml water at 0°C) was added dropwise over 
5 min. The resulting solution was subsequently allowed to stir for 10 min at 0°C, then at rt for 20 
min. A TLC-sample indicated complete dissaperance of the starting material 105 (Rf = 0.48 
(EtOAc/cyclohexane 1/1) and the absence an aldehyde product (Rf = 0.7 (EtOAc/cyclohexane 
1:1). The reaction was cooled to 0°C in ice-bath and isopropanol (5 ml) was added slowly. The 
color changes from orange-brown to deep green and a thick precipitate is formed. Additional 30 
ml acetone was added, followed by some Celite 545. The resulting slurry was filtered on a 
sintered funnel and washed with additional 2x30 ml acetone. The combined filtrates were 
evaporated to a small volume under reduced pressure at 30 °C, yielding a greenish semi-solid 
residue which was  dissolve with 0.05 N HCl (30 ml) and EtOAc (50 ml). The organic layer was 
subsequently washed with further 0.05 N HCl (2x30 ml) followed by brine. After concentration 
under reduced pressure, the residue was purified by filtration through a short pad of silica gel 
(diameter 3 cm, length 8 cm), eluting with a gradient from 10% EtOAc in cyclohexane to 100% 
EtOAc leading to compound 106. Yield = 94% (white solid). Rf = 0.51 (EtOAc/cyclohexane 1/1). 
 1H 
NMR (400 MHz, CDCl3): δ 2.34 (t, J = 6.0, 2H, -CH2COOH), 2.18 (dt, , J = 2.4, 6.0, 2H, -CH2-C≡C), 
1.93 (t, J = 2.1, 1H, -C≡CH ), 1.58 -1.68 (m, 2H), 1.55 -1.47 (m, 2H), 1.45- 1.26 (m, 18H). 13C NMR 
(100 MHz, CDCl3): δ 179.4, 84.8, 68.0, 33.9, 29.6, 29.5, 29.5, 29.4, 29.4, 29.2, 29.1, 29.0, 28.7, 
28.5, 24.7, 18.4.  
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2.12 Synthesis of -keto amide candidate inhibitors  
 
 
Di-tert-butyl 7-(3-(dimethylamino)propylthio)heptylcarbamate (110).45 Alcohol 109 (206 mg, 
0.86 mmol, 1.0 eqv.), triphenylphosphine (916 mg, 3.48 mmol, 4.06 eqv.) and di-tert-butylimino 
dicarboxylate (792 mg, 3.48 mmol, 4.06 eqv.) were placed under argon and dissolved into dry 
DCM (12 ml). The obtained mixture was stirred at 0°C for 10 min before adding di-tert-butyl 
azodicarboxylate (DBAD, 590 mg, 2.56 mmol, 2.96 eqv.) to the reaction mixture which was 
subsequently stirred for 45 min at 0°C. The avancement of the reaction was monitorated by TLC 
using MeOH/DCM 20/80 (less polar compound formed). The reaction mixture was diluted with 
water and EtOAc, and the aqueous layer was extrated with EtOAc (2*20 ml). The combined 
organic layers were washed with brine (20 ml), dried over anhydrous MgSO4, and concentrated 
under reduced pressure. The residue (m =3.1g) was purified by flash chromatography using 2-
10% MeOH/DCM leading to N-Boc-protected amine 110 in 42% yield (slight yellow oil). Rf =0.68 
(10% MeOH/DCM). 1H NMR (400 MHz, CDCl3): δ 3.54 - 3.48 (m, 2H, -CH2NBoc2), 2.55 - 2.44 (m, 
4H, CH2S), 2.41 (t, J = 7.4, 2H, -CH2NMe2), 2.27 (s, 6H, -N(CH3)2), 1.82 – 1.71 (m, 2H), 1.59 – 1.49 
(m, 4H), 1.47 (2*s, 18H, CH3 Boc), 1.39 - 1.20 (m, 6H). 
13C NMR (125 MHz, CDCl3): δ 152.7 (CO, 
2C), 81.9 (CIV Boc, 2C), 58.5, 45.4, 45.1 (2C), 32.1, 29.8, 29.5, 28.9, 28.9, 28.8, 28.05 (6C), 27.2, 
26.7. HRMS (ESI) calc. for C22H44N2O4S [M+H]
+ 433.3094,  found  433.3092. LC-MS (ESI) found 
433.19 for [M+H]+.  
 
 
7-(3-(Dimethylamino)propylthio)heptan-1-amine (111).45 Alcohol 109 (104 mg, 0.42 mmol, 
1.eqv), triphenylphosphine (459 mg, 1.74 mmol, 4.06 eqv.) and di-tert-butylimino dicarboxylate 
(396 mg, 1.74 mmol, 4.06 eqv.) were placed under argon and dissolved into dry DCM (6 ml). The 
obtained mixture was stirred at 0°C for 10 min before adding di-tert-butyl azodicarboxylate 
(DBAD, 294 mg, 1.27 mmol, 2.96 eqv.) to the reaction mixture which was subsequently stirred 
for 30 min at 0°C.  After addition of trifluoro acetic acid (TFA, 1.5 ml) to the mixture, the later 
was stirred at rt for 1H30. Then the reaction was acidified to pH = 1 using 1M HCl, and 
subsequently extracted with EtOAc. The organic layer was discarded and the aqueous layer was 
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basified to pH=12 using NaOH, and subsequently extracted with several portions of EtOAc. 
Combined organic layers were washed with brine, dried over anhydrous MgSO4 and 
concentrated under reduced pressure. The residue (89 mg) was then purified through filtration 
using a sintered funnel (Ø 2 cm) containing in 1cm silica). Unpolar impurities were eluted using 
15% MeOH/DCM, and the silica subsequently washed with 100% MeOH to collect the amine 
111. As most of the compound was aborbed on the silica, the silica was dissolved in 
water/EtOAc and the compound extracted with EtOAc (4*100 ml). After MgSO4 treatment and 
concentratration under reduced pressure, the primary amine 111 was obtained in 14% yield 
(yellow oil). Rf = 0.36 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). 
1H and 13C NMR identical to the one 
decribed previously using the procedure for reduction of the azide to the amine.  
 
 
Ethyl-3-iodopropanoate (112). Compound 112 was synthesized following the general procedure 
for Finkelstein reaction on 138 mmol of ethyl-3-bromopropanoate. Yield = 92% (yellow oil). Rf = 
0.42 (EtOAc/cyclohexane 5/95). IR: 1731 cm-1 (ester, C=O stretch). 1H NMR (400 MHz, CDCl3): δ 
4.16 (q, J = 7.2, 2H, -CH2CH3), 3.31 (t, J =7.0, 2H, -CH2COOR), 2.94 (t, J = 7.2, 2H, -CH2I), 1.26 (t, J = 
7.0, 3H, -CH2CH3).
 13C NMR (125 MHz, CDCl3): δ 170.9, 60.9, 38.6, 14.1, - 3.8. HRMS (EI) calc. for 
C5H9IO2 [M
+.] 227.9642, found [M+.] 227.9640. GCMS found 228 for [M+.].  
 
 
Ethyl-6-iodohexanoate (113). Compound 113 was synthesized following the general procedure 
for Finkelstein reaction on 111 mmol of ethyl-6-bromohexanoate. Yield = 98% (yellow oil). Rf = 
0.42 (EtOAc/cyclohexane 5/95). IR: 1730 cm-1 (ester, C=O stretch).  1H NMR (400 MHz, CDCl3): δ 
4.11 (q, J = 7.2, 2H, -CH2CH3), 3.17 (t, J = 7.0, 2H, -CH2COOR), 2.29 (t, J = 7.4, 2H, -CH2I), 1.82 (p, J 
= 7.2, 2H), 1.63 (p, J = 7.6, 2H), 1.49 - 1.35 (m, 2H), 1.24 (t, J = 7.2, 3H, -CH2CH3). 
13C NMR (125 
MHz, CDCl3): δ 173.3, 60.2, 34.0, 33.0, 29.9, 23.8, 14.4, 6.4. HRMS (ESI) calc. for C8H15IO2 [M+Na]
+ 
293.0009, found [M+Na]+ 293.0010. GCMS found 225 for [M-OEt+.]. GCMS found 225 for [M-
OEt+.]. 
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Ethyl-7-iodoheptanoate (107). Compound 107 was synthesized following the general procedure 
for Finkelstein reaction on 98 mmol of ethyl-7-bromoheptanoate. Yield = 98% (slight orange oil). 
Rf = 0.48 (EtOAc/cyclohexane 5/95). IR: 1731 cm
-1 (ester, C=O stretch).  1H NMR (400 MHz, 
CDCl3): δ 4.10 (q, J = 7.2, 2H, -CH2CH3), 3.16 (t, J = 7.0, 2H, -CH2COOR), 2.27 (t, J = 7.4, 2H, -CH2I), 
1.80 (p, J = 7.2, 2H), 1.61 (p, J = 7.4, 2H), 1.45 – 1.30 (m, 4H), 1.23 (t, J = 7.0, 3H, -CH2CH3).
13C 
NMR (125 MHz, CDCl3): δ 173.3, 60.0, 34.0, 33.1, 29.9, 27.8, 24.5, 14.1, 6.7. HRMS (ESI) calc. for 
C9H17IO2 [M+Na]
+ 307.0165, found [M+Na]+ 307.0168. GCMS found 239 for [M-OEt+.]. 
 
 
Ethyl 3-(3-(dimethylamino)propylthio)propanoate (114). Compound 114 was synthesized 
following the general procedure for S-alkylation using 87 mmol of thioacetate 47 (no purification 
needed). Yield = 94% (colorless oil). Rf = 0.45 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1733 cm
-1 
(ester, C=O stretch). 1H NMR (400 MHz, CDCl3): δ 4.02 (q, J = 7.2, 2H, -COCH2CH3), 2.64 (t, J = 7.0, 
2H, -CH2COOEt), 2.45 (t, J = 7.6, 2H, -CH2S), 2.43 (t, J = 7.4, 2H, -CH2S), 2.20 (t, J = 7.2, 2H, -
CH2NMe2), 2.07 (s, 6H, N(CH3)2), 1.65 – 1.55 (m, 2H), 1.12 (t, J = 7.2, 3H, COCH2CH3). 
13C NMR 
(125 MHz, CDCl3): δ 171.4, 60.2, 58.2, 45.1, 34.6, 29.6, 27.3, 26.7, 13.9. HRMS (ESI) calc. for 
C10H21NO2S [M+H]
+ 220.1366, found 220.1368. GCMS found 219 for [M+.].  
 
 
Ethyl 6-(3-(dimethylamino)propylthio)hexanoate (115). Compound 115 was synthesized 
following the general procedure for S-alkylation using 74 mmol of thioacetate 47. Yield = 77% 
(slight yellow oil). Rf = 0.56 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1733 cm
-1 (ester, C=O 
stretch). 1H NMR (400 MHz, CDCl3): δ 4.01 (q, J = 7.2, 2H, -COCH2CH3), 2.40 (t, J = 7.4, 2H, -CH2S), 
2.39 (t, J = 7.4, 2H, -CH2S), 2.21 (t, J = 7.2, 2H, -CH2COOEt), 2.17 (t, J = 7.4, 2H, -CH2NMe2), 2.09 (s, 
6H, N(CH3)2), 1.65 – 1.57 (m, 2H), 1.55 – 1.43 (m, 4H), 1.34 – 1.24 (m, 2H), 1.13 (t, J = 7.2, 3H, -
COCH2CH3). 
13C NMR (125 MHz, CDCl3): δ 173.2, 59.9, 58.4, 45.2, 33.9, 31.7, 29.7, 29.0, 28.1, 
27.5, 24.3, 14.0. HRMS (ESI) calc. for C13H27NO2S [M+H]
+ 262.1835, found 262.1837. GCMS found 
261 for [M+.].  
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Ethyl 7-(3-(dimethylamino)propylthio)heptanoate (108). Compound 108 was synthesized 
following the general procedure for S-alkylation using 52 mmol of thioacetate 47. Yield = 75% 
(slight yellow oil). Rf = 0.56 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1734 cm
-1 (ester, C=O 
stretch). 1H NMR (400 MHz, CDCl3): δ 4.10 (q, J = 7.2, 2H, -COCH2CH3), 2.52 (t, J = 7.2, 2H, -CH2S), 
2.49 (t, J = 7.4, 2H, -CH2S), 2.39 (t, J = 7.6, 2H, -CH2COOEt), 2.27 (t, J = 7.6, 2H, -CH2NMe2), 2.25 (s, 
6H, N(CH3)2), 1.76 – 1.66 (m, 2H), 1.65 – 1.50 (m, 4H), 1.41– 1.20 (m, 4H), 1.22 (t, J = 7.2, 3H, -
COCH2CH3). 
13C NMR (125 MHz, CDCl3): δ 173.6, 60.1, 58.7, 45.4, 34.2, 32.1, 30.0, 29.4, 28.7, 
28.5, 27.7, 24.8, 14.2. HRMS (ESI) calc. for C14H29NO2S [M+H]
+ 276.1992, found 276.1992. GCMS 
found 275 for [M+.].  
 
 
3-(3-(Dimethylamino)propylthio)propan-1-ol (116).  Compound 116 was synthesized following 
the general procedure for ester reduction on 28.1 mmol ethyl ester 114. Yield =92% (slight 
yellow oil). Rf = 0.28 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). 
1H NMR (400 MHz, CDCl3): δ 3.70 (t, J = 
6.0, 2H, -CH2OH), 3.04 - 2.76 (brs, 1H, -OH), 2.61 (t, J = 7.0, 2H, -CH2S), 2.54 (t, J = 7.2, 2H, -CH2S), 
2.35 (t, J = 7.2, 2H, -CH2NMe2), 2.20 (s, 6H, N(CH3)2), 1.85 – 1.78 (m, 2H), 1.76 – 1.70 (m, 2H). 
13C 
NMR (125 MHz, CDCl3): δ 61.2, 58.4, 45.3 (2C), 32.1, 29.9, 28.7, 27.3. HRMS (ESI) calc. for 
C8H19NOS [M+H]
+ 178.1260, found 178.1257. LC-MS (ESI) found 177.95 for [M+H]+. 
 
 
6-(3-(Dimethylamino)propylthio)hexan-1-ol  (117). Compound 117 was synthesized following 
the general procedure for ester reduction on 2.29 mmol ethyl ester 115. Yield = 87% (slight 
yellow oil). Rf = 0.38 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). 
1H NMR (400 MHz, CDCl3): δ 3.59 (t, J = 
6.6, 2H, -CH2OH), 2.50 (t, J = 7.0, 2H, -CH2S), 2.48 (t, J = 7.2, 2H, -CH2S), 2.31 (t, J = 7.4, 2H, 
CH2NMe2), 2.19 (s, 6H, N(CH3)2), 1.76 – 1.66 (m, 2H), 1.61 – 1.48 (m, 4H), 1.43 – 1.28 (m, 4H). 
13C 
NMR (125 MHz, CDCl3): δ 62.6, 58.7, 45.4 (2C), 32.6, 32.0, 30.0, 29.5, 28.5, 27.6, 25.3. HRMS 
(ESI) calc. for C11H25NOS [M+H]
+ 220.1729, found 220.1726. LC-MS (ESI) found 220.02 for 
[M+H]+. 
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7-(3-(Dimethylamino)propythio)heptan-1-ol (109). Compound 109 was synthesized following 
the general procedure for ester reduction on 28.4 mmol ethyl ester 108. Yield=87% (slight 
yellow oil). Rf = 0.42 (AcOH/EtOAc/ MeOH/H2O 3/3/3/2). 
1H NMR (400 MHz, CDCl3): δ 3.54 (t, J 
= 6.6, 2H, -CH2OH), 2.47 (t, J = 7.0, 2H, -CH2S), 2.45 (t, J = 7.2, 2H, -CH2S), 2.30 (t, J = 7.4, 2H, -
CH2NMe2), 2.17 (s, 6H, N(CH3)2), 1.74 – 1.64 (m, 2H), 1.56 - 1.44 (m, 4H), 1.37 – 1.26 (m, 6H). 
13C 
NMR (125 MHz, CDCl3): δ 62.3, 58.5, 45.2 (2C), 32.6, 32.0, 29.8, 29.4, 28.8, 28.6, 27.4, 25.5. 
HRMS (ESI) calc. for C12H27NOS [M+H]
+ 234.1886, found 234.1885. LC-MS (ESI) found 234.02 for 
[M+H]+. 
 
3-(3-Azidopropylthio)-N,N-dimethylpropan-1-amine (118). Compound 118 was synthesized 
following the general procedure for azide formation on 1.12 mmol alcohol 116. Yield = 57% 
(brown oil). Rf = 0.48 (10% MeOH/DCM). IR: 2092 cm
-1 (N3).  
1H NMR (400 MHz, CDCl3): δ 3.38 (t, 
J = 6.6, 2H, -CH2N3), 2.57 (t, J = 7.2, 2H, -CH2S), 2.52 (t, J = 7.4, 2H, -CH2S), 2.34 (t, J = 7.2, 2H, -
CH2NMe2), 2.21 (s, 6H, N(CH3)2), 1.87 – 1.79 (m, 2H), 1.77 – 1.69 (m, 2H). 
13C NMR (125 MHz, 
CDCl3): δ 58.4, 50.0, 45.3 (2C), 29.9, 28.9, 28.6, 27.4. HRMS (ESI) calc. for C8H18N4S [M+H]
+ 
203.1325, found  203.1320. LC-MS (ESI) found 202.92 for [M+H]+. 
 
 
3-(4-Azidobutylthio)-N,N-dimethylpropan-1-amine  (119). Compound 119 was synthesized 
following the general procedure for azide formation on 10.3 mmol alcohol 52. Yield = 61% 
(brown oil). Rf = 0.42 (10% MeOH/DCM). IR: 2091 cm
-1 (N3).
1H NMR (400 MHz, CDCl3): δ 3.28 (t, 
J = 6.2, 2H, -CH2N3), 2.53 – 2.49 (m, 4H, -CH2S), 2.36 (t, J = 7.4, 2H, -CH2NMe2), 2.22 (s, 6H, 
N(CH3)2), 1.79 - 1.57 (m, 6H). 
13C NMR (125 MHz, CDCl3): δ 58.4, 50.9, 45.3 (2C), 31.5, 29.8, 27.9, 
27.4, 26.5. HRMS (ESI) calc. for C9H20N4S [M+H]
+ 217.1481, found  217.1480. LC-MS (ESI) found 
216.94 for [M+H]+. 
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3-(6-Azidohexylthio)-N,N-dimethylpropan-1-amine (120). Compound 120 was synthesized 
following the general procedure for azide formation on 8.8 mmol alcohol 117. Yield = 54% 
(brown oil). Rf = 0.51 (10% MeOH/DCM). IR: 2092 cm
-1 (N3). 
1H NMR (400 MHz, CDCl3): δ 3.19 (t, 
J = 6.8, 2H, -CH2N3), 2.48 – 2.42 (m, 4H, -CH2S), 2.28 (t, J = 7.2, 2H, -CH2NMe2), 2.16 (s, 6H, 
N(CH3)2), 1.73 – 1.64 (m, 2H), 1.57-1.48 (m, 4H), 1.38 -1.25 (m, 4H). 
13C NMR (125 MHz, CDCl3): 
δ 58.5, 51.1, 45.3 (2C), 31.8, 29.8, 29.2, 28.5, 28.2, 27.5, 26.1. HRMS (ESI) calc. for C11H24N4S 
[M+H]+ 245.1794, found 245.1794. LC-MS (ESI) found 244.97 for [M+H]+. 
 
 
3-(7-Azidoheptylthio)-N,N-dimethylpropan-1-amine (121). Compound 121 was synthesized 
following the general procedure for azide formation on 0.86 mmol alcohol 109. Yield = 68% 
(brown oil). Rf = 0.52 (10% MeOH/DCM). IR: 2091 cm
-1 (N3). 
1H NMR (400 MHz, CDCl3): δ 3.20 (t, 
J = 6.8, 2H, -CH2N3), 2.55 – 2.44 (m, 6H, -CH2S, -CH2S, -CH2NMe2), 2.35 (s, 6H, N(CH3)2), 1.85 – 
1.75 (m, 2H), 1.63 - 1.49 (m, 4H), 1.37 - 1.19 (m, 6H). 13C NMR (125 MHz, CDCl3): δ 58.0, 51.2, 
44.6 (2C), 31.9, 29.5, 29.2, 28.6, 28.6, 28.5, 26.5, 26.4. HRMS (ESI) calc. for C12H26N4S [M+H]
+ 
259.1951, found 259.1949. LC-MS (ESI) found 258.99 for [M+H]+. 
 
 
3-(3-Aminopropylthio)-N,N-dimethylpropan-1-amine  (122). Compound 122 was synthesized 
following the general procedure for reduction azide into amine on 7.66 mmol azide 118. Yield= 
99% (brown oil). Rf = 0.36 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). 
1H NMR (400 MHz, CDCl3): δ 2.79 
(t, J = 6.8, 2H, -CH2NH2), 2.59 – 2.51 (m, 4H, -CH2S), 2.36 – 2.31 (m, 2H, -CH2NMe2), 2.21 (s, 6H, 
N(CH3)2), 1.88 – 1.80 (m, 2H), 1.78 – 1.68 (m, 2H). 
13C NMR (125 MHz, CDCl3): δ 58.6, 45.4 (2C), 
41.0, 33.0, 29.9, 29.4, 27.6. HRMS (ESI) calc. for C8H20N2S [M+H]
+ 177.1420, found 177.1418. LC-
MS (ESI) found 176.97 for [M+H]+. 
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4-(3-(Dimethylamino)propylthio)butan-1-amine (123). Compound 123 was synthesized 
following the general procedure for reduction azide into amine on 5.94 mmol azide 119. Yield = 
86% (brown oil). Rf = 0.28 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). 
1H NMR (400 MHz, CDCl3): δ 2.71 
(t, J = 6.8, 2H, -CH2NH2), 2.55 – 2.49 (m, 4H, -CH2S), 2.43 – 2.38 (brs, 2H, NH2), 2.34 (t, J = 7.4, 
2H, -CH2NMe2), 2.21 (s, 6H, N(CH3)2), 1.78 – 1.68 (m, 2H), 1.66 -1.50 (m, 4H). 
13C NMR (125 MHz, 
CDCl3): δ 58.6, 45.4 (2C), 41.5, 32.4, 31.9, 29.9, 27.6, 26.9. HRMS (ESI) calc. for C9H22N2S [M+H]
+ 
191.1576, found 191.1575. LC-MS (ESI) found 191.04 for [M+H]+. 
 
 
6-(3-(Dimethylamino)propylthio)hexan-1-amine (124). Compound 124 was synthesized 
following the general procedure for reduction azide into amine on 4.25 mmol azide 120. Yield = 
96% (brown oil). Rf = 0.33 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). 
1H NMR (400 MHz, CDCl3): δ 2.69 
(t, J = 7.0, 2H, -CH2NH2), 2.52 – 2.46 (m, 4H, -CH2S), 2.32 (t, J = 7.2, 2H, -CH2NMe2), 2.19 (s, 6H, 
N(CH3)2), 1.76 – 1.66 (m, 2H), 1.61 – 1.51 (m, 2H), 1.48 – 1.25 (m, 6H). 
13C NMR (125 MHz, 
CDCl3): δ 58.6, 45.4 (2C), 41.9, 33.1, 32.0, 29.9, 29.5, 28.6, 27.7, 26.4. HRMS (ESI) calc. for 
C11H26N2S [M+H]
+ 219.1889, found 219.1889. LC-MS (ESI) found 219.03 for [M+H]+. 
 
 
7-(3-(Dimethylamino)propylthio)heptan-1-amine  (111). Compound 111 was synthesized 
following the general procedure for reduction azide into amine on 2.75 mmol azide 121. Yield = 
94% (brown oil). Rf =0.37 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). 
1H NMR (400 MHz, CDCl3): δ 2.69 
(t, J = 7.2, 2H, -CH2NH2), 2.65 - 2.56 (brs, 2H, NH2), 2.52 (t, J = 7.2, 2H, -CH2S), 2.49 (t, J = 7.4, 2H, 
-CH2S), 2.34 (t, J = 7.4, 2H, -CH2NMe2), 2.21 (s, 6H, N(CH3)2), 1.78 – 1.68 (m, 2H), 1.61 – 1.51 (m, 
2H), 1.51 - 1.41 (m, 2H), 1.41 - 1.22 (m, 6H). 13C NMR (125 MHz, CDCl3): δ 58.6, 45.4 (2C), 41.8, 
32.8, 32.1, 29.9, 29.5, 28.9, 28.7, 27.6, 26.6. HRMS (ESI) calc. for C12H28N2S [M+H]
+ 233.2046,  
found  233.2046. LC-MS (ESI) found 233.03 for [M+H]+. 
 
 
Experimental part   203 
 
2-Hydroxyoctanoic acid (126).46 To a solution of 2-bromooctanoic acid 125 (2 g, 8.9 mmol, 1.0 
eqv.) in water (35 ml) was added NaOH (2.9 g, 72 mmol, 8.0 eqv.). The reaction mixture was 
stirred at 80°C for 24 hours and quenched at 0°C by addition of diluted HCl. The mixture was 
then extracted with Et2O and the combined organic layers were washed with H2O followed by 
brine and dried over anhydrous MgSO4. Concentration under reduced pressure leaded to 2-
hydroxyoctanoic acid 126 which was used directly in the next step. Yield= 94% (white solid). Rf = 
0.76 (AcOH/EtOAc/MeOH/H2O 3/14/3/2). IR: 1704 cm
-1 (C=O). 1H NMR (400 MHz, CDCl3): δ 4.27 
(ddd, J = 4.0, 3.4, 3.6, 1H, -CH(OH)R), 1.91 - 1.79 (m, 1H, -CH2CH(OH)R), 1.76 - 1.64 (m, 1H, -
CH2CH(OH)R), 1.55 - 1.23 (m, 8H), 0.88 (t, J = 6.8, 3H, -CH3). 
13C NMR (125 MHz, CDCl3): δ 179.2, 
70.2, 34.2, 31.6, 28.9, 24.7, 22.5, 14.0. HRMS (ESI) calc. for C8H16O3 [M-H]
- 159.1027, found 
159.1024. LC-MS (ESI) found 159.07 for [M-H]-. 
 
 
2-(Tert-butyldimethylsilyloxy)octanoic acid (127).46,47 To 2-hydroxyoctanoic acid 126 (300 mg, 
1.91 mmol, 1.0 eqv.) in DMF (0.8 ml) was added at 0°C imidazole (265 mg, 3.82 mmol, 2.0 eqv.) 
followed by TBDMSCl (1.11 g, 7.25 mmol, 3.8 eqv.) to the reaction mixture which was 
subsequently stirred at rt for 24 hours. The reaction mixture was then diluted with petrolum 
ether/EtOAc 1/1 (50ml) and washed with 10% citric acid (35 ml) followed by H2O and saturated 
aqueous Na2SO4 solution. The organic layer was concentrated under reduced pressure and the 
residue finally dissolved in ice-cold MeOH (20 ml). K2CO3 (690 mg, 5 mmol, 2.6 eqv.) as a 
solution in H2O (6 ml) was added to the reaction mixture which was then stirred at rt for 4 
hours. After concentration under reduced pressure, the residue was diluted with ice-cold water 
and slowly acidified with 10% citric acid to approx. pH 4.0.  After several extractions with EtOAc 
(3*40 ml), the organic layer was dried over anhydrous MgSO4 and concentrated under reduced 
pressure leading to the TBDMS protected carboxylic acid 127 which was used directly in the 
next step. Yield= 76% (white solid).  Rf = 0.67 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1704 cm
-1 
(C=O). 1H NMR (400 MHz, CDCl3): δ 4.28 (dd, J = 5.2, 5.4, 1H, -CH(OTBDMS)R ), 1.87 - 1.62 (m, 
2H, -CH2CH(OTBDMS)R), 1.53 - 1.19 (m, 8H), 0.99 (s, 9H, -C(CH3)3, TBDMS), 0.87 (t, J = 7.0, 3H, -
CH3), 0.12 (s, 6H, 2* -CH3, TBDMS). 
13C NMR (125 MHz, CDCl3): δ 178.9, 72.2, 34.7, 31.6, 28.9, 
25.6 (-C(CH3)3, TBDMS), 24.1, 22.5, 18.1 ( CIV, TBDMS), 14.0, -4.8 (-CH3, TBDMS), -5.2 (-CH3, 
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TBDMS). HRMS (ESI) calc. for C14H30O3Si [M-H]
- 273.1891, found 273.1891. LC-MS (ESI) found 
273.11 for [M-H]-. 
 
 
2-(Tert-butyldimethylsilyloxy)-N-(4-(3-(dimethylamino)propylthiobutyl)octanamide (128). To 
TBDMS protected -hydroxyacid 127 (73 mg, 0.26 mmol, 1.0 eqv.) in dry THF (1 ml) was added 
dropwise at -10°C N-Methylmorpholine (NMM, 24 µl, 0.21 mmol, 0.8 eqv.) followed by isobutyl 
chloroformate (28 µl, 0.21 mmol, 0.8 eqv.). The reaction mixture was stirred at -10°C for 10 
minutes. Amine 123 (60 mg, 0.31 mmol, 1.2 eqv.) in dry THF (1 ml) was subsequently added to 
the reaction mixture which was stirred for 1 hour at -10°C followed by 16 hours at rt. After 
concentration under reduced pressure, the residue was taken in EtOAc and the organic layer 
was washed with brine, dried over anhydrous MgSO4 and concentrated to dryness. After 
purification by flash chromatography (eluent: gradient 1-6% MeOH/DCM) compound 128 was 
obtained. Yield = 57% (yellow oil). Rf = 0.85 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1666 cm
-1 
(amide, C=O). 1H NMR (400 MHz, CDCl3): δ 6.60 (t, J = 5.8, 1H, NH), 4.12 (dd,  J = 4.6, 5.6, 1H, -
CH(OTBDMS)CONHR), 3.37 - 3.17 (m, 2H, -CH2NHCOR), 2.57 - 2.51 ( m, 4H, -CH2S, -CH2S), 2.49 - 
2.43 (m, 2H, -CH2NMe2), 2.31 (s, 6H, -N(CH3)2), 1.90 - 1.55 (m, 8H), 1.40 - 1.20 (m, 8H), 0.92 (s, 
9H, -C(CH3)3, TBDMS), 0.86 (t, J = 7.0, 3H, -CH3), 0.09 (s, 3H, -CH3, TBDMS), 0.07 (s, 3H, -CH3, 
TBDMS). 13C NMR (125 MHz, CDCl3): δ 173.8, 73.6, 58.4, 45.0 (2C), 38.3, 35.3, 31.7, 29.8, 29.2, 
28.9, 26.8, 25.7 (-C(CH3)3, TBDMS), 24.1, 22.6, 18.0 ( CIV, TBDMS), 14.0, -4.8 (-CH3, TBDMS),, -5.2 
(-CH3, TBDMS),. HRMS (ESI) calc. for C23H50N2O2SSi [M+H]
+ 447.3429, found 447.3430. LC-MS 
(ESI) found 447.25 for [M+H]+. 
 
 
N-(4-(3-(dimethylamino)propylthio)butyl)-2-hydroxyoctanamide (129).46,47 To a solution of 
TBDMS protected -hydroxyamide 128 (60.7 mg, 0.136 mmol, 1.0 eqv.) in dry THF (4 ml) was 
added dropwise TBAF (1.0M in THF, 0.8 ml, 0.8 mmol, 6.0 eqv.) at 0°C to the reaction mixture 
which was stirred at rt overnight. The reaction mixture was subsequently poured into brine and 
extracted with several portion of CHCl3. Combined organic layers were washed with water 
followed by brine, dried over anhydrous MgSO4, and concentrated under reduced pressure. 
Purification by flash chromatography (eluent: gradient 1-6% MeOH/DCM) lead to compound 
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129. Yield = 68% (yellow semi-solid). Rf= 0.71 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1610 cm
-1 
(amide, C=O). 1H NMR (400 MHz, CDCl3): δ 6.75 (t, J = 5.6, 1H, NH), 4.02 (ddd, J = 3.8, 4.2, 4.1, 
1H, -CH(OH)CONHR), 3.52-3.41 (m, 1H, -CH2NHCOR), 3.22-3.11 (m, 1H, -CH2NHCOR), 2.60-2.47 
(m, 4H, -CH2S, -CH2S), 2.44-2.33 (m, 2H, -CH2NMe2), 2.25 (s, 6H, -N(CH3)2), 190-1.50 (m, 8H), 
1.48-1.21 (m, 8H), 0.87 (t, J = 6.8, 3H, -CH3). 
13C NMR (125 MHz, CDCl3): δ 174.5, 72.0, 58.6, 45.3 
(2C), 38.1, 34.9, 32.1, 31.7, 30.0, 29.1, 28.3, 27.9, 26.6, 25.3, 22.6, 14.0. HRMS (ESI) calc. for 
C17H36N2O2S [M+H]
+ 333.2570, found 333.2571. LC-MS (ESI) found 333.20 for [M+H]+.  
 
 
N-(4-(3-(dimethylamino)propylthio)butyl)-2-hydroxyoctanamide (129).48 To a solution of 
amine 123 (100 mg, 0.52 mmol, 1.0 eqv.) and unprotected hydroxyacid 126 (106 mg, 0.66 
mmol, 1.27 eqv.) in dry DCM (5 ml) was added EDC.HCl (330 mg, 1.72 mmol, 3.3 eqv.) followed 
by HOBT (84 mg, 0.62 mmol, 1.2 eqv.) at 0° to the reaction which was stirred at 0°C for 1h and 
then at rt overnight. The reaction mixture was extracted with brine and the combined organic 
layers were dried over anhydrous MgSO4 and concentrated under reduced pressure. The 
residue was subsequently purified by flash chromatography using a gradient of MeOH/DCM 1-
10% leading to compound 129. Yield= 76%. Similar characterization reported before after 
TBDMS deprotection.   
 
 
2-Methylenedodecanal (132).49 In a round bottom flask was added aldehyde 131 (169 mmol, 
1.0 eqv.), dimethylamine hydrogen chloride (16.75g, 203 mmol, 1.2 eqv.) followed by 37% 
aqueous formalin (15 ml, 203 mmol, 1.2 eqv.). The mixture was stirred at 70°C for 24 hours with 
progress monitorated by TLC (EtOAc/cyclohexane 1/1, formation of a less polar compound). 
Organic and aqueous layers were separated and the aqueous layer was extracted with several 
portions of hexane. Combined organic layers were dried over anhydrous MgSO4, concentrated 
under reduced pressure and purified by short filtration over silica, leading to compound 132. 
Yield= 76% (slight yellow oil). Rf = 0.79 (EtOAc/cyclohexane 3/7). IR: 1697 cm
-1 (C=O).  1H NMR 
(400 MHz, CDCl3): δ 9.51 (s, 1H, -CHO), 6.21 (d, J = 0.8, 1H, -C=CH2), 5.95 (d, J = 0.8, 1H, -C=CH2),  
2.21 (t, J = 7.4, 2H), 1.45 - 1.36 (m, 2H), 1.31 - 1.18 (m, 14H), 0.85 (t, J = 6.8, 3H, -CH3). 
13C NMR 
(125 MHz, CDCl3): δ 194.8, 150.5, 133.8, 31.9, 29.6, 29.5, 29.4, 29.3, 27.8, 27.7, 26.9, 22.7, 14.1. 
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2-Methylenedodecanoic acid (133).50 In a round bottom flask was added aldehyde 132 (105 
mmol, 1.0 eqv.), sodium chlorite NaClO2 (27.2 g, 241 mmol, 2.3 eqv.), sodium 
dihydrogenphosphate NaH2PO4 (25.45 g, 210 mmol, 2.0 eqv.) followed by 2-methyl-2-butene 
(MeCH=CMe2, 37ml, 315 mmol, 3.0 eqv.) in t-BuOH (375 ml). Water (150 ml) was added 
dropwise over 10 min to the reaction mixture which was stirred at rt for 4 hours. The mixture 
was concentrated under reduced pressure and the residue subsequently resuspended in 2M 
NaOH and hexane (100 ml). The two layers were separated and the organic layer was discarded. 
The basic aqueous layer was re-acidified to pH 2.0 using concentrated HCl and subsequently 
extracted with EtOAc (4*200 ml). Combined organic layers were dried over anhydrous MgSO4 
and concentrated under reduced pressure leading to the carboxylic acid 133, which was used 
directly in the next step.Yield = 86% (white semi-solid). Rf = 0.54 (EtOAc/cyclohexane 3/7). IR: 
1693 cm-1 (C=O). 1H NMR (400 MHz, CDCl3): δ 6.28 (d, J = 1.2, 1H, -C=CH2), 5.64 (d, J = 1.2, 1H, -
C=CH2), 2.29 (t, J = 7.6, 2H, -CH2C=C), 1.52 - 1.42 (m, 2H), 1.38 -1.20 (m, 14H), 0.88 (t, J = 6.8, 3H, 
- CH3). 
13C NMR (125 MHz, CDCl3): δ 172.8, 140.3, 126.8, 31.9, 31.4, 29.6, 29.5, 29.4, 29.3, 29.2, 
28.4, 22.7, 14.1. HRMS (ESI) calc. for C13H24O2 [M-H]
- 211.1704, found  211.1704. GCMS found 
212 for [M+.]. 
 
 
2-Oxododecanoic acid (134).51-53 In a round bottom flask containing α-methylenated carboxylic 
acid 133 (0.94 mmol, 1.0 eqv.) in dioxane/water 3/1 (28 ml) was added catalytic OsO4 (2.5 wt% 
in t-BuOH, 0.75 ml, 6.2 mol %). The dark brown mixture was stirred at rt for 45 min and sodium 
periodate NaIO4 (603 mg, 2.82 mmol, 3.0 eqv.) was added. The reaction mixture was stirred at 
rt overnight until completion of the reaction visible by TLC (eluent EtOAc/cyclohexane 3/7, 
more polar compound formed). After evaporation under reduced pressure, the residue was 
diluted with DCM and 1M HCl. The aqueous layer was extracted with several portion of DCM 
and combined organic layers were finally dried over anhydrous MgSO4 and concentrated under 
reduced pressure at low temperature (30°C) to prevent polymerisation or degradation of the 
product. The last traces of dioxane were removed by co-evaporation with several portions of n-
BuOH, leading to the expected α-keto acid 134 which was used directly in the next step.Yield= 
87% (slight brown semi-solid). Rf = 0.26 (20% MeOH/DCM). IR: 1713 cm
-1 (C=O). 1H NMR (400 
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MHz, CDCl3): δ 2.94 (t, J = 7.4, 2H, -CH2CO), 1.71-1.56 (m, 2H), 1.39 - 1.18 (m, 14H), 0.88 (t, J = 
6.8, 3H, -CH3). 
13C NMR (125 MHz, CDCl3): δ 196.0, 159.5, 37.3, 31.8, 29.5, 29.3, 29.2, 29.2, 28.9, 
23.1, 22.6, 14.1. HRMS (ESI) calc. for C12H22O3 [M-H]
- 213.1496, found 213.1495. LC-MS (ESI) 
found 426.93 for 2* [M-H]-. 
 
 
N-(3-(3-(dimethylamino)propylthio)propyl)-2-oxododecanamide  (135). Compound 135 was 
synthesized following the general procedure for amide formation (method A) on 1.19 mmol 
amine 122. Yield = 23% (slight yellow oil). Rf = 0.24 (5% MeOH/DCM). IR: 1718 cm
-1 (ketone, 
C=O), 1675 cm-1 (amide, C=O). 1H NMR (400 MHz, CDCl3): δ 7.12 (t, J = 6.0, 1H, NH), 3.39 (ddd, J 
= 6.8, 6.8, 6.2, 2H, -CH2NHCOR), 2.89 (t, J = 7.4, 2H, -CH2CO), 2.55 (t, J = 7.2, 2H, -CH2S), 2.54 (t, J 
= 7.4, 2H, -CH2S), 2.37 (t, J = 7.2, 2H, -CH2NMe2,), 2.23 (s, 6H,  -N(CH3)2), 1.88- 1.79 (m, 2H), 1.78 -
1.70 (m, 2H), 1.64-1.54 (m, 2H), 1.35 - 1.19 (m, 14H), 0.87 (t, J = 6.8, 3H, -CH3). 
13C NMR (125 
MHz, CDCl3): δ 199.3, 160.3, 58.4, 45.3 (2C), 38.3, 36.7, 31.8, 29.9, 29.5, 29.5, 29.4, 29.3, 29.2, 
29.0, 28.8, 27.4, 23.2, 22.6, 14.1. HRMS (ESI) calc. for C20H40N2O2S [M+H]
+ 373.2883, found 
373.2885. LC-MS (ESI) found 373.16 for [M+H]+. 
 
 
N-(6-(3-(dimethylamino)propylthio)hexyl)-2-oxododecanamide (136). Compound 136 was 
synthesized following the general procedure for amide formation (method A) on 1.16 mmol 
amine 124. Yield = 40% (light brown solid). Rf = 0.27 (5% MeOH/DCM). IR: 1718 cm
-1 (ketone, 
C=O), 1674 cm-1 (amide, C=O). 1H NMR (400 MHz, CDCl3): δ 6.97 (t, J = 5.8, 1H, NH),  3.28 (ddd, J 
= 6.8, 6.8, 6.2, 2H, -CH2NHCOR), 2.90 (t, J = 7.2, 2H, -CH2CO), 2.53 (t, J = 7.2, 2H, -CH2S), 2.54 (t, J 
= 7.4, 2H, -CH2S), 2.38 (t, J = 7.2, 2H, -CH2NMe2), 2.20 (s, 6H, -N(CH3)2), 1.85 -1.76 (m, 2H), 1.62 - 
1.50 (m, 6H), 1.45 - 1.20 (m, 18H), 0.87 (t, J = 6.8, 3H, -CH3). 
13C NMR (125 MHz, CDCl3): δ 199.5, 
160.2, 58.6, 45.4 (2C), 39.2, 36.7, 32.1, 31.9, 30.0, 29.5, 29.4 (2C), 29.3, 29.3, 29.2, 29.1, 28.4, 
27.6, 26.5, 23.2, 22.7, 14.1. HRMS (ESI) calc. for C23H46N2O2S [M+H]
+ 415.3352, found 415.3347. 
LC-MS (ESI) found 415.21 for [M+H]+. 
 
 
Experimental part   208 
 
N-(7-(3-(dimethylamino)propylthio)heptyl)-2-oxododecanamide (137). Compound 137 was 
synthesized following the general procedure for amide formation (method B) on 0.21 mmol 
amine 111. Yield = 33% (light brown solid). Rf = 0.27 (5% MeOH/DCM). IR: 1720 cm
-1 (ketone, 
C=O), 1657 cm-1 (amide, C=O). 1H NMR (400 MHz, CDCl3): δ  6.94 (t, J = 5.8, 1H, NH), 3.27 (ddd, J 
= 6.8, 6.8, 6.0, 2H, -CH2NHCOR), 2.90 (t, J = 7.2, 2H, -CH2CO), 2.53 (t, J = 7.4, 2H, -CH2S), 2.49 (t, J 
= 7.4, 2H, -CH2S), 2.45 (t, J = 7.4, 2H, -CH2NMe2), 2.29 (s, 6H, -N(CH3)2), 1.84 -1.75 (m, 2H), 1.64 - 
1.48 (m, 6H), 1.43 - 1.18 (m, 20H), 0.87 (t, J = 6.8, 3H, -CH3). 
13C NMR (125 MHz, CDCl3): δ 199.5, 
160.1, 58.4, 45.1 (2C), 39.2, 36.7, 32.1, 31.8, 29.9, 29.5, 29.5, 29.4, 29.3, 29.3, 29.2, 29.0, 28.8, 
28.7, 27.2, 26.7, 23.2, 22.6, 14.1. HRMS (ESI) calc. for C24H48N2O2S [M+H]
+ 429.3509, found 
429.3503. LC-MS (ESI) found 429.23 for [M+H]+. 
 
 
N-(6-(3-(dimethylamino)propylsulfonyl)hexyl)-2-oxododecanamide (138). Compound 138 was 
synthesized following the general procedure for oxidation into sulfone using 0.06 mmol of 
sulfide derivative 136, reaction time 24 hours. Purification by reverse phase chromatography 
using RPC18 column (eluent 0 – 100 % MeOH). Yield= 52% (white semi-solid). Rf = 0.57 
(EtOAc/AcOH/ MeOH/H2O 3/3/3/2). IR: 1717 cm
-1 (ketone, C=O), 1659 cm-1 (amide, C=O), 1293 
cm-1 (SO2, asym. strectch), 1122 cm
-1 (SO2, sym. strectch). 
1H NMR (400 MHz, CDCl3): δ 6.96 (t, J = 
5.8, 1H, NH), 3.28 (ddd, J = 6.8, 6.8, 6.0, 2H, -CH2NHCOR), 3.05- 2.99 (m, 2H, -CH2SO2), 2.98 - 2.93 
(m, 2H, -CH2SO2), 2.90 (t, J = 7.4, 2H, -CH2CO), 2.47 (t, J = 6.8, 2H, -CH2NMe2), 2.26 (s, 6H, -
N(CH3)2), 2.06 - 1.97 (m, 2H), 1.89 - 1.79 (m, 2H), 1.65 -1.16 (m, 22H), 0.87 (t, J = 6.8, 3H, -CH3). 
13C NMR (125 MHz, CDCl3): δ 199.4, 160.1, 57.2, 52.8, 50.4, 44.7 (2C), 38.9, 38.7, 31.9, 29.5, 29.4, 
29.3, 29.3, 29.0, 28.9, 28.0, 26.2, 23.1, 22.6, 21.8, 19.4, 14.1. HRMS (ESI) calc. for C23H46N2O4S 
[M+H]+ 447.3251, found 447.3246, [M+Na]+ 469.3070, found 469.3062. LC-MS (ESI) found 
447.28 for [M+H]+. 
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2.13 Synthesis of -keto CF2CF3/CF3 candidate inhibitors  
 
 
 
3-(3-(Dimethylamino)propylthio)propanoic acid (139). Compound 139 was synthesized 
following the general procedure for ester saponification on 11.4 mmol of ethyl ester 114. White 
solid. Rf = 0.51 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1721 cm
-1 (C=O). 1H NMR (400 MHz, 
CDCl3): δ 3.21 – 3.15 (m, 2H, -CH2COOH), 2.89 - 2.86 (m, 2H, -CH2NMe2), 2.85 (s, 6H, N(CH3)2), 
2.74 – 2.64 (m, 4H, -CH2S), 2.20 – 2.10 (m, 2H). 
13C NMR (125 MHz, CDCl3): δ 174.1, 56.8, 43.3 
(2C), 35.2, 29.2, 27.6, 24.2. HRMS (ESI) calc. for C8H17NO2S [M+H]
+ 192.1052, found 192.1052. LC-
MS (ESI) found 192.00 for [M+H]+. 
 
 
4-(3-(Dimethylamino)propylthio)butanoic acid (140). Compound 140 was synthesized following 
the general procedure for ester saponification on 6.5 mmol of ethyl ester 50. White solid. Rf = 
0.54 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1715 cm
-1 (C=O). 1H NMR (400 MHz, CDCl3): δ 3.20 – 
3.15 (m, 2H, -CH2COOH), 2.85 (s, 6H, N(CH3)2), 2.63 (t, J = 6.8, 2H, -CH2S), 2.62 (t, J = 7.0, 2H, -
CH2S), 2.48 (t, J = 7.0, 2H, -CH2NMe2), 2.20 – 2.11 (m, 2H), 1.97 – 1.87 (m, 2H). 
13C NMR (125 
MHz, CDCl3): δ 175.8, 56.9, 43.2, 32.7, 30.5, 28.3, 24.2, 23.8. HRMS (ESI) calc. for C9H19NO2S 
[M+H]+ 206.1209,  found 206.1209. LC-MS (ESI) found 206.01 for [M+H]+. 
 
 
5-(3-(Dimethylamino)propylthio)pentanoic acid (141). Compound 141 was synthesized 
following the general procedure for ester saponification on 2.65 mmol of ethyl ester 51. Yellow 
solid. Rf = 0.58 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1722 cm
-1 (C=O). 1H NMR (400 MHz, 
CDCl3): δ 3.23 – 3.14 (m, 2H, -CH2COOH), 2.86 (s, 6H, N(CH3)2), 2.61 (t, J = 6.6, 2H, -CH2S), 2.57 (t, 
J = 6.8, 2H, -CH2S), 2.38 (t, J = 6.8, 2H, -CH2NMe2), 2.19 – 2.08 (m, 2H), 1.82 – 1.74 (m, 2H), 1.71 – 
1.63 (m, 2H). 13C NMR (125 MHz, CDCl3): δ 176.5, 57.2, 43.4 (2C), 33.4, 31.4, 28.9, 28.6, 24.2, 
23.2. HRMS (ESI) calc. for C10H21NO2S [M+H]
+ 220.1365, found 220.1365. LC-MS (ESI) found 
220.03 for [M+H]+. 
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6-(3-(Dimethylamino)propylthio)hexanoic acid (142). Compound 142 was synthesized following 
the general procedure for ester saponification on 5.7 mmol of ethyl ester 115. Yellow solid. Rf = 
0.61 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1729 cm
-1 (C=O). 1H NMR (400 MHz, CDCl3): δ 3.19 – 
3.13 (m, 2H, -CH2COOH), 2.84 (s, 6H, N(CH3)2), 2.61 (t, J = 6.8, 2H, -CH2S), 2.55 (t, J = 7.0, 2H, -
CH2S), 2.36 (t, J = 7.0, 2H, -CH2NMe2), 2.19 – 2.10 (m, 2H), 1.73 – 1.57 (m, 4H), 1.52 – 1.44 (m, 
2H). 13C NMR (125 MHz, CDCl3): δ 176.9, 57.1, 43.2 (2C), 33.7, 31.8, 28.7, 28.7, 27.7, 24.2, 24.0. 
HRMS (ESI) calc. for C11H23NO2S [M+H]
+ 234.1522, found 234.1522. LC-MS (ESI) found 234.05 for 
[M+H]+.  
 
7-(3-(Dimethylamino)propylthio)heptanoic acid (143). Compound 143 was synthesized 
following the general procedure for ester saponification on 5.6 mmol of ethyl ester 108. Yellow 
solid. Rf = 0.71 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1722 cm
-1 (C=O).  1H NMR (400 MHz, 
CDCl3): δ 3.22 – 3.16 (m, 2H, -CH2COOH), 2.88 (s, 6H, N(CH3)2), 2.62 (t, J = 7.0, 2H, -CH2S), 2.56 (t, 
J = 7.4, 2H, -CH2S), 2.37 (t, J = 6.8, 2H, -CH2NMe2), 2.25 – 2.23 (m, 2H), 1.71 - 1.59 (m, 4H), 1.51 - 
1.36 (m, 4H). 13C NMR (125 MHz, CDCl3): δ 176.9, 57.2, 43.4 (2C), 33.7, 30.8, 28.6, 28.2, 27.5, 
27.2, 24.1, 23.9. HRMS (ESI) calc. for C12H25NO2S [M+H]
+ 248.1678, found 248.1679. LC-MS (ESI) 
found 248.04 for [M+H]+.  
 
5-(3-(Dimethylamino)propylthio)-1,1,1-trifluoropentan-2-one (145). Compound 145 was 
synthesized following the general procedure for keto-CF3 formation on 0.77 mmol of carboxylic 
acid 140. Yield = 52% (over 2 steps, starting from ester 50, as yellow oil). Rf = 0.71 
(AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1762 cm
-1 (C=O). 1H NMR (400 MHz, CDCl3): δ 2.86 (t, J = 
6.8, 2H, -CH2COCF3), 2.57 (t, J = 6.8, 2H, -CH2S), 2.52 (t, J = 7.4, 2H, -CH2S), 2.37 (t, J = 7.4, 2H, -
CH2NMe2), 2.24 (s, 6H, N(CH3)2), 2.02 – 1.93 (m, 2H), 1.79 – 1.70 (m, 2H). 
13C NMR (125 MHz, 
CDCl3): δ 191.0 (q, CO, J
2 (C-F) = 35Hz), 115.5 (q, CF3, J
1 (C-F)= 290Hz), 58.4, 45.3 (2C), 34.9, 30.8, 
29.5, 27.2, 21.9. 19F NMR (377 MHz, CDCl3): δ -79.6 (s). HRMS (ESI) calc. for C10H18F3NOS [M+H]
+  
258.1134, found  258.1135. GCMS found 257 for [M+.]. 
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6-(3-(Dimethylamino)propylthio)-1,1,1-trifluorohexan-2-one (146). Compound 146 was 
synthesized following the general procedure for keto-CF3 formation on 0.68 mmol of carboxylic 
acid 141. Yield = 53% (over 2 steps, starting from ester 51, as yellow oil). Rf = 0.72 
(AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1762 cm
-1 (C=O). 1H NMR (400 MHz, CDCl3): δ 2.74 (t, J = 
7.2, 2H, -CH2COCF3), 2.53 (2*t, J = 7.2, 4H, -CH2S), 2.35 (t, J = 7.2, 2H, -CH2NMe2), 2.22 (s, 6H, 
N(CH3)2), 1.84 -1.70 (m, 6H), 1.67 - 1.60 (m, 2H).
 13C NMR (125 MHz, CDCl3): δ 191.1 (q, CO, J
2 (C-
F) = 34.7 Hz), 115.4 (q, CF3, J
1 (C-F)= 290 Hz), 58.5, 45.3 (2C), 35.8, 31.5, 29.9, 28.4, 27.4, 21.4. 19F 
NMR (377 MHz, CDCl3): δ - 79.7 (s, CF3). HRMS (ESI) calc. for C11H20F3NOS [M+H]
+ 272.1290, 
found  272.1292. GCMS found 271 for [M+.]. 
 
 
7-(3-(Dimethylamino)propylthio)-1,1,1-trifluoroheptan-2-one (147). Compound 147 was 
synthesized following the general procedure for keto-CF3 formation on 0.67 mmol of carboxylic 
acid 142. Yield = 52% (over 2 steps, starting from ester 115, as yellow oil). Rf = 0.67 
(AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1762 cm
-1 (C=O). 1H NMR (400 MHz, CDCl3): δ  2.72 (t, J = 
7.4, 2H, -CH2COCF3), 2.54 (t, J = 7.2, 2H, -CH2S), 2.52 (t, J = 7.2, 2H, -CH2S), 2.37 (t, J = 7.2, 2H, -
CH2NMe2), 2.24 (s, 6H, N(CH3)2), 1.81 – 1.57 (m, 6H), 1.49 - 1.39 (m, 2H).
 13C NMR (125 MHz, 
CDCl3): δ 191.3 (q, CO, J
2 (C-F) = 34.7 Hz), 115.48 (q, CF3, J
1 (C-F)= 290 Hz), 58.5, 45.2 (2C), 36.2, 
31.7, 29.9, 29.1, 27.8, 27.4, 21.9. 19F NMR (377 MHz, CDCl3): δ - 79.7 (s, CF3). HRMS (ESI) calc. for 
C12H22F3NOS [M+H]
+ 286.1447, found 286.1449. GCMS found 285 for [M+.]. 
 
 
8-(3-(Dimethylamino)propylthio)-1,1,1-trifluorooctan-2-one (148). Compound 148 was 
synthesized following the general procedure for keto-CF3 formation on 0.63 mmol of carboxylic 
acid 143. Yield = 45% (over 2 steps, starting from ester 108, as yellow oil). Rf = 0.73 
(AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1762 cm
-1 (C=O). 1H NMR (400 MHz, CDCl3): δ 2.70 (t, J = 
7.2, 2H, -CH2COCF3), 2.53 (t, J = 7.4, 2H, -CH2S), 2.51 (t, J = 7.4, 2H, -CH2S), 2.35 (t, J = 7.4, 2H, -
CH2NMe2), 2.23 (s, 6H, N(CH3)2), 1.79 – 1.53 (m, 6H), 1.46 - 1.26 (m, 4H).
 13C NMR (125 MHz, 
CDCl3): δ 191.4 (q, CO, J
2 (C-F) = 34.6Hz), 115.5 (q, CF3, J
1 (C-F)= 290 Hz), 58.5, 45.2 (2C), 36.2, 
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31.9, 29.9, 29.2, 28.3, 28.2, 27.3, 22.1. 19F NMR (377 MHz, CDCl3): δ - 79.7 (s, CF3). HRMS (ESI) 
calc. for C13H24F3NOS [M+H]
+ 300.1603, found 300.1606. GCMS found 299 for [M+.]. 
 
 
6-(3-(Dimethylamino)propylthio)-1,1,1,2,2-pentafluorohexan-3-one (150). Compound 150 was 
synthesized following the general procedure for keto-CF2CF3 formation on 0.77 mmol of 
carboxylic acid 140. Yield = 46% (over 2 steps, starting from ester 50, as a yellow-brown oil). Rf = 
0.74 (AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1753 cm
-1 (C=O).  1H NMR (400 MHz, CDCl3): δ 2.89 
(t, J = 7.0, 2H, -CH2COCF2CF3), 2.56 (t, J = 7.0, 2H, -CH2S), 2.52 (t, J = 7.4, 2H, -CH2S), 2.38 (t, J = 
7.2, 2H, -CH2NMe2), 2.25 (s, 6H, N(CH3)2), 2.02 – 1.91 (m, 2H), 1.81 – 1.70 (m, 2H). 
13C NMR (125 
MHz, CDCl3): δ 193.9 (t, CO, J = 26.4), 117.7 (q of t, CF3, J=34Hz, J=283 Hz), 106.8 (t of q, CF2, 
J=265 Hz, J=37.8 Hz), 58.3, 45.1(2C), 35.9, 30.7, 29.4, 27.0, 21.9. 19F NMR (377 MHz, CDCl3): δ -
82.3 (s, CF3), -123.5 (s, CF2). HRMS (ESI) calc. for C11H18F5NOS [M+H]
+ 308.1102, found 308.1104. 
GCMS found 307 for [M+.]. 
 
 
7-(3-(Dimethylamino)propylthio)-1,1,1,2,2-pentafluoroheptan-3-one (151). Compound 151 was 
synthesized following the general procedure for keto-CF2CF3 formation on 0.68 mmol of 
carboxylic acid 141. Yield = 51% (over 2 steps, starting from ester 51, as yellow oil). Rf = 0.72 
(AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1754 cm
-1 (C=O). 1H NMR (400 MHz, CDCl3): δ 2.78 (t, J = 
7.0, 2H, -CH2COCF2CF3), 2.54 (t, J = 7.4, 2H, -CH2S), 2.53 (t, J = 7.2, 2H, -CH2S), 2.36 (t, J = 7.2, 2H, -
CH2NMe2), 2.23 (s, 6H, N(CH3)2), 1.84 -1.71 (m, 4H), 1.67 - 1.59 (m, 2H). 
13C NMR (125 MHz, 
CDCl3): δ 193.9 (t, CO, J = 26.4Hz), 117.7 (q of t, CF3, J = 33.9 Hz, J = 285 Hz), 106.8 (t of q, CF2, J = 
265Hz, J = 37.9 Hz), 58.5, 45.3, 36.8, 31.5, 29.9, 28.4, 27.4, 21.4. 19F NMR (377 MHz, CDCl3): δ - 
82.3 (s, CF3), -127.7 (s, CF2). HRMS (ESI) calc. for C12H20F5NOS [M+H]
+ 322.1258, found 322.1261. 
GCMS found 321 for [M+.]. 
 
 
8-(3-(Dimethylamino)propylthio)-1,1,1,2,2-pentafluorooctan-3-one (152). Compound 152 was 
synthesized following the general procedure for keto-CF2CF3 formation on 0.67 mmol of 
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carboxylic acid 142. Yield = 46% (over 2 steps, starting from ester 115, as yellow oil). Rf = 0.74 
(AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1754 cm
-1 (C=O). 1H NMR (400 MHz, CDCl3): δ 2.75 (t, J = 
7.0, 2H, -CH2COCF2CF3), 2.53 (t, J = 7.2, 2H, -CH2S), 2.51 (t, J = 7.2, 2H, -CH2S), 2.36 (t, J = 7.2, 2H, -
CH2NMe2), 2.23 (s, 6H, N(CH3)2), 1.79 – 1.56 (m, 6H), 1.46 - 1.38 (m, 2H). 
13C NMR (125 MHz, 
CDCl3): δ 194.2 (t, CO, J = 26.2Hz), 117.7 (q of t, CF3, J = 34 Hz, J = 285 Hz), 106.8 (t of q, CF2, J = 
37.8 Hz, J = 265Hz), 58.5, 45.2 (2C), 37.2, 31.7, 29.9, 29.1, 27.8, 27.4, 21.9. 19F NMR (377 MHz, 
CDCl3): δ - 82.3 (s, CF3), -123.7 (s, CF2). HRMS (ESI) calc. for C13H22F5NOS  [M+H]
+ 336.1415, found 
336.1416. GCMS found 335 for [M+.]. 
 
 
9-(3-(Dimethylamino)propylthio)-1,1,1,2,2-pentafluorononan-3-one (153). Compound 153 was 
synthesized following the general procedure for keto-CF2CF3 formation on 0.63 mmol of 
carboxylic acid 143. Yield = 45% (over 2 steps, starting from ester 108, as yellow oil). Rf = 0.80 
(AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1754 cm
-1 (C=O). 1H NMR (400 MHz, CDCl3): δ 2.75 (t, J = 
7.0, 2H, -CH2COCF2CF3), 2.54 (t, J = 7.4, 2H, -CH2S), 2.51 (t, J = 7.2, 2H, -CH2S), 2.36 (t, J = 7.4, 2H, -
CH2NMe2), 2.23 (s, 6H, N(CH3)2), 1.80 – 1.54 (m, 6H), 1.45 - 1.28 (m, 4H). 
13C NMR (125 MHz, 
CDCl3): δ 194.3 (t, CO, J = 26.1 Hz), 117.7 (q of t, CF3, J = 34 Hz, J = 285 Hz), 106.8 (t of q, CF2, J = 
37.8 Hz, J = 265 Hz), 58.6, 45.3 (2C), 37.2, 31.9, 29.9, 29.2, 28.3, 28.2, 27.5, 22.1. 19F NMR (377 
MHz, CDCl3): δ -82.3 (s, CF3), -123.7 (s, CF2). HRMS (ESI) calc. for C14H24F5NOS  [M+H]
+ 350.1571,  
found 350.1573. GCMS found 349 for [M+.]. 
 
 
8-(3-(Dimethylamino)propylsulfonyl)-1,1,1-trifluorooctan-2-one (154). Compound 154 was 
synthesized following the general procedure for oxidation into sulfone using 0.104 mmol of the 
sulfide derivative 148, reaction time 24 hours. Purification by reverse phase chromatography 
using RPC18 column (eluent 0 – 100 % MeOH). Yield = 35% (light brown semi-solid). Rf = 0.48 
(AcOH/EtOAc/MeOH/H2O 3/3/3/2). IR: 1763 cm
-1 (C=O), 1278 cm-1 (SO2 asym. stretch), 1130 cm
-1 
(SO2 sym. stretch).  
1H NMR (400 MHz, CDCl3): δ 3.06 – 3.00 (m, 2H, -CH2SO2), 2.98 – 2.92 (m, 2H, 
-CH2SO2), 2.72 (t, J = 7.2, 2H, -CH2COCF2CF3), 2.41 (t, J = 6.8, 2H, -CH2NMe2), 2.23 (s, 6H, N(CH3)2), 
2.04 - 1.95 (m, 2H), 1.90 -1.81 (m, 2H), 1.76 – 1.63 (m, 2H), 1.53 - 1.34 (m, 4H). 13C NMR (125 
MHz, CDCl3): δ 191.3 (q, CO, J = 34.8 Hz), 115.5 (q, CF3, J = 290Hz), 57.4, 52.8, 50.4, 45.0 (2C), 
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36.1, 28.2, 28.1, 21.9, 21.7, 19.6. 19F NMR (377 MHz, CDCl3): δ - 79.7 (s, CF3). HRMS (ESI) calc. for 
C13H24F3NO3S [M+H]
+  332.1502, found 332.1505. GCMS found 331 for [M+.]. 
 
2.14 Synthesis of -keto oxazole candidate inhibitors 
 
 
 
Methyl isocyanide (157).54 In a four neck round bottom flask equipped with a 100 ml pressure –
equalizing dropping funnel, a egg-shaped stirring bar, a thermometer and a receiver trap, was 
added quinoline (413 ml, 3.43 mol, 4.0 eqv.) and p-toluenesulfonyl chloride (250 g, 1.29 mol, 1.5 
eqv.). The solution was heated at 85°C and the system evacuated to a pressure of 20 mbar. The 
receiver was cooled in a bath of liquid nitrigen. While the solution was vigorously stirred and 
maintained at 85°C, N-methylformamide (51 ml, 85 mmol, 1.0 eqv.) was added dropwise in 
order to keep a smooth distillation rate. The addition was completed in 25 minutes. The material 
which was collected in the receiver was distilled through a 15 cm vigreux column at atmospheric 
pressure. Methyl isocyanide 157 was collected, as a slight yellow liquid at 62°C in a 76% yield. 1H 
NMR (400 MHz, CDCl3): δ 3.05, 3.045, 3.04 (3s, 3H). 
13C NMR (125 MHz, CDCl3): δ 156.9, 156.8, 
156.8 (3C), 21.2, 27.1, 27.0 (3C).  
 
N,N-dimethyl-3-((4-tosyl-4,5-dihydrooxazol-5-yl)methylthio)propan-1-amine (155).55 To a 3 ml 
sealed glass-vial of equipped with a stirring bar was added aldehyde 54 (55.6 mg, 0.29 mmol, 1.0 
eqv.) and K2CO3 (124.5 mg, 0.88 mmol, 3.0 eqv.) in acetonitrile (1.5 ml). TosMIC (61 mg, 0.29 
mmol, 1.0 eqv.) was subsequently added to the reaction mixture which was heated under reflux 
(T=85°C) for 8 hours. After concentration under reduced pressure, compound 155 was obtained 
in 45% yield. 1H NMR (400 MHz, CDCl3): δ 7.81 (d, J = 8.3, 2H), 7.37 (d, J = 7.9, 2H), 6.97 (d, J = 
1.6, 1H), 5.05 (dd, J = 5.9, 12.6, 1H), 4.77 (dd, J = 1.7, 5.8, 1H), 2.59-2.49 (m, 2H), 2.45 (s, 3H, -
CH3), 2.37- 2.28 (m, 4H), 2.21 (s, 6H), 1.84 – 1.62 (m, 6H). 
13C NMR (125 MHz, CDCl3): δ 159.3, 
145.4, 133.0, 129.7, 129.4, 89.7, 78.5, 58.4, 45.3 (2C), 33.9, 31.4, 29.8, 27.5, 24.4, 21.6.  
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N,N-dimethyl-3-(3-(oxazol-5-yl)propylthiol)propan-1-amine (156).56 In a two neck round 
bottom flask equipped with a egg-shaped stirring bar was dissolved aldehyde 54 (203.3 mg, 1.07 
mmol, 1.0 eqv.) into dry MeOH (10 ml). Tosylmethyl isocyanide (215.4 mg, 1.08 mmol, 1.0 eqv.) 
followed by K2CO3 (156.6 mg, 1.11 mmol, 1.0 eqv.) were added to the reaction mixture which 
was heated 1 hour under reflux (T=85°C). A solution of KOH (1.0459 g, 15.84 mmol, 14.8 eqv.) in 
MeOH (14 ml) was subsequently added to the reaction mixture which was stirred under reflux 
for 3 hours (T= 85°C). The reaction was cooled to rt and diluted with water (100 ml) and EtOAc 
(100 ml). The aqueous layer was extracted with EtOAc (2×100 ml) and the combined organic 
extracts were dried over anhydrous MgSO4 and concentrated under reduced pressure. The 
residue was purified by flash chromatography using as eluent 10/90 MeOH/DCM. Yield = 16% 
(clear yellow oil). Rf = 0.43 (EtOAc/AcOH/MeOH/H2O 3/3/3/2). 
1H NMR (400 MHz, CDCl3): δ 7.76 
(s, 1H, H-C=N), 6.78 (t, J = 0.8, 1H, H-C=C), 2.79 (dt, J = 7.4, 0.8, 2H, -CH2-C=C), 2.56 (t, J = 7.2, 2H, 
-CH2S), 2.55 (t, J = 7.4, 2H,-CH2S), 2.38 (t, J = 7.2, 2H, -CH2NMe2), 2.25 (s, 6H, N(CH3)2), 1.96 - 1.88 
(m, 2H), 1.79 - 1.70 (m, 2H). 13C NMR (125 MHz, CDCl3): δ 152.3, 145.1, 122.5, 58.7, 45.5 (2C), 
31.5, 30.1, 27.7, 27.6, 24.5. HRMS (ESI) calc. for C11H20N2OS [M+H]
+ 229.1369, found  229.1368. 
GCMS found 228 for [M+.]. 
 
N,N-dimethyl-3-(3-(oxazol-5-yl)propylthiol)propan-1-amine (156).55,57 To a two neck round 
bottom flask equipped with a egg-shaped stirring bar was added aldehyde 54 (201.3 mg, 1.05 
mmol, 1.0 eqv.) into dry MeOH (10 ml). A solution of NaOMe (6.48 mmol, 149 mg in 7.5 ml of 
dry MeOH, 6.2 eqv.) followed by tosylmethyl isocyanide (256.2 mg, 1.28 mmol, 1.2 eqv.) was 
added to the reaction mixture which was heated under reflux (T=110°C) for 12 hours. The 
reaction was cooled to rt and concentrated under reduced pressure. The residue was diluted 
with water (10 ml) and extracted with several portion of CHCl3 (2×10 ml). The combined organic 
layers were dried over anhydrous MgSO4, and concentrated under reduced pressure. The 
residue was purified by flash chromatography using as eluent 10/90 MeOH/DCM. Yield = 30% 
(clear yellow oil). Rf = 0.43 (EtOAc/AcOH/MeOH/H2O 3/3/3/2). 
1H NMR (400 MHz, CDCl3): δ 7.75 
(s, 1H, H-C=N), 6.77 (t, J = 0.8, 1H, H-C=C), 2.78 (dt, J = 7.4, 0.8, 2H, -CH2-C=C), 2.55 (t, J = 7.4, 2H, 
-CH2S), 2.55 (t, J = 7.4, 2H,-CH2S), 2.38 (t, J = 7.4, 2H, -CH2NMe2), 2.24 (s, 6H, N(CH3)2), 1.96 - 1.88 
(m, 2H), 1.79 - 1.70 (m, 2H). Characterization conformed to the one obtained using the previous 
method.   
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N,N-dimethyl-3-(2-(oxazol-5-yl)ethylthio)propan-1-amine (158). Compound 158 was 
synthesized following the general procedure for the C5-substituted oxazole formation on 4.3 
mmol of ester 114. Yield = 84% (yellow oil). Rf= 0.42 (EtOAc/AcOH/MeOH/H2O 3/3/3/2). 
1H NMR 
(400 MHz, CDCl3): δ 7.71 (s, 1H, H-C=N), 6.77 (t, J = 0.8, 1H, H-C=C), 2.81 - 2.97 (m, 2H, -CH2-C=C), 
2.76 - 2.71 (m, 2H, -CH2S), 2.49 (t, J = 7.4, 2H, -CH2S), 2.26 (t, J = 7.2, 2H, -CH2NMe2), 2.14 (s, 6H, 
N(CH3)2), 1.67 (dd, J = 7.4, 7.2, 2H). 
13C NMR (125 MHz, CDCl3): δ 150.9, 150.1, 122.6, 58.3, 45.3, 
29.9, 29.4, 27.5, 26.1. HRMS (ESI) calc. for C10H18N2OS [M+H]
+ 215.1213, found 215.1211. GCMS 
found 214 for [M+.].  
 
 
N,N-dimethyl-3-(3-(oxazol-5-yl)propylthiol)propan-1-amine (156). Compound 156 was 
synthesized following the general procedure for the C5-substituted oxazole formation on 5.8 
mmol of ester 50 (no purification needed). Yield = 95% (yellow oil). Rf = 0.43 
(EtOAc/AcOH/MeOH/H2O 3/3/3/2). 
1H NMR (400 MHz, CDCl3): δ 7.73 (s, 1H, H-C=N), 6.74 (t, J = 
0.8, 1H, H-C=C), 2.75 (dt, J = 7.4, 0.8, 2H, -CH2-C=C), 2.55 (t, J = 7.2, 2H, -CH2S), 2.54 (t, J = 7.2, 
2H,-CH2S), 2.30 (t, J = 7.2, 2H, -CH2NMe2), 2.17 (s, 6H, N(CH3)2), 1.96 - 1.84 (m, 2H), 1.79 - 1.65 
(m, 2H). 13C NMR (125 MHz, CDCl3): δ 151.7, 149.8, 121.8, 58.1, 45.0 (2C), 30.8, 29.5, 27.3, 27.0, 
23.9. HRMS (ESI) calc. for C11H20N2OS [M+H]
+ 229.1369, found  229.1368. GCMS found 228 for 
[M+.]. 
 
 
N,N-dimethyl-3-(4-(oxazol-5-yl)butylthio)propan-1-amine (159). Compound 159 was 
synthesized following the general procedure for the C5-substituted oxazole formation on 14 
mmol of ester 51 (no purification needed). Yield = 94% (orange oil). Rf = 0.47 
(EtOAc/AcOH/MeOH/H2O 3/3/3/2). 
1H NMR (400 MHz, CDCl3): δ  7.74 (s, 1H, H-C=N), 6.75 (t, J = 
0.8, 1H, H-C=C), 2.66 (dt, J = 7.6, 0.8, 2H, -CH2-C=C), 2.52 (t, J = 7.2, 2H, -CH2S), 2.51 (t, J = 7.4, 2H, 
-CH2S), 2.32 (t, J = 7.2, 2H, -CH2NMe2), 2.20 (s, 6H, N(CH3)2), 1.74 – 1.64 (m, 4H), 1.62 – 1.54 (m, 
2H). 13C NMR (125 MHz, CDCl3): δ 152.5, 149.9, 121.9, 58.5, 45.3 (2C), 31.6, 29.9, 28.8, 27.6, 
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26.6, 24.8. HRMS (ESI) calc. for C12H22N2OS [M+H]
+ 243.1526, found  243.1526. GCMS found 242 
for [M+.]. 
 
 
N,N-dimethyl-3-(5-(oxazol-5-yl)pentylthio)propan-1-amine (160). Compound 160 was 
synthesized following the general procedure for the C5-substituted oxazole formation on 3.9 
mmol of ester 115. Yield = 90% (orange oil). Rf= 0.50 (EtOAc/AcOH/MeOH/H2O 3/3/3/2). 
1H NMR 
(400 MHz, CDCl3): δ  7.73 (s, 1H, H-C=N), 6.73 (t, J = 0.8, 1H, H-C=C), 2.64 (dt, J = 7.6, 0.8, 2H, -
CH2-C=C), 2.51 (t, J = 7.6, 2H, -CH2S), 2.49 (t, J = 7.6, 2H, -CH2S), 2.32 (t, J = 7.4, 2H, -CH2NMe2), 
2.19 (s, 6H, N(CH3)2), 1.74 – 1.51 (m, 6H), 1.45 - 1.34 (m, 2H). 
13C NMR (125 MHz, CDCl3): δ 152.7, 
149.8, 121.7, 58.5, 45.3 (2C), 31.9, 29.9, 29.1, 28.1, 27.6, 27.0, 25.1. HRMS (ESI) calc. for 
C13H24N2OS [M+H]
+ 257.1682, found  257.1682. GCMS found 256 for [M+.] 
 
 
N,N-dimethyl-3-(6-(oxazol-5-yl)hexylthio)propan-1-amine (161) . Compound 161 was 
synthesized following the general procedure for the C5-substituted oxazole formation on 9.8 
mmol of ester 108 (no purification needed). Yield = 92% (orange oil). Rf = 0.50 
(EtOAc/AcOH/MeOH/H2O 3/3/3/2). 
1H NMR (400 MHz, CDCl3): δ  7.70 (s, 1H, H-C=N), 6.69 (t, J = 
0.8, 1H, H-C=C), 2.59 (dt, J = 7.6, 0.8, 2H, -CH2-C=C), 2.47 (t, J = 7.4, 2H, -CH2S), 2.45 (t, J = 7.4, 2H, 
-CH2S), 2.29 (t, J = 7.2, 2H, -CH2NMe2), 2.16 (s, 6H, N(CH3)2), 1.73-1.47 (m, 6H), 1.40 – 1.25 (m, 
4H). 13C NMR (125 MHz, CDCl3): δ  152.9, 149.8,  121.7,  58.6,  45.4 (2C),  32.0,  29.9,  29.4,  28.5,  
28.4,  27.7,  27.3,  25.2.  HRMS (ESI) calc. for C14H26N2OS [M+H]
+ 271.1839, found 271.1840. 
GCMS found 270 for [M+.]. 
 
 
N-methoxy-N-methyldodecanamide (162). Compound 162 was synthesized following the 
general procedure for Weinreb amide synthesis using 115 mmol of acyl chloride (dodecanoyl 
chloride). Yield = 98% (colorless oil). Rf= 0.71 (EtOAc/cyclohexane 1/1). IR: 1668 cm
-1 (amine C=O 
stretch), 2922 -2853 cm-1 (amine N-H stretch). 1H NMR (400 MHz, CDCl3): δ 3.64 (s, 3H, OCH3), 
3.16 (s, 3H, -NCH3), 2.37 (t, J = 7.4, 2H, -CH2CO), 1.62 – 1.56 (m, 2H), 1.34 - 1.13 (m, 16H), 0.83 (t, 
J = 6.6, 3H, CH3). 
13C NMR (125 MHz, CDCl3): δ  174.7, 61.0, 31.8, 29.5 (4C), 29.4, 29.3 (2C), 29.2, 
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24.5, 22.6, 13.9. HRMS (ESI) calc. For C14H29NO2 [M+H]
+ 244.2271, found 244.2270. GCMS found 
243 for [M+.].  
 
 
N-methoxy-N-methyloctanamide (163). Compound 163 was synthesized following the general 
procedure for Weinreb amide synthesis using 164 mmol of acyl chloride (octanoyl chloride). 
Yield = 94% (colorless oil). Rf = 0.67 (EtOAc/cyclohexane 1/1). IR: 1665 cm
-1 (amine C=O stretch), 
2955-2855 cm-1 (amine N-H stretch). 1H NMR (400 MHz, CDCl3): δ 3.64 (s, 3H, OCH3), 3.14 (s, 3H, 
-NCH3), 2.37 (t, J = 7.6, 2H, -CH2CO), 1.62 – 1.55 (m, 2H), 1.34 – 1.19 (m, 8H), 0.84 (t, J = 7.4, 3H, 
CH3). 
13C NMR (125 MHz, CDCl3): δ 174.7, 61.1, 32.1, 31.8, 31.6, 29.3, 29.0, 24.5, 22.5, 13.9. 
HRMS (ESI) calc. for C10H21NO2 [M+H]
+ 188.1645, found 188.1641. GCMS found 187 for [M+.]. 
 
 
1-(5-(2-(3-(Dimethylamino)propylthio)ethyl)oxazol-2-yl)dodecan-1-one (164). Compound 164 
was synthesized following the general procedure for oxazole C2-functionalization using 9.8 
mmol of Weinreb amide 162. Yield = 24% (orange oil). Rf = 0.74 (EtOAc/AcOH/MeOH/H2O 
3/3/3/2). IR: 1699 cm-1 (ketone C=O stretch). 1H NMR (400 MHz, CDCl3): δ  7.01 (t, J = 0.8, 1H, H-
C=C), 2.99 (t, J = 7.0, 2H, -CH2CO), 2.98 (t, J = 6.8, 2H, -CH2S), 2.83 (dt, J = 7.4, 0.8, 2H, -CH2-C=C), 
2.56 (t, J = 7.2, 2H, -CH2S), 2.34 (t, J = 7.2, 2H, -CH2NMe2), 2.22 (s, 6H, N(CH3)2), 1.78- 1.66 (m, 
4H), 1.39 – 1.14 (m, 16H), 0.86 (t, J = 6.8, 3H, -CH3). 
13C NMR (125 MHz, CDCl3): δ  188.5, 157.4, 
154.6, 125.5, 58.3, 45.3 (2C), 38.8, 31.9, 30.0, 29.7, 29.5 (2C), 29.4, 29.3, 29.3, 29.1, 27.4, 26.4, 
24.0, 22.6, 14.1. HRMS (ESI) calc. for C22H40N2O2S [M+H]
+ 397.2883, found  397.2873. LC-MS (ESI) 
found 397.23 for [M+H]+.  
 
1-(5-(3-(3-(Dimethylamino)propylthio)propyl)oxazol-2-yl)dodecan-1-one (165). Compound 165 
was synthesized following the general procedure for oxazole C2-functionalization using 8.6 
mmol of Weinreb amide 162. Yield = 37% (yellow oil). Rf = 0.64 (EtOAc/AcOH/MeOH/H2O 
3/3/3/2). IR: 1698 cm-1 (ketone C=O stretch). 1H NMR (400 MHz, CDCl3): δ  6.96 (t, J = 0.8, 1H, H-
C=C), 3.00 (t, J = 7.6, 2H, -CH2CO), 2.85 (dt, J = 7.2, 0.8, 2H, -CH2-C=C), 2.55 (t, J = 7.2, 2H, -CH2S), 
2.54 (t, J = 7.2, 2H, -CH2S), 2.39 (t, J = 7.2, 2H, -CH2NMe2), 2.25 (s, 6H, N(CH3)2), 2.01 – 1.92 (m, 
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2H), 1.82 – 1.75 (m, 2H), 1.74 – 1.67 (m, 2H), 1.43 - 1.16 (m, 16H), 0.85 (t, J = 6.8, 3H, -CH3). 
13C 
NMR (125 MHz, CDCl3): δ 188.5, 157.4, 155.8, 124.9, 58.3, 45.1 (2C), 38.8, 31.8, 31.2, 29.8, 29.5 
(2C), 29.4, 29.3, 29.3, 29.1, 27.3, 27.1, 24.6, 24.0, 22.6, 14.1. HRMS (EI) calc. for C23H42N2O2S [M
+.] 
410.2962, found 410.2951. GCMS found 410 for [M+.].  
 
 
1-(5-(4-(3-(Dimethylamino)propylthio)butyl)oxazol-2-yl)dodecan-1-one (166). Compound 166 
was synthesized following the general procedure for oxazole C2-functionalization using 8.4 
mmol of Weinreb amide 162. Yield = 29% (yellow oil). Rf= 0.71 (EtOAc/AcOH/MeOH/H2O 
3/3/3/2). IR: 1699 cm-1 (ketone C=O stretch). 1H NMR (400 MHz, CDCl3): δ  6.95 (t, J = 0.8, 1H, H-
C=C), 3.01 (t, J = 7.6, 2H, -CH2CO), 2.75 (dt, J = 7.6, 0.8, 2H, -CH2-C=C), 2.55 (t, J = 7.2, 2H, -CH2S), 
2.54 (t, J = 7.4, 2H, -CH2S), 2.43 (t, J = 7.0, 2H, -CH2NMe2), 2.28 (s, 6H, N(CH3)2), 1.84 – 1.59 (m, 
8H), 1.39 – 1.18 (m, 16H), 0.87 (t, J = 6.8, 3H, -CH3). 
13C NMR (125 MHz, CDCl3): δ 188.5, 157.3, 
156.4, 124.7, 58.4, 45.1 (2C), 38.8, 31.8, 31.6, 29.9, 29.5 (2C), 29.4, 29.3, 29.3, 29.1, 28.9, 27.3, 
26.5, 25.4, 24.0, 22.6, 14.1. HRMS (ESI) calc. for C24H44N2O2S [M+H]
+ 425.3196, found  425.3191. 
LC-MS (ESI) found 425.23 for [M+H]+.  
 
 
1-(5-(5-(3-(Dimethylamino)propylthio)pentyl)oxazol-2-yl)dodecan-1-one (167).  Compound 167 
was synthesized following the general procedure for oxazole C2-functionalization using 7.6 
mmol of Weinreb amide 162. Yield = 34% (yellow oil). Rf= 0.71 (EtOAc/AcOH/MeOH/H2O 
3/3/3/2). IR: 1699 cm-1 (ketone C=O stretch). 1H NMR (400 MHz, CDCl3): δ  6.93 (t, J = 0.8, 1H, H-
C=C), 3.00 (t, J = 7.4, 2H, -CH2CO), 2.72 (dt, J = 7.4, 0.8, 2H, -CH2-C=C), 2.52 (t, J = 7.4, 2H, -CH2S), 
2.50 (t, J = 7.4, 2H, -CH2S), 2.39 (t, J = 7.4, 2H, -CH2NMe2), 2.25 (s, 6H, N(CH3)2), 1.80 – 1.65 (m, 
6H), 1.64 – 1.55 (m, 2H), 1.49 – 1.39 (m, 2H), 1.37 – 1.19 (m, 16H), 0.86 (t, J = 6.8, 3H, -CH3).
13C 
NMR (125 MHz, CDCl3): δ 188.5, 157.2, 156.6, 124.6, 58.3, 45.0 (2C), 38.8, 31.9, 31.8, 29.9, 29.5 
(2C), 29.4, 29.3, 29.3, 29.1, 29.1, 28.2, 27.2, 26.9, 25.6, 24.0, 22.6, 14.1. HRMS (ESI) calc. for 
C25H46N2O2S [M+H]
+ 439.3353, found 439.3346. LC-MS (ESI) found 439.26 for [M+H]+. 
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1-(5-(6-(3-(Dimethylamino)propylthio)hexyl)oxazol-2-yl)dodecan-1-one (168). Compound 168 
was synthesized following the general procedure for oxazole C2-functionalization using 5.7 
mmol of Weinreb amide 162. Yield = 36% (yellow oil). Rf= 0.75 (EtOAc/AcOH/MeOH/H2O 
3/3/3/2). IR: 1698 cm-1 (ketone C=O stretch). 1H NMR (400 MHz, CDCl3): δ  6.91 (t, J = 0.8, 1H, H-
C=C), 2.99 (t, J = 7.4, 2H, -CH2CO), 2.70 (dt, J = 7.6, 0.8, 2H, -CH2-C=C), 2.52 (t, J = 7.2, 2H, -CH2S), 
2.48 (t, J = 7.2, 2H, -CH2S), 2.45 (t, J = 7.6, 2H, -CH2NMe2), 2.29 (s, 6H, N(CH3)2), 1.82 – 1.62 (m, 
6H), 1.60 – 1.50 (m, 2H), 1.43 – 1.17 (m, 20H), 0.85 (t, J = 6.6, 3H, -CH3). 
13C NMR (125 MHz, 
CDCl3): δ 188.5, 157.2, 156.8, 124.6, 58.2, 44.8 (2C), 38.7, 32.0, 31.8, 29.8, 29.5(2C), 29.4, 29.3, 
29.3, 29.2, 29.1, 28.6, 28.3, 27.2, 26.9, 25.6, 24.0, 22.6, 14.0. HRMS (ESI) calc. for C26H48N2O2S 
[M+H]+ 453.3509, found  453.3502. LC-MS (ESI) found 453.32 for [M+H]+. 
 
 
1-(5-(2-(3-(Dimethylamino)propylthio)ethyl)oxazol-2-yl)octan-1-one (169). Compound 169 was 
synthesized following the general procedure for oxazole C2-functionalization using 9.1 mmol of 
Weinreb amide 163. Yield = 25% (orange oil). Rf= 0.71 (EtOAc/AcOH/MeOH/H2O 3/3/3/2). IR: 
1698 cm-1 (ketone C=O stretch). 1H NMR (400 MHz, CDCl3): δ  6.96 (t, J = 0.8, 1H, H-C=C), 2.96 (t, 
J = 7.2, 2H, -CH2CO), 2.94 (t, J = 7.4, 2H, -CH2S), 2.77 (dt, J = 7.4, 0.8, 2H, -CH2-C=C), 2.49 (t, J = 
7.4, 2H, -CH2S), 2.27 (t, J = 7.2, 2H, -CH2NMe2), 2.14 (s, 6H, N(CH3)2), 1.70 – 1.61 (m, 4H), 1.37 – 
1.16 (m, 8H), 0.79 (t, J = 7.0, 3H, -CH3). 
13C NMR (125 MHz, CDCl3): δ 188.4, 157.3, 154.6, 125.4, 
58.2, 45.2 (2C), 38.8, 31.5, 30.0, 29.6, 29.0, 28.9, 27.3, 26.4, 23.9, 22.5, 13.9. HRMS (ESI) calc. for 
C18H32N2O2S [M+H]
+ 341.2257,  found  341.2258. LC-MS (ESI) found 341.15 for [M+H]+. 
 
 
1-(5-(3-(3-(Dimethylamino)propylthio)propyl)oxazol-2-yl)octan-1-one (170). Compound 170 
was synthesized following the general procedure for oxazole C2-functionalization using 8.5 
mmol of Weinreb amide 163. Yield = 34% (yellow oil). Rf = 0.65 (EtOAc/AcOH/MeOH/H2O 
3/3/3/2). IR: 1698 cm-1 (ketone C=O stretch). 1H NMR (400 MHz, CDCl3): δ  6.95 (t, J = 0.8, 1H, H-
C=C), 2.99 (t, J = 7.4, 2H, -CH2CO), 2.84 (dt, J = 7.4, 0.8, 2H, -CH2-C=C), 2.54 (t, J = 6.8, 2H, -CH2S), 
2.52 (t, J = 7.2, 2H, -CH2S), 2.36 (t, J = 7.2, 2H, -CH2NMe2), 2.22 (s, 6H, N(CH3)2), 1.93 - 1.85 (m, 
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2H), 1.72 – 1.58 (m, 4H), 1.34 – 1.12 (m, 8H), 0.85 (t, J = 7.0, 3H, -CH3). 
13C NMR (125 MHz, 
CDCl3): δ 188.5, 157.3, 155.8, 124.9, 58.3, 45.2 (2C), 38.7, 31.6, 31.2, 29.8, 29.1, 28.9, 27.3, 27.0, 
24.6, 24.0, 22.5, 14.0. HRMS (EI) calc. for C19H34N2O2S  [M
+.] 354.2336, found 354.2330. LC-MS 
(ESI) found 355.16 for [M+H]+. 
 
 
1-(5-(4-(3-(Dimethylamino)propylthio)butyl)oxazol-2-yl)octan-1-one (171). Compound 171 was 
synthesized following the general procedure for oxazole C2-functionalization using 8.7 mmol of 
Weinreb amide 163. Yield = 32% (yellow oil). Rf= 0.74 (EtOAc/AcOH/MeOH/H2 3/3/3/2).
 IR: 1698 
cm-1 (ketone C=O stretch). 1H NMR (400 MHz, CDCl3): δ  6.96 (t, J = 0.8, 1H, H-C=C), 3.02 (t, J = 
7.6, 2H, -CH2CO), 2.76 (dt, J = 7.4, 0.8, 2H, -CH2-C=C), 2.56 (t, J =7.2, 2H, -CH2S), 2.55 (t, J = 7.2, 
2H, -CH2S), 2.36 (t, J = 7.2, 2H, -CH2NMe2), 2.22 (s, 6H, N(CH3)2), 1.90 – 1.77 (m, 4H), 1.76 – 1.61 
(m, 4H), 1.42 – 1.21 (m, 8H), 0.87 (t, J = 7.0, 3H, -CH3). 
13C NMR (125 MHz, CDCl3): δ  188.5, 
157.3, 156.4, 124.7, 58.5, 45.3 (2C), 38.7, 31.6, 31.6, 30.0, 29.1, 28.9, 28.8, 27.5, 26.4, 25.3, 24.0, 
22.5, 14.0. HRMS (ESI) calc. for C20H36N2O2S [M+H]
+ 369.2570, found 369.2571. LC-MS (ESI) found 
369.19 for [M+H]+. 
 
 
1-(5-(5-(3-(Dimethylamino)propylthio)pentyl)oxazol-2-yl)octan-1-one (172). Compound 172 
was synthesized following the general procedure for oxazole C2-functionalization using 8.5 
mmol of Weinreb amide 163. Yield = 28% (yellow oil). Rf = 0.77 (EtOAc/AcOH/MeOH/H2O 
3/3/3/2). IR: 1698 cm-1 (ketone C=O stretch). 1H NMR (400 MHz, CDCl3): δ 6.92 (t, J = 0.8, 1H, H-
C=C), 2.99 (t, J = 7.6, 2H, -CH2CO), 2.71 (dt, J = 7.4, 0.8, 2H, -CH2-C=C), 2.51 (t, J = 7.4, 2H, -CH2S), 
2.49 (t, J = 7.4, 2H, -CH2S), 2.35 (t, J = 7.2, 2H, -CH2NMe2), 2.21 (s, 6H, N(CH3)2), 1.80 – 1.66 (m, 
6H), 1.64 – 1.55 (m, 2H), 1.48 – 1.39 (m, 2H), 1.37 – 1.19 (m, 8H), 0.85 (t, J = 7.0, 3H, -CH3). 
13C 
NMR (125 MHz, CDCl3): δ 188.5, 157.2, 156.6, 124.6, 58.5, 45.2 (2C), 38.7, 31.9, 31.6, 29.9, 29.0 
(2C), 28.9, 28.2, 27.4, 26.9, 25.6, 24.0, 22.5, 14.0. HRMS (ESI) calc. for C21H38N2O2S [M+H]
+ 
383.2727, found 383.2733. LC-MS (ESI) found 383.22 for [M+H]+.  
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1-(5-(6-(3-(Dimethylamino)propylthio)hexyl)oxazol-2-yl)octan-1-one (173). Compound 173 was 
synthesized following the general procedure for oxazole C2-functionalization using 6.6 mmol of 
Weinreb amide 163. Yield = 32% (yellow oil). Rf = 0.73 (EtOAc/AcOH/MeOH/H2O 3/3/3/2). IR: 
1699 cm-1 (ketone C=O stretch). 1H NMR (400 MHz, CDCl3): δ  6.92 (t, J = 0.8, 1H, H-C=C), 2.99 (t, 
J = 8.0, 2H, -CH2CO), 2.76 (dt, J = 7.6, 0.8, 2H, -CH2-C=C), 2.51 (t, J = 7.2, 2H, -CH2S), 2.50 (t, J = 
7.0, 2H, -CH2S), 2.41 (t, J = 7.4, 2H, -CH2NMe2), 2.26 (s, 6H, N(CH3)2), 1.81 – 1.62 (m, 6H), 1.61- 
1.50 (m, 2H), 1.45 – 1.17 (m, 12H), 0.85 (t, J = 7.0, 3H, -CH3). 
13C NMR (125 MHz, CDCl3): δ  188.5, 
157.2, 156.8, 124.6, 58.4, 45.1(2C), 38.8, 32.0, 31.6, 29.9, 29.3, 29.1, 28.9, 28.6, 28.3, 27.2 (2C), 
25.6, 24.0, 22.5, 14.0. HRMS (ESI) calc. for C22H40N2O2S [M+H]
+ 397.2883, found 397.2873. LC-MS 
(ESI) found 397.24 for [M+H]+. 
 
 
1-(5-(2-(3-(Dimethylamino)propylsulfonyl)ethyl)oxazol-2-yl)dodecan-1-one (174). Compound 
174 was synthesized following the general procedure for oxidation into sulfone using 0.42 mmol 
of sulfide derivative 164, reaction time 60 hours. Purification by reverse phase chromatography 
using RPC18 column (eluent 0 – 100 % MeOH). Yield = 76% (white semi-solid). Rf= 0.54 
(EtOAc/AcOH/MeOH/H2O 3/3/3/2). IR: 1694 cm
-1 (ketone C=O stretch), 1304 cm-1 (SO2 asym. 
stretch), 1112 cm-1 (SO2 sym. stretch). 
1H NMR (400 MHz, CDCl3): δ  7.10 (t, J = 0.8, 1H, H-C=C), 
3.42 – 3.27 (m, 4H, -CH2SO2), 3.18 – 3.11 (m, 2H, -CH2CO), 3.04 - 2.98 (m, 2H, -CH2-C=C), 2.70 - 
2.61 (m, 2H, -CH2NMe2), 2.39 (s, 6H, N(CH3)2), 2.16 – 2.07 (m, 2H), 1.76 – 1.66 (m, 2H), 1.41 – 
1.15 (m, 16H), 0.87 (t, J = 6.8, 3H, -CH3). 
13C NMR (125 MHz, CDCl3): δ  188.5, 157.7, 151.8, 126.1, 
56.9, 50.8, 50.3, 44.5 (2C), 38.9, 31.9, 29.6, 29.4, 29.3 (2C), 29.1, 23.9, 22.7, 19.1, 18.7, 14.1. 
HRMS (ESI) calc. for C22H40N2O4S [M+H]
+ 429.2782, found  429.2776. LC-MS (ESI) found 429.22 
for [M+H]+.  
 
 
1-(5-(3-(3-(Dimethylamino)propylsulfonyl)propyl)oxazol-2-yl)dodecan-1-one (175). Compound 
175 was synthesized following the general procedure for oxidation into sulfone using 0.43 mmol 
of sulfide derivative 165, reaction time 60 hours. Purification by reverse phase chromatography 
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using RPC18 column (eluent 0 – 100 % MeOH). Yield = 75% (white semi-solid). Rf= 0.53 
(EtOAc/AcOH/MeOH/H2O 3/3/3/2). IR: 1699 cm
-1 (ketone C=O stretch), 1318 cm-1 (SO2 asym. 
stretch), 1129 cm-1 (SO2 sym. stretch). 
1H NMR (400 MHz, CDCl3): δ  7.03 (t, J = 0.8, 1H, H-C=C), 
3.20 – 3.14 (m, 2H, -CH2SO2), 3.11 – 3.05 (m, 2H, -CH2SO2),  3.02 (t, J = 7.6, 2H, -CH2CO), 2.96 (dt, 
J = 7.4, 0.8, 2H, -CH2-C=C), 2.83 - 2.74 (m, 2H, -CH2NMe2), 2.49 (s, 6H, N(CH3)2), 2.30 – 2.20 (m, 
2H), 2.16 – 2.07 (m, 2H), 1.76 – 1.66 (m, 2H), 1.41 – 1.15 (m, 16H), 0.87 (t, J = 7.0, 3H, -CH3). 
13C 
NMR (125 MHz, CDCl3): δ  188.5, 157.6, 154.3, 125.5, 57.0, 51.8, 50.6, 44.6 (2C), 38.9, 31.9, 
29.6(2C), 29.5, 29.3, 29.3, 29.2, 24.4, 24.0, 22.7, 20.1, 19.1, 14.1. HRMS (ESI) calc. for 
C23H42N2O4S [M+H]
+ 443.2938, found   443.2936. GCMS found 442 for [M+.].   
 
 
1-(5-(4-(3-(Dimethylamino)propylsulfonyl)butyl)oxazol-2-yl)dodecan-1-one (176). Compound 
176 was synthesized following the general procedure for oxidation into sulfone using 0.38 mmol 
of sulfide derivative 166, reaction time 60 hours. Purification by reverse phase chromatography 
using RPC18 column (eluent 0 – 100 % MeOH). Yield = 73% (white semi-solid). Rf= 0.53 
(EtOAc/AcOH/MeOH/H2O 3/3/3/2). IR: 1701 cm
-1 (ketone C=O stretch), 1274 cm-1 (SO2 asym. 
stretch), 1111 cm-1 (SO2 sym. stretch). 
1H NMR (400 MHz, CDCl3): δ  6.99 (t, J = 0.8, 1H, H-C=C), 
3.22 – 3.16 (m, 2H, -CH2SO2), 3.11 – 3.05 (m, 2H, -CH2SO2), 3.01 (t, J = 7.4, 2H, -CH2CO), 2.97 – 
2.90 (m, 2H, -CH2-C=C), 2.83 - 2.76 (m, 2H, -CH2NMe2), 2.61 (s, 6H, N(CH3)2), 2.30 - 2.19 (m, 2H), 
1.97 - 1.81 (m, 4H), 1.75 – 1.66 (m, 2H), 1.41 - 1.18 (m, 16H), 0.87 (t, J = 6.8, 3H, -CH3). 
13C NMR 
(125 MHz, CDCl3): δ  188.6, 157.4, 155.5, 125.1, 56.7, 52.5, 50.0, 43.9 (2C), 38.8, 31.9, 29.6 (2C), 
29.4, 29.3, 29.3, 29.1, 26.2, 25.2, 24.0, 22.6, 21.3, 18.4, 14.1. HRMS (ESI) calc. for C24H44N2O4S 
[M+H]+ 457.3095, found  457.3087. LC-MS (ESI) found 457.26 for [M+H]+.   
 
 
1-(5-(5-(3-(Dimethylamino)propylsulfonyl)pentyl)oxazol-2-yl)dodecan-1-one (177). Compound 
177 was synthesized following the general procedure for oxidation into sulfone using 0.38 mmol 
of sulfide derivative 167, reaction time 60 hours. Purification by reverse phase chromatography 
using RPC18 column (eluent 0 – 100 % MeOH). Yield =74% (white semi-solid). Rf= 0.58 
(EtOAc/AcOH/MeOH/H2O 3/3/3/2). IR: 1701 cm
-1 (ketone C=O stretch), 1320 cm-1 (SO2 asym. 
stretch), 1127 cm-1 (SO2 sym. stretch). 
1H NMR (400 MHz, CDCl3): δ  6.95 (t, J = 0.8, 1H, H-C=C), 
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3.10 – 3.05 (m, 2H, -CH2SO2), 3.01 (t, J = 7.4, 2H, -CH2CO), 2.99 – 2.96 (m, 2H, -CH2SO2), 2.76 (dt, J 
= 7.4, 0.8, 2H, -CH2-C=C), 2.56 (t, J = 6.8, 2H, -CH2NMe2), 2.33 (s, 6H, N(CH3)2), 2.12 – 2.02 (m, 
2H), 1.94 - 1.83 (m, 2H), 1.80 - 1.68 (m, 4H), 1.58 - 1.48 (m, 2H), 1.42 - 1.17 (m, 16H), 0.87 (t, J = 
6.8, 3H, -CH3). 
13C NMR (125 MHz, CDCl3): δ 188.6, 157.4, 156.1, 124.8, 57.2, 52.8, 50.4, 44.7 
(2C), 38.8, 31.9, 29.6 (2C), 29.4, 29.3, 29.3, 29.2, 27.9, 26.9, 25.4, 24.0, 22.7, 21.6, 19.3, 14.1. 
HRMS (ESI) calc. for C25H46N2O4S [M+H]
+ 471.3251, found 471.3243. LC-MS (ESI) found 471.27 for 
[M+H]+.   
 
 
1-(5-(6-(3-(Dimethylamino)propylsulfonyl)hexyl)oxazol-2-yl)dodecan-1-one  (178). Compound 
178 was synthesized following the general procedure for oxidation into sulfone using 0.35 mmol 
of sulfide derivative 168, reaction time 60 hours. Purification by reverse phase chromatography 
using RPC18 column (eluent 0 – 100 % MeOH). Yield = 69% (white semi-solid). Rf=0.62 
(EtOAc/AcOH/MeOH/H2O 3/3/3/2). IR: 1703 cm
-1 (ketone C=O stretch), 1276 cm-1 (SO2 asym. 
stretch), 1109 cm-1 (SO2 sym. stretch). 
1H NMR (400 MHz, CDCl3): δ  6.94 (t, J = 0.8, 1H, H-C=C), 
3.08 – 3.05 (m, 2H, -CH2SO2), 3.01 (t, J = 7.4, 2H, -CH2CO), 2.99 – 2.96 (m, 2H, -CH2SO2), 2.73 (dt, J 
= 7.4, 0.8, 2H, -CH2-C=C), 2.61 - 2.52 (m, 2H, -CH2NMe2), 2.33 (s, 6H, N(CH3)2), 2.12 – 2.02 (m, 
2H),  1.90 – 1.79 (m, 2H), 1.77 – 1.67 (m, 4H), 1.54 - 1.19 (m, 20H), 0.87 (t, J = 7.0, 3H, -CH3). 
13C 
NMR (125 MHz, CDCl3): δ  188.6, 157.3, 156.5, 124.7, 57.3, 53.0, 50.3, 44.8 (2C), 38.8, 31.9, 29.6 
(2C), 29.5, 29.3, 29.3, 29.2, 28.5, 28.1, 27.0, 25.6, 24.1, 22.7, 21.8, 19.3, 14.1. HRMS (ESI) calc. for 
C26H48N2O4S [M+H]
+ 485.3408, found 485.3399. LC-MS (ESI) found 485.30 for [M+H]+.  
 
 
1-(5-(2-(3-(Dimethylamino)propylsulfonyl)ethyl)oxazol-2-yl)octan-1-one (179). Compound 179 
was synthesized following the general procedure for oxidation into sulfone using 0.48 mmol of 
sulfide derivative 169, reaction time 60 hours. Purification by reverse phase chromatography 
using RPC18 column (eluent 0 – 100 % MeOH). Yield = 79% (white semi-solid). Rf = 0.51 
(EtOAc/AcOH/MeOH/H2O 3/3/3/2). IR: 1694 cm
-1 (ketone C=O stretch), 1287 cm-1 (SO2 asym. 
stretch), 1111 cm-1 (SO2 sym. stretch). 
1H NMR (400 MHz, CDCl3): δ  7.10 (t, J = 0.8, 1H, H-C=C), 
3.40 – 3.29 (m, 4H, -CH2SO2), 3.16 – 3.10 (m, 2H, -CH2CO), 3.04 - 2.99 (m, 2H, -CH2-C=C), 2.56 (t, J 
= 6.8, 2H, -CH2NMe2), 2.33 (s, 6H, N(CH3)2), 2.13 – 2.03 (m, 2H), 1.76 – 1.66 (m, 2H), 1.40 – 1.22 
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(m, 8H), 0.87 (t, J = 6.8, 3H, -CH3). 
13C NMR (125 MHz, CDCl3): δ  188.5, 157.7, 151.8, 126.1, 57.0, 
51.0, 50.3, 44.7 (2C), 38.9, 31.6, 29.0, 28.9, 23.9, 22.5, 19.3, 18.7, 14.0. HRMS (ESI) calc. for 
C18H32N2O4S [M+H]
+ 373.2156, found 373.2157. LC-MS (ESI) found 373.16 for [M+H]+. 
 
 
1-(5-(3-(3-(Dimethylamino)propylsulfonyl)propyl)oxazol-2-yl) octan -1-one (180). Compound 
180 was synthesized following the general procedure for oxidation into sulfone using 0.46 mmol 
of sulfide derivative 170, reaction time 60 hours. Purification by reverse phase chromatography 
using RPC18 column (eluent 0 – 100 % MeOH). Yield = 69% (white semi-solid). Rf= 0.50 
(EtOAc/AcOH/MeOH/H2O 3/3/3/2). IR: 1701 cm
-1 (ketone C=O stretch), 1318 cm-1 (SO2 asym. 
stretch), 1130 cm-1 (SO2 sym. stretch). 
 1H NMR (400 MHz, CDCl3): δ  7.04 (t, J = 0.8, 1H, H-C=C), 
3.19 – 3.12 (m, 2H, -CH2SO2), 3.11 – 3.05 (m, 2H, -CH2SO2),  3.01 (t, J = 7.4, 2H, -CH2CO), 2.97 (dt, 
J = 7.4, 0.8, 2H, -CH2-C=C), 2.74 (t, J = 7.0, 2H, -CH2NMe2), 2.46 (s, 6H, N(CH3)2), 2.33 – 2.22 (m, 
2H), 2.20 – 2.10 (m, 2H), 1.77 – 1.67 (m, 2H), 1.40 – 1.16 (m, 8H), 0.87 (t, J = 6.8, 3H, -CH3). 
13C 
NMR (125 MHz, CDCl3): δ 188.5, 157.6, 154.3, 125.5, 56.9, 51.8, 50.4, 44.4 (2C), 38.8, 31.6, 29.1, 
29.0, 24.3, 23.9, 22.5, 20.1, 18.9, 14.0. HRMS (EI) calc. for C19H34N2O4S  [M
+.]  386.2239, found 
386.2227. GCMS found 386 for [M+.].   
 
 
1-(5-(4-(3-(Dimethylamino)propylsulfonyl)butyl)oxazol-2-yl)octan-1-one (181). Compound 181 
was synthesized following the general procedure for oxidation into sulfone using 0.45 mmol of 
sulfide derivative 171, reaction time 60 hours. Purification by reverse phase chromatography 
using RPC18 column (eluent 0 – 100 % MeOH). Yield = 76% (white semi-solid). Rf = 0.51 
(EtOAc/AcOH/MeOH/H2O  3/3/3/2). IR: 1692 cm
-1 (ketone C=O stretch), 1277 cm-1 (SO2 asym. 
stretch), 1110 cm-1 (SO2 sym. stretch). 
 1H NMR (400 MHz, CDCl3): δ  6.98 (t, J = 0.8, 1H, H-C=C), 
3.15 – 3.09 (m, 2H, -CH2SO2), 3.06 – 3.02 (m, 2H, -CH2SO2),  3.01 (t, J = 7.4, 2H, -CH2CO), 2.83 - 
2.77 (m, 2H, -CH2-C=C), 2.69 (t, J = 7.0, 2H, -CH2NMe2), 2.43 (s, 6H, N(CH3)2), 2.17 – 2.09 (m, 2H), 
1.96 – 1.81 (m, 4H), 1.76 -1.67 (m, 2H), 1.41- 1.19 (m, 8H), 0.87 (t, J = 6.8, 3H, -CH3). 
13C NMR 
(125 MHz, CDCl3): δ 188.6, 157.4, 155.4, 125.1, 57.0, 52.5, 50.3, 44.5 (2C), 38.8, 31.6, 29.1, 28.9, 
26.3, 25.2, 24.0, 22.6, 21.4, 19.0, 14.0. HRMS (ESI) calc. for C20H36N2O4S [M+H]
+ 401.2469, found  
401.2460. LC-MS (ESI) found 401.21 for [M+H]+.  
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1-(5-(5-(3-(Dimethylamino)propylsulfonyl)pentyl)oxazol-2-yl)octan-1-one (182). Compound 
182 was synthesized following the general procedure for oxidation into sulfone using 0.42 mmol 
of sulfide derivative 172, reaction time 60 hours. Purification by reverse phase chromatography 
using RPC18 column (eluent 0 – 100 % MeOH). Yield = 74% (yellow semi-solid). Rf=0.54 
(EtOAc/AcOH/MeOH/H2O 3/3/3/2). IR: 1696 cm
-1 (ketone C=O stretch), 1278 cm-1 (SO2 asym. 
stretch), 1118 cm-1 (SO2 sym. stretch).  
1H NMR (400 MHz, CDCl3): δ  6.96 (t, J = 0.8, 1H, H-C=C), 
3.24 – 3.18 (m, 2H, -CH2SO2), 3.10 – 2.97 (m, 6H, -CH2SO2, -CH2CO, -CH2-C=C), 2.75 (t, J = 7.4, 2H, -
CH2NMe2), 2.71 (s, 6H, N(CH3)2), 2.35 – 2.23 (m, 2H), 1.93 – 1.81 (m, 2H), 1.80 – 1.66 (m, 4H), 
1.57 – 1.47 (m, 2H), 1.39 – 1.19 (m, 8H), 0.87 (t, J = 7.0, 3H, -CH3). 
13C NMR (125 MHz, CDCl3): δ 
188.6, 157.3, 156.2, 124.8, 56.5, 52.9, 49.8, 43.7 (2C), 38.8, 31.6, 29.1, 29.0, 27.8, 26.9, 25.3, 
24.0, 22.5, 21.4, 18.0, 14.0. HRMS (ESI) calc. for C21H38N2O4S [M+H]
+ 415.2625, found  415.2619. 
LC-MS (ESI) found 415.21 for [M+H]+.  
 
 
1-(5-(6-(3-(Dimethylamino)propylsulfonyl)hexyl)oxazol-2-yl)octan-1-one  (183). Compound 183 
was synthesized following the general procedure for oxidation into sulfone using 0.38 mmol of 
sulfide derivative 173, reaction time 60 hours. Purification by reverse phase chromatography 
using RPC18 column (eluent 0 – 100 % MeOH). Yield = 84% (white semi-solid). Rf= 0.56 
(EtOAc/AcOH/MeOH/H2O 3/3/3/2). IR: 1694 cm
-1 (ketone C=O stretch), 1278 cm-1 (SO2 asym. 
stretch), 1110 cm-1 (SO2 sym. stretch). 
1H NMR (400 MHz, CDCl3): δ  6.95 (t, J = 0.8, 1H, H-C=C), 
3.34 – 3.25 (m, 4H, -CH2SO2), 3.09 – 2.97 (m, 4H, -CH2CO, -CH2-C=C), 2.84 (s, 6H, N(CH3)2), 2.73 (t, 
J = 7.6, 2H, -CH2NMe2), 2.50 – 2.41 (m, 2H), 1.90 -1.81 (m, 2H), 1.77 – 1.66 (m, 4H), 1.55 – 1.22 
(m, 12H), 0.87 (t, J = 6.8, 3H, -CH3). 
13C NMR (125 MHz, CDCl3): δ 188.6, 157.3, 156.5, 124.7, 56.3, 
53.5, 49.3, 43.2 (2C), 38.8, 31.6, 29.1, 28.9, 28.4, 27.9, 26.9, 25.5, 24.0, 22.6, 21.7, 17.4, 14.0. 
HRMS (ESI) calc. for C22H40N2O4S [M+H]
+ 429.2782, found  429.2776. LC-MS (ESI) found 429.24 
for [M+H]+. 
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N,N,N-trimethyl-3-(2-(2-dodecanoyloxazol-5-yl)ethylthio)propan-1-ammonium iodide (184). 
Compound 184 was synthesized following the general procedure for amine quaternization using 
0.071 mmol of oxazole 164. Yield = 71% (yellow semi-solid). Rf= 0.38 (EtOAc/AcOH/MeOH/H2O 
3/3/3/2). IR: 3450 cm-1 (quaternary amine), 1696 cm-1 (ketone C=O stretch).  1H NMR (400 MHz, 
DMSO): δ  7.29 (s, 1H, H-C=C), 3.34 – 3.30 (m, 2H, -CH2NMe3
+), 3.08 – 3.06 (m, 2H, -CH2-C=C), 
3.05 (s, 9H, N(CH3)3
+), 2.97 (t, J = 7.4, 2H, -CH2CO), 2.87 (t, J = 7.2, 2H, -CH2S), 2.57 (t, J = 7.0, 2H, -
CH2S), 2.02 – 1.90 (m, 2H), 1.65 -1.53 (m, 2H), 1.34 - 1.16 (m, 16H), 0.85 (t, J = 7.0, 3H, -CH3). 
13C 
NMR (125 MHz, DMSO): δ  187.7, 156.7, 154.8, 125.6, 64.3, 52.2 (3C), 38.0, 31.2, 28.9 (2C), 28.8, 
28.7, 28.6, 28.4, 28.3, 27.5, 25.4, 23.3, 22.3, 22.0, 13.9. HRMS (ESI) calc. for C23H43N2O2S  [M]
+ 
411.3040, found 411.3036. LCMS (ESI) found 411.27 for [M]+. 
 
 
N,N,N-trimethyl-3-(4-(2-dodecanoyloxazol-5-yl)butylthio)propan-1-ammonium iodide (185). 
Compound 185 was synthesized following the general procedure for amine quaternization using 
0.060 mmol of oxazole 166. Yield = 70% (white semi-solid). Rf= 0.53 (EtOAc/AcOH/MeOH/H2O 
3/3/3/2). IR: 3470 cm-1 (quaternary amine), 1696 cm-1 (ketone C=O stretch). 1H NMR (400 MHz, 
DMSO): δ  7.22 (s, 1H, H-C=C), 3.37 – 3.28 (m, 2H, -CH2NMe3
+), 3.05 (s, 9H, N(CH3)3
+), 2.96 (t, J = 
7.2, 2H, -CH2CO), 2.78 (t, J = 7.4, 2H, -CH2-C=C), 2.57 (t, J = 7.2, 2H, -CH2S), 2.52 (t, J = 7.2, 2H, -
CH2S), 2.01 – 1.88 (m, 2H), 1.76 – 1.64 (m, 2H), 1.64 - 1.52 (m, 4H), 1.34 - 1.14 (m, 16H), 0.85 (t, J 
= 6.6, 3H, -CH3). 
13C NMR (125 MHz, DMSO): δ  187.7,  156.7, 156.3, 124.8, 64.3, 52.2 (3C), 37.9, 
31.2, 30.3, 28.9 (2C), 28.8, 28.7, 28.6, 28.4, 28.1, 27.5, 25.9, 24.3, 23.3, 22.3, 22.0, 13.9. HRMS 
(ESI) calc. for C25H47N2O2S [M]
+ 439.3353, found 439.3351. LCMS (ESI) found 439.28 for [M]+. 
 
 
N,N,N-trimethyl-3-(6-(2-dodecanoyloxazol-5-yl)hexylthio)propan-1-ammonium iodide (186). 
Compound 186 was synthesized following the general procedure for amine quaternization using 
0.072 mmol of oxazole 168. Yield = 64% (white solid). Rf= 0.69 (EtOAc/AcOH/MeOH/H2O 
3/3/3/2). IR: 3491 cm-1 (quaternary amine), 1695 cm-1 (ketone C=O stretch). 1H NMR (400 MHz, 
DMSO): δ  7.21 (s, 1H, H-C=C), 3.38 – 3.28 (m, 2H, -CH2NMe3
+), 3.05 (s, 9H, N(CH3)3
+), 2.96 (t, J = 
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7.2, 2H, -CH2CO), 2.74 (t, J = 7.6, 2H, -CH2-C=C), 2.57 – 2.50 (m, 4H, -CH2S), 2.01 – 1.90 (m, 2H), 
1.67 - 1.45 (m, 6H), 1.41 - 1.17 (m, 20H), 0.85 (t, J = 6.8, 3H, -CH3). 
13C NMR (125 MHz, DMSO): δ  
187.8, 156.7, 156.6, 124.8, 64.5, 52.3 (3C), 38.0, 31.3, 30.8, 28.9 (2C), 28.8, 28.7 (2C), 28.7, 28.4, 
27.9, 27.8, 27.7, 26.7, 24.8, 23.4, 22.4, 22.1, 13.9. HRMS (ESI) calc. for C27H51N2O2S [M]
+ 
467.3666, found 467.3666. LCMS (ESI) found 467.25 for [M]+. 
 
 
N,N,N-trimethyl-3-(2-(2-octanoyloxazol-5-yl)ethylthio)propan-1-ammonium iodide (187). 
Compound 187 was synthesized following the general procedure for amine quaternization using 
0.067 mmol of oxazole 169. Yield = 72% (yellow oil). Rf= 0.45 (EtOAc/AcOH/MeOH/H2O 3/3/3/2). 
IR: 3456 cm-1 (quaternary amine), 1695 cm-1 (ketone C=O stretch). 1H NMR (400 MHz, DMSO): δ  
7.29 (t, J = 0.8, 1H, H-C=C), 3.36 – 3.30 (m, 2H, -CH2NMe3
+), 3.10 – 3.06 (m, 2H, -CH2-C=C), 3.06 (s, 
9H, N(CH3)3
+), 2.98 (t, J = 7.2, 2H, -CH2CO), 2.88 (t, J = 7.4, 2H, -CH2S), 2.58 (t, J = 7.0, 2H, -CH2S), 
2.03 – 1.92 (m, 2H), 1.67 – 1.58 (m, 2H), 1.34 - 1.19 (m, 8H), 0.85 (t, J = 6.8, 3H, -CH3). 
13C NMR 
(125 MHz, DMSO): δ  187.7, 156.7, 154.8, 125.6, 64.3, 52.3 (3C), 38.0, 31.0, 28.4 (2C), 28.3, 27.4, 
25.4, 23.3, 22.3, 21.9, 13.9. HRMS (ESI) calc. for C19H35N2O2S [M]
+ 355.2414, found 355.2412. 
LCMS (ESI) found 355.18 for [M]+. 
 
 
N,N,N-trimethyl-3-(4-(2-octanoyloxazol-5-yl)butylthio)propan-1-ammonium iodide (188). 
Compound 188 was synthesized following the general procedure for amine quaternization using 
0.105 mmol of oxazole 171. Yield = 71% (yellow semi solid). Rf= 0.51 (EtOAc/AcOH/MeOH/H2O 
3/3/3/2). IR: 3468 cm-1 (quaternary amine), 1695 cm-1 (ketone C=O stretch).  1H NMR (400 MHz, 
DMSO): δ  7.22 (t, J = 0.8, 1H, H-C=C), 3.37 – 3.31 (m, 2H, -CH2NMe3
+), 3.06 (s, 9H, N(CH3)3
+), 2.97 
(t, J = 7.2, 2H, -CH2CO), 2.78 (dt, J = 7.4, 0.8, 2H, -CH2-C=C), 2.58 (t, J = 7.2, 2H, -CH2S), 2.52 (t, J = 
7.2, 2H, -CH2S), 2.01 – 1.90 (m, 2H), 1.76 - 1.67 (m, 2H), 1.64 - 1.54 (m, 4H), 1.34 - 1.17 (m, 8H), 
0.85 (t, J = 7.0, 3H, -CH3). 
13C NMR (125 MHz, DMSO): δ 187.7, 156.7, 156.3, 124.8, 64.3, 52.2 
(3C), 37.9, 31.0, 30.3, 28.4 (2C), 28.1, 27.5, 25.9, 24.4, 23.3, 22.3, 21.9, 13.9. HRMS (ESI) calc. for 
C21H39N2O2S [M]
+ 383.2727, found 383.2732. LCMS (ESI) found 383.20 for [M]+. 
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N,N,N-trimethyl-3-(6-(2-octanoyloxazol-5-yl)hexylthio)propan-1-ammonium iodide (189). 
Compound 189 was synthesized following the general procedure for amine quaternization using 
0.088 mmol of oxazole 173. Yield = 60% (white solid). Rf= 0.43 (EtOAc/AcOH/MeOH/H2O 
3/3/3/2). IR: 3456 cm-1 (quaternary amine), 1695 cm-1 (ketone C=O stretch). 1H NMR (400 MHz, 
DMSO): δ  7.21 (s, 1H, H-C=C), 3.37 – 3.28 (m, 2H, -CH2NMe3
+), 3.05 (s, 9H, N(CH3)3
+), 2.96 (t, J = 
7.2, 2H, -CH2CO), 2.74 (t, J = 7.4, 2H, -CH2-C=C), 2.56 - 2.51 (m, 4H, -CH2S), 1.99 – 1.87 (m, 2H), 
1.65 - 1.48 (m, 6H), 1.43 - 1.17 (m, 12H), 0.85 (t, J = 6.8, 3H, -CH3). 
13C NMR (125 MHz, DMSO): δ  
187.7, 156.7, 156.5, 124.7, 64.3, 52.2 (3C), 37.9, 31.0, 30.8, 28.7, 28.4 (2C), 27.9, 27.7, 27.6, 26.7, 
24.7, 23.3, 22.3, 21.9, 13.9. HRMS (ESI) calc. for C23H43N2O2S [M]
+ 411.3040, found 411.3037. 
LCMS (ESI) found 411.26 for [M]+. 
 
 
N,N,N-trimethyl-3-(2-(2-dodecanoyloxazol-5-yl)ethylsulfonyl)-propan-1-ammonium iodide 
(190). Compound 190 was synthesized following the general procedure for amine quaternization 
using 0.070 mmol of oxazole 174. Yield = 45% (yellow salt). Rf= 0.34 (EtOAc/AcOH/MeOH/H2O 
3/3/3/2). IR: 3409 cm-1 (quaternary amine), 1694 cm-1 (ketone C=O stretch), 1283 cm-1 (SO2 
asym. stretch), 1114 cm-1 (SO2 sym. stretch). 
1H NMR (400 MHz, DMSO): δ 7.35 (s, 1H, H-C=C), 
3.65 -3.56 (m, 2H, -CH2SO2), 3.44 – 3.34 (m, 2H, -CH2NMe3
+), 3.28 – 3.21 (m, 4H, -CH2SO2, -CH2-
C=C), 3.08 (s, 9H, N(CH3)3
+), 2.98 (t, J = 7.4, 2H, -CH2CO), 2.23 - 2.08 (m, 2H), 1.67 - 1.51 (m, 2H), 
1.35 - 1.11 (m, 16H), 0.85 (t, J = 7.2, 3H, -CH3). 
13C NMR (125 MHz, DMSO): δ  187.7, 156.8, 152.9, 
125.8, 63.3, 52.2 (3C), 48.8, 48.5, 38.0, 31.2, 28.9 (2C), 28.8, 28.7, 28.6, 28.4, 23.3, 22.0, 18.1, 
15.8, 13.9. HRMS (ESI) calc. for C23H43N2O4S [M]
+ 443.2938, found 443.2933. LCMS (ESI) found 
443.29 for [M]+. 
 
N,N,N-trimethyl-3-(3-(2-dodecanoyloxazol-5-yl)propylsulfonyl)-propan-1-ammonium iodide 
(191).  Compound 191 was synthesized following the general procedure for amine 
quaternization using 0.070 mmol of oxazole 175. Yield = 50% (white solid). Rf= 0.36 
(EtOAc/AcOH/MeOH/H2O 3/3/3/2). IR: 3414 cm
-1 (quaternary amine), 1690 cm-1 (ketone C=O 
stretch), 1265 cm-1 (SO2 asym. stretch), 1129 cm
-1 (SO2 sym. stretch). 
1H NMR (400 MHz, DMSO): 
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δ  7.28 (s, 1H, H-C=C), 3.44 – 3.34 (m, 2H, -CH2NMe3
+), 3.28 - 3.20 (m, 4H, -CH2SO2), 3.08 (s, 9H, 
N(CH3)3
+), 3.02 – 2.91 (m, 4H, -CH2CO, -CH2-C=C), 2.21 – 1.97 (m, 4H), 1.66 – 1.52 (m, 2H), 1.35 – 
1.08 (m, 16H), 0.85 (t, J = 7.0, 3H, -CH3). 
13C NMR (125 MHz, DMSO): δ 187.7, 156.8, 154.9, 125.2, 
63.4, 52.2 (3C), 50.7, 48.2, 38.0, 31.2, 28.9 (2C), 28.8, 28.7, 28.6, 28.4, 23.5, 23.2, 22.0, 19.6, 
15.7, 13.9. HRMS (ESI) calc. for C24H45N2O4S [M]
+ 457.3094, found 457.3086. LCMS (ESI) found 
457.36 for [M]+. 
 
 
N,N,N-trimethyl-3-(4-(2-dodecanoyloxazol-5-yl)butylsulfonyl)-propan-1-ammonium iodide 
(192). Compound 192 was synthesized following the general procedure for amine quaternization 
using 0.065 mmol of oxazole 176. Yield = 68% (yellow solid). Rf= 0.34 (EtOAc/AcOH/MeOH/H2O 
3/3/3/2). IR: 3432 cm-1 (quaternary amine), 1701 cm-1 (ketone C=O stretch), 1282 cm-1 (SO2 
asym. stretch), 1120 cm-1 (SO2 sym. stretch). 
1H NMR (400 MHz, DMSO): δ 7.23 (s, 1H, H-C=C), 
3.43 -3.35 (m, 2H, -CH2NMe3
+), 3.27 -3.12 (m, 4H, -CH2SO2), 3.08 (s, 9H, N(CH3)3
+), 2.97 (t, J = 7.4, 
2H, -CH2CO), 2.85 - 2.77 (m, 2H, -CH2-C=C), 2.20 – 2.08 (m, 2H), 1.82 - 1.67 (m, 4H), 1.65 – 1.54 
(m, 2H), 1.35 - 1.14 (m, 16H), 0.85 (t, J = 6.8, 3H, -CH3). 
13C NMR (125 MHz, DMSO): δ 187.7, 
156.8, 155.9, 124.9, 63.4, 52.2 (3C), 51.0, 48.3, 37.9, 31.2, 28.9 (2C), 28.8, 28.7, 28.6, 28.4, 25.5, 
24.3, 23.3, 22.0, 20.6, 15.7, 13.9. HRMS (ESI) calc. for C25H47N2O4S [M]
+ 471.3251, found 
471.3250. LCMS (ESI) found 471.28 for [M]+. 
 
 
N,N,N-trimethyl-3-(5-(2-dodecanoyloxazol-5-yl)pentylsulfonyl)-propan-1-ammonium iodide 
(193). Compound 193 was synthesized following the general procedure for amine quaternization 
using 0.064 mmol of oxazole 177. Yield = 44% (yellow solid). Rf= 0.36 (EtOAc/AcOH/MeOH/H2O 
3/3/3/2). IR: 3477 cm-1 (quaternary amine), 1697 cm-1 (ketone C=O stretch), 1286 cm-1 (SO2 
asym. stretch), 1115 cm-1 (SO2 sym. stretch). 
1H NMR (400 MHz, DMSO): δ  7.22 (s, 1H, H-C=C), 
3.42 -3.35 (m, 2H, -CH2NMe3
+), 3.21 – 3.12 (m, 4H, -CH2SO2), 3.08 (s, 9H, N(CH3)3
+), 2.96 (t, J = 
7.2, 2H, -CH2CO), 2.76 (t, J = 7.4, 2H, -CH2-C=C), 2.20 – 2.06 (m, 2H), 1.77 - 1.54 (m, 6H), 1.51 - 
1.40 (m, 2H), 1.35 - 1.16 (m, 16H), 0.85 (t, J = 6.8, 3H, -CH3). 
13C NMR (125 MHz, DMSO): δ 187.7, 
156.7, 156.4, 124.8, 63.4, 52.2, 51.2 (3C), 48.2, 37.9, 31.2, 28.9 (2C), 28.8, 28.7, 28.6, 28.4, 27.0, 
Experimental part   231 
26.2, 24.6, 23.3, 22.0, 20.8, 15.7, 13.9. HRMS (ESI) calc. for C26H49N2O4S [M]
+ 485.3408, found 
485.3408. LCMS (ESI) found 485.30 for [M]+. 
 
 
N,N,N-trimethyl-3-(6-(2-dodecanoyloxazol-5-yl)hexylsulfonyl)-propan-1-ammonium iodide 
(194). Compound 194 was synthesized following the general procedure for amine quaternization 
using 0.052 mmol of oxazole 178. Yield = 62% (yellow solid). Rf= 0.41 (EtOAc/AcOH/MeOH/H2O 
3/3/3/2). IR: 3455 cm-1 (quaternary amine), 1697 cm-1 (ketone C=O stretch), 1282 cm-1 (SO2 
asym. stretch), 1131 cm-1 (SO2 sym. stretch). 
1H NMR (400 MHz, DMSO): δ  7.21 (t, J = 0.8, 1H, H-
C=C), 3.41 – 3.35 (m, 2H, -CH2NMe3
+), 3.18 – 3.12 (m, 4H, -CH2SO2), 3.08 (s, 9H, N(CH3)3
+), 2.96 (t, 
J = 7.2, 2H, -CH2CO), 2.75 (dt, J = 7.4, 0.8, 2H, -CH2-C=C), 2.19 – 2.04 (m, 2H), 1.73 - 1.50 (m, 6H), 
1.47 -1.14 (m, 20H), 0.85 (t, J = 6.8, 3H, -CH3). 
13C NMR (125 MHz, DMSO): δ  187.7, 156.7, 156.5, 
124.8, 63.4, 52.2 (3C), 51.4, 48.2, 37.9, 31.2, 28.9 (2C), 28.8, 28.7, 28.6, 28.4, 27.8, 27.2, 26.4, 
24.7, 23.3, 22.0, 20.9, 15.7, 13.9. HRMS (ESI) calc. for C27H51N2O4S [M]
+ 499.3564, found 
499.3565. LCMS (ESI) found 499.29 for [M]+. 
 
 
N,N,N-trimethyl-3-(2-(2-octanoyloxazol-5-yl)ethylsulfonyl)propan-1-ammonium iodide (195). 
Compound 195 was synthesized following the general procedure for amine quaternization using 
0.068 mmol of oxazole 179. Yield = 79% (yellow semi-solid). Rf = 0.33 (EtOAc/AcOH/MeOH/H2O 
3/3/3/2). IR: 3451 cm-1 (quaternary amine), 1693 cm-1 (ketone C=O stretch), 1298 cm-1 (SO2 
asym. stretch), 1122 cm-1 (SO2 sym. stretch). 
1H NMR (400 MHz, DMSO): δ 7.35 (s, 1H, H-C=C), 
3.64 – 3.57 (m, 2H, -CH2SO2), 3.43 – 3.36 (m, 2H, -CH2NMe3
+), 3.34 – 3.20 (m, 4H, -CH2SO2, -CH2-
C=C), 3.09 (s, 9H, N(CH3)3
+  ), 2.98 (t, J = 7.2, 2H, -CH2CO), 2.22 – 2.11 (m, 2H), 1.66 - 1.55 (m, 2H), 
1.35 - 1.15 (m, 8H), 0.85 (t, J = 6.8, 3H, -CH3). 
13C NMR (125 MHz, DMSO): δ 187.7,  156.8, 152.9, 
125.8, 63.3, 52.2 (3C), 48.8, 48.5, 38.0, 31.0, 28.3 (2C), 23.3, 21.9, 18.1, 15.8, 13.8. HRMS (ESI) 
calc. for C19H35N2O4S [M]
+ 387.2312, found 387.2316. LCMS (ESI) found 387.17 for [M]+. 
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N,N,N-trimethyl-3-(3-(2-octanoyloxazol-5-yl)propylsulfonyl)propan-1-ammonium iodide (196). 
Compound 196 was synthesized following the general procedure for amine quaternization using 
0.085 mmol of oxazole 180. Yield = 85% (yellow oil). Rf= 0.34 (EtOAc/AcOH/MeOH/H2O 3/3/3/2). 
IR: 3447 cm-1 (quaternary amine), 1695 cm-1 (ketone C=O stretch), 1285 cm-1 (SO2 asym. stretch), 
1120 cm-1 (SO2 sym. stretch). 
1H NMR (400 MHz, DMSO): δ  7.27 (t, J = 0.8, 1H, H-C=C), 3.42 – 
3.35 (m, 2H, -CH2NMe3
+), 3.28 -3.17 (m, 4H, -CH2SO2), 3.08 (s, 9H, N(CH3)3
+ ), 2.97 (t, J = 7.4, 2H, -
CH2CO), 2.93 (dt, J = 7.2, 0.8, 2H, -CH2-C=C), 2.19 – 2.00 (m, 4H), 1.66 – 1.56 (m, 2H), 1.35 – 1.19 
(m, 8H), 0.85 (t, J = 6.8, 3H, -CH3). 
13C NMR (125 MHz, DMSO): δ  187.7, 156.8, 154.9, 125.2, 63.4, 
52.2 (3C), 50.7, 48.2, 38.0, 31.0, 28.4 (C2), 23.5, 23.3, 22.0, 19.6, 15.7, 13.9. HRMS (ESI) calc. for 
C20H37N2O4S [M]
+ 401.2469, found  401.2463. LCMS (ESI) found 401.20 for [M]+. 
 
 
N,N,N-trimethyl-3-(4-(2-octanoyloxazol-5-yl)butylsulfonyl)propan-1-ammonium iodide (197). 
Compound 197 was synthesized following the general procedure for amine quaternization using 
0.084 mmol of oxazole 181. Yield = 87% (brown oil). Rf = 0.35 (EtOAc/AcOH/MeOH/H2O 3/3/3/2). 
IR: 3447 cm-1 (quaternary amine), 1694 cm-1 (ketone C=O stretch), 1285 cm-1 (SO2 asym. stretch), 
1119 cm-1 (SO2 sym. stretch). 
1H NMR (400 MHz, DMSO): δ 7.23 (t, J = 0.8, 1H, H-C=C), 3.43 – 
3.35 (m, 2H, -CH2NMe3
+), 3.26 -3.21 (m, 2H, -CH2SO2), 3.19 3.13 ( m, 2H, -CH2SO2), 3.08 (s, 9H, 
N(CH3)3
+ ), 2.97 (t, J = 7.2, 2H, -CH2CO), 2.86 – 2.78 (m, 2H, -CH2-C=C), 2.20 – 2.09 (m, 2H), 1.82 – 
1.69 (m, 4H), 1.67 -1.54 (m, 2H), 1.35 -1.16 (m, 8H), 0.85 (t, J = 7.0, 3H, -CH3). 
13C NMR (125 MHz, 
DMSO): δ 187.7, 156.8, 155.9, 124.9, 63.4, 52.2 (3C), 51.0, 48.3, 37.9, 31.0, 28.4 (2C), 25.5, 24.3, 
23.3, 21.9, 20.6, 17.7, 13.9. HRMS (ESI) calc. for C21H39N2O4S [M]
+ 415.2625, found 415.2621. 
LCMS (ESI) found 415.22 for [M]+. 
 
 
N,N,N–trimethyl-3-(5-(2-octanoyloxazol-5-yl)pentylsulfonyl)propan-1-ammonium iodide (198). 
Compound 198 was synthesized following the general procedure for amine quaternization using 
0.060 mmol of oxazole 182. Yield = 66% (brown oil). Rf = 0.34 (EtOAc/AcOH/MeOH/H2O 3/3/3/2). 
IR: 3448 cm-1 (quaternary amine), 1696 cm-1 (ketone C=O stretch), 1282 cm-1 (SO2 asym. stretch), 
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1118 cm-1 (SO2 sym. stretch). 
1H NMR (400 MHz, DMSO): δ  7.22 (s, 1H, H-C=C), 3.41 - 3.34 (m, 
2H, -CH2NMe3
+), 3.21 – 3.11 (m, 4H, -CH2SO2), 3.07 (s, 9H, N(CH3)3
+), 2.96 (t, J = 7.2, 2H, -CH2CO), 
2.76 (t, J = 7.2, 2H, -CH2-C=C), 2.19 – 1.96 (m, 2H), 1.78 - 1.55 (m, 6H), 1.51 - 1.40 (m, 2H), 1.34 - 
1.19 (m, 8H), 0.85 (t, J = 6.8, 3H, -CH3). 
13C NMR (125 MHz, DMSO): δ  187.7, 156.7, 156.5, 124.9, 
64.3, 53.0, 52.9, 49.3, 38.7, 31.6, 29.0, 28.9, 27.6, 26.8, 25.3, 23.9, 22.5, 21.4, 21.3, 17.4, 16.7, 
14.0. HRMS (ESI) calc. for C22H41N2O4S [M]
+ 429.2782, found 429.2778. LCMS (ESI) found 429.23 
for [M]+. 
 
 
N,N,N-trimethyl-3-(6-(2-octanoyloxazol-5-yl)hexylsulfonyl)propan-1-ammonium iodide (199). 
Compound 199 was synthesized following the general procedure for amine quaternization using 
0.056 mmol of oxazole 183.  Yield = traces (white solid). Rf= 0.34 (EtOAc/AcOH/MeOH/H2O 
3/3/3/2). IR: 3441 cm-1 (quaternary amine), 1695 cm-1 (ketone C=O stretch), 1281 cm-1 (SO2 
asym. stretch), 1111 cm-1 (SO2 sym. stretch). 
1H NMR (400 MHz, DMSO): δ  7.21 (s, 1H, H-C=C), 
3.35 – 3.25 (m, 2H, -CH2NMe3
+), 3.19 – 3.09 (m, 4H, -CH2SO2), 3.08 (s, 9H, N(CH3)3
+), 2.96 (t, J = 
7.4, 2H, -CH2CO), 2.75 (t, J = 7.4, 2H, -CH2-C=C), 2.10 – 1.98 (m, 2H), 1.73 – 1.54 (m, 6H), 1.47 – 
1.16 (m, 12H), 0.85 (t, J = 7.0, 3H, -CH3). 
13C NMR (125 MHz, DMSO): δ 187.7, 156.7, 156.5, 124.7, 
64.3, 52.2 (3C), 37.9, 35.6, 31.0, 30.7, 28.7, 28.4, 27.9, 27.7, 27.6, 26.7, 24.7, 23.3, 22.3, 21.9, 
13.9. HRMS (ESI) calc. for C23H43N2O4S [M]
+ 443.2938, found  443.2930. LCMS (ESI) found 443.25 
for [M]+. 
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Summary 
Palmitoylated proteins constitute an important class of signaling components controlling various 
cellular processes, such as cell proliferation and apoptosis, both frequently deregulated in 
carcinogenesis. The reversible character of palmitate lipid anchoring is of utmost importance for 
maintaining steady-state protein localization and subsequent signaling. Therefore, targeting 
protein depalmitoylation by inhibiting depalmitoylating enzymes might be a valid therapeutical 
strategy for modulating aberrant cell signaling.  
Targeting Ras depalmitoylation   
Design, Synthesis of acyl protein thioesterase 1 (APT1) inhibitors  
Given the importance of Ras mutations in carcinogenesis (33% of all cancers), targeting Ras 
protein depalmitoylation by inhibiting Ras depalmitoylating enzymes have been considered as 
an attractive anti-cancer target. In particular, efforts to inhibit the serine hydrolase acyl protein 
thioesterase 1 (APT1) have led to the development of the β-lactone inhibitor palmostatin B (1) 
based on the Protein Structure Similarity Clustering approach. A cell permeable TAMRA-labeled 
palmostatin B analogue (2) was subsequently synthesized and used to confirm the direct 
interaction between palmostatin B and APT1 in cells using Fluorescence Lifetime Imaging 
Microscopy (Figure 1A). 
 
Figure 1. Designed APT1 inhibitors (1
st
 and 2
nd
 generation).  A) Structure of palmostatin B (1
st
 generation) 
and of its fluorescent analogue TAMRA-palmostatin B. B) Structure of palmostatin M (2
nd
 generation) 
based on natural substrate considerations.  
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Subsequently, a 2nd generation of -lactones inhibitors was developed based on native APT1 
substrates leading to palmostatin M (3), found more potent compared to palmostatin B in the 
biochemical assay (IC50= 2.13 +/-0.31 nM versus 5.37 +/-0.38 nM using 5nM APT1) and in cellular 
assays (Figure 1B).  
 
Application of acyl protein thioesterase 1 (APT1) inhibitors  
To confirm APT1 as a cellular target of the -lactone inhibitors and to identify additional target 
proteins relevant to Ras depalmitoylation such as the close APT1 homologue known as APT2, in-
cellulo Activity-Based Proteome Profiling (ABPP) experiments were performed. Several cell 
permeable ABPP-alkyne probes derived from palmostatin B and M were synthesized, including 
two regioisomeric palmostatin M-derived probes, designed to maximize the accessibility of the 
alkyne group for the click ligation when covalently bound into enzyme active sites (Figure 2).  
 
Figure 2. Principle of Activity-Based Proteome Profiling experiments. Incubation of the alkyne probe with 
HeLa cells allows its covalent binding to its target proteins through its reactive -lactone group. After cell 
lysis, target proteins are tagged through click ligation with a trifunctional fluorescent reporter group 
allowing their enrichment using biotin/streptavidin affinity. After isolation and separation by SDS-gel 
electrophoresis, target proteins are detected by fluorescence read-out and are subsequently digested 
with trypsin to allow their identification by mass spectrometry. 
 
In conclusion, the strong discrimination observed between the two regioisomeric palmostatin 
M-derived probes in their ability to label APT1, have confirmed the binding mode for the -
lactone inhibitors in the APT1 active site, which was found in accordance with their substrate-
based design. More importantly, proteomic analyses have allowed not only to identify APT1 
among the cellular targets of palmostatin B and M, but also the close homologue of APT1 called 
acyl protein thioesterase 2 (APT2). Subsequently, the ability of APT1 and APT2 to depalmitoylate 
biologically active semi-synthetic N-Ras proteins was demonstrated in vitro by an ADIBAF assay 
(Kristina Görmer), thereby providing the first experimental proof that both enzymes are 
thioesterases relevant to Ras depalmitoylation. Taken as a whole, these findings suggest that no 
further hydrolases in general are involved in Ras depalmitoylation in cells.  
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Targeting Fas depalmitoylation  
Recently, the lipase inhibitor orlistat and later the APT1 inhibitor palmostatin B were shown to 
restore Fas-mediated apoptotic signaling in Chronic Lymphocytic Leukaemia (CLL) cells, without 
affecting healthy peripheral blood mononuclear cells. With the reported importance of Fas 
palmitoylation for Fas–mediated death signaling, absence or dysfunction of Fas palmitoylation 
may account for the accumulation of malignant B cells characteristic for this disease. In this 
context, a similar chemical proteomic approach was employed in collaboration with Wendtner 
et al. (academic hospital of Cologne) to rationalize the observed apoptotic effect. Experiments 
conducted in human cells from leukaemia and healthy patients respectively, have allowed the 
identification of few hydrolases possibly involved in CLL pathogenesis such as APT1, APT2, 
ABHDA, ABHEB and ESTD. Wendtner and co-workers are currently investigating their possible 
involvement in Fas depalmitoylation. Although plenty of work still remains to be done, APT1 and 
APT2 represent good Fas depalmitoylating enzyme candidates given their Ras depalmitoylating 
activity and the overexpression of APT1 in CLL cells in comparison to healthy B-cells.  
 
Targeting all palmitoylated proteins 
Subsequently, SILAC experiments employing an inert alkynylated palmitate analogue in double 
metabolic labelling were performed in order to evaluate the effect of palmostatin B on the 
complete palmitome. Although, these experiments have not permitted so far any quantification, 
this strategy may allow the systematic evaluation of the effect of palmostatin B on all 
palmitoylated proteins. This would permit to discover new interesting applications for -lactones 
in general and thioesterase-mediated processes in particular.   
 
Discovery ofpotent fatty acid amide hydrolase (FAAH) inhibitors 
With the discovery of APT1 and APT2 as Ras depalmitoylating enzymes, targeting both proteins 
constitute a viable anti-cancer approach to interfere with aberrant H- and N-Ras signaling. In this 
context, various APT1/2 inhibitor candidates such as -keto-amides, -keto-CF3, keto-CF2CF3 
and -keto oxazoles were synthesized, which would, in contrast to the previous β-lactone 
inhibitors, be regarded as stable transition state mimics of the depalmitoylation process. 
Although no or weaker inhibitors were obtained in comparison to the -lactones, some of the -
keto oxazoles turned out to be potent and selective FAAH inhibitors. In particular, this work 
revealed the importance of a short C5-side chain, of a long aliphatic chain, and of electrostatic 
stabilizing interactions for the FAAH inhibitory activity of -keto oxazoles substituted at the C5 
position with non-aromatic substituents.  
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Zusammenfassung 
Palmitoylierte Proteine stellen eine wichtige Klasse von Signalkomponenten dar, die 
unterschiedliche zelluläre Prozesse, darunter Zellproliferation und Apoptose, kontrollieren, die 
beide in der Karzinogenese als missreguliert gelten. Der reversible Charakter der 
palmitatabhängigen Membranverankerung ist von höchster Wichtigkeit für die 
Aufrechterhaltung von Proteinlokalisation und –Signalweiterleitung. Aus diesen Gründen kann 
die Beeinflussung der Proteindepalmitoylierung durch Inhibierung der entsprechenden Enzyme 
als eine vielversprechende therapeutische Strategie angesehen werden, korrigierend in 
Zellsignaltransduktionwege einzugreifen. 
 
Targeting der Ras-Depalmitoylierung 
Design und Synthese von Acyl protein thioesterase (APT1)-Inhibitoren 
Aufgrund der Wichtigkeit von Ras-Mutationen in der Karzinogenese (33% in allen Fällen von 
Krebs) wird das Targeting der Ras-Depalmitoylierung durch Inhibierung von Ras-
depalmitoylierenden Enzymen als attraktive Anti-Krebs-Strategie angesehen. Insbesondere 
Anstrengungen, die Serinhydrolase Acyl protein thioesterase 1 (APT1) zu inhibieren, haben zu 
der Protein Structure Similarity Clustering approach-basierten Entwicklung des β-Lacton-
Inhibitors Palmostatin B geführt. Ein zellgängiges, TAMRA-markiertes Palmostatin B-Analogon (2) 
wurde synthetisiert und dazu genutzt, um die direkte Interaktion zwischen Palmostatin B und 
APT1 mittels Fluorescence Lifetime Imaging Microscopy (Figure 1A) nachzuweisen. 
 
Figure 1. APT1-Inhibitoren-Design (1. und 2. Generation) A) Struktur von Palmostatin B (1. Generation) 
und seinem fluoreszierendem Analog TAMRA-Palmostatin B. B) Struktur von Palmostatin M (2. 
Generation), an das natürliche Substrat angelehnt. 
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Im Folgenden wurde eine 2. Generation von β-Lacton-Inhibitoren synthetisiert, die auf nativen 
APT1-Substraten basieren. Dies führte zur Entwicklung von Palmostatin M (3), ein im Vergleich 
zu Palmostatin B potenterer Inhibitor, was sowohl biochemisch (IC50= 2.13 +/-0.31 nM verglichen 
mit 5.37 +/-0.38 nM, mit 5 nM APT1), als auch in zellbasierten Versuchen nachgewiesen werden 
konnte (Figure 1B). 
 
Anwendung von Acyl protein thioesterase 1 (APT1)-Inhibitoren 
Um APT1 als zelluläres Target der β-Lacton-Inhibitoren nachzuweisen und um weitere Proteine 
zu identifizieren, die für die Ras-Depalmitoylierung relevant sind (wie z.B. das APT1-Homolog 
APT2), wurden  in-cellulo Activity-Based Proteome Profiling (ABPP)-Experimente durchgeführt. 
Es wurden mehrere zellpermeable ABPP-Alkin-Sonden synthetisiert (Palmostatin B und M-
Derivate, darunter zwei Regioisomere (von Palmostatin M abgeleitete Sonden). Diese Sonden 
wurden entworfen, um die Zugänglichkeit der Alkingruppe bei Bindung an das aktive Zentrum 
des Enzyms für die Click-Ligation zu maximieren (Figure 2). 
 
Figure 2. Prinzip der Activity-Based Proteome Profiling-Experimente. Inkubation der Alkylprobe mit HeLa-
Zellen ermöglicht die kovalente Bindung an das Zielprotein durch die reaktive β-Lacton-Gruppe. Nach dem 
Zellaufschluss wurden die Zielproteine mittels click-Ligation mit einer trifunkionalen, fluoreszierenden 
Reportergruppe markiert, welche eine Bindung mittels des Biotin/Streptavidin-Systems ermöglicht. Nach 
der Isolation und Trennung der Proben mittels SDS-PAGE wurden die Zielproteine durch 
Fluoreszenzdetektion ausgelesen, im Folgenden mit Trypsin verdaut und schließlich mittels 
Massenspektrometrie identifiziert. 
 
Durch den beobachteten, erheblichen Unterschied zwischen beiden regioisomeren Sonden in 
ihrer Fähigkeit, APT1 zu markieren, konnte der Bindungsmodus der  β-Lacton-Inhibitoren im 
aktiven Zentrum bestätigt werden, was sich in Einklang mit ihrem substratbasierten Design 
befindet. Darüber hinaus konnten Proteomanalysen nicht nur dazu beitragen, APT1 als zelluläres 
Target für Palmostatin B und M zu identifizieren, sondern auch das nahe Homolog Acyl protein 
thioesterase 2 (APT2). Im Folgenden wurde die Fähigkeit von APT1 und APT2, semisynthetisches 
N-Ras zu depalmitoylieren, in vitro in einem ADIFAB-Assay demonstriert (Kristina Görmer). Dies 
stellt einen ersten experimentellen Beweis für die Relevanz beider Enzyme für die Ras-
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Depalmitoylierung dar. Zusammengenommen zeigen diese Ergebnisse, dass keine weiteren 
Hydrolasen in die Ras-Depalmitoylierung involviert sind. 
 
Targeting der Fas-Depalmitoylierung 
Es konnte kürzlich gezeigt werden, dass der Lipase-Inhibitor Orlistat und der APT1-Inhibitor 
Palmostatin B den Fas-vermittelten Signalweg in Chronic Lymphocytic Leukaemia (CLL)-Zellen 
wiederherstellen, ohne gesunde periphere mononukleare Blutzellen zu beeinflussen. Aufgrund 
der Wichtigkeit von Fas könnte die Fehlfunktion seiner Depalmitoylierung zur Akkumulation von 
bösartigen  B-Zellen, was für diese Krankheit charakteristisch ist, beitragen. In diesem 
Zusammenhang wurde gemeinsam mit Wendtner et al ein Ansatz entwickelt, um den 
apoptotischen Effekt zu untersuchen. Experimente, die in humanen Leukämiezellen und 
vergleichsweise in Zellen von gesunden Probanden durchgeführt wurden, haben zur 
Identifikation einiger Hydrolasen geführt, die in der CLL-Pathogenese überexprimiert werden, 
darunter  APT1, APT2, ABHDA, ABHEB und ESTD. Wendtner und seine Mitarbeiter untersuchen 
zurzeit die mögliche Verwicklung dieser Proteine in die Fas-Depalmitoylierung. Obwohl es noch 
viel Arbeit zu tun gibt, sind APT1 und APT2 vernünftige Kandidaten für Fas-depalmitoylierende 
Enzyme, wenn man ihre Ras-Depalmitoylierungsaktivität und die Überexpression von APT1 in 
CLL-Zellen im Vergleich zu gesunden B-Zellen in Betracht zieht. 
 
Targeting von neuen palmitoylierten Proteinen 
Im Folgenden wurden SILAC-Experimente durchgeführt, die den Effekt von Palmostatin B auf das 
Protom mittels eines inert alkynylierten Palmitatanalogons untersucht haben. Obwohl diese 
Experimente noch keine Quantifizierung hervorgebracht haben, könnte diese Strategie eine 
systematische Evaluierung des Effekts von Palmostatin B auf alle palmitoylierten Proteine 
ermöglichen. Dies würde die Entwicklung neuer interessanter Anwendungen für β-Lactone im 
Allgemeinen als auch für Thioesterase-vermittelter Prozesse im Speziellen ermöglichen.  
 
Entdeckung potenter Fatty acid amide hydrolase (FAAH)-Inhibitoren 
Nach der Entdeckung von APT1 und APT2 als Ras-depalmitoylierende Enzyme stellt das Targeting 
dieser beiden Proteine einen wesentlichen Anti-Krebs-Ansatz dar, um gestörte H- und N-Ras-
Signalwege zu beeinflussen. In diesem Zusammenhang wurden unterschiedliche APT1/2-
Inhibitoren synthetisiert (-keto-amide, -keto-CF3, keto-CF2CF3 und -keto oxazole), die im 
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Gegensatz zu den reversiblen β-Lacton-Inhibitoren den Übergangszustand der 
Depalmitoylierungsreaktion nachahmen. Obwohl keine oder im Vergleich zu den β-Lactonen nur 
schwächere Inhibitoren gefunden wurden, erwiesen sich einige der -keto-Oxazole als potente 
und selektive FAAH-Inhibitoren. Diese Arbeit stellt die Wichtigkeit einer kurzen C5-Seitenkette, 
einer langen aliphatischen Kette, sowie von elektrostatisch stabilisierenden Interaktionen für die 
inhibitorische Aktivität der -keto-Oxazole heraus, bei denen die C5-Position durch 
nichtaromatische Teile substituiert wurden. 
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